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Abstract
Carbon monoxide (CO), synonymous of the “silent killer”, is rapidly emerging as 
an  important  and  versatile  mediator  of  physiological  processes.  The  study  of 
CO  has  been  hampered  by  the  lack  of  a  means  to  simulate  its  release 
biologically.  Current means to replicate the effects of CO include,  most notably, 
the use of CO gas and  upregulation of haem oxygenase-1  (HO-1) to generate 
endogenous  CO.  Both  are  limited  in  their  approach  and  offer  only  a  partial 
solution. The recent discovery that certain transition metal carbonyls function as 
CO-releasing  molecules  (CO-RMs)  in  biological  systems  highlighted  the 
potential  of exploiting this and similar classes of compounds  as a stratagem to 
deliver  CO  for  research  and  therapeutic purposes.  Initially  a  large  portfolio  of 
CO-RMs  was  investigated  to  determine  their  CO  releasing  capability.  This 
thesis examines a  number of aspects  related to the characterisation  of a core 
group of CO-RMs including:  a) CORM-3, the prototypic water soluble transition 
metal carbonyl; b) CORM-A1, a water soluble CO-RM without a metal centre;  c) 
CORM-319,  an  iron  based  water  soluble  CO-RM;  and  d)  CORM-311,  an 
ethanol  soluble  iron  centred  CO-RM.  Specifically,  the  study will  examine  CO- 
RMs  for  their  ability  to:  i)  release  CO;  ii)  suppress  LPS-induced  nitrite 
production;  iii)  promote  toxicity;  iv)  induce  haem  oxygenase  (HO)  activity  and 
HO-1  expression  and  v)  modulate  inducible  nitric  oxide  synthase  (iNOS) 
expression. These different aspects of CO-RM characterisation were addressed 
using  biochemical,  molecular biology and cell  culture techniques.  Further work 
was  also  carried  out  determining  certain  chemical  aspects  of  each  CO-RM 
including  the  decomposition  rate  and  pH/temperature  stability.  The  study  into 
the  CO  release  of the  new CO-RMs  emphasizes  the  versatile  potential  of theABSTRACT
metal  carbonyl  complexes and  related  compounds.  This  research  on  CO-RMs 
will help lay the foundations for a novel therapeutic agent based on the delivery 
of safe and controlled quantities of CO.LIST OF CONTENTS
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1   Introduction
1.1  The Haem Oxygenase Pathway
Haem  oxygenase  (HO)  is the  rate  limiting  step  in  the  catabolism  of haem.  Its 
activity has  been found to  be present in  almost all  animal  species  and tissues 
(Maines,  1988). A schematic diagram of the pathway can be seen in Figure 1.1.
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Figure 1.1:- Schematic representation of the haem oxygenase pathway.
The  diagram  shows  the  major  components  of  the  pathway  and  the  various 
enzymes  involved  in  haem  metabolism.  Extract  from  Ryter  et  al,  Mol  Cell 
Biochem. 2002 May-Jun;234-235(1-2):249-63.
HO was only identified about 2 decades ago as a distinct microsomal entity that 
is  regulated  by  metal  ions  (Maines  1997).  It  is  anchored  to  the  endoplasmic 
reticulum by a hydrophobic sequence of amino acids at the carboxyl terminus of 
the  protein  (Xia  et al.  2002).  Haem  is  oxidatively  cleaved  by  HO  to  biliverdin, 
carbon monoxide (CO) is then generated and the ferrous iron (Fe) is released.
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There are at present three identified forms of HO:  HO-1  or the inducible enzyme 
(Maines  et  al.  1986);  HO-2  or  the  constitutive  isoform  (Cruse  and  Maines, 
1988);  and  HO-3 which  unlike  HO-1  or HO-2  is a  poor haem  catalyst  and  has 
yet to be investigated further (McCoubrey et al.  1997) (see Table 1.1)
Table 1.1:- Comparison of all three isoforms of haem oxygenase
Properties HO-1 HO-2 HO-3
Cellular Localisation Microsomes Mitochondria ?
Chromosomal 22 q 12 16p13.3 ?
Localisation
Molecular Weight 32 KD 36 KD 33 KD
Tissue Distribution Liver, kidney, heart, 
vascular smooth 
muscle, endothelium, 
lung and brain
Nervous system, 
vessels, testes, and 
intestine
Thymus, spleen, 
heart, testes, brain
Roles Cellular homeostasis, 
anti inflammatory
Neural signalling 
and vascular 
regulation
?
Regulation Haem, oxidative 
stress, heavy metals, 
nitric oxide, hypoxia
Glucocorticoids,
opiates
?
Modified  from  (Maines 
1997)
HO-1,  also  known  as heat shock protein (HSP) 32,  is exquisitely sensitive,  not 
only to metals but to many stimuli and agents that cause oxidative stress and by 
several pathological conditions e.g.  heat shock (Ewing,  Weber,  & Maines  1993; 
Redaelli  et  al.  2001),  ischaemia  (Nimura  et  al.  1996;  Maulik,  Sharma,  &  Das 
1996;  Masini  et al.  2003),  glutathione  (GSH)  depletion  (Fulton  & Jeffery  1994; 
Hoekstra  et  al.  2003),  radiation  (Keyse  &  Tyrrell  1989;  Reeve  &  Tyrrell  1999; 
Suzuki  et  al.  2002),  hypoxia  (Foresti  et  al.  2001;  Appleton  et  al.  2002), 
hyperoxia  (Motterlini  et  al.  1995a;  Dennery  et  al.  1997;  Taylor,  Carraway,  & 
Piantadosi  1998) and cellular transformations and disease states (Mayer 2000; 
Kyokane  et al.  2001;  Choi  &  Otterbein 2002).  In fact,  to date there  is no other 
enzyme  studied  that  is  induced  by so  many  diverse  stimuli  as  HO-1.  HO-2  on
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the other hand  is  only  known  to  be  induced  by adrenal  glucocorticoids  (Gcs); 
hence,  its  label  as  a  constitutive  isoform  (Maines,  Eke,  &  Zhao  1996;  Raju, 
McCoubrey, & Maines 1997).
The  catalytic  activity  of  the  HO  system  plays  an  important  role  in  the 
maintenance  of  cellular  haem  homeostasis  and  haemoprotein  levels,  among 
which  are  the  enzymes  nitric  oxide  synthase  (NOS)  and  soluble  guanylate 
cyclase (sGC).  HO also acts to protect the cell from the haem  molecule,  which 
promotes  lipid  peroxidation  and  oxygen  free  radical  formation  (Koehler  & 
Traystman  2002).  In  addition  to  the  action  of  HO  itself,  the  products  of  its 
activity are also capable of performing various  important functions.  Indeed,  the 
study  on  biliverdin,  bilirubin,  CO  and  Fe  has  intensified  and  many  more 
biological  roles  are  now  attributed  to  these  molecules.  Both  biliverdin  and 
bilirubin  have  been  shown  to  be  potent  antioxidants  (Nakagami  et  al.  1993; 
Dore et al.  1999;  Baranano et al. 2002b), while biliverdin has also been shown 
to inhibit viral replication  (Mori et al.  1991).  Similarly,  Fe has been shown to be 
involved  in the regulation of several  genes  including  NOS  (Anning  et al.  1999; 
Otterbein  et al.  2003c).  CO,  as will  be discussed  later,  has  developed  into an 
important  area  of research  undoubtedly  becoming  a  keystone  molecule  in  the 
physiology of life. This chain of events involving the products of HO is,  however, 
triggered  as  a  secondary  line  of  defence.  In  fact,  during  normal  metabolism, 
antioxidants  such  as  superoxide  dismutase  (SOD),  catalase  and  glutathione 
peroxidase  are  constitutively  expressed  and  provide  the  baseline  protection 
against  oxidative  stress.  When  this  primary  defence  is  overcome,  the  HO-1 
pathway  is  activated  and  becomes  a  potent  detoxifying  system  (Clark  et  al. 
2000a;  Foresti  and  Motterlini,  1999).  Failure  of  HO-1  to  be  induced  results  in
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inadequate  cellular defence  leading  to  cellular and  tissue  injury  (Yachie  et  al. 
1999).
Haem degradation is not specifically linked to HO.  Haem can be degraded both 
chemically  (coupled-oxidation)  and  enzymatically.  Both  mechanisms  require 
oxygen  (O2)  and  a  reducing  agent  needed  for  the  activation  of  O2  and  the 
reduction  of  the  haem  iron  from  ferric  (Fe3+)  to  ferrous  (Fe2+)  and/or 
maintenance  of  iron  in  the  Fe2+  state  (Atamna  &  Ginsburg  1995).  The  HO 
system  uses  nicotinamide  adenine  dinucleotide  phosphate  (NADPH)  as  a 
reducing  agent.  NADPH  activates  O2  by  the  donation  of  an  electron  thus 
initiating the multistep cleavage of the a,  p, y, and 5 methene carbon bridges of 
haem.  In  the  mammalian  HO  system  only  the  a-methene  carbon  bridge  is 
cleaved  to form  CO  and  biliverdin.  Other minor pathways  of haem  breakdown 
include;  xanthine  oxidase  and  hydrogen  peroxide  (H2O2)  plus  NADPH- 
cytochrome P450 reductase (Lincoln, Aw, & Bonkovsky 1989;  Balia et al.  1991). 
However,  in these instances a mixture of pyrollic compounds and not biliverdin 
or CO are formed (Maines 1997; Koehler & Traystman 2002).
Vital  for the functioning  of HO  is the  microsomal  enzyme  NADPH-cytochrome 
P450  reductase.  It  transfers  an  electron  from  NADPH  to  haem  and  utilises 
oxygen for the  cleavage  of haem  (Wang  & de  Montellano  2003).  Haem  is,  as 
mentioned  previously,  specifically  cleaved  at the  a-methene  bridge.  For  each 
molecule  of  haem  oxidized  three  molecules  of  O2  and  three  molecules  of 
NADPH are used.  For each  mole of O2 used in the reaction one mole of water 
(H2O) is produced making HO a mixed-function oxidase (Maines 1997).
It is interesting to note that HO-1  and HO-2 are products of two different genes, 
share  little  amino  acid  or  nucleotide  sequence  and  have  little  in  common  in
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terms of amino acid composition, transcript number or size (Wilks 2002; Weng 
et al.  2003).  HO-1  is the smaller of the two with a molecular weight of -32 kDa, 
whilst  HO-2  is about 36  kDa  in size.  As well  as differing  in  gene organisation, 
structure and  chromosomal  localization  both  HO-1  and  HO-2 vary  in  cell  type, 
tissue distribution  and  regulation (Parfenova et al.  2001;  Weng,  Yang, Weis,  & 
Dennery  2003).  But  it  is  the  similarity  in  their  mechanism  of  haem  catalysis, 
substrate  specificity  and  cofactor/coenzyme  requirements  that  groups  them. 
HO-1  and  HO-2  are  both  single  copy  genes;  however,  HO-1  protein 
transcription requires only a single -1.8 kb message, whereas HO-2 requires 2 
or more transcripts (Zou et al. 2000; Scapagnini et al. 2002). These various HO- 
2  transcripts  have  been  shown  to  arise  from  the  usage  of  three  different  5’ 
untranslated  regions  (UTRs)  and two different poly A signals with  as  many  as 
five different transcripts being identified in the rat testes.
Interestingly,  both  HO-1  and  HO-2  have  been  evolutionarily conserved  in  both 
primary  amino  acid  and  nucleotide  sequences.  This  is  best  displayed  by  an 
>80% homology for HO-1  in rat,  mouse and human whilst HO-2 cDNA showed 
over 90% conservation between rat, rabbit and human. There exists in both HO- 
1   and  HO-2  a  24  amino  acid  long  segment that  is  perfectly  conserved  in  rat, 
rabbit and  human with the only exception  being a conservative substation of a 
leucine residue found in all  HO-1  proteins for a methionine residue found  in all 
HO-2  proteins.  The  flanking  regions  also  display  substantial  amino  acid 
sequence  and  structure  similarity  in  both  isoforms.  The  24  residue  segment 
itself is  hydrophobic and forms  a  haem  pocket that  binds  haem  pyrrole  ring  1 
and  2   containing  a  vinyl  side  chain  through  electrostatic  interactions,  allowing 
isomer specific attack of the activated O2 on the a-methene carbon bridge. The
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consensus  sequence  Leu-Leu-Val-Ala-His-Ala-Tyr-Thr-Arg  is  highly  conserved 
throughout nearly all species and is recognised as the signature of HO (Maines 
1997;  Wilks 2002).  In  HO-1,  the  histidine  residue  132  is  absolutely  necessary 
for haem catalysis (Chu et al.  1999).  The  HO haem  pocket only has specificity 
towards  the  side  chains  of the  porphyrin  ring,  thus  it  does  not  recognize  the 
metal  moiety  of  the  metalloporphyrins  and  hence  non  physiological 
metalloporphyrins such as zinc protoporphyrin  (Zn-PP),  tin  protoporphyrin  (Sn- 
PP)  and  others  can  compete  with  iron  protoporphyrin  (Fe-PP)  and  inhibit 
enzyme activity (Appleton et al.  1999).  A facet which has been exploited to the 
fullest  in  studies  determining  the  functioning  and  role  of  the  HO  pathway 
(Labbe, Vreman, & Stevenson 1999; Mancuso et al.  1999).
Differences in the regulation of both genes stem from the promoter regions. The 
promoter  region  of  HO-1  has  many  regulatory  elements  containing  the 
consensus sequences necessary for binding several regulatory factors such as; 
heat shock protein (hsp),  activating protein-1  (AP-1),  nuclear factor-xB (NF-kB), 
Nrf2 and metal regulatory elements (Alam,  Camhi, & Choi 1995). Whereas, only 
a  single  glucocorticoid  response  element  (GRE)  is  present  and  functioning  in 
the  HO-2 gene.  GRE  is not a strong transcriptional  promoter and  Gcs exerts a 
prominent  regulatory  effect  on  HO-2  expression  at  the  protein  level  (Raju, 
McCoubrey, & Maines 1997).
HO-1  gene  structure  and  regulation  differ  from  that  of  other  stress  proteins. 
Unlike  other  HSP’s  HO-1  has  four  introns  which  are  presumed  not  to  be 
required  for  rapid  transcriptional  activation  (Immenschuh  et  al.  1998).  HO-1 
induction  by  heat stress  is  a  common  and  coordinated  response  in  organs  of
- Page 6 -INTRODUCTION
different species, reaching its peak after about  1  h in the heart,  liver,  kidney and 
brain again differentiating it from other HSP’s.
An  increase  in  HO-1  messenger  ribonucleic  acid  (mRNA)  transcription  is 
accompanied  by  an  increase  in  the  binding  of  heat-shock  nuclear  factor(s) 
(HSF) to the promoter region of the gene and involves message stabilisation as 
a major factor in the accumulation of the ~1.8 kb transcript.  Metals on the other 
hand,  increase  HO-1  primarily  by  increasing  the  transcription  rate  (Maines  & 
Kappas 1976).
HO  activity  varies  greatly  among  tissues  with  the  highest  HO  activity  being 
found in the spleen, testes and brain (Oshiro et al. 1999; Xia, Cui, Zhang,  Shen, 
Wang,  Li, Chen, & Yu 2002).  Interestingly, the spleen is the only organ in which 
HO-1  is the predominantly expressed isozyme under normal conditions (Maines 
1997).  HO-2  is  expressed  in  neuronal  populations  in  the  forebrain, 
hippocampus,  midbrain,  basal  ganglia,  thalamic  regions,  cerebellum  and  brain 
stem  (Yamanaka  et  al.  1996;  Scapagnini,  DAgata,  Calabrese,  Pascale, 
Colombrita, Alkon,  & Cavallaro 2002). Throughout the brain many neurons that 
express  HO-2  also express high  sGC  and  cyclic guanosine 5'-monophosphate 
(cGMP);  for  instance,  the  purkinje  neurons  of the  cerebellum,  which  normally 
don’t  express  NOS,  display  high  levels  of  cGMP  (Baranano  &  Snyder 2001). 
Such  high  levels  of  HO  expression  and  the  lack  of  NO  in  certain  neurons 
suggest that CO is a major signaling molecule in the hippocampus (Baranano & 
Snyder 2001).  The  hippocampal  complex  is  a  region  of the  brain  involved  in 
learning and memory and  is an integral pathway for carrying impulses from the 
neocortex  through  dentate  gyrus  to  other  brain  regions.  Interestingly, 
pathophysiological  changes  in  this  region  have  been  linked  to  various
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neurological  diseases  and  age  related  dysfunction  (Scapagnini,  D'Agata, 
Calabrese, Pascale, Colombrita, Alkon, & Cavallaro 2002).
Adrenal  steroid  HO-2 expression in the development stage of growth has been 
shown  to  be  intimately  linked  with  neurons  involved  in  motor  function  and 
cognition,  thus demonstrating  a pivotal  role of adrenal  steroids in  brain  growth 
and differentiation (Maines 1997).
HO-1  and  HO-2 have been shown to play an important role in the reproductive 
system as well (Mancuso et al.  1997a).  Both isoforms show a cell type-specific 
pattern  of  expression  as  well  as  a  developmentally  linked  expression  of five 
different  HO-2  transcripts.  HO-2  has  been  shown  to  be  expressed  in  a  stage 
specific  manner  linking  it to  spermatogenesis,  possibly  providing  iron which  is 
essential for the process to take place.  It has also been implicated to play a part 
in  signal transduction  and cell cycle events  (Mancuso et al.  1997b;  McLean et 
al. 2000). The presence of both isozymes throughout the reproductive system is 
evidence in  itself of the role of HO  isozymes  in the control  of the  reproductive 
system function.
In  the  cardiovascular system,  HO-2  is  predominantly  expressed  under  normal 
conditions.  It is worth noting that under conditions of stress the increase in HO-1 
mRNA expression in the heart,  kidneys and vasculature is significant (Otterbein 
& Choi 2000; Morse & Choi 2002). HO-2 has been detected in blood vessel wall 
constituents (endothelial and smooth  muscle cells),  connective tissue elements 
(fibrocytes  and  fibroblasts),  visceral  smooth  muscle  cells,  mesothelial  cells  of 
serous  membranes,  select  epithelial  cell  populations,  carotid  body 
chemoreceptors and in the adventitial neurons of blood vessels (Siow,  Sato,  & 
Mann  1999).  The  arterioventricular  (AV)  node  of  the  heart  and  myocytes
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expresses particularly high levels of HO-1  when stressed.  CO generated by HO 
activity in the heart has been suggested to regulate cGMP production (Duckers 
et al. 2001;  Liu,  Song,  & Lee 2001).  Interestingly,  oxidative stress of the kidney 
(ischemia) is translated into a prominent and sustained increase in HO-1  mRNA 
and  protein  expression  in  the  heart  and  aorta,  suggesting  an  intimate  link 
between these organs (Maines & Kappas 1976).  It is also important to note the 
absence of  HO-2 from  striated  muscle  and  that  it appears  to  be  coexpressed 
with  NOS  in  vascular  endothelial  cells  and  in  certain  parasympathetic  and 
sensory ganglia nerve cells (Maines 1997).
As with  the  brain  and  testes,  the  liver displays  developmentally  regulated  HO 
expression  (Maines  1990).  However,  the  total  HO  activity  decreases  as  the 
newborn matures. This is due to an initial surge in HO-1, which rapidly declines 
during  maturity  and  is  superseded  by  a  gradual  increase  in  HO-2  levels. 
Regulation  of  both  HO-1  and  HO-2  were  first  compared  in  the  liver  and  it  is 
known that HO activity due to the induction of HO-1  can be increased up to 100 
fold  in  the  presence  of  oxidative  stress  inducing  compounds  without  a 
concomitant increase in HO-2 (Maines  1997).  CO,  meanwhile has been shown 
to  function  as  an  endogenous  modulator  of  vascular  perfusion  in  the  liver 
suggesting  that  the  huge  increase  in  HO-1  when  exposed  to  oxidative  stress 
inducing  compounds  may  be  a  pathophysiological  factor  in  liver  disease 
(Suematsu, Wakabayashi, & Ishimura 1996b).
The  sources  of  haem  for  HO  mediated  degradation  are  plentiful:  cytochrome 
and  tissue  haemoproteins;  hemoglobin;  myoglobin  or  newly  synthesized  free 
haem  (prior  to  apoprotein  incorporation).  But  why  does  the  haem  molecule 
become available for haem degradation? We must consider a number of factor
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to  understand  the  answer:  i)  all  tissues  synthesise  haem  and  part  of  newly 
synthesized haem  is readily degraded by HO (Maines & Kappas  1976;  Maines 
1980);  ii) under conditions of stress, non-HSP synthesis is all but halted leading 
to  a  decreased  demand  for  haem  and  thus  more  availability of free  haem  for 
degradation;  iii)  cellular  membranes  being  susceptible  to  damage  by  free 
radicals  and  changes  in  redox  potential  in  the  vasculature  allow  access  to 
circulating hemoglobin (Maines,  Chung,  & Kutty 1982;  Maines et al.  1993);  and 
iv) haemoproteins are often denatured by free radicals (Maines & Kappas 1975; 
Trakshel,  Sluss,  & Maines 1992).  Examples of such denatured proteins include 
cytochrome P420, myoglobin and cytochrome c haem. With so many sources of 
haem  for  HO  activity  under  normal  unstressed  conditions,  HO-2  is  likely  to 
utilize free  haem  and  haem  of cellular haemoproteins.  While during  conditions 
of  stress  HO-1  may find  haem  from  additional  sources  that  affect the  rate  of 
haemoprotein  denaturation  e.g.  cytochrome  P450  to  P420  conversion, 
hemoglobin,  myoglobin  denaturation,  causing  an  availability  of  extracellular 
haem for degradation.
As such,  HO-1  may serve as a primary line of defence in the cellular scenario. 
Its  activation  and  subsequent  degradation  of  the  prooxidant  haem  molecule 
result in the generation of the antioxidant bile pigments and CO.  In addition the 
iron released would induce ferritin synthesis, the iron storage protein; iron being 
an  effective  catalyst  for  lipid  peroxidation  (Eisenstein  et  al.  1991).  The 
haemoprotein  NOS  would  be  subject  to  all  the  factors  effecting  other 
haemoproteins  stability,  synthesis  and  turnover.  Thus,  stress-induced  CO 
production could overcome the attenuated  ability of the cell  to generate cGMP 
as NO production is decreased thus playing a role in cellular defence, therefore,
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HO-2,  could function in the maintenance of basal cGMP production alone or in 
conjunction with NOS depending on the cell type and tissue.
The  similarity  between the  HO  system  and  NOS  pathway  is  undeniable.  Both 
HO  and  NOS  enzymes  have  been  clarified  in  a  constitutive  and  an  inducible 
form,  the  inducible  form  of  each  responding  to  very  similar  inducers  e.g. 
bacterial  endotoxins,  cytokines  and  reactive  oxygen  intermediates.  Both 
inducible  forms  are  also  present  and  active  in  many  organs  and  tissues  and 
their  induction  involves  gene  activation  and  de  novo  protein  synthesis. 
Interestingly,  Gcs  has an  opposing  effect on  expression  of the two  proteins  in 
the  brain  with  HO  increased  and  NOS  decreased.  Both  HO-1  and  iNOS  are 
however  highly  upregulated  in  cells  involved  in  the  resolution  of  inflammation 
e.g.  macrophages,  neutrophils,  polymorphonuclear and mononuclear cells. The 
similarities between NO and CO suggest a possible sharing in the control of the 
relaxation processes (Foresti and Motterlini,  1999).
An X-ray crystal  structure  of human  HO-1  in  complex with  its  substrate  haem 
can  be  seen  in  Figure  1.2.  Interestingly,  a  direct  link between  HO-1  induction 
and  NO  has  been  demonstrated.  Indeed,  NO  has  been  shown  to  up-regulate 
the expression of HO-1  in a variety of tissues and cells (Foresti  and  Motterlini, 
1999;  Motterlini  et al.  2000;  Sammut et al.  1998;  Foresti  et al.  1999;  Vesely et 
al.  1998;  Clark et al.  1997;  Foresti et al.  1997; Motterlini et al.  1996; Motterlini et 
al.  1996)  (Sawle  et  al.  2001).  The  range  of  NO  releasing  agents  capable  of 
stimulating  HO-1  induction  is  vast,  including  chemicals  such  as  sodium 
nitroprusside  (SNP)  and  S-nitroso-N-acetylpenicillamine  (SNAP).  Furthermore, 
the  level of HO-1  induction appears to be directly related to the decomposition 
rate of the NO donor.
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Figure  1.2:-  X-ray  crystal  structure  of  human  HO-1  in  complex  with  its 
substrate haem captured via X-ray diffraction.
The  figure  was  rendered  using  Protein  Data  Bank  3DB  Browser,  which  is 
available on line at http://pdb-browsers.ebi.ac.uk/pdb-bin/pdbmain.
As  eluded  to  earlier,  HO-1  itself  is  not  a  cytoprotective  molecule  but  the 
products  it generates  from  haem  degradation  are.  The  activation  of the  HO-1 
pathway  results  in  the  production  of  the  powerful  antioxidants  biliverdin  and 
bilirubin  (Clark  et  al.  2000a;  Clark  et  al.  2000b;  Foresti  et  al.  1999)  and  the 
vasoactive CO (Sammut et al.  1998; Motterlini et al.  1998).
The physiological need for this pathway is highlighted by the numerous inducers 
of HO-1  known to date and the sensitivity of the pathway to a diversity of stimuli. 
Such a system allows for a rapid up-regulation of cellular defences in response 
to a threatening situation, such as the presence of a strong oxidant.
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Haem  serves  as  a vital  cofactor for proteins  involved  in  oxygen  transport  and 
storage (haemoglobin,  myoglobin) and  in enzymes essential for critical  cellular 
processes such as respiration,  inflammation or drug metabolism.  Haemoprotein 
turnover  leads to the  production  of CO  as  a consequence  of haem  utilisation. 
Conversely,  the  physiological  effects  of  CO  depend  on  its  ability  to  form 
complexes with the haem moieties of cellular haemoproteins.
Let  us  now  consider  the  biological  activities  of  two  products  of  HO  activity; 
bilirubin and iron.
1.2  Bilirubin
Bilirubin is a lipophilic linear tetrapyrrole abundant in blood plasma which occurs 
uniquely in mammals (see Figure 1.3) (Baranano et al. 2002a).  Bilirubin is best 
known  as  a  yellow  pigment  contained  in  bile,  which  is  released  from  the 
gallbladder into the duodenum to aid digestion.  Hipocratic medicine considered 
yellow bile as one of the four bodily fluids or humors that promoted health when 
in balance and illness when not. An excess of yellow bile was believed to make 
one  choleric  (easily  irritated;  irascible,  inclined  to  anger),  whilst,  in  China 
bilirubin has long been used in traditional  Chinese medicines (Niu  Huang) as a 
potent fat  soluble  antioxidant  (McDonagh  2001).  It was  not  until  the  middle  of 
the last century that the chemical structure was determined and the synthesis of 
bilirubin  achieved.  Hans  Fisher,  a  German  chemist,  was  awarded  the  Noble 
Prize for his work on the bilirubin precursor haem. The difficulty to work with and 
obtain  a  pure  yield  as  well  as  the  inherent  instability  of  both  biliverdin  and 
bilirubin compared to haem,  meant it was not until recently that scientists began 
to study them in any real depth.
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Figure 1.3:- The linear, tetrapyrrole chemical structure of bilirubin.
Bilirubin  formation  is  catalysed  by  biliverdin  reductase  (BVR)  (Salim,  Brown- 
Kipphut,  & Maines 2001).  BVR is coexpressed in cells that display HO-1  and/or 
HO-2 under normal conditions as well as in regions and cell types that have the 
potential to express heat shock inducible HO-1.  Bilirubin, a bile pigment and the 
reduced form  of biliverdin,  is  an  important  product of haem  degradation.  Both 
bilirubin  and  biliverdin  are  produced  in  adults  at  the  rate  of  ~0.25g  per  day 
(McDonagh  2001).  The  pathway  is  vital  for the  homeostasis  of haem,  for the 
biosynthesis of plant and algal pigments, and in animals it appears to play a key 
role  in  oxidative  stress  defence  (Greenberg  2002;  Baranano,  Rao,  Ferris,  & 
Snyder 2002a).
The reason for the production of bilirubin in mammals is intriguing. Why convert 
biliverdin  IXa,  a  non-toxic,  easily  excretable  waste  product  into  bilirubin,  a 
substance that is less water soluble, neurotoxic,  seeds gallstones and has to be 
further  metabolised  for disposal? Although  there  is  not  a  definitive  answer as 
yet,  emerging  evidence  suggests  that  bilirubin  is  a  potent  regeneratable  lipid- 
soluble antioxidant which  protects against free radical  and oxy-radical  damage 
both  systemically  and  at  local  sites  of  injury in  vivo  (Galbraith  1999;  Ryter &
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Tyrrell 2000;  Clark et al.  2000c;  McDonagh 2001).  Bilirubin has been shown to 
possess several biological activities:  antioxidant, antimutagen,  anti-complement 
and  cytoprotector  (Clark  et  al.  2000a;  Clark,  Foresti,  Sarathchandra,  Kaur, 
Green,  &  Motterlini  2000c).  In fact,  bilirubin,  is the  most  powerful  endogenous 
antioxidant known in vitro and is also a potent physiological antioxidant in vivo. 
The antioxidant properties of bilirubin have been associated with a reduced risk 
of coronary artery disease  (CAD)  in  individuals with  a  mildly  increased  serum 
bilirubin  level  (Hopkins  et  al.  1996;  Mayer  2000).  The  extent  of this  effect  is 
comparable  to  that  of  HDL-cholesterol.  Interestingly,  individuals  who  smoke 
significantly lower their serum  bilirubin level and attenuate the protective effect 
of the antioxidant (Van Hoydonck, Temme, & Schouten 2001).
It has been suggested by Dennery et al that neonatal  hyperbilirubinemia could 
be a transitional  antioxidative mechanism  in the circulation of human neonates 
(Dennery  et  al.  1995).  The  authors  showed  thiol  barbituric  acid  reactive 
substances  (TBARS)  in  Gunn  rats  exposed  to  hyperoxia  were  significantly 
decreased  in  jaundice  pups,  while,  other  serum  antioxidants  (catalase, 
glutathione  (GSH),  vitamins  A,  C,  E  and  uric  acid)  remained  the  same  in 
jaundice and non-jaundice groups.
Bilirubin and the bilirubin-albumin complex present in serum  are scavengers of 
O2' and peroxyl radical, their potency increasing with decreasing pH. The ability 
of  bilirubin  to  scavenge  peroxyl  radicals  is  much  higher  than  that  of  serum 
albumin and of the same order as the bilirubin-albumin complex found in serum. 
Studies  have  also  demonstrated  that  free  and  albumin  bound  bilirubin  are 
efficient  co-antioxidants  for  a-tocopherol  (Young  &  Caughey  1986;  Day  et  al. 
1999).  For  example,  the  antioxidant  activity  of  bilirubin  on  oxidation  of  low-
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density  lipoprotein  (LDL)  is  mediated  by  interaction  of  the  bile  pigment  with 
LDL’s  a-tocopherol.  It  has  also  been  demonstrated  that  bilirubin  protects  its 
carrier  protein,  serum  albumin,  from  oxidative  damage  exerted  by  hydroxyl 
(OH*)  radicals (Adhikari  &  Gopinathan  1996).  Along with  ascorbate  and  urate, 
bilirubin is a very important antioxidant in plasma rivalling vitamin E in lipophilic 
microenvironments  e.g.  lipoproteins,  membranes.  It  has  also  been  speculated 
that  bilirubin  may  be  an  important  cytoprotector  for  tissues  which  are  less 
equipped for antioxidant defence like myocardium and nervous tissue (Otterbein
6 Choi 2000; Baranano & Snyder 2001).
Interestingly,  bilirubin  has been shown to  possess  antimutagenic properties by 
inhibiting  the  direct  acting  mutagenicity  of  4-nitriquinoline-1-oxide  (4NQO)  in 
strain TA100 of salmonella typhimurium (Camoirano et al.  1994).  Biliverdin also 
possesses  this  ability  but  to  a  lesser  extent  due  to  bilirubin’s  greater 
nucleophilicity. While conjugated bilirubin and biliverdin show an inhibitory effect 
on complement dependent reactions in vitro blocking the complement cascade, 
especially at the  C1  step  (Nakagami,  Toyomura,  Kinoshita,  &  Morisawa  1993; 
Arriaga, Mottino, & Almara 1999).
Were  conversion  of haem  to  biliverdin  solely a  route for disposal  of metabolic 
waste,  as  once  thought,  it  would  hardly  matter  which  particular  isomer  is 
produced  since  all  are  easily  excreted.  However,  only  one  of  the  four,  the 
isomer IXa, generates a lipophilic rubin on reduction and the same isomer is the 
only one that can  serve  as  a  biosynthetic precursor for the  phytochromobilins 
and phycobilins of plants,  algae,  and cyanobacteria (McDonagh 2001).  Thus,  it 
is hardly surprising that HO cleaves the haem with such high regiospecificity for
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the  a-methene  carbon  bridge.  Nevertheless,  very  small  amounts  of the  other 
three isomers, particularly IXp, are produced in humans and other mammals.
As  mentioned,  bilirubin  is  potentially  neurotoxic.  When  hepatic  bilirubin 
glucuronosyl transferase activity is low or absent,  as in newborn babies or rare 
genetic disorders, the pigment accumulates in the circulation bound to albumin. 
If the  albumin  binding  capacity  is  compromised,  excess  bilirubin  may  partition 
into  the  brain  and  cause  irreversible  damage  or  even  death.  Each  year 
countless  thousands  of  babies  are  treated  for  hyperbilirubinemia  and  an 
unfortunate few die or are  left permanently  injured  (Baranano  & Snyder 2001; 
Greenberg 2002).  Conversley a neuroprotective role for bilirubin has also been 
demonstrated.  Dore  et  al  showed  that  H2O2  toxicity  was  increased  in 
hippocampal  neuron  cultures  from  HO-2  knockout  mice  (Dore,  Takahashi, 
Ferris,  Hester,  Guastella,  &  Snyder  1999).  Upon  addition  of free  bilirubin  or 
albumin-bilirubin  conjugate  there  was  an  improvement  in  survival.  They  also 
showed that after focal  cerebral  ischemia,  induced  by occlusion  of the  middle 
cerebral  artery  followed  by  repurfusion  or  intracerebral  injection  of  the 
excitotoxic amino acid N-methyl-D-aspartate, injury was more extensive in HO-2 
knockout mice than  in wild type  mice,  which  is  consistent with  a  role  of HO-2 
products  in  protection  from  ischemia  (Dore,  Takahashi,  Ferris,  Hester, 
Guastella, & Snyder 1999).
Bilirubin  is  responsible  for the  yellow  discolouration  of the  skin  in jaundice  in 
newborns  (Stevenson  et  al.  2001;  Baranano,  Rao,  Ferris,  &  Snyder  2002a). 
Erythroblastosis  fetalis,  a  condtion  which  usually  occurs  from  Rhesus  (Rh) 
blood  group  incompatibility  between  mother  and  neonate,  results  in  the 
accumulation  of  bilirubin  due  to  antibody  induced  hemolysis  with  the
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subsequent degradation  of free haem to  bilirubin  (Mukhopadhyay et al.  2003). 
Treatment  involves  phototherapy  and  an  exchange  transfusion  to  prevent 
kernicterus  in  which  high  concentrations  of  bilirubin  gain  access  to  the  basal 
ganglia and other brain structures resulting  in  lethargy,  rigidity,  seizures,  death 
and  in  long  term  survivors,  choreothetosis,  hearing  loss  and  Parinaud’s 
syndrome (paralysis of upward gaze).  Hepatocellular disorders and extrahepatic 
biliary obstruction can also result in jaundice where excess bilirubin in the blood 
becomes deposited  in elastin  rich tissues such  as skin  and  sclera  (Greenberg 
2002).
Classically  bilirubin  is  seen  at  sites  of  recent  bleeding,  such  as  haematomas 
under the  skin -  commonly  known  as  bruising  (seeFigure  1 .4)  (Beschorner et 
al.  2000).  Yellow  colouration  of  cerebrospinal  fluid  is  also  a  sign  of 
subarachnoid haemorrhage.
Bilirubin  has  been  shown  to  be  an  antioxidant  capable  of scavenging  peroxyl 
radicals  and  has  been  reported  to  protect  against  a  variety  of  pathological 
processes  including complement-mediated anaphylaxis  (Nakagami,  Toyomura, 
Kinoshita,  & Morisawa  1993),  myocardial  ischemia (Marilena  1997),  pulmonary 
fibrosis (Choi & Alam 1996) and cyclosporine nephrotoxicity (Polte et al. 2002). 
Kernicterus  pathophysiology exemplifies the toxicity of bilirubin.  This toxicity  is 
achieved at micromolar concentrations,  causing death of cultured  neurons and 
cerebral microvascular endothelial cells in vitro, which has features of apoptotic 
cell  death.  Specific  glutamate  receptors  have  been  implicated  in  the 
pathogenesis  of  bilirubin  toxicity  as  N-methyl-D-aspartate  (NMDA)  receptor 
antagonists can protect neurons from its toxicity (McDonald et al. 1998).
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Figure 1.4:- Resolution of a sub-dermal haematoma.
Initial colouration is due to the presence of blood in the wound.  As the haem  is 
degraded  we  can  see  the  greenish  hue  of  biliverdin  and  finally  the  yellow 
pigmentation associated with bilirubin.
Takahashi  et  al  identified  proteins  that  interact  with  HO-2  (Takahashi  et  al. 
2000b). They found one such protein,  amyloid precursor protein (APP), which is 
the source of p-amyloid  in Alzheimer’s disease and  is mutated in some familial 
forms  of  the  disorder.  Interaction  of  wild  type  APP  with  HO-2  inhibited  the 
activity  of  HO-2  suggesting  an  intriguing  connection  between  HO-2  and 
Alzheimer’s disease. Moreover, cortical neuron cultures expressing the Swedish 
mutation showed  bilirubin production defects and  enhanced toxicity from  H202, 
suggesting  that  HO  may  help  to  regulate  the  oxidative  injury  in  Alzheimer’s 
which  is one way that haem deficiency could impact the disease (Takahashi  et 
al. 2000a).
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It  is  interesting to consider that,  the  concentrations of bilirubin  present  in  cells 
are  in  the  order  of  nanomolar  concentrations  compared  to  the  high 
concentrations of oxidants which locally may reach micromolar levels.  It would, 
therefore,  seem  a  mechanism  that  amplifies  the  antioxidant  effect  of the  bile 
pigment is required.  Baranano has proposed a redox cycling  process whereby 
bilirubin  interaction  with  the  ROS  species  results  in  its  oxidation  back  to 
biliverdin  which  is  subsequently  reduced  back  to  bilirubin  by  BVR,  thus 
multiplying  the  antioxidant  effect  of  bilirubin.  This  would  mean  ROS  promote 
biliverdin synthesis,  while,  depletion of BVR would  increase levels of ROS and 
their toxic effects,  both of which were confirmed  by Baranano (Baranano,  Rao, 
Ferris, & Snyder 2002a).
Baranano et al have also shown that as little as 10 nM bilirubin protects against 
almost  1 0 ,0 0 0  fold higher concentrations of H2O2 indicating that bilirubin cannot 
be acting simply as a stoichiometric antioxidant against H2O2. As such,  bilirubin 
acts  in  a  catalytic  fashion  whereby  bilirubin  oxidised  to  biliverdin  is  rapidly 
reduced  back  to  bilirubin  a  process  that  could  readily  afford  1 0 ,0 0 0   fold 
amplification. Thus,  a redox cycle based on BVR activity provides physiological 
cytoprotection  as  BVR  depletion  exacerbates  the  formation  of  ROS  and 
augments cell death (Baranano, Rao, Ferris, & Snyder 2002a).
Cells  depleted  of GSH  or  BVR  indicate that  BVR  is  of comparable  or greater 
importance than  GSH  in  physiological  cytoprotection.  Several  parallels  can  be 
drawn between the bilirubin redox cycle and the cycling of GSH,  another chain 
breaking  antioxidant.  Both  involve  a  single  chemical  that  exists  as  either  an 
oxidised or reduced form,  in both cases the  reduced form  predominates  under 
healthy conditions.  Both are also part of a concerted stress response,  including
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heat shock proteins, that are induced when cells are challenged with a stressful 
insult.  Disruption  to  either the  BR/BV  or  GSH  cycle  results  in  an  increase  in 
oxidative stress and consequently cell death.  However, while bilirubin levels are 
well  below  100  nM,  GSH  concentrations  are  in  the  millimolar  range. 
Interestingly  though,  the  abundance  of  BVR  activity  in  all  tissues  indicates 
bilirubin cycles at a much higher rate than GSH. There are also,  however,  some 
major  differences  between  the  two  cycles.  For  instance,  biliverdin  is  oxidised 
directly to bilirubin unlike GSH which requires the presence of a peroxidase,  a 
reductase  and  distinct  enzymes  for  synthesising  it.  Conceivably,  bilirubin  and 
GSH provide physiological antioxidant activities for distinct types of intracellular 
molecules.  Bilirubin,  which  is  highly  lipophilic,  is intimately associated with cell 
membranes  where  it  might  prevent  lipid  peroxidation  and  protect  membrane 
proteins from oxidative damage. On the other hand, GSH is highly water-soluble 
and  might  be  expected  to  protect  cytoplasmic  constituents  (Baranano,  Rao, 
Ferris, & Snyder 2002a).
Biliverdin reductases  are  unusual,  possibly unique,  in their ability to  use either 
NADPH  or NADH  as  cofactors,  with  a different pH  optimum for each  cofactor. 
They catalyse regiospecific reduction of just one of some fifteen  double  bonds 
in the biliverdin substrate and they are selective for particular biliverdin isomers. 
The  location  of the  propionate  side  chains  of biliverdin  being  key to  turning  it 
into bilirubin (Baranano, Rao, Ferris, & Snyder 2002a).
BVR  may  also  have  a  special  use  in  the  placenta  of  mammals.  In  adults, 
bilirubin  IXa  has  to  be  converted  to  more  polar  glucuronide  conjugates  by 
bilirubin  glucuronosyl  transferase  or  to  photoisomers  for  excretion  by  the 
hepatobiliary  system.  In  the foetus,  the  activity  of glucuronosyl  transferase  is
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low.  Since  neither  biliverdin  nor  bilirubin  glucuronides  cross  the  placenta  as 
readily as  the  much  more  lipophilic bilirubin,  reduction  of  biliverdin  to  bilirubin 
facilitates  the  disposal  of  haem  derived  pigment  across  the  placenta  and 
prevents their accumulation in the foetus.  High proportions of bilirubin IXp (up to 
87% of total bilirubin) occur in foetal bile (Blumenthal et al.  1980). This has been 
taken  as  evidence  that  haem  catabolism  in  utero  is  different  and  less 
regiospecific than adults.  However,  it has been suggested that the IXp isomer in 
foetal  bile  represents  a tiny fraction  of the total  haem  catabolised  and that  its 
relatively high concentration is simply a consequence of the different placental 
permeabilities of the IXp and IXa isomers.
Continuing with  the  products of haem  catabolism we  now  consider iron,  while 
CO will be discussed later in the Introduction.
1.3  Iron
Iron  is  vital  for  all  living  organisms;  however,  excess  iron  can  be  lethal  as  it 
facilitates free radical formation. A newborn infant has a total body iron of about 
250  mg.  During  growth  iron  absorption  must exceed  iron  loss  by ~0.5  mg  per 
day in order to maintain a body iron concentration of about 60 parts per million. 
An adult male (70 kg) has a total body iron of about 4 g which remains constant 
throughout adult life (Conrad & Umbreit 2002). Thus,  iron absorption is carefully 
regulated to maintain an equilibrium  between absorption and body loss of iron. 
Much of the body iron is derived from dietary haem since haem binds few of the 
dietary  chelators  that  bind  inorganic  iron  in  the  gut.  This  is  especially  true  in 
countries where meat is a significant part of the diet.  The iron present in haem 
is  released  by  HO  to  enter  plasma  as  inorganic  iron.  Ferric  iron  is  then
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absorbed  via  a  P3  integrin  and  mobilferrin  pathway  (IMP).  The  association  of 
IMP with divalent metal transport-1  (DMT-1)  in the cytoplasm produces a large 
protein complex called paraferritin which serves as a ferrireductase.  Paraferritin 
solubilises  iron  binding  proteins  and  reduces  iron  to  make  iron  available  for 
production of iron containing proteins such as haem (Conrad & Umbreit 2002). 
Too little absorption or too great a loss of iron results in iron depletion while too 
much  absorption  or  too  little  loss  results  in  hemosiderosis  and 
hemochromatosis.
It is interesting to note that human subjects conserve iron more efficiently than 
other  animals.  Typical  examples  of  iron  loss  from  the  body  include: 
haemorrhage,  desquamated  epithelium  of  skin,  intestinal  cells,  and  intestinal 
secretions.  Tissue iron stores generally dictate the level of iron absorption, e.g. 
the  rate  of  erythropoiesis  and  hypoxia,  while  haemorrhage,  haemolysis  or 
hypoxia  accelerated  RBC  production  and  rapid  plasma  iron  turn-over  also 
increase iron absorption.  Diminished erythropoiesis, blood transfusion,  return to 
sea level from high altitude and starvation all decrease iron absorption.
It  has  been  demonstrated  by  numerous  laboratories  that vertebrates  possess 
an  anti-infective/anti-neoplastic  defence  system  which  has  been  termed  “iron 
withholding”.  Very  simply,  the  system  attempts  to  deny  availability  of  iron  to 
invading microbial and neoplastic cells while permitting normal host cells access 
to the metal (Weinberg 1992).  Both lactoferrin and transferrin,  two powerful iron 
binding  proteins,  are constitutive components of the system found  in all  bodily 
fluids  except  urine.  At  times  of  microbial  or  neoplastic  cell  invasion  these 
components  are  activated  by  the  release  of  inflammatory  cytokines  such  as 
interleukin-1  (IL-1),  IL-6  and  tumour  necrosis  factor-a  (TNF-a).  The  defensive
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response includes:  i) suppression of intestinal assimilation of iron, ii) retention of 
iron  by  macrophages  that  have  digested  haemoglobin  from  decaying 
erythrocytes,  iii) synthesis of ferritin to permit enhanced  intracellular storage of 
the  metal,  iv)  mobilisation  of  neutrophils  to  sites  of  invasion  of  extracellular 
bacteria  with  release  of  the  contents  of  cytoplasmic  granules  that  contain 
apolactoferrin,  v)  scavenging  of  iron  at  invasion  sites  by  apolactoferrin  and 
acquisition  of  the  ferrated  proteins  by  macrophages,  and  vi)  synthesis  of 
immunoglobulins  against  protein  components  of  microbial  uptake  systems 
(Weinberg  1992).  This system  is highly effective against extracellular microbial 
pathogens  but  less  useful  in  combating  bacteria,  fungi  and  protozoa  that  act 
intracellularly.  However,  additional  methods of iron modulation and metabolism 
exist to  counteract  this further threat.  This  set  of  mechanisms  also  known  as 
“iron depletion” includes: i) the removal of non-haem iron from the invading cells 
and  from  infected  host  cells  via  the  use  of  reactive  nitrogen  intermediates 
derived from  nitric oxide  synthase,  which  destroy  iron-sulphur centres,  and  ii) 
the reduction in net uptake of iron into infected host cells via down-regulation of 
expression of transferrin receptors (TfRs) (Weinberg 1992).
HO-1  releases ferrous iron (Fe2+)during the catabolism of haem. The release of 
Fe2+ from  the  core  of the  haem  molecule  leads to the  rapid  expression  of the 
iron-sequestering  protein ferritin  as well  as  activating  an ATPase  pump  which 
actively removes  intracellular iron from the  cell.  The  extracellular iron  chelator 
desferoxamine mesylate (DFO) or the intracellular iron chelator salicylaldehyde 
isonicotinoyl  hydrazone  (SIH)  perform  some  of  the  iron-depleting  functions 
associated  with ferritin  (Otterbein et al.  2003b).  Ferritin  sometimes  appears  to 
subsume the role of HO-1  and other times  it does not.  Ferritin expression was
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originally reported to be the mechanism by which  HO-1  conferred resistance to 
oxidative  stress  in  endothelial  cells  (Friebe  et  al.  1998).  In  addition,  ferritin 
mediated  the  protection  seen  with  HO-1  induction  by  haem  in  a  model  of 
hyperoxic  lung  injury  (Taylor,  Carraway,  &  Piantadosi  1998).  In  contrast,  the 
potent cytoprotection provided by HO-1  induction in a model of endotoxic shock 
in  rats appeared to  be ferritin-independent as apoferritin and  iron  dosing were 
ineffective  at  conferring  protection  (Otterbein  et  al.  1997).  The ATPase  pump 
that  actively  removes  intracellular  iron  from  the  cell  contributes  to  decreasing 
the overall intracellular pool of Fe2+ and protecting the cells from apoptosis. The 
contribution  of  both  the  iron  pump  versus  ferritin  to  the  overall  cytoprotective 
effect  of  HO-1  is  unclear,  but  both  are  crucial  mechanisms  for  preventing 
oxidative  damage  in  a  variety  of  situations  in  which  HO-1  expression  is 
increased.
Iron is also present in the protoporphyrin ring of sGC, a molecule that facilitates 
many of the actions of HO.
1.4  Soluble Guanylate Cyclase
The  soluble form  of guanylate  cyclase,  sGC  is a  haemoprotein  (Maines  1997; 
Koesling  1999). The enzyme is a dimer of two similar but not identical peptides 
that bind two haems per dimer (see Figure 1.5).  It is known that the presence of 
the  tetrapyrrole  ring  is  required  for  the  catalytic  activity  of  sGC  and  there  is 
evidence to suggest that iron protoporphyrin (Fe-PP) is involved in the enzymes 
activity and binding of NO (Ignarro,  Barrot, & Wood 1984).
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Figure  1.5:-  Schematic  structure  of  soluble  guanylate  cyclase  showing 
known stimulators of the enzyme.
PPIX  =  protoporphyrin  IX.  Extract  from  Alexis  Biochemicals  Guanylyl 
cyclase/gaunosine phosphate metabolism web page.
CO  can  also  bind  to  the  haem  iron  activating  soluble  guanylate  cyclase, 
although  with  an  affinity  much  lower  compared  to  NO  (Friebe  et  al.  1996). 
However,  the  presence of YC-1,  a  benzylindazole derivative,  has  been  shown 
to  increase the affinity of sGC for CO,  in  vitro,  by 4000%  and there  exists the
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possibility of a biologically similar molecule present in nature (Friebe & Koesling 
1998;  Friebe, Mullershausen, Smolenski, Walter, Schultz, & Koesling 1998). 
Interaction of sGC with haem is thought to involve hydrophobic interactions with 
porphyrin  side  chains  much  the  same  as  HO  interaction  with  haem.  This 
ensures that various porphyrin complexes without a metal  chelate can activate 
the  enzyme  and  that  Zn-PP  an  Mg-PP  could  not  inhibit  its  activity  (Ignarro, 
Barrot,  & Wood  1984).  This haem pocket,  as described for HO,  does not have 
specificity for  the  chelated  metal  but  is  specific for  the  porphyrin  side  chains 
(Maines & Kappas 1977).  In the case of sGC, propionic acids on pyrrole rings 3 
and  4  are  required  for  its  activation,  referring  to  its  increase  in  Vm ax  for  the 
conversion  of  guanosine-5'-triphosphate  (GTP)  to  cGMP  (Ignarro,  Barrot,  & 
Wood 1984). Activation involving the interaction of a ligand with its haem moiety 
suggested  the  binding  of  CO  generated  by  HO  is  a  possibility,  which  was 
subsequently proven.  Further to this,  CO stimulation of cGMP production in cell 
and  tissue preparations  and  promotion  of cGMP-dependent activities  has  also 
been demonstrated (Brune & Ullrich 1988;  Utz & Ullrich  1991).  Studies showing 
HO-2 protein or transcripts colocalising with cGMP and/or sGC in cells in which 
NOS  is nearly absent are consistent with sGC activation by HO generated  CO 
(purkinje  neurons)  (Maines  1997;  Koesling  1999).  The  effect  of 
metalloporphyrins  on  both  HO  and  sGC  requires  that  they  are  used  in 
sufficiently low concentrations to discriminate between HO and sGC inhibitions. 
Obviously  HO  has  to  be  transcribed  before  it  can  act.  One  of  the  principal 
methods of transcription is via the mitogen activated protein kinases (MAPK).
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1.5  Mitogen Activated Protein Kinases
1.5.1  Overview of the Cascade
The MAPKs are a large family of proline-directed serine/threonine kinases that 
require  tyrosine  and  threonine  phosphorylation  of  a  ThrXTyr  motif  in  the 
activation  loop for activation  (Torres 2003).  Receptor ligand activation  leads to 
activation of a phosphorylation cascade where the minimal module is formed by 
MAPK, MAPK kinase (MAPKK) and MAPKK kinase (MAPKKK). MAPK and their 
activation cascades are critical pathways connecting extracellular ligands to the 
transcriptional  machinery.  MAPKs  have  been  shown  to  be  part  of  well 
conserved  signalling  pathways  that  control  proliferation,  differentiation, 
embryogenesis and cell death (Cobb & Goldsmith 1995; Torres 2003).
Four  separate  MAPK  and  activating  cascades  have  been  identified  in 
mammalian cells and are activated by separate kinase cascades. These are:  i) 
the classical extracellular signal regulated kinase (ERK, TEY) ERK1/2;  ii) the c- 
jun N-terminal kinase (JNK, TPY) JNK1/2/3; iii) the p38MAPKa/p/y/5 (TGY), the 
latter two families also being referred to as the stress activated protein kinases 
(SAPK)  and  iv)  ERK5  (TEY)  also  called  Big  MAPK/BMK1  because  of its  high 
molecular mass (Cobb & Goldsmith 1995; Torres 2003).
The  activation  step  of  MAPKs  are  very  specific  and  are  carried  out  by  dual 
specificity  kinases,  the  MAPKK,  which  are  themselves  activated  by 
phosphorylation  by MAPKKK.  Thus  MAPK are the terminal  kinases  of a  three 
tiered  module  of kinases that are  sequentially activated  by  a variety  of stimuli 
acting through diverse receptor families (Torres 2003).
ERK  was  the  first  mammalian  MAPK  to  be  identified.  It  is  a  42  kDa  protein 
which  increases  tyrosine  phosphorylation  upon  stimulation  with  mitogens,
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cytokines  and  ligands  for  G-protein  linked  receptors  hence  the  name  ERK to 
reflect  its  diversity  of  regulators.  All  of  the  components  of the  ERK  module, 
ERK1  or ERK2,  MEK1  or MEK2 and Raf isoforms,  have been known for over a 
decade although questions still remain relating to the function and regulation of 
each component. The ERK pathway mediates cellular responses to growth and 
differentiation factors including platelet derived growth factor,  epidermal  growth 
factor and IL-5 (Cobb & Goldsmith 1995; Torres 2003).
JNK  and  p38MAPK  are  primarily  activated  by  cellular  stresses  such  as 
inflammatory cytokines although they have also been shown to be regulated by 
UV and  y-irradiation.  Much  still  remains to  be  elucidated  about  JNK pathways 
but homologous recombination of JNK genes in mice has shown that,  although 
viable,  the  mice  are  defective  in  apoptotic  and  immune  responses.  A  double 
knockout mouse  model  of JNK1  and JNK2 resulted  in embryonic death.  Gene 
targeting  of  p38  resulted  in  various  outcomes  although  all  mice  died  during 
embryonic  development.  Two  MAPKK  have  been  identified  as  the  kinases 
phosphorylating  JNK  (MKK4  and  MKK7).  Studies  have  suggested  that  the 
cooperation of both MKK4 and MKK7 is required to activate JNK in response to 
environmental  stress.  In  contrast  only  MKK7  is  required  for TNK activation  of 
JNK (Cobb & Goldsmith 1995; Torres 2003).
The  p38MAPK are  activated  by the dual  specificity  kinases  MKK3  and  MKK6. 
Only  MMK3  is  required  for  TNF-a  induced  p38  activation  and  cytokine 
expression.
Both  JNK and  p38MAPKs  are activated  by stress  related  stimuli  such  as  heat 
shock,  inflammation,  hyperosmolarity,  UV and,  y-irradiation  (Cobb & Goldsmith 
1995; Torres 2003).
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Activation  of the  MAPKs  must  be terminated  at  a  precise  time for  proper cell 
function as the duration and extent of MAPK activation which is governed by the 
equilibrium  between  the  activity  of  kinases  and  MAPK  phosphatases  (MKP) 
may determine the biological outcome.
The  MAPKs play an  important role  in the  regulation  of gene expression  either 
by  directly  phosphorylating  transcription factors  or  by  activating  other  kinases 
with  transcription factors  as  substrates.  The consequences  of phosphorylation 
on the function of transcription factors are multiple;  i) it can regulate activation, 
DNA binding ability, and association with co-regulators; ii) it can regulate protein 
stability  by  preventing  ubiquitination  thus  prolonging  half-life;  and  iii)  it  can 
control the subcellular localization (see Figure 1.6) (Torres 2003).
The essential  role of ROS involvement in  bacterial  killing  has been extensively 
documented  in  the  literature.  This  ROS  involvement seems to  require tyrosine 
phosphorylation.  Stimulation  of  macrophages  with  zymosan  activated  serum 
results  in  an  increase  in  ROS  and  subsequent  ERK1/2  activation,  which 
requires the  presence of H2O2.  Other studies have shown that  ROS  produced 
by phagocytosis of fibres in rat alveolar macrophages induced activation of ERK 
and p38MAPK.
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Figure 1.6:- Schematic diagram of the MAPK signalling pathway.
Various  stimuli  such  as  stress  or  cytokines  activate  MKK  which  in  turn 
phosphorylates  specific tyrosine and threonine  residues  in  MAPK activating  it. 
These  activated  MAPKs  can  then  phosphorylate  cytoplasmic  proteins  or 
regulate  gene  transcription  including  the  MKPs  which  provide  a  negative 
feedback mechanism and inactivate MAPK.  Extract from Farooq A,  Cell Signal. 
2004 Jul;16(7):769-79.
While  recent  studies  have  also  demonstrated  that  lipopolysaccharide  (LPS) 
stimulates  ROS  production  in  macrophages  via  a  mechanism  that  is  partly 
dependent on  NADPH  oxidase.  LPS  in these cells activated  all  three forms of 
MAPK.  Production  of  IL-1  in  LPS  stimulated  macrophages  was  shown  to  be 
dependent  on  ROS  and  a  PTK/P13K/Rac/p38  pathway.  ROS  mediated 
activation  of  the  MAPK  pathways  plays  a  significant  role  in  cytokine  gene 
regulation and may act in concert with the NF-kB pathway (Torres 2003).
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The MAPKs have also been shown to play a role in HO-1  regulation, which will 
be discussed further in the next paragraph.
1.5.2  HO-1  Regulation by MAPKs
HO-1  transcriptional activation,  like in the case of other genes,  is mediated by a 
plethora  of  signalling  pathways  which  modulate  the  activities  of  transcription 
factors  and  target  gene  expression  (Alam,  Camhi,  &  Choi  1995;  Alam  et  al. 
1999; Alam et al. 2000).
One  of the  key  components  of the  signalling  cascade  is  the  MAPK  pathway 
which as described previously regulate a number of cellular processes such as 
cell growth, differentiation, stress response and apoptosis (Torres 2003).
Like  other  heavy  metals,  arsenic  (in  the  form  of sodium  arsenite)  is  a  potent 
inducer  of  HO-1.  The  mechanism  of  induction  seems  to  be  cell  and  species 
dependent.  Arsenite is known to induce the ERK,  JNK and  p38 cascade which 
appears to be mediated by the activation of She due to tyrosine phosphorylation 
and  recruitment  of  the  Grb2-Sos  complex  which  can  activate  the  p21  small 
GTPases of the Rho family Ras and  Rac.  Ras  in turn then activates either the 
ERK pathway or via action on PAK the JNK or p38 pathway.  Rac activation can 
lead again to PAK activation and subsequently to the activation of JNK and p38. 
MAPK involvement in  HO-1  gene activation  in various tumour cell  lines seems 
to be throwing  up conflicting  data in many studies (Kietzmann,  Samoylenko,  & 
Immenschuh 2003).
Kietzmann et al demonstrated that kinases of the JNK pathway are  involved  in 
the induction of rat HO-1  gene expression by sodium arsenite in primary culture 
rat  hepatocytes  (Kietzmann,  Samoylenko,  &  Immenschuh  2003).  Rat  HO-1
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gene expression is induced by Ras via MAPKs through the JNK (MEKK1,  JNK) 
pathway but not via MAPKs of the ERK (Raf,  ERK2) pathway. The activation of 
JNK was  mediated  by a CRE/AP-1  element which was bound  mainly by c-jun. 
MKK3,  which  acts  as  both  an  inducer  of  HO-1  and  a  specific  inhibitor  of 
p38MAPK,  did not inhibit HO-1  induction by sodium arsenite alone. The MKK3 
dependent induction was partially mediated by p38MAPK via an E-box element 
(-471-42)  which  also  appeared  to  be  the  target  for  direct  inhibition  of  HO-1 
expression  by the  p38  kinases  a,  (3  and  5.  The  target  site for direct  inhibition 
was  bound  by  Max.  Overexpression  of  Max,  like  p38  a,  p  and  6  isoforms, 
inhibited HO-1  expression (Kietzmann,  Samoylenko, & Immenschuh 2003). 
Recently Kacimi et al have reported the involvement of p38MAPK in regulation 
of  HO-1  expression  under  hypoxic  conditions.  They  also  observed  that 
SB203580  inhibited  hypoxia  inducible  HO-1  expression  in  cardiomyocytes 
whereas PD98059 or tyrosine inhibitors had no effect.
Ryter and colleagues demonstrated that inhibitors of MAPK pathway dependent 
on p38MAPK and MEK1  activate HO-1  mRNA expression in  PAEC and VSMC 
under  hypoxic  conditions  and  to  a  lesser  extent  under  normoxia  (Ryter  et  al. 
2002).
There would also appear to be an  intermediary role for MAPK activation during 
chemical  induction  of  HO-1  gene  expression.  For  example,  induction  of ho-1 
transcription  in  MCF-7  cells  by  cadmium  chloride  (CdCh)  was  blocked  by 
SB203580 but not PD98059.  The paradigm from the previous studies implies a 
general  positive  correlation  between  p38MAPK  and  ho-1  activation.  It  is 
apparent,  however,  that  the  regulatory  function  and  relative  importance  of 
p38MAPK  and  MEK1/2-dependent  pathways  in  the  regulation  of  ho-1  gene
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expression  may  vary  significantly  in  a  tissue  and  inducer  specific  manner 
(Ryter, Xi,  Hartsfield, & Choi 2002).
Otterbein  and  co-workers  have  recently  shown  that  the  actions  of  CO,  an 
important  product of  HO  activity,  clearly  involve  the  MAPK signalling  cascade 
(Otterbein et al.  2003a).  In particular,  they implicate the MKK3/p38 p pathway. 
They showed that deletion and/or inhibition of the MKK3/p38 p pathway not only 
modulated the expression of the inflammatory cytokines but also abrogated the 
CO mediated cytoprotection against oxidant lung injury. The JNK pathway was 
shown not to be involved in this elicitation of function.  Meanwhile,  studies have 
also  shown  that  CO  can  prevent  apoptosis  through  activation  of  the  p38 
pathway  (Otterbein,  Otterbein,  Ifedigbo,  Liu,  Morse,  Feams,  Ulevitch, 
Knickelbein, Flavell, & Choi 2003a).
An  alternate  form  of  HO  induction  lies  in  myeloperoxidase,  a  haem  protein 
involved in host defence.
1.6  Myeloperoxidase
Nearly a century ago the potential  biological  utility of hypochlorite as  a wound 
disinfectant  was  described.  Some  fifty  years  later Agner  identified  the  ‘green 
haem  protein’  myeloperoxidase  (MPO)  as  an enzymatic source  of chlorinating 
oxidants  (Podrez,  Abu-Soud,  &  Hazen  2000).  MPO  is  a  member  of  the 
homologous mammalian peroxidase family and  is the most abundant protein of 
neutrophils (polymorphonuclear leukocytes) accounting for approximately 5% of 
their  dry weight.  MPO  is  principally  involved  in  host  defence  and  a  means  of 
invoking  tissue  injury.  It  does  this  via  the  H2O2/CI'  system  which  generates
- Page 34 -INTRODUCTION
HOCI, a potent chlorinating agent, and other chlorinating oxidants (Podrez, Abu- 
Soud, & Hazen 2000; Carr,  McCall, & Frei 2000).
MPO  has  been found  in  human  and  animal  atherosclerotic  lesions  along with 
ceruloplasmin,  lipoxygenase,  endothelial  NOS  (eNOS),  and  inducible  NOS 
(iNOS)  all  of  which  can  cause  or  contribute  to  LDL  oxidation  in  vitro  (Carr, 
McCall, & Frei 2000).
MPO is a tetrameric,  heavily glycosylated basic haem protein of  50 kDa.  It is 
comprised of two identical disulfide linked protomers,  each of which possesses 
a  protoporphyrin containg 59-64 kDa heavy subunit and a 14  kDa  light subunit 
(Podrez, Abu-Soud, & Hazen 2000).
The haem  protein is secreted from  its store,  in the primary azurophilic granules 
of  leukocytes,  into  the  extracellular  milieu  and  phagolysomal  compartment 
following  phagocyte  activation.  The  activation  of  phagocyte  and  excretion  of 
MPO are often accompanied by an oxidative burst generating  superoxide (O2") 
and  H2O2 via the  NADPH complex (Hazen et al.  1999).  The oxidising potential 
of H2O2 is amplified by MPO through a peroxidase cycle to generate a host of 
reactive  oxidants  and  diffusible  radical  species.  MPO  is  capable  of  forming 
multiple  intermediary states which are  influenced  by the availability of reduced 
oxygen species such as  0 2 ',  and H2O2 and  NO. At ground state MPO exists  in 
the  ferric  (Felll)  form  (see  Figure  1.7)  (Podrez,  Abu-Soud,  &  Hazen  2000; 
Burner et al. 2000).
The  ability  of  MPO  to  generate  chlorinating  oxidants  under  physiological 
conditions is a unique and defining activity for the mammalian enzyme. 
Substrates for MPO are generally of low molecular weight due to its active site 
being  located  at  the  base  of  a  narrow,  deep,  hydrophobic  pocket.  Naturally
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occurring  substrates for MPO  include  nitrite  (N02'),  tyrosine,  ascorbate,  urate, 
catecholamines,  estrogens,  and serotonin.  Diffusible oxidant species generated 
by the substrates can lead to the formation of potent signalling molecules,  such 
as  through  initiation  of  lipid  peroxidation  or xenobiotic  intermediate  activation 
(Podrez, Abu-Soud, & Hazen 2000).
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Figure 1.7:- Kinetic model for myeloperoxidase.
An extract from Podrez etal Free Radic Biol Med. 2000 Jun 15;28(12):1717-25.
Regulation  of  MPO  activity  was  thought  to  primarily  rely  on  the  rate  of  02_  
production,  H2O2 availability,  and other cosubstrates,  or the level  of antioxidant 
species  such  as  ascorbate  or  methionine.  However,  recent  studies  have 
identified a role for NO in the modulation of MPO activity (Hazen,  Zhang,  Shen, 
Wu,  Podrez,  MacPherson,  Schmitt,  Mitra,  Mukhopadhyay,  Chen,  Cohen,  Hoff, 
& Abu-Soud  1999).  Both NOS and MPO are colocalised in the primary granule 
of  leukocytes.  Upon  activation  of  phagocytes  both  are  secreted  into  the 
phagolysosome  and  extracellular  compartements  where  upon  nitration  of
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bacteria proteins occur.  Low NO levels are associated with an increase in MPO 
catalysed  peroxidation  of  substrates.  High  NO  levels,  however,  result  in 
reversible  inhibition  of  MPO  through  the  formation  of  an  MPO-Fe(lll)-NO 
complex.  Furthermore,  NO  can  increase the turnover rate of MPO  through the 
peroxidase cycle by nearly 1000-fold. These interactions of NO and MPO mean 
that MPO  can  serve  as  a  catalytic sink for  NO,  thus  limiting  its  bioavailability, 
whilst, also detailing just how complex the regulation of MPO is (Hazen,  Zhang, 
Shen, Wu,  Podrez,  MacPherson,  Schmitt,  Mitra,  Mukhopadhyay,  Chen,  Cohen, 
Hoff, & Abu-Soud 1999).
Immunohistochemical  studies have demonstrated that nitrotyrosine  is enriched 
in  human  atherosclerotic  intima  and  LDL  recovered  from  human  atheroma 
(Beckmann  et al.  1994).  Recent studies have demonstrated that there are two 
MPO  dependent  pathways  for  nitrotyrosine  formation  via  reactive  nitrogen 
species  intermediates  (see  Figure  1.8)  (Hazen,  Zhang,  Shen,  Wu,  Podrez, 
MacPherson,  Schmitt,  Mitra,  Mukhopadhyay,  Chen,  Cohen,  Hoff,  & Abu-Soud
1999).  The first  pathway  involves  MPO  dependent  oxidation  of  NO2',  an  end 
product of NO metabolism, forming a RNS, whilst, the second pathway involves 
secondary  oxidation  of  NO2’  by  MPO  generated  HOCI.  Both  free  and  protein 
bound tyrosine residues can be converted into nitrotyrosine by these pathways. 
Studies  have  shown  that  the  MPO-H2O2-NO2'  pathway  initiates  lipid 
peroxidation  in  complex biological  media  such  as  human  serum.  While  recent 
investigations  have  identified  MPO-dependent  oxidation  of  N02-  as  a  primary 
mechanism for promoting LDL lipid peroxidation (particularly at low rates of NO 
flux) (Carr, McCall, & Frei 2000).
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Figure  1.8:-  Potential  pathways  of  NO  derived  oxidant formation  by  MPO 
and leukocytes.
Extract from  Podrez et al Free RadicBiol  Med.  2000 Jun  15;28(12):1717-25.
MPO  is now established as one mechanism for promoting oxidative modification 
of  proteins  and  lipids  at  sites  of  cardiovascular  disease  and  has  a  role  in 
immune  surveillance  and  host  defence  as  demonstrated  by  an  enhanced 
susceptibility  to  fungal  and  yeast  infection  in  humans  and  specific  MPO  knock 
out  mice  (Aratani  et  al.  2000).  It  is  also  tempting  to  speculate  that  MPO  may 
have  many  more  biological  functions  considering  its  abundance  in  both 
neutrophils  and  monocytes  (Babior  2000;  Podrez,  Abu-Soud,  &  Hazen  2000; 
Lefkowitz & Lefkowitz 2001).
- Page 38 -INTRODUCTION
1.7  The Role of NF-kB and Ik-Bo
NF-kB  is  a  sequence  specific  binding  protein  complex  otherwise  known  as  a 
transcription  factor  (Arenzana-Seisdedos  et  al.  1995;  Bell  et  al.  1996).  It  is 
known to regulate the expression of a wide variety of genes,  particularly those 
involved  in  the  immune  and  inflammatory  response  (such  as  inducible  nitric 
oxide synthase - iNOS) (Peng,  Libby,  & Liao 1995; Goldring et al.  1995;  Hecker 
et  al.  1996;  Hattori,  Nakanishi,  &  Kasai  1997;  Katsuyama  et  al.  1998).  NF-kB 
proteins were first  identified  by  Sen  and  Baltimore  in  1986  as  a  DNA  binding 
activity  which  recognised  an  11  base  pair  sequence  (5’  GGGGACTTTCC  3’) 
(Matthews & Hay  1995).  So far,  all  NF-kB dependent transcription genes  have 
been  shown  to  share  the  previously  mentioned  specific  DNA  binding  motif  in 
their  promoters  for  NF-kB  (Peng,  Libby,  &  Liao  1995;  Arenzana-Seisdedos, 
Thompson, Rodriguez,  Bachelerie, Thomas, & Hay 1995).
NF-kB  itself  is  composed  of  two  separate  subunits  made  of  different  sized 
polypeptide sequences; the p50 subunit (molecular weight 50,000) and the p65 
subunit  (molecular  weight  65,000)  (Peng,  Libby,  &  Liao  1995;  Arenzana- 
Seisdedos,  Thompson,  Rodriguez,  Bachelerie, Thomas,  & Hay 1995;  Matthews 
& Hay  1995;  Matthews et al.  1996a).  Both belong to the multigene re/family of 
proteins which is composed of proteins involved in the transcriptional regulation 
of  processes  such  as  the  expression  of  inflammatory  cytokines  (Arenzana- 
Seisdedos,  Thompson,  Rodriguez,  Bachelerie, Thomas,  & Hay 1995;  Matthews 
et al.  1996b).  The rel domains present in rel proteins regulate gene expression 
by allowing dimerisation, nuclear translocation and DNA binding (Peng,  Libby, & 
Liao 1995; Arenzana-Seisdedos, Thompson,  Rodriguez,  Bachelerie, Thomas, & 
Hay 1995;  Renard et al. 2000).
- Page 39 -UCL INTRODUCTION
Regulation of NF-kB  is accomplished  by control  of the  intracellular localisation 
of the  molecule  (Peng,  Libby,  &  Liao  1995;  Arenzana-Seisdedos,  Thompson, 
Rodriguez,  Bachelerie, Thomas, & Hay 1995; Matthews & Hay 1995;  Matthews, 
Botting,  Panico,  Morris,  &  Hay  1996b;  de Vera  et  al.  1997;  Jeon  et  al.  1998; 
Renard,  Percherancier,  Kroll,  Thomas,  Virelizier,  Arenzana-Seisdedos,  & 
Bachelerie 2000).  In un-stimulated cells NF-kB is retained in the cytoplasm  in a 
non-DNA binding form  by  kBa  proteins  (Peng,  Libby,  &  Liao  1995;  Arenzana- 
Seisdedos, Thompson,  Rodriguez,  Bachelerie, Thomas,  & Hay 1995;  Matthews 
&  Hay  1995;  Matthews,  Botting,  Panico,  Morris,  &  Hay  1996b;  Renard, 
Percherancier,  Kroll,  Thomas,  Virelizier,  Arenzana-Seisdedos,  &  Bachelerie
2000).  kBa  (also  referred  to  as  MAD-3)  belongs  to  a  family  of  inhibitory 
proteins,  including  kBp,  kBy,  BcL-3 and  IkB,  all of which are characterised  by 
their  ability  to  bind  one  or  more  rel family  members  and  to  contain  multiple 
ankyrin  domains  (Arenzana-Seisdedos,  Thompson,  Rodriguez,  Bachelerie, 
Thomas,  &  Hay  1995;  Matthews  &  Hay  1995).  These  ankyrin  repeat  motifs  in 
kBa  are  responsible for the  inhibition  of the  DNA binding  activity in  rel family 
proteins (Matthews & Hay 1995).  NF-kBIrel proteins have been shown to share 
another common feature, this being the presence of a nuclear localisation signal 
(NLS).  The  NLS  sequence  is  important  in  allowing  the  nuclear  uptake  of  NF- 
KB/re/family proteins and has also been shown to be necessary for kB/ankyrin 
repeat  motif  interactions  (Arenzana-Seisdedos,  Thompson,  Rodriguez, 
Bachelerie,  Thomas,  &  Hay  1995;  Matthews  &  Hay  1995;  de  Vera,  Taylor, 
Wang,  Shapiro,  Billiar,  &  Geller  1997).  Under  conditions  of  no  stress  (i.e. 
normality)  kBa  is  bound  to  the  NLS  which  has  two  important  effects;  as 
mentioned  earlier  NF-kB  is  retained  in the cytoplasm  due to  kBa  masking the
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NLS,  and secondly it causes NF-kB to undergo an allosteric change preventing 
it from  binding  DNA (Arenzana-Seisdedos,  Thompson,  Rodriguez,  Bachelerie, 
Thomas, & Hay 1995; Matthews & Hay 1995).
In response to an inflammatory stimuli, however,  IkB proteins are proteolytically 
degraded by the 26S  multicatalytic proteasome thus freeing  NF-kB (see Figure 
1.9)  (Schini-Kerth  et  al.  1997;  Katsuyama,  Shichiri,  Marumo,  &  Hirata 
1998;Nomura,  Uehara,  & Nishiya  1999;  Renard,  Percherancier,  Kroll,  Thomas, 
Virelizier,  Arenzana-Seisdedos,  &  Bachelerie 2000).  IkB  proteins  are  targeted 
for degradation by the phosphorylation of serine residues 32 -  36.  Interestingly, 
it has been suggested that NO may modulate the phosphorylation of IkB.  It has 
been  shown that  NO  can  activate  protein  phosphatases in  blood  mononuclear 
cells which  leads to the possibility that NO could prevent the release of NF-kB 
by dephosphorylation of IkB (Peng,  Libby, & Liao 1995). Once kBa is degraded 
the  NLS  sequence  is  unmasked  and,  therefore,  NF-kB  is  transported  to  the 
nucleus  where  it  is  able  to  bind  to  its  specific  DNA  binding  motif and  initiate 
transcription  (see  Figure  1.10)  (Arenzana-Seisdedos,  Thompson,  Rodriguez, 
Bachelerie,  Thomas,  &  Hay  1995;  Schini-Kerth,  Boese,  Busse,  Fisslthaler,  & 
Mulsch 1997; Katsuyama, Shichiri, Marumo, & Hirata 1998).
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Figure 1.9:- Schematic diagram of kBa degradation.
(a)  kB a  is  phosphorylated  at  residues  S32  and  S36,  after  signal  induction, 
converting  it  into  a  substrate for a  specific ubiquitin  ligase.  (b)  kB a  dissociates 
from  NF-kB when  covalently  modified  by ubiquitin.  (c) The free  NF-kB  is able to 
translocate to the  nucleus,  (d) The  ubiquinated  kBa  is  rapidly  degraded  by the 
proteasome.  Extract from (Matthews & Hay  1995).
As  well  as  transcribing  important  inflammatory  genes,  such  as  iNOS,  HIV  and 
IL-2R,  NF-kB  also  binds  to  kBa  promoters  thus  increasing  the  transcription  of 
this  inhibitory  protein  (Arenzana-Seisdedos,  Thompson,  Rodriguez,  Bachelerie, 
Thomas,  &  Hay  1995).  This results in a massive accumulation of kB a in the cell 
which,  interestingly,  coincides  with  a  loss  of  NF-kB  binding  activity  and  the 
termination  of  NF-kB  dependent  transcription  (Renard,  Percherancier,  Kroll, 
Thomas,  Virelizier,  Arenzana-Seisdedos,  &  Bachelerie  2000).  The  mechanism
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by  which  NF-kB  dependent  transcription  is  terminated  has  not  been  fully 
elucidated  although  it  is  thought to  proceed  as follows.  When  kBa  is  initially 
synthesised it is not permitted to enter the nucleus as it has no NLS sequence. 
However,  it has the capacity to enter the nucleus when the protein is present in 
vast quantities, which occurs when the cell  is placed under conditions of stress 
and  NF-kB  is over-expressed.  This newly synthesised  kBa binds any free  NF- 
kB  in  the  cytoplasm  masking  its  NLS  and  preventing  it  from  entering  the 
nucleus.  While  any  kBa that  does  get transported  into  the  nucleus  is  able to 
disassociate DNA bound NF-kB by evoking an allosteric change in the structure 
of  the  transcription  factor  as  discussed  earlier  (Arenzana-Seisdedos, 
Thompson,  Rodriguez,  Bachelerie,  Thomas,  &  Hay  1995;  Matthews  &  Hay 
1995;  de  Vera,  Taylor,  Wang,  Shapiro,  Billiar,  &  Geller  1997;  Li  et  al.  2003). 
Finally any NF-kB/IkBo complexes present in the nucleus are transported back 
to  the  cytoplasm  as  kBa  again  masks  the  NLS  sequence,  thus  ensuring  that 
NF-kB  dependent  transcription  is  only  transient  (Arenzana-Seisdedos, 
Thompson,  Rodriguez,  Bachelerie,  Thomas,  &  Hay  1995;  Matthews,  Botting, 
Panico,  Morris,  & Hay  1996b;  Renard,  Percherancier,  Kroll,  Thomas,  Virelizier, 
Arenzana-Seisdedos, & Bachelerie 2000).
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Figure 1.10:- Schematic diagram of NF-kB dependent gene transcription.
A  proposed  mechanism  for  the  re-export  of  NF-kB  -  kB a  complexes  from  the 
nucleus to the  cytoplasm which  ensures transient activation and transcription of 
NF-kB dependent genes.  Extract from (Matthews & Hay  1995).
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Interestingly,  NF-kB  dependent transcription has been  shown to  be  modulated 
by  a  product  of  one  of  the  genes  it  transcribes.  Indeed,  a  growing  area  of 
research is investigating the effects of NO generated by the iNOS gene on NF- 
kB  dependent  transcription  (Chen  et  al.  1995;  Matthews,  Botting,  Panico, 
Morris, & Hay 1996b; Togashi et al. 1997).
1.8  Nitric Oxide Synthase
The  NOS  enzymes  were  first  identified  and  described  back  in  1989. 
Subsequent  cloning  and  purification  of the  isoforms  was  carried  out  between 
1991  and  1994.  Since  1994  there  have  been  over  16,000  papers  on  NOS 
published  with  an  average  of  2800  published  every  single  year  making  the 
study  of  NOS  one  of  the  most  focused  areas  of  research.  There  is  intense 
interest in all aspects of its function and structure (Alderton, Cooper, & Knowles
2001).
NOS  is  a  haem-containing  enzyme  with  a  sequence  similar  to  that  of 
cytochrome  P-450  reductase  (see  Figure  1.11)  (Moncada,  Higgs,  &  Furchgott 
1997; Alderton, Cooper, & Knowles 2001).
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Figure 1.11:- The structure of the human iNOS enzyme.
Diagram  (A)  displays the protein structure, while diagram  (B)  reveals the protein 
motifs  present  in  iNOS.  Both  diagrams  were  rendered  using  Protein  Data  Bank 
3DB  Browser,  which  is  available  on  line  at  http://pdb-browsers.ebi.ac.uk/pdb- 
bin/pdbmain.
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Generally  the  NOS  enzymes  are  referred  to  as  dimeric  in  their  active  forms 
although  this  ignores  the  required  presence  of  calmodulins  (CaMs),  which 
actually  mean  they  are  tetramers  (Bruch-Gerharz,  Ruzicka,  &  Kolb-Bachofen 
1998;  Alderton,  Cooper,  &  Knowles  2001).  The  enzymes  contain  relatively 
tightly  bound  cofactors  (6R)-5,6,7,8-tetrahydrobiopterin  (BH4),  flavin  adenine 
dinucleotide  (FAD),  flavin  mononucleotide  (FMN),  and  haem,  and  catalyse  a 
reaction  of L-arginine,  NADPH  and  oxygen  to the free  radical  NO,  citrulline  and 
NADP  (see  Figure 1.12).
Calmodulin
NADPH
BH
FMN NADP
Citrulline 
NO (or NO )
Reductase
Arginine
Ca
FAD
Oxygenase
Figure 1.12:- Schematic diagram of NOS structure and activity.
Arginine  is converted to NO  (or NO') by the enzyme  NOS  in the presence of the 
cofactors haem,  FAD,  FMN  and  BH4.  Extract from Alderton W.  et al;  Biochem J. 
2001  Aug  1 ;357(Pt 3):593-615
There  are  currently  three  distinct  isoforms  of  NOS  known  to  exist,  each  a 
product  of  different  genes,  with  different  localisation,  regulation,  catalytic 
properties  and  inhibitor  sensitivity  (Kubes  2000;Alderton,  Cooper,  &  Knowles
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2001;  Parfenova,  Neff,  III,  Alonso,  Shlopov,  Jamal,  Sarkisova,  &  Leffler 2001). 
There is a 51-57% homology between the human isoforms. The three isoforms 
have been labelled as follows;  i) nNOS (also known as Type I,  NOS-I and NOS- 
1) the first identified isoform and mostly found in neuronal tissue;  ii) iNOS (also 
known  as  Type-ll,  NOS-II  and  NOS-2)  a  highly  inducible  isoform  widely 
distributed in both cells and tissues;  iii) eNOS (Type-Ill,  NOS-III and NOS-3) an 
isoform first found in vascular endothelial cells (Weinberg et al.  1995;  Colleluori, 
Morris, Jr., & Ash 2001; Alderton, Cooper, & Knowles 2001). The three isoforms 
have  been  differentiated  in  a  number  of  ways.  Firstly  on  the  basis  of  their 
constitutive (eNOS, nNOS) versus inducible (iNOS) expression and secondly by 
their  calcium  (Ca2+)  dependence  (eNOS,  nNOS)  or  independence  (iNOS). 
However the  discovery  of splice  variants  and  the  possibility  that further  NOS 
enzymes  will  be  discovered  means  that further ways  to  differentiate  between 
groups may be necessary.
Each human NOS has a distinct gene with a single copy of nNOS ,  eNOS,  and 
iNOS in the haploid human genome (Alderton,  Cooper,  & Knowles 2001). They 
all  have  similar  genomic  structure  suggesting  a  possible  common  ancestral 
NOS gene.  NOS enzymes exhibit a biodomain structure in which an N-terminal 
oxygenase  domain  containing  binding  sites  for  haem,  BH4  and  L-arginine  is 
linked by a CaM recognition site to a C-terminal reductase domain that contains 
binding  sites for  FAD,  FMN,  and  NADPH.  Both  the  oxygenase  and  reductase 
domain were defined by limited proteolysis.  Both domains have been shown to 
be catalytically active and,  interestingly, reconstitution of the second step of NO 
synthesis  has  been  achieved  by  the  combination  of  the  reductase  and 
oxygenase of human eNOS and murine iNOS respectively.
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The  human  iNOS  oxygenase  domain  (amino  acids  82-508)  is  an  elongated 
shape with a novel a-p fold resembling a baseball mit in which the haem group 
is  located  in  its  palm.  The  NOS  distal  pocket  is  primarily  constructed  from  p 
sheets which differs considerably from the distal  pockets of other haem  based 
oxygenases such a cytochrome P450,  peroxidases, and catalases which are all 
largely  a-helical.  The  two  enzymes  families  appear  to  have  achieved  similar 
catalytic activity through convergent evolution.
iNOS  dimer formation  is more  dependent on the  presence  of BH4 than  nNOS 
and  eNOS.  However,  BH4 as well  as  haem  and  L-arginine  all  promote  and/or 
stabilise the  active  dimeric form  of all  three  isoforms.  The  presence  of  haem 
appears  to  be  mandatory,  with  BH4  and  L-arginine  promoting  dimer formation 
and  stabilising  the  dimer  once  formed  (Sato  et  al.  1998).  It  has  also  been 
shown,  in  the  case of  iNOS that once the dimer is formed there  is  little  or no 
significant  return  to  the  monomer  again  in  the  presence  of  very  potent 
dimerisation inhibitors. Thus,  it is not possible to be sure of the physiological or 
pathophysiological  relevance  of  monomeric  and  dimeric  NOS  distribution 
(Alderton, Cooper, & Knowles 2001).
NADP  and  citrulline  are  both  products  of  NOS  activity  with  Nw -hydroxy-L- 
arginine  (NHA)  as  an  intermediate  reaction  product.  Many  authors  state  L - 
citrulline as a product but it is not known whether it is  l- or o/L-citrulline (Bruch- 
Gerharz,  Ruzicka,  & Kolb-Bachofen  1998; Alderton,  Cooper,  & Knowles 2001). 
Interestingly,  the synthesis of NO by NOS is a matter of much debate, whilst,  it 
is  clear  that  cells  and  tissues  containing  NOS,  and  extracts  from  them,  can 
make  NO,  this  does  not  necessarily  mean  that  is  the  initial  reactive  nitrogen 
species  (RNS)  formed,  and  NO  synthesis  is  often  inferred  from  the
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accumulation of breakdown products such a nitrite and  nitrate or from  reaction 
with  haem  proteins  such  as  the  oxidation  of  oxyheamoglobin  to 
methaemoglobin  or the  stimulation  of guanylate  cyclase  (Alderton,  Cooper,  & 
Knowles 2001).
Other  potential  RNS  (e.g.  nitroxyl  -   NO'  or  the  protonated  species  HNO, 
peroxynitrite -  ONOO' ion or the protonated species ONOOH, and nitrosothiols) 
could  in  principle  be  formed  first,  with  the  same  products  and  reactions 
occurring either directly or indirectly after the subsequent reactions to form NO. 
Indeed,  a number of studies have shown  interesting results in this area.  Hobbs 
et al showed  enhanced  NO  synthesis  by  iNOS  and  nNOS  in the  presence  of 
SOD  (Hobbs,  Fukuto,  &  Ignarro  1994).  It was  concluded  that  NO' was  being 
formed  and  oxidised  to  NO  in  a  reaction  catalysed  by  SOD,  whilst,  studies  of 
purified nNOS showed that unless SOD was present they were unable to detect 
NO  formation.  This,  however,  may  not  be  that  surprising  since  SOD  can 
enhance  NO formation  by removing  O2' which would otherwise go  on to  react 
with  NO  to  from  ONOO'.  The  NO  spin  trap  N-methyl-o-glucamine- 
dithiocarbamate  did  detect  NO  under  these  conditions  leading  many  to 
conclude that  NO  is the  major product of NOS,  although,  this  has  since  been 
questioned with the suggestion that N-methyl-D -glucamine-dithiocarbamate may 
also trap NO'.  Interestingly, in the presence of BH4 and L -arginine substrate, NO 
formation  seems to  be favoured,  whereas  in the absence of BH4 and  NHA as 
the  substrate  NO'  is  the  product.  Thus,  it  seems  likely  that  under  different 
conditions  in  vitro  it  is  possible to  get  either product.  The  debate  as  to which 
RNS  NOS  produces is vitally important in understanding both the physiological 
and  pathophysiological  implications  of NOS  and their inhibition.  Which  may  in
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part  explain  the  difference  between  activation  of  NOS  and  addition  of 
exogenous NO in so many studies.
Due  to  the  stability  of ferrous  nitrosyl  (Fe2+-NO)  complexes,  any  enzyme  that 
forms a reduced ferrous haem  intermediate has the potential to be inhibited by 
NO.  NOS is no exception. For example, the reduction of the suggested Fe3+-NO 
intermediate  would  generate  Fe2+-NO,  as would  the  reaction  of  NO'  with  the 
ferric enzyme  (Alderton,  Cooper,  &  Knowles 2001).  Both  iNOS  and  nNOS can 
form  inhibitory nitrosyl  species during turnover.  NO  inhibition  of iNOS  appears 
to  be  weak  and  is  partially  due  to  the  build  up  of  the  Fe3+-NO  complex; 
however,  up  to  95%  of  nNOS  is  in  the  inhibitory  Fe2+-NO  form  seen  in  the 
steady state.  Unlike iNOS,  nNOS also seems to be able to react with NO within 
the enzyme active site,  as the addition of exogenous NO scavengers has  little 
effect on inhibition (Turcanu, Dhouib, & Poindron 1998b).  It has been suggested 
that an Fe3+-NO complex is the final intermediate in the catalytic cycle and that 
the  dissociation  of NO  from  this  complex  (normal  catalysis)  competes  with  its 
reduction  to  the  Fe2+-NO  species  (auto  inhibition).  In  general,  there  are  a 
number  of ways  to  prevent  NO  inhibition  of ferrous  haem  proteins;  i)  kinetic 
prevention of the  bond being formed;  ii) an  increase in the dissociation  rate of 
NO;  iii)  a  modification  of  the  chemical  activity  of  the  bond.  NOS  enzymes 
generally follow the  latter course.  The  Fe2+-NO bond reacts rather quickly with 
oxygen  generating  nitrate and ferric iron.  This  reaction  occurs quickly in  iNOS 
but  relatively  slowly  in  nNOS.  As  such,  the  rate  of oxygen  reactions  with  the 
nitroxyl  complex  is  one  of  the  steps  limiting  turnover  in  the  steady  state  of 
nNOS.  This  appears  to  be  due  to  the  presence  of  a  conserved  tryptophan 
residue (Tyr409) in nNOS that hydrogen bonds to the haem thiolate ligand and
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increases  the  stability of the  nitroxyl  complex thus  allowing the  enzyme  to  be 
controlled by its product.
CaM  was  the  first  protein  shown  to  interact  with  NOS  and  has  been 
demonstrated to be necessary for the activity of all three isoforms.  Both  nNOS 
and  eNOS  have  a  much  higher  Ca2+  requirement  than  iNOS.  The  binding  of 
CaM  increases the  rate at which electrons are transferred from  NADPH to the 
reductase  domain flavins  and  artificial  electron  acceptors  such  as ferricyanide 
and  cytochrome c;  it also triggers electron transfer from the  reductase domain 
to  the  haem  centre.  Both  nNOS  and  eNOS  have 40-50  amino  acid  inserts  in 
their  FMN  binding subdomain,  which  seems to destabilise  CaM  binding  at low 
Ca2+  concentration  and  inhibits  electron  transfer  from  FMN  to  haem  in  the 
absence  of  Ca2+/CaM.  Phosphorylation  of  NOS  (nNOS  and  eNOS)  has  also 
been  shown  to  have  an  effect  on  its  activity.  Fluid  shear  stress  elicited 
phosphorylation  of  eNOS  results  in  an  increase  in  electron  flux  through  the 
reductase domain and an  increase in NO formation (Boo et al.  2002;  Iwakiri  et 
al.  2002;  Boo & Jo 2003;  Davis et al.  2004), whilst,  nNOS  phosphorylation  by 
CaM-dependent  kinases  leads  to a  decrease  in  NOS  activity.  There  has  also 
been some speculation that an 89 amino acid protein called protein inhibitor of 
NOS  (PIN)  could  regulate  NOS  activity,  however,  it  is  unclarified  and  awaits 
further investigation.  As mentioned in  paragraph  1.11.3,  CO  is also capable of 
binding to the haem of NOS and modulating its activity (White & Marietta  1992; 
McMillan  et  al.  1992).  Finally,  HSP90  has  been  identified  as  a  regulator  of 
eNOS activity (Shah et al.  1999).
As their abbreviations suggest,  eNOS was originally discovered  in the vascular 
endothelium  and  nNOS  in  the  neuronal  tissue,  spinal  cord  and  peripheral
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nervous system.  However,  later studies have shown that eNOS  is also present 
in  platelets  and  in  certain  neuronal  populations  in  the  brain,  while  nNOS  has 
been found in skeletal muscle and in the epithelium of the bronchi and trachea. 
Also of interest was the discovery that different tissues from the same species 
contained  slightly  different  forms  of  the  iNOS  enzyme  (Moncada,  Higgs,  & 
Furchgott  1997; Wink et al.  1999).  Interestingly,  RAW cells and other types of 
macrophage  had  been  reported  to  express  only  iNOS,  which  generated  NO 
after  immunological  stimulation.  Schmidt  et  al;  however,  demonstrated  a 
constitutive NOS activity in RAW264.7 macrophages which was found to be as 
a  result of Ca2+-dependent eNOS  which  was  detected  in  the  supernatant and 
particulate  fractions  (Schmidt  et  al.  1992).  It  was  also  found  that  iNOS  and 
eNOS activities in RAW264.7 cells were inversely regulated by LPS and  INF-y, 
which induced the former and down-regulated the latter.
Other situations  known  to  activate  nNOS  and  eNOS  include extreme forms  of 
exercise  and  pregnancy  (Moncada,  Higgs,  &  Furchgott  1997).  The  iNOS 
enzyme on the other-hand is activated by a number of factors, which are mainly 
immunological or inflammatory stimuli such as cytokines (Niemann,  Bjorklund, & 
Eizirik  1994;  Moncada,  Higgs,  &  Furchgott  1997;  Wink  &  Mitchell  1998b). 
However,  as with both nNOS and eNOS, iNOS has also been found to break its 
‘mould’.  Indeed,  iNOS  has been shown to be constitutively expressed  in  some 
tissues including;  human bronchial epithelium and some fetal tissue (Moncada, 
Higgs, & Furchgott 1997).
This  L-arginine/NO  pathway  has  been  shown  to  be  inhibited  by  several 
analogues  of  L-arginine  including:  N“-monomethyl-L -arginine  (L-NMMA),  N“- 
nitro-L-arginine methyl ester (L-NAME) and N^-N^-dimethyk-arginine (ADMA or
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L-ADMA)  (Moncada,  Higgs,  &  Furchgott  1997;  Lancaster,  Jr.  1997;  Joshi, 
Ponthier,  & Lancaster,  Jr.  1999).
1.9  Nitric Oxide
NO  is  a  free  radical  species  which  is  synthesised  intracellulary  by  the  enzyme 
NOS  and  has  been  characterised  as  the  endothelium  derived  relaxing  factor 
(EDRF)  (Ignarro et al.  1987).  The  metabolism  and  some  of the activities  of NO 
that will be mentioned in this section are highlighted  in Figure  1.13.
Figure 1.13:- Nitric oxide Metabolism.
This figure illustrates the metabolism of NO  and some of the biological  activities 
that  NO  is  involved  in.  Modified  from  the  Sigma  Aldrich  Website: 
http://www.siqmaaldrich.com/Area  of  Interest/Life  Science/Cell  Signaling/Path 
wav  Slides  and  Charts/Nitric  Oxide  Metabolism.html
MnSOD
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NO  is  involved  in  several  important  physiological  processes,  which  include: 
control  of  smooth  muscle  tone,  neurotransmission,  inhibition  of  platelet 
aggregation  and  host  defence  (Moncada,  Palmer,  &  Higgs  1991;  Brune, 
Messmer, & Sandau 1995a).
Recent evidence reveals that the cellular functions of NO’ cannot be attributed 
only to the action of this radical species,  but rather to the reactivity of its redox 
forms.  These  are  specifically,  the  nitrosonium  cation  (NO+)  and  the  nitroxyl 
anion  (NO'),  the  one  electron  reduction  and  oxidation  products  of  NO, 
respectively (Stamler 1994). The use of organic compounds that are capable of 
releasing  NO  and  its  redox  activated  forms  has  facilitated  the  study  on  the 
interactions  of NO with various intracellular components  (Feelisch  1998a).  NO 
has  been  found  to  have  a  high  affinity for  haem-iron  molecules.  This  is  best 
exemplified by the interaction of NO with the haem moiety of guanylate cyclase 
leading to increased generation of the second messenger,  cGMP (Griffith et al. 
1984;  Brune,  Messmer,  &  Sandau  1995b;  Vaziri  & Wang  1999).  NO  also will 
react readily with thiols to form S-nitrosothiols.  Such S-nitrosothiols are thought 
to  be involved  in the stabilisation and  metabolism  of NO  owing to their  EDRF- 
like  characteristics  (Myers  et al.  1990).  NO  can  also  interact with  protein  thiol 
groups leading to the formation of S-nitrosoproteins (Stamler et al.  1992).  This 
post-translational  modification  is  reminiscent of protein  phosphorylation  and  is 
considered  to  be  an  important  process  in  transducing  signals  within  the  cell 
(Hausladen et al.  1996).
NO has been implicated in many diverse physiological functions including;  SMC 
relaxation,  platelet inhibition,  neurotransmission,  immune  regulation and  penile 
erection.  The  biochemical  pathways  in  these  processes  share  two  common
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features: the enzymatic synthesis of NO from L -arginine and the formation of an 
iron nitrosyl complex in target (haem) proteins to evoke the functional response 
(Murphy & Sies 1991).
The  broad  chemistry  of  NO  involves  many  interrelated  redox forms:  the  NO+, 
nitric oxide (NO*) and the NO'.  Needless to say there is much disagreement as 
to the specific generation of each of these forms and the roles they play in the 
biological system (Feelisch 1998b).
NO  has  the  capacity  to  modulate  the  activity  of  certain  proteins  through  a 
reversible  reaction  with  the  available  functional  group,  most  notably  Fe  and 
thiols.  Guanylyl  cyclase  activation  via  the  binding  of  NO  to  its  haem  iron  is  a 
very important example of this as many cellular responses (vasorelaxation  and 
platelet inhibition) are the result of sGC mediated  increases  in cGMP  (Sogo et 
al.  2000).  The  likely  method  of  NO  sGC  enzyme  activation  is  via  an  induced 
structural change, similar to that of O2 binding haemoglobin. The oxidation state 
of NO itself and the enzyme critically affect the NO-dependent activation of sGC 
(Wink & Mitchell 1998a).
The  nitrosylation  of  free  thiols  has  also  been  shown  to  modulate  specific 
enzyme activity (Foresti et al.  1997).  The fact many diverse proteins of varying 
function  contain  critical  thiol  groups  suggest  nitrosylation  may  be  involved  in 
broad regulatory actions. The reaction of NO with cell surface thiols for example 
has  been  associated  with  antimicrobial  effects,  modulation  of  ligand-gated 
receptor (NMDA) activity,  and alterations of SMC function  (Nathan & Hibbs,  Jr. 
1991;  MacMicking,  Xie,  &  Nathan  1997).  Signal  transduction  mediated  by 
adenosine  diphosphate  (ADP)-ribosylation  of  protein  sulphydryls  may  be 
regulated  by  s-nitrosylation  and  thus  link  NO  biochemistry  to  cGMP
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independent processes (Ignarro et al. 2001). S-nitrosylation of glyceraldehydes- 
3-phosphate  dehydrogenase  has  been  shown  to  promote  ADP-ribosylation  of 
the enzyme and is associated with the inhibition of its activity.  Nitroxyl has also 
been  implicated  in  the  inhibition  of  sulphydryl  dependent  enzyme  activity 
(Padgett & Whorton 1995).
The  preference  of  NO  for various functional  groups  is  influenced  by  its  redox 
state.  This  is  best  shown  by  the  interaction  of  haemoglobin  and  NO*,  which 
reacts with the haem site to inactivate NO, and by way of alternate redox forms 
of NO at intramolecular amine (NO+) and sulphydryl (NO+  and NO-) centres. 
Under  physiological  conditions  NO  can  be  interconverted  among  redox forms 
which all have distinct chemistries (Stamler, Singel, & Loscalzo 1992).
After  release,  NO*  is  susceptible  to  both  oxidation  and  reduction  to  NO+   and 
NO'  respectively.  Both  act  as  primary  reaction  products  that  allow  secondary 
target  interactions.  In  biological  systems  NO  can  react  with  O2,  O2',  and 
transition  metals  forming  NOx,  OONO'  and  metal-NO  adducts  respectively 
(Brune, Messmer, & Sandau 1995b). These reaction products can then go on to 
react  further  via  redox  or  additive  chemistry  interactions.  The  intracellular 
prevalence  and  reactivity  of thiols  (RSH/RS)  over  other  nucleophiles  support 
nitrosative  reactions  (NO+)  for  s-nitrosothiols  (RS-NO)  formation.  Thus, 
receptors,  ion  channels,  enzymes  or transcription factors  containing  metals  or 
thiols  located  at the  active  or allosteric  sites  are  essential  components  of NO 
signaling (Brune, Messmer, & Sandau 1995b).
The  interaction  of  NO  with  the  sGC  haem  regulatory  subunit  is  a  vitally 
important physiological  reaction.  The  EDRF  like function  is the  key transducer 
of the vasodilator message from the endothelium to the vascular cells (Wagner
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et  al.  1997;  Hartsfield  et  al.  1997;  Grover  et  al.  2000).  Activation  of  sGC, 
formation of cGMP, and concomitant protein phosphorylation forms an inter and 
intracellular NO responsive regulatory network.
NO  cytotoxicity  is  not  only  directed  against  bacteria,  microorganisms,  and 
tumour cells as a part of the non-specific immune response but can also affect 
NO producing cells like macrophages (Schwarz et al.  1995;  Brune, Messmer,  & 
Sandau  1995b).  NO  toxicity  has  been  implicated  in  major  neurodegenerative 
diseases  and  pancreatic  p-cell  destruction  linked  to  type-l  diabetes  (Gross  & 
Wolin 1995; Mandrup-Poulsen 2001;  Boje 2004).  NO induced cell death is likely 
mediated via OONO' formation,  inhibition of FeS enzymes,  like the Krebs cycle 
aconitase,  complex  I  and  II  of  the  mitochondrial  respiratory  chain,  or 
ribonucleotide  reductase,  deregulation  of  poly  ADP-ribosyltransferase,  and 
energy  depletion  (Brune,  Messmer,  &  Sandau  1995b).  However,  NO  toxicity 
depends on the contents of the surrounding biological  mileu.  NO reactions with 
reactive  oxygen  species  can  have  favourable  protective  outcomes  as  well  as 
less  favourable  toxicity.  In  neuronal  cells,  the  diffusion  linked  reaction  of  NO 
with  ROS  species  results  in  the  generation  of  toxic  OONO',  whereas 
mesencephalic  cells  or  lung  fibroblasts  are  protected  by  NO  during  ischemia 
reperfusion injury (Brune, Messmer, & Sandau 1995b).
In  macrophages  (RAW264.7)  and  p-cell  line  (RIN  m5F),  NO-mediated 
cytotoxicity  proceeds  through  an  apoptotic  course  of  cell  death  and  not 
necrosis.  This  would  appear  to  be  mediated  by  p53,  a  tumour  suppressor 
protein that is important in maintaining genetic integrity and has been suggested 
to  act  as  a  ‘guardian  of  the  genome’  monitoring  the  state  of  the  cells  DNA 
(Brune, Messmer, & Sandau 1995b).
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Recent studies into iNOS expression have indicated that NO may function as a 
negative  feedback  modulator  of  iNOS,  thus  regulating  the  production  of  NO 
(Buga et al.  1993;  Griscavage et al.  1993;  Park,  Lin,  & Murphy 1994;  Colasanti 
et  al.  1995;  Griscavage,  Hobbs,  &  Ignarro  1995;  Weisz,  Cicatiello,  &  Esumi 
1996;  Matthews,  Botting,  Panico,  Morris,  &  Hay  1996b;  Togashi,  Sasaki, 
Frohman,  Taira,  Ratan,  Dawson,  & Dawson  1997;  Park,  Lin,  & Murphy  1997b; 
Hinz,  Brune,  &  Pahl 2000).  A number of mechanisms have been suggested to 
explain how NO might modulate its own production,  many of these focusing on 
NF-kB  activation  (Colasanti,  Persichini,  Menegazzi,  Mariotto,  Giordano, 
Caldarera,  Sogos,  Lauro,  & Suzuki  1995;  Matthews,  Botting,  Panico,  Morris,  & 
Hay  1996b;  Park,  Lin,  &  Murphy  1997b;  Hinz,  Brune,  &  Pahl  2000).  Indeed, 
several recent studies have shown that exposure of macrophages to NO donors 
(such  as  sodium  nitroprusside  -   SNP  and  S-nitroso-N-acetylpenicillamine  - 
SNAP)  leads  to  inhibition  of  lipopolysaccharide  /  tumour  necrosis  factor  a 
(LPS/TNFa)-elicited  NF-kB  activation  (Colasanti,  Persichini,  Menegazzi, 
Mariotto,  Giordano,  Caldarera,  Sogos,  Lauro,  &  Suzuki  1995;  Griscavage, 
Hobbs,  &  Ignarro  1995;  Ma  et  al.  1996).  As  NF-kB  is  the  transcription  factor 
involved in iNOS gene transcription,  decreasing its activation will  likely result in 
the  generation  of  less  NO  and,  therefore,  an  eventual  increase  in  NF-kB 
activation.
NO  is  thought  to  regulate  NF-kB  activation  by  a  variety  of  mechanisms. 
Perhaps,  the  most  interesting  and  important  of these  is  the  stabilisation  and 
increased  transcription  of  kBa  (Matthews,  Botting,  Panico,  Morris,  &  Hay 
1996b;Hinz,  Brune,  & Pahl 2000). As discussed earlier,  kBa  is responsible for 
retaining  NF-kB in the cytoplasm and also preventing  it from binding  DNA thus
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inhibiting  NF-kB  dependent transcription.  NO  can  stabilise  kBa  preventing  its 
proteolytic degradation  as  mentioned  in  paragraph  1.7  and,  therefore,  keep  it 
bound to NF-kB (Peng,  Libby,  & Liao  1995;  Griscavage, Wilk,  & Ignarro 1996). 
While activating its transcription  increases the level of kBa present in the cell. 
This  results  in  kBa  being  present  in  a  higher concentration  and  increases  its 
capacity to  bind  any free  NF-kB  in the  cytoplasm  and facilitates  kBa entering 
the  nucleus to  dissociate  any  DNA  bound  NF-kB  (Matthews,  Botting,  Panico, 
Morris,  &  Hay  1996b;  Togashi,  Sasaki,  Frohman,  Taira,  Ratan,  Dawson,  & 
Dawson 1997). NO is also thought to inhibit NF-kB through S-nitrosylation of the 
cysteine 62 residue of p50 (Togashi, Sasaki, Frohman, Taira,  Ratan, Dawson, & 
Dawson 1997). The DNA binding activity of NF-kB is located on the p50 subunit 
and  is  dependent  on  the  oxidation-reduction  state  of  cysteine  on  residue  62 
(with a reduced form of cysteine required for DNA binding activity). NO might be 
able  to  alter  these  critical  thiol  groups  changing  the  conformation  (and, 
therefore,  the function) thus preventing  NF-kB binding  DNA (Chen,  Kuhn,  Sun, 
Gaydos,  &  Demers  1995;  Matthews,  Botting,  Panico,  Morris,  &  Hay  1996b; 
Togashi,  Sasaki,  Frohman, Taira,  Ratan,  Dawson, & Dawson 1997;  Park,  Lin, & 
Murphy 1997a).
It  has  also  been  suggested  that  basal  levels  of  NO  are  able  to  keep  iNOS 
expression  suppressed  by inhibiting  NF-kB  activation  (Rogers &  Ignarro  1992; 
Colasanti,  Persichini,  Menegazzi,  Mariotto,  Giordano,  Caldarera,  Sogos,  Lauro, 
&  Suzuki  1995;  Matthews,  Botting,  Panico,  Morris,  &  Hay  1996b;  Togashi, 
Sasaki,  Frohman,  Taira,  Ratan,  Dawson,  &  Dawson  1997).  This  implies  that 
iNOS could be regulated by the endogenous NO generated by constitutive NOS 
(eNOS)  (such  as  endothelial  NOS  -   eNOS  and  neuronal  NOS  -   nNOS)
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(Colasanti,  Persichini, Menegazzi,  Mariotto,  Giordano, Caldarera, Sogos,  Lauro,
6  Suzuki  1995;  Matthews,  Botting,  Panico,  Morris,  &  Hay  1996b;  Togashi, 
Sasaki,  Frohman,  Taira,  Ratan,  Dawson,  &  Dawson  1997).  Assuming  that the 
basal  level  of  NO  is  kept  at  a  concentration  capable  of  suppressing  iNOS 
expression,  then  the  endogenous  NO  may  contribute to  avoid  an  undesirable 
and  potentially harmful  induction of iNOS expression.  If on the other hand,  the 
NO level goes below this threshold value,  iNOS expression may become easily 
achievable.  In  this  respect,  it  seems  worthwhile  noting  that  a  combination  of 
LPS  and  interferon  y  (IFNy),  which  induces  the  iNOS  gene,  is  also  able  to 
simultaneously  decrease  eNOS  mRNA  expression  in  human 
monocyte/macrophage  cells.  Furthermore,  TNFa  has  been  shown  to  regulate 
eNOS by shortening its mRNA half-life in endothelial cells (Colasanti,  Persichini, 
Menegazzi, Mariotto, Giordano, Caldarera,  Sogos, Lauro, & Suzuki 1995).
Finally,  NO  is thought to prevent NF-kB dependent transcription by scavenging 
the reactive oxygen  species (ROS) that are  required for NF-kB  activation.  One 
such  mechanism  could  involve  the  activation  of the  HO  pathway  (Colasanti, 
Persichini,  Menegazzi,  Mariotto,  Giordano,  Caldarera,  Sogos,  Lauro,  &  Suzuki 
1995; Motterlini et al.  1996; Turcanu, Dhouib, & Poindron 1998a).
1.10  Interaction of HO and NOS Pathways
Regulation  of  HO  activity  and  NOS  production  are  intimately  linked  (Datta, 
Gross,  &  Lianos  2002;  Johnson  et  al.  2002;  Andre  &  Felley-Bosco  2003).  As 
well  as  maintaining/supplementing  the  cells  ability to  generate  cGMP  there  is 
evidence  to  suggest  HO  regulates  the  NOS  generation  of  NO  (Datta  et  al.
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1999). This is very important as the dissociation of NO with sGC proceeds very 
slowly  and  reversal  of  NO  binding  of  the  haem  would  not  be  an  effective 
mechanism  for  a  rapid  halt  in  sGC  activation  which  is  crucial  for  maintaining 
cellular homeostasis.  HO-1  induction can modulate NO production in a number 
of ways;  i) as NOS is a haemoprotein and requires two haems for its active site 
HO  activity  would  accelerate  newly  synthesised  haem  degradation  thus 
impairing  de  novo  synthesis  of  NOS;  ii)  due  to  NOS  being  a  P450  type 
haemoprotein and cytochromes P450 in intact or denatured form scan substrate 
for  both  HO-1  and  HO-2  an  increased  HO  activity  could  accelerate  NOS 
turnover.  Cytochrome P450 and  HO activity show a reciprocal relationship with 
HO-1  stimuli  causing  a  concomitant  decrease  in  cytochrome  P450;  iii)  both 
neuronal  and  macrophage  NOS  have  been  shown  to  bind  CO  raising  the 
possibility that HO  generated  CO could  bind and  inactivate  it;  iv)  iron released 
by  haem  degradation  could  prevent  the  nuclear  transcription  of  NOS;  v) 
competition of both  HO and  NOS for NADPH would favour  HO due to  its  high 
ratio of concentration plus the need for NADPH  in the reduction of biliverdin to 
bilirubin;  vi)  HO  dependent  haem  availability  could  modulate  the  negative 
feedback regulation of NO on  NOS  mRNA expression.  NO could  also regulate 
HO activity and CO production by modulating the activity of 5-aminolevulvinate 
synthase  (ALAS),  the  rate  limiting  enzyme  in  haem  biosynthesis  and  the 
synthesis  of  the  iron  storage  protein  ferritin  (Figure  1.14)  (Ponka  1999; 
Taramelli  et  al.  2000).  Iron  has  been  shown  to  increase  HO  activity  as  it 
downregulates  ALAS  activity.  It  is  thought  iron  reguation  of ALAS  is  via  iron 
responsive elements (IRE’s) and iron regulatory protein-1  (IRP-1) whilst HO-1  is 
upregulated  via  free  radical  generation.  Iron  metabolism,  in  turn,  can  be
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influenced  by  NO  control  of  IRE  binding  activity  and  repression  of  ferritin 
synthesis with a possible end result being an increase in HO-1  induction by the 
free  iron  made  available  by  a  decreased  need  for  the  metal  in  haem 
biosynthesis and repression of ferritin synthesis.
The  interaction  of  the  two  systems  is  present  in  a  number  of  cell  types  for 
example  in  macrophages  where  NOS  is  present  in  the  cytosolic fraction  and 
HO-1  is  highly  inducible,  this  form  of  the  oxygenase  would  become  the 
predominant  modulator  of  NOS  activity  and  NO  would  activate  HO-1  gene 
expression  (Johnson,  Teran,  Prieto-Carrasquero,  & Johnson 2002).  As well  as 
its  haem/haemoprotein  level  regulation  and  generation  of  biologically  active 
components  it  is  possible  that  HO  (specifically  HO-2)  could  have  a  role  as  a 
haem/oxygen  sensor for the  cell  (Prabhakar  1999).  This  has  been  suggested 
since  there  is  a  1 0 0 %  match  in  part  of  its  sequence  to  that  of  the  oxygen 
consensus  sequence  and  because  unlike  other  haem  binding  proteins  it  has 
two  haem  regulatory  motifs  (HRMs)  not  involved  in  haem  catalysis  but  in 
activation  of oxygen  which  could  then  go  on to  activate AP-1  and  NF-kB  two 
transcription  factors  activated  in  the  presence  of  oxygen  free  radicals.  HO-2 
could  thus  function  in  a  regulatory  capacity  for  genes  regulated  by  oxygen 
radicals, haem, or iron e.g. ferritin, iNOS, and HO-1.
HO  may also  promote  cell  injury  and  killing  mediated  by the free  radical  NO*. 
NO-  interaction  with  oxygen  free  radicals  generated  in  the  course  of  cellular 
oxygen  metabolism can  lead to the formation of peroxynitrite,  nitrogen  dioxide, 
and  hydroxyl  radicals,  all  of  which  are  more  toxic  than  NO-.  The  oxygen 
generating activity of haem bound to HO-2 HRMs as described in the interaction 
of  HO  and  NOS  section  via  the  iron  catalysed  Fenton  reaction  could  be  the
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catalyst for the toxic injury to target molecules or cells (Maines 1997;  Brune, von 
Knethen,  &  Sandau  1998;  Jeney  et  al.  2002).  Generation  of  OH*  and 
superoxide (O2') free radicals is an important mechanism of cytocidal pathways 
including therapeutic agents,  ionising radiation, and toxic chemicals (Brune, von 
Knethen, & Sandau 1998; Li et al. 2002).
Willis et al observed  that an  increase  in  HO  activity during  acute  complement 
development  inflammation  results  in  the  recruitment  of  polymorphonuclear 
(PMN’s)  cells  followed  by  the  later  influx  of  mononuclear  (Mns)  cells  in  the 
pleural activity of carrageenin treated rats. This results in a marked suppression 
of the inflammatory response.  Inhibition of HO activity potentiates this response. 
This is consistent with the idea of HO-2 generation of oxygen radicals in PMN’s 
and  Mns  to  defend  against  infection.  Further  to  this  is  the  ability  of  HO  to 
generate  cGMP,  produce  antioxidants,  and  deplete  haem,  which  is  needed  to 
produce inflammatory arachidonic acid metabolites.
The action of haem can increase bacterial virulence;  its binding to receptors on 
the surface of bacteria is recognised as a virulence marker. Thus degradation of 
haem by HO could interfere with this and make bacteria avirulent.  Regulation of 
iNOS  in  such  instances of inflammatory response would  also  play a  beneficial 
and protective role (Genco, Odusanya, & Brown 1994).
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MITOCHONDRIA
TCA
CYCLE
Succinyl-CoA 
Glycine  j
(B)
5-Aminolevulinate
Porphobilinogen
5-Aminolevulinate
(C & D)
Uroporphyrinogen
Coproporphyrinogen III
(F)
Protoporphyrinogen IX
(G&H)
Cytochrome c  ^
^   Haemoglobin  ^
Figure 1.14:- The metabolism of haem in mammals, birds and bacteria.
The  enzymes  are  as  follows;  (F)  =  coproporphrinogen  oxidase;  (G)  =
protoporphrinogen  oxidase;  (A)  =  5-aminolevulinate  synthase;  (E)  =
uroporphyrinogen  decarboxylase;  (B)  =  porphobilinogen  synthase;  (C)  =
uroporphyrinogen-lll  synthase;  (D)  =  hydroxymethylbilane synthase;  (H)  =
ferrochelatase.
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1.11  Carbon Monoxide
1.11.1  Overview
Carbon  monoxide  (CO),  the  diatomic  oxide  of  carbon,  is  a  colourless, 
odourless, tasteless,  non-corrosive gas of about the same density as air, and is 
the most commonly encountered and pervasive poison in our environment (Von 
Burg  1999).  It is this  aspect  of CO that thrust  it into the  scientific domain  and 
ensured a wide investigation into its effects on humans.  CO,  one of the main air 
pollutants in the atmosphere originates from oxidation or combustion of organic 
matter,  including wood,  tobacco,  coal,  coke  and  natural  gas.  It  is  abundant  in 
the  atmosphere  (0.19  parts  per  million  (ppm)),  90%  of which  is  derived  from 
natural  sources  while  the  remaining  10%  is  attributable  to  various  human 
activities.  Thus  avoiding  dailly  exposure  to  even  small  amounts  of  CO  is 
practically impossible (Figure 1.15).
Waste Treatment 0.4%
Other Transport 11.3%
Road Transport 
61.6%
Energy Production 2.8%
Commercial, Institutional & Rsidential 6.0%
Industry 11.3%
Production Processes 5.6%
Fossil Fuel Extraction & Distribution 0.01%
Total Emissions of carbon monoxide = 3737 kilotonnes  Source: NAEI
Figure 1.15:- Non-natural carbon monoxide emissions in the UK for 2001.
Emissions from human activities.  Extract from the environment agency records.
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The  roles  of CO  in  life  may  date from  the  prehistoric environments  that were 
rich in CO,  and may be linked to biological pathways that developed during the 
origins  of  life.  It  has  recently  been  proposed  that  CO  made  a  significant 
contribution  to  the  synthesis  of  the  first  amino  and  nucleic  acids  along  with 
oxygen and nitrogen (Kasting 1993).
CO is the anhydride of formic acid; however, it does not react with water without 
substantial  energy  input.  Although  CO  is  combustible,  its  formal  triple  bond 
makes it chemically quite stable under physiological conditions.  Its reaction with 
molecular oxygen (O2) is slow and has a high energy of activation; however,  CO 
is  involved  in  redox  reactions  (Piantadosi  2002).  In  its  free  state,  CO  resists 
attack by most common reducing agents, including hydrogen (Piantadosi 2002). 
The  reactivity  of  coordinated  CO  is  much  greater  than  the  free  gas,  and 
transition  metals  are  particularly  effective  in  promoting  reduction  of  CO.  CO 
readily  forms  metal  carbonyls,  which  are  susceptible  to  the  attack  of the  CO 
oxygen  atoms  by  electrophiles.  Chemical  reduction  of  CO,  however,  requires 
temperature  in excess of 100°C well  above physiological  levels.  The  oxidation 
or oxygenation of CO to CO2 is also well appreciated in chemistry but again this 
requires temperatures beyond physiological tolerance for most organisms.
It is important to understand some of the chemical interactions between CO and 
nitric oxide (NO) in systems where iron and other redox-active transition metals 
are available.  CO,  like NO,  avidly binds  Fe(ll)Hp,  but unlike  NO does not  bind 
Fe(lll)Hp (Piantadosi 2002).  Experimentally,  low concentrations of CO stimulate 
NO  release  and  production  of  the  strong  oxidant  peroxynitrite,  e.g.  in  blood 
platelets  and  vascular  cells  (Thom  &  Ischiropoulos  1997;  Thom,  Xu,  & 
Ischiropoulos 1997b). A chemical mechanism for CO-mediated NO-release has
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been  proposed  based  on  the  redistribution  of  NO  in  the  cell,  a  hypothesis 
consistent with different equilibrium constants for metal binding of the two gases 
(Olson,  Rohlfs,  &  Gibson  1987;  Thom  &  Ischiropoulos  1997).  NO  is  the  most 
reactive of the physiological gases,  having the same effective size and  polarity 
as the O2 molecule. The rate limiting step for the overall NO binding reaction to 
haemoproteins  (Hp)  such  as  myoglobin  is  actually  NO  entry  into  the  binding 
pocket  (Ponka  1999).  Thus,  the  overall  association  constants  for  NO  with 
Fe(ll)Hp  are  much  faster  than  the  association  constants  for  CO.  For 
haemoglobin, the affinity of NO for Fe(ll) is 1,500 times greater than that of CO. 
The extent to which CO  displaces  NO from  Hp at physiological  concentrations 
of CO,  NO and O2 is unknown.  It seems  more  likely that preformed  CO  bound 
to Fe(ll),  e.g., of cellular Hp, would increase or decrease the bioactivity of newly 
synthesised NO in response to physiological stimulation or pathological  events. 
This  effect  would  produce  differences  in  the  apparent  effects  of  CO  as  a 
function of the concentrations and metabolic fates of all three gases.  Direct CO- 
NO interactions will not occur in the met-Hp because CO does not bind to Fe(lll) 
(Sato,  Nomura,  Sagami,  Ito,  Daff,  &  Shimizu  1998).  Finally,  the  interactions 
among  CO,  NO  and  O2  will  be  influenced  by  generation  of  reactive  oxygen 
species  that  depend  on  the  presence  of  reduced  transition  metals  (Maines 
1997; Sato,  Nomura, Sagami,  Ito,  Daff, & Shimizu 1998).
Living  organisms  encounter  CO  through  incidental  environmental  exposure, 
usually  by  inhalation.  Cigarette  smoke  accounts  for  a  major  source  of  CO 
exposure in humans.  CO at certain concentrations,  like all  agents including  life 
sustaining oxygen,  has limits of tolerability. At high concentrations (HbCO  level
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of 70 % or more), exposure to CO is lethal, usually through accidental smoke or 
exhaust inhalation in enclosed spaces.
In  addition  to  uptake  of exogenous  gas,  cells  and  tissues  produce  significant 
amounts  of CO  as  an  elimination  product  of cellular  metabolism,  largely from 
haem  degradation  catalysed  by  HO  enzymes.  To  better  appreciate  the 
controversial  standing  of  CO  in  the  scientific  community  we  will  review  the 
discoveries that have led to where we are today.
1.11.2  History of Carbon Monoxide
It was first shown that human blood carries a small but measurable CO content 
over some 50 years ago but the roots of its scientific interest stem from earlier 
in history (Piantadosi 2002).  CO first came to biological attention in  1857 when 
the  French  physiologist  Claude  Bernard  determined  that  the  gas  produces 
asphyxia  by  reversibly  combining  with  haemoglobin  (Bernard  1991).  In  1895, 
J.S.  Haldane  demonstrated  that  CO  binding  to  haemoglobin  could  be 
antagonised  by  high  partial  pressures  of  O2  (PO2)  and  that  mammals  would 
survive  lethal  CO  poisoning  if  a  large  amount  of  O2  was  dissolved  in  blood 
plasma  (Haldane  1895).  During World War  II,  Roughton  and  Darling  reported 
that carboxyhaemoglobin (HbCO) shifted the oxyhemoglobin dissociation curve 
to the  left because the  unoccupied  haems of the  haemoglobin tetramer bound 
O2 with  greater affinity  after the  addition  of CO  to  one  site.  This  effect  of CO 
made  it  more  difficult  for  the  haemoglobin  molecule  to  unload  oxygen  in  the 
tissues  (Roughton  &  Darling  1944).  These  pioneering  studies  gave  rise to the 
common  concept  of  the  pathophysiology  of  CO  poisoning  based  on  tissue 
hypoxia.  Accordingly,  the decreased  arterial  O2 content (Ca0 2 )  in combination
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with  increased  affinity of HbCO for O2 led  to a  decrease  in  tissue  P0 2 ,  which 
produced  manifestations  of  hypoxia  in  the  tissues  (Stewart  1975).  Although 
these  principles  have  formed  a  sound  scientific  basis  for  understanding  the 
many biological  effects of CO  and the treatment of CO  poisoning,  they do  not 
tell  the  whole  story.  Principally,  they  fail  to  explain  the  classical  differences 
between the cellular effects of simple hypoxia and those of CO hypoxia.
In addition to early work on  its physiological effects,  CO was used as a tool to 
study  tissue  respiration.  In  ground-breaking  studies  to  discover the  source  of 
cellular respiration, Otto Warburg,  David Keilin, and others, found CO invaluable 
as  a  tool  to  study  the  biochemical  behaviour  of  intrinsic  tissue  pigments, 
identified  subsequently  as  myoglobin  and  cytochrome  c  oxidase  (cytochrome 
0 ,0 3) (Warburg 1930; Keilin & Hartree 1939; Keilin 1966).  In the 1920s, Warburg 
engaged  in the study of the role of iron  in respiration and found that CO could 
inhibit  respiration  in  yeast  in  a  light-sensitive  manner,  extending  the  1896 
observation  of Haldane  and  Smith,  who  had  discovered  that  HbCO  could  be 
dissociated  by exposure to  light of appropriate wavelengths  (Haldane & Smith 
1896).  Even  now,  photodissociation  of  CO  from  Hp  at  picosecond  and 
nanosecond  resolution  is  a  powerful  approach  for  studying  molecular  ligand 
binding (Olson & Phillips,  Jr.  1996).  In the 1930s,  Fenn and Cobb reported that 
living tissues burned CO by oxidising it to CO2;  however,  mitochondria were not 
shown to be the source of this oxidising power until almost 50 years later (Fenn
1970).
The  many fascinating  and  curious  aspects  of CO  biology  stimulated  efforts  in 
the latter half of the 20th  century to understand the biological chemistry of CO.  In 
1952,  Sjostrand and Coburn reported that decomposition of haemoglobin in vivo
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led  to  CO  generation  and  that,  certain  pathological  conditions  e.g.,  anaemia 
could  augment  it  further  (SJOSTRAND  1952).  Increases  in  HbCO  were 
attributable to metabolic CO production, particularly after haem degradation had 
been  stimulated  by hemolysis  (Coburn,  Williams,  &  FORSTER  1964;  Coburn, 
Williams,  & Kahn 1966).  Specific drugs and chemicals were found to accelerate 
endogenous  CO  production,  including  progesterone.  At  about  the  same  time 
Tenhunen et al conducted biochemical studies which indicated that endogenous 
CO was produced primarily from haem catabolism by HO (Tenhunen, Marver, & 
Schmid  1968).  Furthermore,  in the microsomal fractions of cells,  CO was found 
to  bind  to  unique  cytochromes,  now  called  mixed-function  oxidases,  and  the 
appearance  of the  broad  CO  band  of the  reduced  enzyme  in  the  Soret  (UV) 
region of the spectrum  led to the name cytochrome P450 (Estabrook,  Franklin, 
& Hildebrandt 1970).
At the  university of Pennsylvania  in the  1960s and  1970s,  largely through  the 
physiological  studies of Coburn,  the CO  store  in the  body was  measured,  and 
the  uptake  of  CO  by  tissues,  particularly  skeletal  and  cardiac  muscle,  was 
shown during ambient exposures.  Coburn recognised that the amount of CO  in 
tissues  increased  substantially during  hypoxia  due to  transfer of the  gas from 
blood to tissue and binding of CO to Hp such as myoglobin (Coburn & Mayers
1971).  Similarly,  it  was  demonstrated  that  CO  diffused  out  of  the  maternal 
circulation across the placenta and bound to foetal  haemoglobin in  vivo (Hill  et 
al.  1977).
Within  the  last  25  years,  it  has  been  documented  that  CO  is  oxidised  in  the 
body  to  CO2  by  mitochondria  (Young  &  Caughey  1986;  Young  &  Caughey 
1990).  CO  alters  the  mitochondrial  redox  state  and  energy  provision  in  the
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brain; these effects persist after HbCO has been cleared from the blood (Brown 
&  Piantadosi  1992).  By  activating  guanylate  cyclase,  CO  inhibits  platelet 
aggregation  and acts as a direct vasodilator (Brune &  Ullrich  1987).  Toxic and 
presumed  subtoxic CO  exposure  are  associated with  significant  oxidative  and 
nitrosative  stress  (Thom  1990;  Thom,  Xu,  &  Ischiropoulos  1997a;  Thom  et  al. 
1999a).  It was not until  1991  when Marks et al published a paper entitled “Does 
carbon  monoxide  have  a  physiological  function?”  that  the  idea  of  CO  as 
something more than a waste product was considered (Marks et al.  1991). The 
reasoning behind this idea was that CO could perhaps play a similar role to NO 
in  cell  function,  regulation  and  communication  due  to  their  similar  chemistry. 
The findings that both  biliverdin and  bilirubin,  two other long considered waste 
products  of  haem  catabolism,  had  beneficial  properties  added  credence  to 
these new claims (Stocker et al.  1987;  Stocker,  Glazer,  & Ames  1987;  Stocker 
1990).  As  time  passed  and  the  number  of  publications  in  favour  of  CO  as 
beneficial  end  product  of  haem  catabolism  grew,  the  initial  scepticism  that  a 
long  regarded  toxic  gas  could  have  an  important  role  to  play  physiologically 
subsided.
Finally, over the past decade, endogenous CO production has been associated 
with  changes  in  intra  and  intercellular  signalling  processes,  e.g., 
neurotransmission  and  vasodilation  by  activating  guanylate  cyclase  (Verma  et 
al.  1993;  Maines  1997).  Some  of  these  effects  of  CO  appear  to  be  closely 
related to those of NO whereas others may  be direct  influences  of CO  on the 
behaviour of NO through  interactions with  iron  or other metals.  The  effects  of 
CO  are  proving to be  important in  regulating  inflammation,  cell  death,  and  cell
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proliferation in vivo, although the links to specific biochemical reaction in the cell 
still await elucidation.
Since  its  discovery  as  an  endogenously formed  product of haem  degradation 
the  number  of  biological  activities  associated  with  CO  has  been  steadily 
increasing.
1.11.3  Carbon Monoxide Bioactivity
The release of CO from vascular cells may have important physiological and/or 
pathophysiological  consequences.  Under  normal  conditions,  endogenous  CO 
binds to  red  blood  cells  (RBC) forming  HbCO  and  is  transported  to the  lungs 
(Goldbaum,  Orellano,  &  Dergal  1976).  The  HbCO  is  equilibrated with  inhaled 
oxygen within the lungs and CO expelled from the body via exhalation, although 
approximately 1% is retained (see Figure 1.16).
In healthy blood vessels,  the basal release of CO by endothelial cells,  primarily 
via the constitutive HO-2 enzyme,  may exert important paracrine effects on the 
underlying smooth muscle cells (SMC) and on circulating blood cells (Durante & 
Schafer 1998;  Dulak et al. 2002). CO has been shown to maintain vascular tone 
in  large  and  small  arteries  and  directly  relax  vascular  smooth  muscle  in  a 
reversible  manner  (Durante  &  Schafer  1998;  Kaide  et  al.  2001).  A  threshold 
concentration  of  1   pM  CO was  sufficient to  induce  these  effects  and  was  not 
dependent on the presence of an intact endothelium unlike NO (Maines 1997).
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Figure 1.16:- Gas exchange in the body.
CO generated in the tissues diffuses to blood vessels and binds to haemoglobin 
(Hb) which transports it to the lungs to be expelled where upon the Hb takes up 
oxygen to deliver to the tissues and the process starts again.
The  effects  of  CO  on  blood  pressure  may  be  regulated  directly  through  the 
promotion of vasodilation or indirectly via acting on the nucleus tractus solitaius 
in the brain, which leads to an alteration of glutamatergic transmission and thus 
a  lowering  of  blood  pressure  (Maines  1997;  Johnson,  Kozma,  &  Colombari 
1999;Morse  &  Sethi  2002).  The  ablumenal  release  of CO  by endothelial  cells 
may  play  an  important  fundamental  role  in  regulating  blood  flow  by  inhibiting 
smooth  muscle tone and  SMC  proliferation,  while  CO  released  into the vessel
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lumen may modulate blood fluidity by preventing the aggregation and adhesion 
of platelets  (Morita  et al.  1995).  In  addition,  the  constitutive  release  of CO  by 
HO-2  in vascular SMC  may also contribute  in an autocrine manner to regulate 
SMC contraction and growth.
In the liver,  where all the HO isoforms are expressed,  inhibition of their activity 
(but  not  NOS  activity)  increased  hepatic  vascular  resistance  which  was 
reversed by 1   pM exogenous CO (Suematsu, Wakabayashi,  & Ishimura 1996a; 
Wakabayashi  et  al.  1999;  Suematsu  &  Ishimura  2000).  Moreover,  the 
constitutive  expression  of  HO-2  or  the  induction  of  HO-1  in  endothelial  cells 
points to the possibility of CO  regulating  blood  pressure in  vivo,  during  normal 
and stressful conditions (Motterlini et al.  1998a; Motterlini et al.  1998b; Johnson, 
Kozma, & Colombari 1999). The vasorelaxation capability of CO is not common 
to  all  vascular  tissues  as  cerebral  arteries  seem  to  be  refractive  to  CO,  but 
responsive only to NO; the differential response to these two gases  in cerebral 
arteries  is  not  entirely  clear  at  present.  The vascular  effects  of CO  are  likely 
mediated by the activation of soluble guanylate cyclase and the consequent rise 
in  intracellular  cGMP  (Durante  et  al.  1997).  In  this  respect,  the  physiological 
roles of CO parallel those of NO, and thus these two diatomic gases may exert 
constitutively  additive  or  synergistic  actions  on  the  maintenance  of  vascular 
tone  and  blood fluidity.  However,  at sites  of vascular injury,  where  endothelial 
cells are lost or damaged, vascular SMC may be capable of subsuming some of 
the  vasodilatory,  anti-proliferative,  and  anti-thrombotic  properties  of  the 
endothelium  by  upregulating  CO  production  via  the  inducible  HO-1  enzyme 
(Stanford et al. 2003).  Following local injury of the blood vessel wall,  circulating 
monocytes and macrophages are recruited to the site of injury, where they are
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activated and release various inflammatory cytokines,  including 1 1 -1  p and TNF-a 
(Ndisang et al.  2002;  Morisaki et al.  2002).  These inflammatory mediators  can 
further stimulate the production of cytokines by the blood vessel wall leading to 
locally  elevated  levels  of  cytokines  and  the  induction  of  HO-1.  CO-mediated 
inhibition  of platelet activation and  neutrophil  migration  are  likely stimulated  by 
an  increasing  concentration  of  cGMP.  These  characteristics  have  been 
suggested  as  a  mechanism  by  which  CO  promotes  survival  of  transplanted 
organs  as  expression  of  HO-1  has  been  shown  to  protect  against  chronic 
rejection  (Luckraz et al.  2001;  Nakao  et al.  2003b).  Furthermore,  a  direct  link 
between  CO formation  and  suppression  of xenograft  rejection  in  mouse-to-rat 
cardiac  and  liver  transplants  models  was  demonstrated  by  Soares  and  co­
workers,  as  inhibition  of  HO-1  induction  with  tin  protoporphyrin  promoted  an 
acute  rejection  episode,  whereas  exogenous  CO  restored  long-term xenograft 
survival  (Sato et al.  2001). A number of publications have highlighted the anti­
inflammatory ability of HO-1  to suppress endothelial cell apoptosis via activation 
of  the  p38  mitogen  activated  protein  kinase  (MAPK)  signal  transduction 
pathway  (Brouard  et  al.  2000;  Soares  et  al.  2002).  Moreover,  at  sites  of 
endothelial loss, vascular SMC may be directly exposed to arterial levels of fluid 
shear stress,  which  acts  as  a  potent  stimulus for HO-1  expression.  Based  on 
the  finding  that  haemodynamic forces  selectively  induce  HO  but  not  NOS  in 
vascular  SMC,  CO  (but  not  NO)  is  likely to  be  the  principle  mediator of flow- 
dependant  changes  in  the  vascular  tone  at  sites  of  blood  vessel  damage 
(Wagner,  Durante,  Christodoulides,  Heliums,  &  Schafer  1997).  The  focal 
induction  of  HO-1  and  CO  release  by  SMC  at  sites  of  vascular  injury  may 
promote  vascular  homeostasis  by  preventing  blood  vessel  spasm  and  SMC
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proliferation (Otterbein et al.  2003d).  SMC can also  inhibit platelet aggregation 
via  HO-1  catalysed  release of CO,  suggesting that SMC  derived CO  may play 
an  important  role  in  regulating  thrombus  formation  in  vivo,  at  sites  of  injury 
(Durante & Schafer 1998).
The  induction  of  HO-1  and  the  generation  of  CO  may  also  be  of 
pathophysiological  significance.  Ischemia-reperfusion results  in  HO-1  induction 
in both the kidney and the heart (Maines 1997; Zhang et al. 2003).  Under these 
conditions,  the  induction  of HO-1  may  serve  as  an  important  cellular defence 
mechanism  by  enhancing  the  degradation  of the  pro-oxidant  molecule,  haem. 
Induction  of  HO-1  also  results  in  the  generation  of  bilirubin  and  biliverdin  as 
discussed  earlier.  Both  these  haem  metabolites  are  efficient  scavengers  of 
reactive  oxygen  species  and  inhibit lipid  peroxidation  (Neuzil  &  Stocker  1994; 
Kranc et al.  2 0 0 0 ).  HO-1  mediated production of CO also improves blood supply 
to these  organs  by dilating the blood vessels.  Similarly,  the  induction  of  HO-1 
expression following a subarachnoid haemorrhage may serve to increase haem 
clearance,  and enhance the production of anti-oxidant bile pigments as well as 
vasorelaxant  CO,  thus  reducing  the  damage  resulting  from  lipid  peroxidation 
and  vasospasm  (Koehler & Traystman 2002;  Otterbein,  Soares,  Yamashita,  & 
Bach 2003b).
The  capacity  of  NO  to  induce  HO-1  activity  in  vascular  cells  may  also  be  of 
pathophysiological relevance.  In response to blood vessel  injury,  vascular cells 
express inducible NOS (iNOS) generating copious amounts of NO that could be 
cytotoxic.  The release of CO following HO activation  may provide an important 
mechanism  in  limiting  NO  release  since  CO  directly  inhibits  NOS  activity  by 
binding  to the  haem  moiety  of the  enzyme  (Stone  &  Marietta  1994;  Foresti  &
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Motterlini  1999).  In addition,  because haem is essential for both the intracellular 
assembly of the  active  dimeric NOS  and  its catalytic activity,  increases  in  HO 
activity  may  reduce  intracellular haem  levels,  thereby  limiting  the formation  of 
active  NOS  enzyme.  Finally,  iron  released  during  the  course  of  haem 
degradation  could  further  inhibit  NOS  synthesis  by  inhibiting  its  nuclear 
transcription  (Wolff et al.  1996). Thus  NO induced  HO-1  induction  may provide 
an  important  negative feedback mechanism  in  limiting the  release of cytotoxic 
levels  of  NO  by  vascular  cells  while  still  preserving  blood  flow  at  sites  of 
vascular injury by releasing CO.
The  discovery  of  a  neuronal  role  for  NO  led  to  the  suggestion  that  CO  may 
function  as  a  neurotransmitter,  intracellular  messenger,  and  modulator  of 
neuroendocrine  function  (Marks,  Brien,  Nakatsu,  &  McLaughlin  1991; 
Prabhakar  1998;  Baranano  &  Snyder  2001;  Dulak  &  Jozkowicz  2003).  The 
discovery  of  HO  isoforms,  particularly  HO-2  throughout  the  central  nervous 
system  (CNS)  and  peripheral  nervous  system  (PNS)  has  added  weight to the 
hypothesis that CO is an important gaseous neural messenger, while in certain 
cases  CO  formation  may  substitute  for  decreased  or  absent  NOS  activity 
(Morse,  Sethi,  & Choi 2002).  In the digestive system,  mice  lacking  HO-2  have 
an impaired nonadrenergic,  noncholinergic (NANC) relaxation response in their 
mysenteric  plexus,  a  phenotype  that was  also  observed  in  mice  lacking  NOS 
(Chakder et al.  2000;  Boehning et al.  2003).  In  another study,  it was  reported 
that  CO  and  NO  act  as  coneurotransmitters  in  the  modulation  of  neuronal 
activity  in  the  enteric  nervous  system  (Baranano  &  Snyder  2001).  These 
examples  illustrate  the  neurotransmitter  capacity  of  CO  and  support  the 
possibility  that  CO  and  NO  act  as  coneurotransmitters  in  the  same  neurons.
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Certain neurodegenerative disorders, e.g., Alzheimer’s and Parkinson’s disease 
sufferers  (AD  and  PD  respectively),  show  an  increased  expression  of  HO-1 
protein  in regions with senile plaques and neurofibrillary tangles, while amyloid 
precursor protein, which is postulated to be a major cause in the neurotxicity of 
AD,  leads to inhibition of HO (Frankel,  Mehindate,  & Schipper 2000;  Baranano 
& Snyder 2001). The precise function and mechanism of haem oxygenase and, 
therefore,  CO  in  these  and  other  neurodegenerative  disorders  is  unclear  at 
present. Another possible neurological function for CO is in the area of learning 
and memory as there is evidence to support a role for the molecule in long-term 
potentiation (Zhuo et al.  1993; Piantadosi et al.  1997).
Carbon monoxide also seems to play a role in various aspects of reproduction. 
During  pregnancy,  CO  maintains  normal  vascular  tone  to  protect  against 
preeclampsia and relaxes smooth muscle in the uterus (Kreiser et al.  2004).  In 
the  placenta,  CO  has  been  muted  to  control  functional  and  developmental 
maturity as haem  oxygenase  isoforms are widely distributed  in the  placenta at 
different  periods  of  gestation  (McLaughlin  et  al.  2001;  Lyall  2003).  The 
reproductive effects of CO are conveyed through the regulation of the endocrine 
system.  For  example,  CO  inhibits  the  release  of  corticotrophin-releasing 
hormone (CRH),  arginine vasopressin,  and oxytocin,  but promotes the release 
of  luteinising  hormone-releasing  hormone,  all  of  which  are  involved  in  the 
hypothalamus-pituitary-adrenal axis control of pregnancy (Mancuso et al.  1998). 
Within  the  male  reproductive  track,  CO  originating  from  specific  neuronal 
populations  within  the  vas  deferens  may  act  as  a  neurotransmitter  in  the 
regulation  of  ejaculation  as  mice  with  a  targeted  deletion  of  HO-2  exhibit 
ejaculatory abnormalities (Snyder, Jaffrey, & Zakhary 1998;  Burnett et al.  1998).
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Secondly, cholinergic nerves which innervate the corpus cavernosum (CC) and 
spongiosum (CS) contain haem oxygenase isoforms, which suggests a role for 
CO in penile erection (Ushiyama et al. 2004).
While the local induction of HO-1  and CO production by vascular cells following 
vascular injury may serve an important protective role in maintaining blood flow 
and  limiting  oxidative  damage,  a  more  generalised  induction  of CO  synthesis 
may have deleterious effects.  In this respect,  a  recent study suggests that the 
widespread induction of HO-1  in the vasculature and the subsequent production 
of large  amounts  of CO  may  contribute to the  severe  hypotension  associated 
with endotoxin shock (Penney 1988).  In addition, high levels of CO can directly 
damage  vascular  cells  by  generating  reactive  oxygen  species.  CO  binds  to 
mitochondrial  haem  proteins  and  disrupts  mitochondrial  electron  transport 
leading  to  the  release  of  superoxide  anions.  High  CO  exposure  also 
competitively  discharges  NO  from  haem  proteins  which  subsequently  reacts 
with  superoxide  to  yield  cytotoxic  peroxynitrite  (Thom,  Xu,  &  Ischiropoulos 
1997b; Thom et al.  1999b). Thus, depending on the amounts generated CO can 
exert both  beneficial  and  harmful  effects  on the vascular system.  Pathological 
excess  of  CO  production  results  in  a  range  of  toxic  effects,  the  earliest 
detectable difference being an increase in HbCO levels (10-20%), which due to 
the  high affinity of Hb for CO  (~240 times greater than  oxygen)  interferes with 
oxygen  delivery.  CO  levels  of  40-60%  generally  result  in  death  due  to  the 
binding  of CO with  other haemoproteins  e.g.,  CYP-450,  myoglobin  (see Table 
1.2).
Measurement of CO in the blood (HbCO) and breath lends itself well to use as 
an  indicator  of  haem  degradation  and  bilirubin  formation  as  it  is  expelled
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primarily  via  the  lungs  and  is  derived  from  HO  in  a  1:1  ratio  with  bilirubin. 
Excess  HbCO  in the  blood  gives  a  rosy  hue to the  complexion  of the  sufferer 
much the same as bilirubin excess causes a yellowing of the skin.
In  adults,  CO  is  formed  at  a  rate  of  0.4  ml/h  (16.4  pmol/h).  The  rate  of  CO 
production  (Vco)  is  normally  relatively  constant  in  males;  however,  both 
newborns and females exhibit variations.  Under pathological conditions the Vc0 
can  increase  in  an  adult male from  18 to  160  pmol/h.  The effects of which are 
detailed in Table 1.3 (Stevenson, Vreman, Wong, & Contag 2001).
Table  1.2:-  The  symptoms  and  effects  of  various  carboxyhaemoglobin 
levels in man.
HbCO
Level
Signs and Symptoms
0 % Usually none
1 0 % Frontal headache
2 0 % Throbbing headache, dyspnea with exertion
30% Impaired  judgment,  nausea,  dizziness,  visual 
disturbance, fatigue
40% Confusion, syncope
50% Coma, seizures
60% Hypotension, respiratoryfailure
70% Death
Reisdorff EJ,  Wiegenstein  JG.  Carbon  monoxide  poisoning.  In:  Tintinalli 
JE,  Krome  RL,  Ruiz  E.  Emergency  Medicine:  A  Comprehensive  Study 
Guide. 3rd Ed. New York: McGraw Hill; 1992:704.
Approximately 86% of endogenous  CO  production  is derived from the result of 
HO  action.  The remaining  14%  is  attributable to non-enzymatic sources which 
include;  lipid  peroxidation,  photo-oxidation  of  natural  or  synthetic
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photosensitisers  e.g.,  riboflavin,  bilirubin  and  some  metalloporphyrins  and 
intestinal bacteria (Maines 1997; Archakov et al. 2002).
Table 1.3:- Effects of excess CO on the human body.
Neuropsychiatric
Coma  seizures,  agitation,  leukoencephalopathy,  cerebral  edema,  behavioral  disorders, 
decreased  cognitive  ability,  Tourette-like syndrome,  mutism, fecal  and  urinary incontinence, 
parietal  lobe  dysfunction,  ataxia,  muscular  rigidity,  Parkinsonism,  peripheral  neuropathy, 
psychosis, memory impairment, gait disturbance, abnormal EEG, personality changes.
Cardiovascular
Angina, tachycardia,  ST-segment changes,  hypotension,  arrhythmias,  myocardial  infarction, 
heart block.
Pulmonary
Pulmonary edema and hemorrhage, unilateral diaphragmatic paralysis.
Ophthalmologic
Flame-shaped  retinal  hemorrhages,  decreased  light  sensitivity,  decreased  visual  acuity, 
cortical blindness, retrobulbar neuritis, papilledema, paracentral scotomas.
Vestibular and Auditory
Central hearing loss, tinnitus, vertigo, auditory nystagmus.
Gastrointestinal
Vomiting, diarrhea, hepatic necrosis, hematochezia, melena.
Dermatologic
Bullae, alopecia, sweat gland necrosis, “cherry-red" skin color (rare), edema, cyanosis, pallor, 
erythematous patches.
Musculoskeletal
Rhabdomyolysis, myonecrosis, compartment syndrome.
Renal
Acute renal failure secondary to myoglobinuria, proteinuria.
Metabolic
Lactic  acidosis,  non-pancreatic  hyperamylasemia,  diabetes  insipidus,  hyperglycemia, 
hypocalcemia, polycythemia.
Foetal
Death, cerebral atrophy, microcephalus,  low birth weight,  psychomotor retardation, seizures, 
spasticity.
Reisdorff EJ, Wiegenstein JG. Carbon monoxide poisoning.  In: Tintinalli JE, Krome RL, Ruiz 
E. Emergency Medicine: A Comprehensive Study Guide. 3rd edition. New York: McGraw Hill; 
1992:704.
The discovery that CO can bind to the iron within the haem moiety of sGC, thus 
activating  the  enzymatic  conversion  of  GTP  to  cGMP,  suggests  that  CO 
mediates  its  biological  effects  via  a  cGMP  pathway  (Durante  &  Schafer  1998;
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Steiner  &  Branco  2001).  This  mechanism  of  activating  sGC  is  similar  to  that 
elicited  by  NO  but  differs  with  respect  to  the  bonds  formed  and  intensity  of 
upregulation  of the  enzyme.  Furthermore,  the  benzylindazole  derivative  YC-1 
can enhance the activation of sGC by CO > 4000%, suggesting an endogenous 
‘YC-1  like’  molecule  may enable  a  higher degree  of activation  of sGC  by  CO 
akin to NO (Friebe & Koesling  1998;  Friebe, Mullershausen,  Smolenski, Walter, 
Schultz,  &  Koesling  1998).  Although  many  studies  of  CO  function  have 
employed  metalloporphyrins  (e.g.  tin  protoporphyrin)  as  inhibitors  of  haem 
oxygenase  the  use  of such  agents  has  been  questioned  due  to  the  possible 
inhibition of sGC and modulation of NOS activity (Grundemar & Ny 1997).
There  is  still  a  great  deal  about  CO  to  be  discovered  and  as  Barinaga 
commented in Science in 1993, “...  this gas is likely to provide fuel to run plenty 
of labs” (Barinaga 1993).
1.11.4  The Development of Carbon Monoxide-Releasing Molecules
The  importance  of  CO  in  the  biological  environment  is  strongly  emerging.
Consistent findings  have  revealed  a  series  of  important  cellular functions  that 
support a versatile and previously unidentified role for CO gas.  It is  interesting 
that many of the novel  properties  pertaining to  CO  have strong analogies with 
the well-established biological activities elicited by NO.  Research  in the field of 
NO  has  been  largely  facilitated  by  the  development  of  a  variety  of  organic 
compounds that spontaneously release  NO  and can reproduce a physiological 
or pathophysiological function of NO; however,  no attempts have been made to 
identify or develop similar compounds capable of delivering CO.
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The  idea  that  CO  could  be  delivered  into  the  body  to  target  physiological  or 
pathophysiological  problems  such  as  the  highly  successful  NO  donors  is  an 
intriguing one. Such a compound could also be used as a research tool to aid in 
the  elucidation  of  further  functions  of  CO  in  vivo  and  in  vitro.  Without  the 
existence of this compound  researchers  have tried  using  inhalation of CO gas 
as  an  internalisation  method,  although,  the  results  have  been  promising  the 
delivery method  is  not targeted and  lacks any real  control  of how much  CO  is 
actually  being  delivered  to  the  site  where  upon  it  is  required  to  act.  Not  to 
mention the systemic effect of CO gas on oxygen transport and delivery.
During  the  past  few  years  our  laboratory  has  been  working  on  the 
characterisation  of  biological  activities  associated  with  transition  metal 
carbonyls as potential CO releasing molecules (CO-RMs) (Motterlini et al. 2001; 
Motterlini,  Foresti,  &  Green  2002;  Mann  &  Motterlini  2002;  Motterlini  et  al. 
2002a;  Johnson et al.  2003;  Boehning,  Moon,  Sharma,  Hurt,  Hester,  Ronnett, 
Shugar, & Snyder 2003;  Motterlini et al. 2003b;  Clark et al. 2003b;  Foresti et al. 
2004).  These  complexes  are  compounds  that  contain  a  transition  metal  e.g., 
iron,  manganese  and  are surrounded  by carbonyl  (CO) groups as coordinated 
ligands and are used as catalysts in organic synthesis.  Already metal  carbonyl 
complexes are finding novel applications in research in the fields of cell biology, 
immunology,  and  pharmacology (Mosi  et al.  2002).  Their application  in  cancer 
therapy, drug receptor interaction, and malaria is also extremely promising.  Bio- 
organometallic  chemistry  has  now  become  an  emerging  discipline  that  may 
offer innovative solutions to biological problems.  Progress in this field has been 
possible  despite  the  fact  that  the  majority  of  biologists  and  pharmacologists 
generally and incorrectly view transition metals ions as toxic ‘heavy metals’. The
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chemical  development  of  anticancer  drugs  as  well  as  immuno-suppressants 
based on ruthenium provides evidence of how metal-containing compounds can 
be  used  for  the  development  of  new  pharmaceuticals  (Motterlini,  Mann, 
Johnson, Clark, Foresti, & Green 2003b).
From  inorganic chemical  studies  conducted  on  these  substances  in  vitro,  it  is 
known that certain  ligands in a metal complex can  promote,  either sterically or 
electronically,  the  dissociation  of CO.  Furthermore,  photodissociation  and  the 
consequent elimination of the CO group(s) following exposure to light has been 
reported  in  the  case  of specific  metal  carbonyls  (Motterlini  et  al.  2002b).  The 
discovery  that  carbonyl  complexes  posses  such  interesting  and  promising 
features in vitro prompted our laboratory to examine the ability of some of these 
compounds  to  promote  a  physiological  response  in  biological  systems.  The 
molecules were initially tested to see  if they released  CO  using a set up  as  in 
Figure  1.17  (Motterlini,  Clark,  Foresti,  Sarathchandra,  Mann,  &  Green 2002a). 
The  release  of  CO  was  stimulated  either  by  the  exposure  of  the  carbonyl 
solution  to  cold  light  in  the  case  of  iron  pentacarbonyl  and  dimanganese 
decacarbonyl  ([Mn2(CO)io)]),  or by direct addition to the myoglobin  in the case 
of  tricarbonyldichlororuthenium  (II)  dimer  ([RufCO^Chb)-  Due  to  the  high 
affinity of myoglobin for CO any released would  be captured by the  myoglobin 
and  the  subsequent  conversion  of  the  deoxygenated  myoglobin  to  carboxy 
myoglobin results in a change in the absorbance curve which gives a measure 
of the  CO  released  (Motterlini,  Clark,  Foresti,  Sarathchandra,  Mann,  &  Green 
2 0 0 2 b).
- Page 85 -UCL INTRODUCTION
0.4 pm anapore membrane 
cell cullpre well
light source
2 cm
parafilm cover
1.5 ml experimental solution 
(either cell culture medium or 
deoxyMb)
0.5 ml CO-donor in solution 
(either DMSO or MeOH)
inverted 20ml "universal" tube
Figure  1.17:-  Schematic  diagram  showing  the  CO  release  measurement 
setup  for  light  stimulated  compounds  iron  pentacarbonyl  and 
dimanganese decacarbonyl.
CO  released  by  the  CO-RM  would  pass  through  a  0.4  pM  Anapore™ 
membrane and into the myoglobin solution above. Adapted from Motterlini et al, 
Curr Pharm Des. 2003;9(30):2525-39.
At this point further investigations on iron pentacarbonyl were abandoned due to 
its deposition  of a  green  brown  precipitate.  As there were  no  previous studies 
on  the  use  of  metal  carbonyl  complexes  in  biological  systems  the  potential 
cytotoxic effects of each was evaluated.  Neither [Ru(CO)3CI2]2 or [Mn2(CO)i0)] 
caused  any  appreciable  decrease  in  cell  viability  over  time  at  concentrations 
below  400  pmol/L  (Motterlini,  Clark,  Foresti,  Sarathchandra,  Mann,  &  Green 
2002a). The structure of each is shown in Figure 1.18.
- Page 86 -UCL INTRODUCTION
CO
OC— M
oc
CO
CO
n u
sCO
CO
OC
✓
n— CO
CO
B
OC
CO
\
Ru
O C/
C l
C l
C l
C l
CO
\
CO
CO
Figure 1.18:- Structure of A) dimanganese decacarbonyl ([Mn2(CO)i0)]) and 
B) tricarbonyldichlororuthenium  (II) dimmer ([RufCOhCljz),  CORM-1  and 
CORM-2 respectively.
The effect of [Ru(CO)3Cl2]2 was then  studied  in  an  isolated  aortic rings  model 
(Motterlini,  Clark,  Foresti,  Sarathchandra,  Mann,  &  Green  2002a).  The 
compound exhibited significant vasodilatory effects after the first addition (4 5 % 
greater  than  control)  and  was  shown  to  have  a  long  term  effect  as 
phenylephrine  induced  contraction  was  not  able  to  be  restored  even  after 
extensive washings. This vasodilatory effect was significantly attenuated by the 
addition of myoglobin to the buffer (which as mentioned earlier avidly binds CO) 
and  ODQ  (a  selective  inhibitor of guanylate  cyclase).  Interestingly,  ODQ  only 
has an observed effect over the first two additions of [Ru(CO)3CI2]2 but the third
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addition elicited a substantial vasodilatory effect despite the presence of ODQ. 
This data shows that CO released from this early identified CO-RM is at least in 
part  cGMP  dependent.  The failure  of ODQ  to  completely  prevent vasodilation 
may  result  from  CO  being  in  sufficiently  high  levels  to  displace  ODQ  from 
guanylate cyclase or to circumvent this pathway altogether and exert relaxation 
via  other  independent  cellular  pathways  (Motterlini,  Clark,  Foresti, 
Sarathchandra, Mann, & Green 2002b).
Experiments  using  the  isolated  heart  model  and  [Mn2(CO)io)]  confirmed  the 
vasoactive  properties  of  this  CO-RM  further.  This  metal  carbonyl  markedly 
attenuated L-NAME mediated increase in coronary perfusion pressure;  notably, 
this effect could only be achieved when [Mn2(CO)io)] was stimulated by light to 
release  CO.  This corroborates evidence showing that endogenously produced 
CO can profoundly modulate cardiac vessel function but was achieved using an 
exogenously applied CO-RM (Motterlini, Clark,  Foresti, Sarathchandra, Mann, & 
Green 2002b).
Further experiments were carried out investigating the antihypertensive actions 
of [Ru(CO)3CI2]2 in animals. As seen with previous experiments using hemin to 
upregulate  HO-1,  [Ru(CO)3CI2]2 was  found  to  suppress  the  increase  in  mean 
arterial  pressure  elicited  by  the  intravenous  administration  of  L-NAME 
supporting  further  the  potential  of  CO  to  be  used  in  vivo  (Motterlini,  Clark, 
Foresti, Sarathchandra, Mann, & Green 2002b).
These  initial  experiments  opened  the door to a  host of exciting  possibilities  in 
the world of CO releasing molecules. In addition, with the success of exogenous 
CO gas delivery models in anti-inflammatory and anti-apoptotic the potential of 
a  therapeutic  application  for  CO-RMs  was  strongly  emerging  (Figure  1.19).
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There  was  scope  to  engineer  molecules  that  could  release  CO  with  distinct 
kinetics  and  have  molecules  that  were  highly  specific  and  thus  deliver  CO 
directly to an  area of insult.  On the back of these first successful  experiments 
our  group  went  on  to  develop  CO-RMs  more  compatible  with  the  biological 
system.
CO CO-RMs HO pathway
Cytochrome c oxidase
NADPH oxidase
iNOS p38 MAPK
Guanylate cyclase
Anti-inflammation Anti-apoptosis
GTP Vasoregulation
Neurotransmission
cGMP
p21 Anti-proliferation
Figure 1.19:- Biological action of CO.
Endogenously  derived  CO  has  been  shown  to  exert  many  effects.  Most 
endogenously  generated  CO  is  derived  from  the  HO  pathway  but  could  CO- 
RMs  be  used to  achieve  similar outcomes?  Extract from  Ryter et al,  Mol  Cell 
Biochem. 2002 May-Jun;234-235(1-2):249-63.
The  original  CO-RMs  were  only  soluble  in  organic  solvents  and  required 
physical  (i.e.  irradiating  light)  or  chemical  (i.e.  steric  ligands)  intervention  to 
favour  CO  dissociation  from  these  complexes.  Interestingly,  the  versatile
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chemistry  of  transition  metals  allows  them  to  be  cleverly  modified  by 
coordinating  biological  ligands  to  the  metal  centre  in  order  to  render  the 
molecule  less  toxic,  more  water  soluble,  and  to  modulate  the  release  of  CO. 
The first  such  modified  molecule was  Tricarbonylchloro(glycinato)ruthenium(ll) 
(CORM-3)  which  released  CO  and  was  water  soluble  (Figure  1.20)  (Clark, 
Naughton,  Shurey,  Green,  Johnson,  Mann,  Foresti,  &  Motterlini  2003b).  The 
development  of  such  a  molecule  was  hugely  important  as  it was  biologically 
‘friendly’  and  could  be  used  as  a  prototypic  chemical  in  the  development  of 
pharmacologically  active  compounds  capable  of delivering  CO  for therapeutic 
purposes  (Motterlini  et al.  2003a;  Motterlini,  Mann,  Johnson,  Clark,  Foresti,  & 
Green 2003b).
Figure 1.20:- Chemical structure of CORM-3, a water soluble CO-releasing 
molecule.
This first water soluble  CO-RM  has  been  extensively tested  by our group  and 
results obtained with this molecule in  my studies will  be examined  later in  this 
Thesis.  Early  investigation  of CORM-3  involved  testing  the  CO  release  using 
the  myoglobin  assay  preparing  the  molecule  in  a  number  of  solutions.  The
- Page 90 -g __________________________________________________INTRODUCTION
liberation of CO from  CORM-3 in biological systems occurs very rapidly (within 
1-5 minutes (min)) (Motterlini, Mann, Johnson, Clark, Foresti, & Green 2003a). 
Interestingly, it was found that CORM-3 remained stable in water (H20) left over 
night at room temperature; however, when prepared and left in Krebs buffer (pH 
=  7.4)  in  the  same  conditions  it  was  unable  to  convert  deoxy  myoglobin  to 
MbCO and was  in effect inactive (iCORM-3) (Motterlini,  Mann,  Johnson,  Clark, 
Foresti,  &  Green  2003b).  Infrared  spectroscopy  suggests  that  iCORM-3  is  a 
dicarbonyl  species,  consistent  with  the  loss  of  one  molecule  of  CO  in  its 
formation from CORM-3. This discovery presented us with a negative control for 
the compound which would aid in distinguishing between the effects of CO and 
the compound itself.  CORM-3 was also shown not to cause any change in cell 
viability at concentrations between 10 and 50 pmol/L (Clark,  Naughton,  Shurey, 
Green,  Johnson,  Mann,  Foresti,  &  Motterlini  2003b).  This  new  water  soluble 
CO-RM was shown to significantly attenuate the loss in viability of H9c2 cardiac 
cells exposed to hypoxia for 24 h and reoxygenation for 6 h (Clark et al. 2003a). 
This protective effect was not observed  using  iCORM-3  implicating  CO  as the 
mediator.  The effect was totally abolished when  5-HD,  an  inhibitor of mitoKATP 
channels,  was  added.  Opening  of the  channels  has  been  shown  to  decrease 
intracellular  calcium  overloading  and  protect  the  heart  against  ischemia- 
reperfusion  injury,  and  has  been  directly  implicated  in  the  mechanism  of 
preconditioning  associated  with  cardioprotection  (Clark,  Naughton,  Shurey, 
Green,  Johnson,  Mann,  Foresti,  &  Motterlini  2003a).  Preservation  of 
mitochondrial function during myocardial ischemia by the use of drugs such  as 
nicorandil  has  also  been  attributed  to  activation  of  mitoKATP  channels.  The 
protective effect  promoted  by the opening of mitoKATP  channels appears to  be
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linked to  a delay in apoptosis as well  as alteration  in  mitochondrial  membrane 
potential.  Notably, CORM-3 even preserved cell viability when added during the 
reoxygenation  period.  This  protective  effect  was  also  demonstrated  in  cells 
exposed to paraquat,  a superoxide anion generator used to promote oxidative 
stress  (Clark,  Naughton,  Shurey,  Green,  Johnson,  Mann,  Foresti,  &  Motterlini 
2003a).
These effects of CORM-3 were not limited to cell models. CORM-3 was used to 
protect  hearts  (male  Lewis  rats)  from  30  min  global  ischemia  and  60  min 
reperfusion  in  a  Langendorff  model.  Predictably,  iCORM-3  showed  no  such 
beneficial  effects on  hemodynamic,  biochemical  or histological  parameters.  In 
addition, the cardioprotective action of CORM-3 was significantly attenuated by 
the  presence  of 5-HD.  As with the  cell  model  this data  demonstrated  that  CO 
was the likely mediator of action and that the activation of the mitoKATP channel 
was again involved in eliciting this response. CORM-3 was also used in a model 
of  cardiac  allograft  rejection  to  verify  its  pharmacological  action  in  vivo.  The 
survival  time  of  hearts  transplanted  into  mice  receiving  CORM-3  was 
significantly  prolonged  with  40%  of  hearts  still  viable  at  30  days.  There  was 
some  protection  by  iCORM-3  but significantly  less than that of CORM-3.  This 
protection could indicate that in vivo the metal carbonyl is further metabolised to 
release  the  residual  CO  groups.  This  data  demonstrated  CORM-3  had  the 
potential  to  attenuate  organ  rejection  (Clark,  Naughton,  Shurey,  Green, 
Johnson, Mann, Foresti, & Motterlini 2003a).
Since those initial experiments,  CORM-3 has been studied in quite some detail. 
Its  stability  has  been  explored further and  has  been  shown  to  remain  inert  in 
water and acidic pH for over 24 h, whilst,  it has been  demonstrated to release
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CO  in  a  number of physiological  solutions  and  biological  fluids  such  as  PBS, 
Krebs  buffer,  cell  culture  medium  and  human  blood  plasma  (Motterlini,  Mann, 
Johnson,  Clark,  Foresti,  & Green 2003b).  It has also been found that CORM-3 
is able to increase HO activity whilst iCORM-3 does not suggesting that some of 
the  effects  witnessed  may  be  partially  attributable  to  this  phenomenon 
(Motterlini, Mann, Johnson, Clark, Foresti, & Green 2003a).
The  development  of future  CO-RMs which  are  more  biologically  suitable  and 
able  to  release  CO  in  a  more  targeted  fashion  continues.  There  are  many 
aspects of CO-RMs that can be modified to suit the end user.  For example, the 
use  of various  metal  ions  may elicit less  of a toxic effect and  aid  in  biological 
compatibility  (i.e.  iron).  There  is  even  the  potential  to  synthesise  non-metal 
containing  CO-RMs  as  will  be  demonstrated  later  in  this  Thesis.  Another  key 
area of CO-RM development is the kinetics of CO release.  By manipulating the 
ligands,  the  rate  at  which  CO  is  released  can  be  altered,  allowing  for  slow 
delivery of CO over a period of time or a faster release where needed.  CO-RMs 
that  release  CO  very  rapidly  (“fast  releasers”)  in  biological  systems  would  be 
ideal for therapeutic applications where CO acts as a prompt signaling mediator 
(i.e.  neurotransmission,  acute  hypertension,  angina,  ischemia-reperfusion). 
However,  the discovery of chemicals that release CO with a slow kinetic (“slow 
releasers”) would  implement the design of pharmaceuticals that could be more 
versatile  in  the  treatment  of certain  chronic diseases  (i.e.  inflammatory  states 
and  chronic  hypertension;  rejection  of  transplanted  organs)  where  the 
continuous  and  long-lasting  effect  of  CO  may  be  required.  There  are  also 
various  solubilities  to  consider.  Currently water-soluble  CO-RMs  exist  but  the 
need for lipid soluble ones may also be considered. The most intriguing aspect
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of CO-RM development is specific intra-cel I ular targeting.  The molecules could 
be  synthesised  with  receptor specific  proteins  or even  some  kind  of antibody 
targeting  which  would  allow  for  the  delivery  of  CO  to  an  exact  target  thus 
negating the  need for a holistic CO release and any associated side effects of 
such  an  approach.  The  attempt  to  diversify  the  multiplicity  of  CO-RMs  that 
possess a variety of chemical characteristics (i.e. water-soluble vs.  lipid-soluble, 
slow vs.  fast  releasers)  will  help  to  elucidate the  biological  function  of cellular 
targets that are responsive to CO and will facilitate in due course the design of 
versatile agents that could be used for the therapeutic delivery of CO in a safe, 
measurable and controllable fashion (Chatterjee 2004b).
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1.12  Hypothesis and Objectives
1.12.1  Hypothesis
NO donors have had a fundamental role in the elucidation of the function of NO 
in  the  biological  system.  They  have  also  offered  a  means  of  treating  certain 
pathophysiological  conditions associated with the role of NO  in the  body  such 
as hypertension.  In recent years, CO has been shown to exert many similar and 
coordinated responses to NO,  thus,  the development of compounds capable of 
releasing  CO  and  exerting  a  physiological  action  is  an  attractive  proposition. 
Metal carbonyls have been used for many years in pure chemical processes but 
the CO releasing potential of these compounds in a biological scenario was only 
investigated  very  recently  (Motterlini,  Clark,  Foresti,  Sarathchandra,  Mann,  & 
Green  2002a).  Since  initially  identifying  the  first  CO-RM,  our  group  has 
continued developing further CO-RMs in conjunction with Professor Brian Mann 
at  the  University  of  Sheffield.  Investigating  and  understanding  the  actions  of 
CORM-3, the prototypic water soluble CO-RM,  has resulted in the development 
of further CO-RMs  with  different  chemical  properties.  Thus,  will  the  biological 
activity of these CO-RMs allow the elucidation of the action of CO in vitro and in 
vivo  and  will  they  potentially  have  therapeutic  value  in  pathophysiological 
conditions?  Are  the  actions  of  CO-RMs  elicited  by  the  release  of  CO,  the 
molecule itself, or by its effect on other biological pathways?
Overall Hypothesis
CO-RMs,  through  the  action  of  CO,  can  mimick  the  action  of  endogenously 
genereated CO in a murine model of inflammation.
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1.12.2  Objectives
This  is  a  list  of  the  objectives  set  out  at  the  start  of  the  PhD  to  assist  in 
answering the hypothesis.
i)  Test the prototypic water soluble  CO-RM  (CORM-3) to determine  its 
toxicity  in  various  cell  lines,  its  effect  on  the  HO  system  and  its 
regulation  of the  inflammatory  response  inferred  from  TNF-a,  nitrite 
and iNOS levels in macrophages.
ii)  Investigate  the  ability  of newly  synthesised  CO-RMs  to  release  CO 
using  the  myoglobin  assay  to  determine  new  CO-RMs  with  the 
potential to forward the study.
iii)  Test  compounds  deemed  to  be  worthy  of further  study  from  (ii)  to 
determine their toxicity, effect on the HO system and regulation of the 
inflammatory response.
iv)  Determine  the  CO  releasing  profile  and  bioactive  properties  of 
CORM-A1,  a  newly  identified  CO  generator that  does  not  contain  a 
transition metal.
v)  Demonstrate how structure can affect CO  release,  toxicity and  nitrite 
using CORM-F compounds.
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2  Materials and Methods
2.1  Reagents
Hemin  (ferriprotoporphyrin  IX  chloride),  tin  protoporphyrin  IX  (SnPPIX)  and 
biliverdin  (biliverdin  IX hydrochloride) were purchased from  Porphyrin  Products 
Inc (Logan,  Utah,  USA).  Stock concentrations of SnPPIX (10 mM) and biliverdin 
(10 mM) were prepared  in sodium  hydroxide (NaOH)  (0.1  M),  kept on  ice and 
used  only  on  the  day  of  treatment.  Working  stocks  of  hemin  (2  mM)  were 
prepared  by  solubilising  in  1   ml  0.1M  NaOH  and  making  up  to  5  ml  using 
phosphate buffered saline (PBS) (pH = 7.4),  kept on ice and used on the day of 
treatment.  Sodium boranocarbonate (Na2[H3BC02] or CORM-A1 ) was prepared 
as  previously  described  by  Alberto  and  coworkers  (ALBERTO  2001). 
Tricarbonylchloro(glycinato)ruthenium  (II)  ([Ru(CO)3CI(glycinate)]  or  CORM-3), 
CORM-319  ([Fe(n-C3H5)(CO)4][BF4]),  and  CORM-311  ([Et3NH][HFe3(CO)11]) 
were  synthesised  by  Professor  Brian  Mann  (University  of  Sheffield).  Stock 
solutions of CORM-3 and CORM-A1  (10 mM) were freshly prepared before the 
experiments  by  dissolving  the  compounds  in  pure  distilled  water.  CORM-319 
(10 mM) was preprared in distilled water immediately prior to addition due to its 
inherent  instability.  CORM-311  was  prepared  as  a  10  mM  stock  in  reagent 
grade  ethanol  (Fisher).  In  our  preliminary  tests,  we  noticed  that  acidic  pH 
significantly  accelerate  the  spontaneous  release  of  CO  from  CORM-A1.  We 
therefore took advantage of this specific property of CORM-A1  and  generated 
an  inactive  form  (iCORM-A1)  to  be  used  as  a  negative  control  by  initially 
dissolving  CORM-A1  in  0.1  M  HCI  and  then  bubbling  pure  N2  through  the 
solution  for  10  min  in  order  to  remove  the  residual  CO  gas.  The  solution  of 
iCORM-A1  was finally adjusted to pH = 7.4 and tested with the myoglobin assay
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(Paragraph  2.4)  prior to  each  experiment  to  verify  its  inability  to  liberate  CO. 
Tricarbonyldichlororuthenium(ll)  dimer  ([Ru(CO)3Cl2]2  or  CORM-2)  was 
obtained  from  Sigma  Aldrich.  Dimethylsulphoxide  (DMSO)  was  used  to 
solubilise the  compound  to  prepare  a  10  mM  stock.  An  inactive form  of each 
compound  was  also  used  in  this  study.  CORM-3  and  CORM-319  were 
‘inactivated’  by addition to cell culture medium and  incubation at 37 °C  in a 5% 
C02 humidified atmosphere for 18 h to liberate CO (iCORM-3 and iCORM-319). 
In the case of CORM-2 a related molecule (Ru(DMSO)4 CI2 or iCORM-2) where 
the  carbonyl  groups  have  been  replaced  with  DMSO  groups  was  utilised. 
Lipopolysachharide  (LPS  - E.Coli serotype 026:B6) was  obtained from  Sigma. 
Initially a 10 mg/ml stock was prepared, aliquoted and then stored at -80°C until 
required. Working stock solutions (0.1  mg/ml) were prepared by the addition of 
10  pi  of  10  mg/ml  LPS  stock  to  990  pi  sterile  dh^O  (Sigma).  Polyclonal 
antibodies against HO-1  were from Bioquote Ltd (York,  UK) whereas polyclonal 
anti-iNOS  antibodies  were  purchased  from  Santa  Cruz  Biotechnology  Inc 
(Insight  biotechnology,  Wembley,  Middlesex,  UK).  All  other  chemicals  were 
reagent grade and obtained from Sigma unless otherwise stated.
2.2  Synthesis of Tricarbonylchloro(glycinato)ruthenium (II) (CORM-3)
Tricarbonylchloro(glycinato)ruthenium  (II)  ([Ru(CO)3CI(glycinate)]  or  CORM-3) 
was  synthesised  starting  from  a  commercially  available  compound, 
tricarbonyldichlororuthenium(ll)  dimer  ([Ru(CO)3CI2]2)  (Sigma  Aldrich).  Briefly, 
[Ru(CO)3CI2]2 (0.129g)  and  glycine  (0.039g)  were  placed  under  nitrogen  in  a 
round-bottomed  flask.  Methanol  (75ml)  and  sodium  ethoxide  (0.034g)  were 
added and the reaction was allowed to continue under stirring for 18 h at room
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temperature.  The  solvent  was  then  removed  under  pressure  and  the  yellow 
residue redissolved in tetrahydrofuran (THF); this was filtered and excess 40 to 
60 light petroleum added. The resulting yellow solution was evaporated down to 
give a pale yellow solid (0.142g, 96% yield). CORM-3 was stored in sealed vials 
at -20°C and used freshly on the day of experiment.
2.3  Synthesis of Sodium Boranocarbonate (CORM-A1)
H3BCO  was  prepared  from  commercially  available  H3B THF  solutions  and 
reacted in situ with an alcoholic solution of sodium hydroxide to give CORM-A1 
(Na2[H3BC0 2 ]). The key to the preparation is the control of equilibrium between 
H3BCO  and  H3B THF.  THF  is  selectively condensed from  the  gas  stream  at - 
50°C,  while  H3BCO  (boiling  point  -64°C)  passes  on,  carried  by  a  stream  of 
carbon monoxide.  Subsequently, this gas mixture is directly bubbled though an 
ethanolic solution of NaOH  at -78°C.  Nucleophilic attack of [OH]' at the  highly 
electrophilic  carbon  in  H3BCO  leads  to  the formation  of  Na2[H3BC0 2 ]  in  high 
yield.  Carbon monoxide was slowly bubbled through 30 cm3 of a  1   M  H3B THF 
solution. The gas stream was passed over a reflux condenser at -50°C and then 
bubbled through a solution of 2.8 g NaOH in 200 cm3 ethanol in a Schlenk tube 
at -78°C. After 2 h the Schlenk tube was disconnected and heated to reflux for 
about  1  h.  Na2[H3BC02] precipitates as a white solid in large amounts and was 
filtered  and  washed  with  cold  ethanol  and  diethyl  ester  to  obtain  the  pure 
product.  CORM-A1  was stored in sealed vials at -20°C and used freshly on the 
day of experiment.
- Page 99 -m   ___________________________________MATERIALS AND METHODS
2.4  Detection of CO Release
The  release  of  CO  from  metal  carbonyl  compounds  was  assessed 
spectrophotometrically  by  measuring  the  conversion  of  deoxy-myoglobin 
(deoxy-Mb)  to  carbonmonoxy  myoglobin  (MbCO)  (Motterlini,  Clark,  Foresti, 
Sarathchandra,  Mann,  &  Green  2002a;  Motterlini,  Mann,  Johnson,  Clark, 
Foresti,  &  Green  2003a).  The  amount  of  MbCO  formed  was  quantified  by 
measuring the absorbance at 540 nm (extinction coefficient = 15.4 mmol/L"1  cm' 
1).  Stock  solutions  of  myoglobin  (lyophilized  horse  heart)  (Sigma)  ( 6 6   pmol/L 
final  concentration) were prepared fresh by dissolving the  protein in  PBS  (0.01 
M,  pH  =  7.4)  (Sigma).  Sodium  dithionite (0.1%)  (Sigma) was added to convert 
the myoglobin stock to deoxy-Mb prior to each experiment.  A 1   ml  quantity of 
this was measured to obtain a deoxy-Mb curve and then bubbled with CO to get 
a  MbCO  curve.  CO-RMs  (20,  40  or 60  pM)  were  added  (5  pi)  directly  to  the 
myoglobin in the cuvette (Sarstedt,  Leicester,  UK),  mixed using a Gilson (1000 
pi) and then overlaid with 500 pi mineral oil (Sigma) to prevent CO escaping or 
the  myoglobin  becoming  oxygenated.  Samples  were  immediately  read  on  a 
spectrophotometer (Unicam HeAios a) and then read every 5 min for the first 30 
min.  The  maximal  absorption  peak  of  myoglobin  at  560  nm  is  gradually 
converted  over  time  by  CO  to  spectra  typical  of  MbCO  with  two  maximal 
absorption peaks at 540 and 578 nm,  respectively (see Figure 2.1).  Subsequent 
readings were  taken  every  30  min  or when  deemed  necessary.  Normally  the 
readings  were  continued  until  the  CO  release  reached  a  plateau  for  2  
consecutive readings.  A step by step  protocol for the  myoglobin  assay can  be 
found in the appendix (paragraph 11.4).
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Figure 2.1:- The various spectra of myoglobin.
This figure shows the alternate spectra that are generated by reducing (sodium 
dithionite) or exposing  myoglobin to carbon monoxide  (MbCO)  or 95%  oxygen 
(OxyMb).
In  order to calculate the total  myoglobin  in the solution,  deoxyMb  solution was 
bubbled for 5 min with  1   % CO gas until the absorbance at 540 nm  reached  a 
maximum. This OD value was taken as the maximum MbCO concentration and 
therefore  the  total  myoglobin  concentration  of the  mixture,  although,  in  theory 
the  solution  of  myoglobin  was  converted  to  -100%   MbCO  the  measured 
amount was never as high as 66 pM (the initial calculated concentration of Mb) 
because the myoglobin used was 90% pure and thus contained impurities such 
as  salts  and  denatured  myoglobin  in  the  original  myoglobin  solutions.  Total 
myoglobin concentration was calculated using Equation 2.1.
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Equation 2.1:- Equation for calculating total myoglobin concentration in a 
saturated solution of carmoxy-myoglobin  (MbCO).  e = extinction  coefficient 
of MbCO = 15.4 mM'1cm'1
Although  the  maximum  absorbance  at  540  nm  after  saturation  with  CO  gas 
gives  the  total  MbCO  concentration  (MbCOm ax),  any  intermediate  values  of 
MbCO (between -100 % deoxyMb in and ~100 % MbCO) have to be calculated 
by mathematical iteration from the OD540 reading. This is performed as follows: 
Firstly,  it must be assumed that in the deoxyMb  solution there  is -0  %  MbCO, 
so  the  OD540  at  this  point  (always  a  positive  value)  indicates  0 pM  MbCO. 
Assuming this,  a  new extinction coefficient (82)  must be calculated to take  into 
account the change in absorbance at 540 nm  (AODs4o)-  To aid in the accuracy 
of this  calculation,  another wavelength  is  used  as  a  constant  reference  point. 
Conveniently,  the  deoxyMb  and  MbCO  spectra  share  four  isosbestic  (ODiso) 
points between 500 and 600 nm (— 510,  -550, -570 and -585 nm). The value at 
510  nm  (ODisosio)  was  taken  for  these  set  of  experiments.  Thus,  the  new 
extinction coefficient was calculated:
Equation 2.2:- Equation needed to calculate an unknown MbCO extinction 
coefficient.
Taking into account the change in absorbance at the isosbestic point ( A O d j S05 io )  
and the change in absorbance at 540 nm  ( A O D 5 4 0 )   a new extinction coefficient 
(8 2 )  can be calculated.
MbCO max xlOOO
v   s
iso510
MbCO max
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From these calculations,  the concentration of MbCO  in a solution of myoglobin 
can be calculated if three things are known about the solution:  i) the change in 
OD540 between deoxy- and saturated MbCO (by saturating the Mb solution with 
CO  gas);  ii) the  change  in  the  ODjS O   in  the  sample  from  original  deoxyMb 
solution  and;  iii) the  OD540  and  ODjS O   of  the  sample  solution.  The  following 
equation is therefore used to calculate the [MbCO] of the unknown sample:
Equation 2.3:- Calculation of unknown MbCO concentrations.
Where AOD540 is the change in absorbance at 540 nm,  A O D iS o  is the change in 
absorbance  at  the  isosbestic  point,  MbCOm ax  is  the  MbCO  concentration 
calculated  after  saturation  of  the  Mb  with  CO  gas  and  82  is  the  calculated 
absorption coefficient.
After all the time points have been calculated, the data can be converted from a 
concentration  (pM)  to  absolute  MbCO values  (nmoles)  by  multiplication  of the 
pM  value  by the  volume  of  myoglobin  in  the  solution  (in  I).  From  a  graph  of 
MbCO  (nmoles)  vs.  time  (min),  the  incubation  time  required  for  any  MbCO 
concentration  can  be  calculated;  therefore  cells  can  be  exposed  to  a  known 
concentration of CO using this system.
2.5  Cell Culture
Murine RAW264.7 monocyte macrophages were purchased from the European 
Collection  of Cell  Cultures  (Salisbury,  Wiltshire,  UK)  and  cultured  in  complete 
medium  consisting  of:  Dulbecco’s  modified  Eagle’s  medium  (DMEM)
supplemented  with  10%  fetal  bovine  serum,  2  mM  L-glutamine,  100  units/ml
A O D 540  -  A O D iS o5io
MbCO x 1 0 00
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penicillin and 0.1  mg/ml streptomycin.  Initially the existing medium in each flask 
was  removed  and  discarded.  Cells were then washed with  5  ml warm  (37  °C) 
10x  PBS  (Gibco,  Paisley,  UK)  which  was  replaced  with  8  ml  warm  (37  °C) 
DMEM  and  the  cells  scraped  using  a  rubber  plastic  Thomas  policeman 
(Thomas  Scientific,  Swedesboro,  NJ)  to  remove  them from  the  flask surface. 
The cells were then pipetted (2 ml) into 4 new T-75 flasks (Sarstedt,  Leicester, 
UK) each containing 8 ml DMEM and returned to the incubator (LEEC).
Bovine  aortic  endothelial  cells  were  purchased  from  Coriell  Cell  Repositories 
(Camden,  NJ,  USA)  and  cultured  in  complete  medium  consisting  of:  Iscoves 
modified  Dulbecco’s  medium  which  was  supplemented  with  10%  fetal  bovine 
serum,  2  mM  L-glutamine,  100  units/ml  penicillin  and 0.1  mg/ml  streptomycin. 
Cells were sub-cultured approximately every 3 days to maintain the cell line for 
subsequent experiments.  Confluent cells (>80% coverage of 75 cm2 flask) were 
firstly washed with  5  ml  of warm  (37  °C)  PBS to facilitate the action  of trypsin 
(0.25%  trypsin-EDTA  solution,  Sigma).  Once  the  PBS  was  removed,  trypsin 
(also 37 °C) was added to remove cells from the surface of the flask.  Cells were 
then  briefly  incubated  at 37  °C for approximately 3  min  to  allow the  trypsin  to 
act. The trypsin (now including the cells) was removed and pipetted into 8 ml of 
fresh medium to neutralise its action and prevent over exposure of the cells to 
this agent which could be detrimental. Cells were then centrifuged (1500 x g) for 
5  min  in a bench top centrifuge (SANYO,  Harrier 15/80).  The supernatant was 
removed  and  fresh  medium  was  added  to  re-suspend  the  pellet  (a  1:3  split 
would  require  6  ml  to  re-suspend the  pellet).  Then,  2  ml  of the  re-suspended 
cells were pipetted into pre-prepared T-75 flasks containing  8 ml fresh medium 
and  incubated.  Over an  extended  period  of slow  growth  where  cells  failed  to
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reach confluence within 3-4 days, the medium was replaced with fresh medium. 
Cultures  were  maintained  at  37  °C  in  a  5%  CO2  humidified  atmosphere  and 
experiments were conducted on cells at approximately 80-90% confluence. 
Girardi  (human  heart)  cells  and  wild  type  smooth  muscle  cells  (bovine)  were 
purchased from  the  European  Collection  of Cell  Cultures  (Salisbury,  Wiltshire, 
UK)  and  cultured  in  complete  medium  consisting  of:  Dulbecco’s  modified 
Eagle’s  medium  (DMEM)  which  was  supplemented  with  10%  fetal  bovine 
serum,  3.5  mM  L-glutamine,  1%  non-essential  amino  acids  (NEAA),  100 
units/ml  penicillin  and  0.1  mg/ml  streptomycin.  Cells  were  sub-cultured 
approximately  every  3  days  to  maintain  the  cell  line  for  subsequent 
experiments.  Confluent  cells  (>80%  coverage  of  75  cm2  flask)  were  firstly 
washed with 5 ml of warm (37 °C) PBS to facilitate the action of trypsin (0.25% 
trypsin-EDTA  solution,  Sigma).  Once  the  PBS  was  removed,  trypsin  (also  37 
°C) was  added  to  remove  cells from the  surface of the flask.  Cells were  then 
briefly incubated at 37 °C for approximately 3 min to allow the trypsin to act. The 
trypsin  (now  including  the  cells) was  removed  and  pipetted  into  8  ml  of fresh 
medium  to  neutralise  its  action  and  prevent over exposure  of the  cells  to this 
agent which could be detrimental.  Cells were then centrifuged (1500 x g) for 5 
min  in  a  bench  top  centrifuge  (SANYO,  Harrier  15/80).  The  supernatant  was 
removed  and  fresh  medium  was  added  to  re-suspend  the  pellet  (a  1 :3  split 
would  require  6   ml  to  re-suspend the  pellet).  Then,  2  ml  of the  re-suspended 
cells were pipetted into pre-prepared T-75 flasks containing  8 ml fresh medium 
and  incubated.  Over an  extended  period  of slow  growth  where  cells  failed  to 
reach confluence within 3-4 days, the medium was replaced with fresh medium.
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Cultures  were  maintained  at  37  °C  in  a  5%  CO2  humidified  atmosphere  and 
experiments were conducted on cells at approximately 80-90% confluence.
All cell culture work was carried out using an ESB JBIO CL II category II hood.
2.6  Subculture of Cells into 24 Wells
Cells  were  prepared  as  per  paragraph  2.5  up  until  the  pellet  was  to  be  re­
solubilised  (BAEC,  Girardi) or the cells had been  scraped  (RAW264.7).  At this 
stage  the  pellet was  re-solubilised  using  2  ml  of complete  medium  whilst the 
macrophages  were  left  as  they were.  From  either  cell  suspension,  2  ml  was 
then added to a pre-prepared  Falcon tube (50  ml,  NUNC)  containing 49  ml  of 
complete  medium.  From this,  2  ml was added  to each well  of a 24 well  plate, 
with  any  remaining  cell  /  medium  suspension  discarded.  The  plate was  then 
incubated at 37 °C until confluent.
2.7  Subculture of Cells into 6 Wells
Cells  were  prepared  as  per  paragraph  2.5  up  until  the  pellet  was  to  be  re­
solubilised  (BAEC,  Girardi) or the cells had  been  scraped (RAW264.7).  At this 
stage  the  pellet was  re-solubilised  using  3  ml  of complete  medium  whilst the 
macrophages  were  left  as  they were.  From  either  cell  suspension,  3  ml  was 
then added to a pre-prepared  Falcon tube  (50  ml,  NUNC)  containing 47  ml  of 
complete medium. From this, 2 ml was added to each well of a 6  well plate, with 
any  remaining  cell  /  medium  suspension  discarded.  The  plate  was  then 
incubated at 37 °C until confluent.
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2.8  Preparation of Liver Cytosol and Liver Microsomes
Liver  cytosol  was  obtained  from  male  Sprague  Dawley  rats  (250-300  g). 
Following  sacrifice  by anaesthetization with  phenobarbital  Lethobarb® sodium 
BP  (500  pi,  i.p.) and cervical dislocation,  a 50 ml  syringe was  used to  perfuse 
cold  (4°C)  buffer  (1.15%  (w/v)  KCI)  through  the  liver  lobes  to  remove  any 
residual blood, while clotted tissue was discarded. The organ was weighed,  cut 
finely with  scissors  and  homogenised  in  2-3  volumes  of  homogenising  buffer 
(20 mM Tris-HCI,  pH  = 7.4,  containing  1.15%  (w/v)  KCI),  and then  shared  out 
equally  into a set of polyallomer centrifuge tubes  (Beckman  Coulter  Ltd.,  High 
Wycombe,  UK).  After  centrifuging  (5,000  x  g)  for  20  min  at  4°C  in  an 
ultracentrifuge  (Beckman  LE-80  ultracentrifuge)  the  supernatant  was  retained 
and  then  re-centrifuged  (105,000  x  g)  for  90  min  at  4°C.  Following  each 
centrifugation,  the  turbid  lipid  layer was  removed  with  a  Pasteur  pipette.  The 
supernatant  was  collected,  and  protein  and  haem  oxygenase  activity  were 
measured as described in paragraph 2.13 and 2 .1 0 , respectively, then aliquoted 
and stored at -80°C.
The  preparation  of liver microsomes  is  analogous to  that for liver cytosol  with 
the following variations. The rat was pre-treated with hemin (50 mg/kg,  i.p.) 24 h 
prior to harvest to  induce  HO.  The  lobes were  perfused with  cold  (4°C)  saline 
(0.9%  (w/v)  NaCI) and homogenised  in 5 volumes of sucrose solution  (0.25  M 
sucrose,  0.05  M  Tris-HCI,  pH  =  7.4)  then  centrifuged.  After  the  last 
centrifugation step, the resulting microsomal pellet was resuspended gently in  1 
ml  of phosphate  buffer (pH  = 7.4).  Protein  and  haem  oxygenase  activity were 
determined  according  to the  protocols  described  in  paragraph  2.13  and  2 .1 0 , 
respectively, followed by storage at -80°C.
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2.9  Collection of Samples
Before  each  experiment,  cells were washed with  10  ml  Dulbecco’s  PBS  at  37 
°C  to  remove  cell  debris,  detached  cells  or  unwanted  chemical  factors  in  the 
culture. After each treatment,  confluent cells were washed with 5 ml cold  (4°C) 
PBS (10x),  and the buffer removed.  Cold (4°C) PBS (5 ml) (1x) was then added 
and  cells  were  gently  scraped  using  a  rubber  plastic  policeman.  The  cell 
suspension was transferred to a 14 ml plastic tube (Sarstedt,  Leicester,  UK) and 
a  further  5  ml  PBS  was  added  to  the  flask  to  collect  the  remaining  cells. 
Samples were then centrifuged (1800 x g) (SANYO,  Harrier 15/80) for 10 min (4 
°C).  The supernatant was removed and cells were re-suspended with either:  1) 
1 0 OmM  PBS  -  2mM  MgCh  buffer (550  pi) for the  HO  activity  assay  or 2)  1 % 
Triton PBS (300 pi) for the Western blot. Samples were stored at -80°C until the 
assays were performed.
2.10  Determination of Haem Oxygenase Activity
Stock solutions of the assay reagents,  i.e.  glucose-6 -phoshate (G6 P)  (20 mM), 
glucose-6 -phoshate dehydrogenase (G6 PDH)  (50  U/ml) and  NADPH  (40  mM), 
were  prepared  with  phosphate  buffer  (0.01  M,  pH  =  7.4)  and  stored  at  -80°C 
until required.  The NADPH was wrapped  in foil as it is light sensitive.  Hemin (2 
mM)  was  prepared  freshly  for  each  assay  using  0.5%  (v/v)  NaOH  (2  M)  and 
phosphate  buffer  (pH  =  7.4).  Rat  liver  cytosol  and  liver  microsomes  were 
prepared according to paragraph 2 .8 .
The  samples,  collected  according  to  paragraph  2.9,  were  disrupted  by  three 
rounds of freeze-thawing (-80 °C to 37  °C) then  placed on  ice.  A  1 0 0   pi  aliquot 
was retained for protein determination according to paragraph 2.13.  To a set of
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glass  tubes,  which  were  maintained  on  ice,  the  cell  suspension  (400  pi)  was 
added to the reaction mixture (final volume, 900 pi) containing: phosphate buffer 
(pH = 7.4), 20 pM hemin, 2 mM G6 P, 0.5 U/ml G6 PDH, 3 mg of rat liver cytosol, 
as  a  source  of biliverdin  reductase  (BVR),  and  0.8  mM  NADPH.  The  negative 
and positive controls (rat liver microsomes) contained proportionate volumes of 
phosphate  buffer  (pH  =  7.4)  instead  of  the  cell  suspension.  The  tubes  were 
vortexed  well  and  incubated  in  the  dark  for  1  h  at  37  °C.  The  activity  of  the 
cytosolic  and  microsomal  fractions  was  verified  by  replacing  hemin  with 
biliverdin  (1  mM), and the samples incubated in the dark for 30 min at 37 °C.
The  reaction was  terminated  by the  addition  of chloroform  (1  ml),  then  mixed 
thoroughly by vortexing, followed by centrifuging (1800 x g) 2 times for 5 min at 
room temperature using the bench-top centrifuge  (SANYO,  Harrier 15/80)  until 
three  distinct  layers  were  formed.  The  lower  organic  (clear)  layer,  which 
contains  the  chloroform  and  bilirubin,  was  placed  in  a  quartz  cuvette  and  the 
difference in absorption between 464 nm and 530 nm  (extinction  coefficient (z) 
for bilirubin  in  chloroform,  40  mM'1cm'1)  was  measured with  the  UVikon  81 OP 
spectrophotometer (Kontron  Instruments)  against a  blank of chloroform.  Haem 
oxygenase activity was expressed as picomoles of bilirubin formed per mg  cell 
protein per h using Equation 2.4.
Equation 2.4:- Calculation of haem oxygenase activity, 
pmoles bilirubin  ( AOD (O D ^ -
mg protein in 60 min 40
mg protein  x10
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2.11  Glutathione Measurement
To  measure the  glutathione  concentration  of treated  cells  and  hence  infer the 
redox levels, a glutathione assay was carried out as previously described by our 
group (FOREST11997). The medium of treated 6  well plates was discarded and 
cells were washed for 5  min with 2  ml  of warm  (37  °C)  sterile  10X  PBS.  The 
PBS was removed and replaced with 600 pi of a 2 % (w/v) 5-sulfosalicylic acid 
solution,  for  cell  lysis  and  deproteinisation,  which  was  prepared  in  distilled 
water.  Cells were then  scraped and the cell  suspension  centrifuged  (Beckman 
Avanti™  30 centrifuge) at 10,000 g for 5 min at 25°C. The supernatant (500 pi) 
of each sample was removed and added to a cuvette containing 500 pi of 5,5’- 
dithiobis-(2-nitrobenzoic  acid)  (DTNB)  buffer  and  allowed  to  react  for  5  min. 
DTNB  buffer  was  prepared  fresh  each  time  and  consisted  of  0.3M  sodium 
phosphate buffer (NaHP0 4  7H20),  ethylenediamine tetraacetic acid  (EDTA)  1 0  
mM  and  DTNB  0.2  mM  prepared  in  distilled water  (pH  =  7.5).  Samples were 
then  read  on  a  UVikon  81 OP  spectrophotometer at 412  nm  blanking  against a 
cuvette  containing  500  pi  5-sulfosalicylic  acid  and  500  pi  DTNB.  Positive  and 
negative  controls  consisted  of  cells  treated  for  24  h  with  100  mM  N-acetyl- 
cysteine  (NAC),  a  precursor  of glutathione,  and  100  mM  DL-butathione-[S,R] 
sulfoxide,  a  selective  inhibitor  of  glutathione  biosynthesis,  respectively.  The 
concentration  of  each  sample  was  determined  as  in  Equation  2.5  where  the 
extinction coefficient (e) was 14.3 mM'1 cm'1.
Equation 2.5:- Calculation of glutathione concentration
Absorbance 
Concentration =  -------- :----------
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2.12  Assay for Nitrite Levels
Nitrite  levels  were  determined  using  the  Griess  assay  protocol,  a  colorimetric 
assay.  The  medium from  treated  cells cultured  in 24 well  plates was  removed 
and centrifuged (Beckman Avanti™ 30 centrifuge) at 10,000 g for 5 min at 25°C 
to remove any cells before it was plated out on to a 96 well plate in triplicate (50 
pi  per  well).  In  addition  50  pi  of  standards  (prepared  using  sodium  nitrite  - 
NaNCb) (0 pM to 300 pM) were added to the plate in triplicate (Figure 2.2).
1.50-1
1.25-
1 .00 -
0.75-
0.50-
0.25-
0.00 J
100 200 300 400 0
Nitrite (pM)
Figure 2.2:- Sample standard curve for nitrite assay
Next,  50  pi  of Griess reagent (125 mg of sulphanilamide and  12.5  mg of N-(1- 
naphtyl)ethylenediamine  (dihydrochloride)  (Sigma)  dissolved  in  5  ml  of  dH20 
and 0.735 ml of orthophosphoric acid  (H 3 P O 4 )  (85%), the total volume was then 
brought up to 25 ml  using dH20) was added to each well to begin the reaction. 
The plate was then shaken for 10 min to allow the reagents to mix and then the 
absorbance  read  at 550  nm  on  a plate reader  (Molecular  Devices VERSAmax
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tunable microplate reader).  Nitrite levels of each sample were determined using 
the standard curve.
2.13  Protein Determination
The  level  of protein  in  each  sample was  determined  colourimetrically with  the 
aid of the DC Protein Assay (Bio-Rad Laboratories Ltd).  The assay is similar to 
the Lowry assay and is based on the reaction of protein with an alkaline copper 
tartrate solution and Folin reagent. As with the Lowry assay, there are two steps 
which  lead to colour development:  The reaction between  protein and copper in 
an  alkaline  medium,  and  the  subsequent  reduction  of  Folin  reagent  by  the 
copper-treated protein.  Colour development is primarily due to the amino acids 
tyrosine and tryptophan,  and to a lesser extent,  cystine,  cysteine,  and histidine. 
Proteins effect a reduction of Folin reagent by  loss of 1,  2,  or 3 oxygen atoms, 
thereby producing one or more of several possible reduced species which have 
a characteristic blue colour with maximum absorbance at 750 nm and minimum 
absorbance at 405 nm. The darker and more intense the blue colour the higher 
the  protein  concentration.  Samples  were  prepared  for their  respective  assays
i.e.  freeze / thawing.  Initially the working  reagent was  prepared which  is either 
entirely  reagent  A  if the  samples  contain  no  detergent  (i.e.  haem  oxygenase 
assay)  or  supplemented  with  reagent  S  (4%  v/v)  if  the  samples  do  contain 
detergent  (i.e.  western  blot  analysis).  To  determine  protein  levels,  100  pi  of 
each  sample  and  500  pi  of  working  reagent  were  pipetted  into  clean 
polypropylene test tubes and the contents briefly vortexed. A blank was also run 
where  1 0 0  pi of the buffer used to prepare the sample was used in place of the 
sample.  Next,  4  ml  of reagent  B  was  dispensed  into  each  tube  and  vortexed
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immediately.  The  samples  were  then  left  for  20  min  to  allow  for  colour 
development  after  which  the  absorbance’s  were  read  at  750  nm  on  a 
spectrophotometer (UVikon® 810 P). When running protein assays a number of 
standards  (bovine  serum  albumin)  were  also  run  to  prepare  a  standard  curve 
(Figure  2.3).  The  standards,  of  which  there  were  5-6  dilutions  containing 
between 0.2  pg/ml and  1.5 pg/ml  protein, were treated  in the same way as the 
samples.
1.00~i
0.75-
0.50-
0.25-
0 .0 0 J
0.0  0.5  1.0  1.5  2.0  2.5  3.0
[Protein] mg/ml
Figure 2.3:- Sample standard curve for protein assay
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2.14  Cell Viability Determination
To determine cell  viability three  independent techniques were carried out each 
quantifying a particular aspect of cell  health. The combination of all three gives 
a good measure of the overall viability of cells subsequent to treatment.
2.14.1  Alamar Blue Assay
Cell metabolism was determined using an Alamar Blue assay kit and carried out 
according  to  the  manufacturer’s  instructions  (Serotec,  UK).  The  medium  of 
treated cells was removed from all wells on the plate(s) and replaced by  1  ml of 
a  10% Alamar  Blue  :  90%  complete cell  culture  medium  mixture.  The  plate(s) 
was then  left to  incubate for 4 h after which 200 jxl from each well was  loaded 
on to a 96 well plate to be read on a plate reader (Molecular Devices) at 570 nm 
(subtracting  any  background  absorbance  present  at  600  nm).  The  assay  is 
based on the detection of metabolic activity of living cells using a redox indicator 
which changes from an oxidised form (blue) to a reduced form (red).  It has been 
shown  that  ionophores,  a  molecule  which  carries  or  transports  charged 
compounds or ions across cell  membranes,  block the reduction of Alamar Blue 
preventing  its  reduction  in  cell  free  extracts.  It will,  however,  accept electrons 
from  the  electron  transport  chain.  The  Eh  (oxidation-reduction  potential)  of 
Alamar Blue is similar to that of the cytochromes. The redox dye in Alamar Blue 
accepts  electrons from  the  electron  transport  chain  in  a  similar fashion  to  the 
terminal  reduction of oxygen. The reduced form of Alamar Blue is secreted out 
of the cell and back into the media.
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The  intensity  of the  red  colour  is  proportional  to  the  metabolism  of the  cells, 
which  is calculated as the  difference  in  absorbance  between  570  nm  and 600 
nm and expressed as a percentage of control.
2.14.2  Trypan Blue Assay
The potential deterioration of the plasma membrane of cells exposed to various 
treatments was  examined  using  trypan  blue  (Sigma,  UK).  The  dye  permeates 
cells  in  which  the  cell  membrane  has  been  breached  indicating  a  loss  of 
viability. The medium of treated cells was removed from all wells on the 6 well 
plate(s) and discarded.  It was replace with 0.5 ml of a 1:1  solution of trypan blue 
and warm  (37  °C)  1X PBS.  The  1X PBS was prepared as a  1   in  10 dilution of 
10X  PBS  in  sterile distilled water.  The cells were then  incubated at 37  °C  and 
5% CO2 for 15 min after which the trypan blue was removed and replaced with 
1  ml of warm (37 °C)  1X PBS.  Cells were then viewed under a Olympus Tokyo 
CK microscope (20 X Magnification) and the ratio of cells stained blue (in which 
the dye has been taken up) to cells which remain unstained (and thus have an 
intact cell membrane) used to determine the percentage that are not viable.
2.14.3  Lactate Dehydrogenase Assay
Lactate  dehydrogenase  (LDH)  is  a  stable  cytoplasmic  enzyme  present  in  all 
cells.  It is rapidly released into the cell culture supernatant upon damage of the 
plasma  membrane.  The  LDH  based  cytotoxicity  detection  kit  (Roche 
Diagnostics,  UK)  gives  a  method  for  the  colourimetric  assay  for  the 
quantification  of  cell  death  and  cell  lysis  based  on  the  measurement  of  LDH 
activity  released  from  the  cytosol  of damaged  cells  into  the  supernatant.  The
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assay  was  carried  out  according  to  the  manufacturer’s  instructions.  Upon 
completion  of  treatment  the  medium  of  each  group  was  spun  (Beckman 
Avanti™ 30 centrifuge) at 500 g for 5 min at 25°C to remove any cellular debris. 
Cell free culture supernatant (100  pi) was transferred to  a clear flat bottom  96 
well  plate  (NUNC,  UK)  to  which  100  pi  of  reaction  mixture  was  added.  The 
reaction  mixture consisted of a lysophilised catalyst which was reconstituted  in 
1  ml of distilled water and an INT dye. The ratio of catalyst to dye was 1:46. The 
plate was then  incubated at 37  °C  and 5%  CO2 for 15 min and protected from 
light.  Samples  were  read  on  a  plate  reader  (Molecular  Devices  VERSAmax 
tunable  microplate  reader)  at 490  nm  with  a  reference wavelength  of 690  nm 
and  blanked  against  cell  culture  medium.  The  percentage  cytotoxicity  was 
determined as in Equation 2.6.  Samples were run in triplicate and a 1   % triton / 
medium  mixture  was  added  to  some  wells  as  a  positive  control,  since  triton 
degrades cell membranes and hence releases maximal LDH activity.
Equation 2.6:- Calculation of LDH activity associated cytotoxicity
Exp. Value -  Low Control 
Cytotoxicity <%) -   High  Control  -   Low  X 100
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2.15  Molecular Biology Procedures
2.15.1  Western Blot Protein Analysis
Total  protein of each  sample was calculated as  per paragraph 2.13.  A general 
sequence of events for the Western Blot can be seen in Figure 2.4.
Figure  2.4:- The  sequence  of antibody-substrate  incubations for Western 
blot.
1) the nitrocellulose  membrane will  contain a number of antigens;  2)  a specific 
polyclonal  (raised  in  rabbit)  antibody to the  required  antigen  is  bound;  3)  anti- 
rabbit  IgG  with  a  biotin  tail  is  then  bound  to  the  1°  antibody;  4)  Extravidin 
alkaline  phosphatase  specifically  binds  to the  biotin  and,  finally;  5)  addition  of 
the  substrate  gives  a  red  precipitate  indicating  the  presence  of  the  antigen. 
(Figure designed by Dr James Clark).
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An  appropriate  volume  of each  unknown  sample was combined with  Laemmli 
(loading)  buffer  (Bio-Rad  Laboratories  Ltd.),  containing  5%  (v/v)
P-mercaptoethanol  (total  volume  30  pi),  so  that the final  concentration  loaded 
onto  each  lane  was  equal  to  30-40  pg  protein.  The  HO-1  positive  control 
(Bioquote Ltd., York,  UK) was diluted to 1   pg/ml in loading buffer. Samples were 
pulsed for 20-30 seconds (sec) on the bench-top microcentrifuge (SANYO MSE 
Micro  Centaur) followed  by denaturing of the proteins for  10  min  at 90°C  on  a 
heating block (Techne DB2A, Techne GmBH,  Germany).  The molecular weight 
marker (MWM) (Invitrogen LifeTechnologies Ltd.) was not heated but placed on 
ice  until  required.  After  heating,  the  samples  were  re-pulsed  and  30  pi  of 
samples,  15  pi of MWM and 30  pi  positive control were  loaded carefully  using 
gel loading tips (Fischer,  UK) into the wells of a 12% tris-glycine Ready gel (Bio- 
Rad  Laboratories Ltd.).  Electrophoresis was carried out at room temperature in 
a  tank  containing  running  buffer  (0.025  M  Tris,  0.192  M  glycine,  0.1%  (v/v) 
SDS)  (Fischer,  UK)  using  the  Mini-PROTEAN®  II  system  and  Power-Pac 300 
power supply  (Bio-Rad  Laboratories  Ltd.)  at a  constant voltage  of  120 V  until 
the loading buffer had migrated to the base of the gel.
While  the  gel  was  running  appropriately  sized  sheets  of  nitrocellulose 
membrane  45  pm  pore  size  (Amersham  Biosciences  UK  Ltd.,  Little  Chalfont, 
Buckinghamshire,  UK)  and  3MM  Whatman™  blotting  paper  were  cut  and 
presoaked  in  dhhO  and  transfer  buffer  (0.025  M  Tris,  0.192  M  glycine,  0.1% 
(v/v)  SDS,  20%  (v/v)  methanol)  respectively for  10  min.  After  electrophoresis 
was  completed,  a  ‘gel  sandwich’  (see  Figure 2.5 for  assembly)  was  prepared 
upon the clear (positive electrode) side of a gel cassette within a shallow vessel 
containing some transfer buffer.  After removal  of any air bubbles,  the cassette
- Page 118 -A MATERIALS AND METHODS
was  placed  into  the  electrode  module with  the  black (negative  electrode)  side 
facing  the  black  (cathode)  panel  of  the  module.  This  orientation  ensures  the 
proteins  migrate from the  gel  onto the  nitrocellulose  membrane.  Extra transfer 
buffer was added and overnight transfer was carried out at 4 °C  in a cold  room 
with  a constant voltage of 30 V using  a  1000/500 transfer unit and  Mini  Trans- 
Blot® electrophoretic transfer cell, both from Bio-Rad Laboratories Ltd.
Gel
Whatman paper Nitrocellulose
1
Positive electrode Negative electrode
Foam pads
Figure 2.5:- Arrangement of gel sandwich assembly.
All  subsequent  procedures were  performed  at  room  temperature  on  an  orbital 
shaker (Denley Instruments  Ltd.,  Billingshurst,  Sussex,  UK) at low speed.  Non­
specific  binding  (NSB)  of  the  antibodies  was  prevented  by  incubating  the 
membrane  in  blocking  solution  (5%  (w/v)  non-milk  dried  fat  in  PBS  (0.01  M 
phosphate  buffer,  pH  =  7.4,  containing  0.2%  Tween-20),  for  2  h  at  room 
temperature. This was followed by a single 5 min wash with 10 ml of PBS (pH =
7.4).  All  subsequent washes were for 5  min with  10  ml  of the  named  solution. 
The  membrane  was  incubated  for  2  h  with  the  anti-HO-1  primary  antibody 
(Bioquote  Ltd.,  York,  UK)  diluted  1:1000  in  tris  buffered  saline  (TBS)  (0.05  M 
Tris-HCI,  0.0037  M  KCI,  0.7137  M  NaOH,  pH  = 7.4).  When  iNOS  protein was
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analysed the antibodies, which were purchased from Santa Cruz Biotechnology 
(Santa  Cruz  Biotechnology  Inc,  Insight  biotechnology,  Wembley,  Middlesex, 
UK)  were  diluted  (1:1000)  in  TBS.  Next,  the  membrane  was  washed  three 
times,  once with  PBS-T (PBS 0.01  M,  pH  = 7.4,  containing 0.05%  (v/v) Tween 
20), then twice with TBS (pH = 7.4).
Proteins were visualised using an  ExtrAvidin® alkaline phosphatase staining  kit 
(Sigma).  The biotinylated anti-rabbit IgG antibody,  diluted  1:1000 in TBS (pH  =
7.4),  was  incubated  with  the  membrane for  1  h.  The  membrane was  washed 
three  times  with  TBS  (pH  =  7.4)  and  the  ExtrAvidin®  alkaline  phosphatase 
conjugate,  diluted  1:1000 in TBS (pH  = 7.4),  applied for 1   h. The three washes 
with  TBS  (pH  =  7.4)  were  repeated.  After  the  last  wash  a  freshly  prepared 
substrate solution (9.8 ml of 0.1  M Tris buffer, pH = 8.2, containing 200 pi of 1% 
(w/v) Napthol-AS-BI phosphate in N-N-N-dimethyl formamide and a  10 mg Fast 
Red  DT  salt  tablet)  was  incubated  with  the  membrane  until  red/pink  bands, 
which indicates the location of the antigen-antibody complexes of the protein on 
the nitrocellulose membrane, was observed. After maximal colour development 
was attained,  any excess substrate solution was washed off with distilled water 
(dH20)  and  the  membrane  stored  in  foil,  until  scanned  into  a  PC  (Epsom  -  
Epsom Perfection 1650).
2.15.2  Enzyme-Linked Immunosorbent Assay for Cytokines
The  quantification  of  IL-10,  IL-6  and  TNF-a  in  cell  culture  supernatants  was
determined  using  an  enzyme-linked  immunosorbent  assay  kit  and  carried  out 
according  to  the  manufacturers  instructions  (R&D  systems,  UK).  The  basic 
principle of an ELISA is shown in Figure 2.6.
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Figure 2.6:- The principle of the ELISA system.
1) Wells are coated with a polyclonal antibody specific for mouse TNF-a;  2) the 
TNF-a  present  in  the  samples  or  standards  binds  to  the  primary  antibody 
forming  a  stable  complex;  3)  a  polyclonal  antibody  against  mouse  TNF-a 
conjugated to horseradish peroxidase is added which binds the TNF-a bound to 
the  primary  antibody  ;  4)  the  substrate  (3,  3\  5,  5’
tetramethylbenzidine/hydrogen  peroxide),  reacts  with  the  antibody-bound 
peroxidase-labelled TNF-a  causing a change in colour in the well.  (Based on  a 
figure designed by Dr James Clark).
Treated  cell  culture  supernatant was  removed  and  spun  at  500 g for 5  min  at 
25°C  (Beckman  Avanti™  30  centrifuge)  to  remove  any  cellular  debris.  Assay 
dilutent  (50  pi)  was  added  to  each  well  on  the  plate,  pre-coated  with  the 
corresponding  antibody relating to the cytokine of interest,  prior to the addition 
of the standards,  control  and  samples (50 pi).  The samples were gently mixed 
by tapping for 1   min, covered with an adhesive plastic cover strip and incubated 
for 2 h at room temperature.  Each well was then aspirated and washed with 400 
pi of wash buffer in a process that was repeated a total of 5 times. After the last 
wash,  any  remaining  wash  buffer was  aspirated  and  the  plate  blotted  against
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clean  paper  towels.  Following  the  washing,  an  enzyme-linked  polyclonal 
antibody specific to the cytokine of interest was added (100 pi) to each well. The 
plate was covered with an adhesive strip and incubated at room temperature for 
2  h.  As  before  the  plate  was  aspirated  and  washed  five  times.  Substrate 
solution  (100  pi) was then added to each well  and the plate incubated at room 
temperature for 30 min in the dark. To halt the reaction,  100 pi of stop solution 
was  added  to  each  well  and  the  absorbance  read  at  450  nm  (correction 
wavelength of 570 nm) on a Molecular Devices VERSAmax tunable microplate 
reader.  Cytokine  concentration  was  determined  by  plotting  the  unknown 
samples on a standard curve of known cytokine concentrations (Figure 2.7).
2.0-1
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0.5-
T T r
0  250  500  750  1000  1250  1500  1750
pg/ml TNF-a 
Figure 2.7:- Standard curve from TNF-a ELISA
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2.16  Statistical Analysis
Statistical  analysis  was  performed  using  one-way ANOVA  combined  with  the 
Bonferroni test where more than two treatments were applied.  Differences were 
considered  to  be  significant  at  P  <  0.05.  The  measurement  of  only  a  single 
variable during different treatments meant the use of a non-parametric statistical 
test  such  as  one-way  ANOVA  was  appropriate.  To  compare  the  statistical 
significance  of  one  treatment  to  another  a  Bonferroni  post  test  was  used 
subsequent to  the ANOVA.  All  statistics were  carried  out  using  the  Graphpad 
computer software PRISM version 4.  Prism evaluates the data to determine if it 
is  normally  distributed  prior  to  running  a  statistical  analysis.  Data  which  is 
unsuitable for the specific statistical test to be used is not analysed.
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3  Chapter 3: Bioactivity of CORM-3
3.1  Introduction
Ever since  NO was characterised  as the  EDRF,  it has  been  studied  in  minute 
detail  (Ignarro,  Buga, Wood,  Byms,  & Chaudhuri  1987;  Grisham,  Jourdheuil,  & 
Wink  1999).  The  studies  into  the  biological  function  of  NO  were  made 
significantly easier with the development of NO donors,  compounds capable of 
releasing NO in a biological environment (Willmot et al. 2005; Al Sa'doni & Ferro 
2005;  Low 2005). The biological activity of NO donors is exemplified by the use 
in  the  clinical  setting  of organic  nitrites  in  the  treatment  of  pathophysiological 
conditions such as systemic and pulmonary hypertension,  angina and vascular 
dysfunction (Napoli & Ignarro 2003).
Not long after NO was established as an important signaling mediator,  Marks et 
al  suggested  that  CO  may  play  a  similar  role  (Marks,  Brien,  Nakatsu,  & 
McLaughlin  1991).  After  all,  both  are  diatomic  gases  of  a  similar  molecular 
weight  and  both  the  HO  pathways  (CO  generation)  and  NOS  pathways  (NO 
formation)  seemed  to  be  not  only  alike  in  components  (inducible  and 
constitutive isozymes) but were also inextricably linked and shown to function in 
a coordinate manner.
Although  initially  much  scepticism  surrounded  the  idea  that  CO  could  have  a 
beneficial  role  in  vivo,  more  and  more  publications  have  attributed  positive 
effects to  CO,  whilst,  the other products of HO  activity (biliverdin,  bilirubin  and 
Fe),  once  thought  of  as  waste,  have  also  been  found  to  play  an  important 
biological role lending credence to the claims of CO’s beneficial role.
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The study on  CO  biology has been restricted as compounds that could  imitate 
the effect of CO were lacking.  Scientists had to rely on upregulating HO activity 
or using exogenously applied CO gas but these methods are incable of directly 
addressing the basic role of CO in biological systems.
The  discovery that transition  metal  carbonyls  could  be  used  to  release  CO  in 
vitro  and  in  vivo  by  our  laboratory  opened  a  new  avenue  into the  potential  of 
such  molecules  to be  used  to facilitate  research  and  possibly  in  the future for 
therapeutic purposes (Johnson,  Mann,  Clark,  Foresti,  Green,  & Motterlini 2003; 
Motterlini,  Mann, Johnson,  Clark, Foresti, & Green 2003b). The early indentified 
CO-RMs  were  not  soluble  in  biological  buffers  but  it  was  found  that  the 
coordination  of  a  biological  ligand  onto  the  metal  centre  could  make  it  more 
water-soluble.  The first prototypic water-soluble  CO-RM  has  been  synthesised 
and  was  labelled  CORM-3  (Clark,  Naughton,  Shurey,  Green,  Johnson,  Mann, 
Foresti,  &  Motterlini  2003b).  With  the  development  of  this  molecule  it  was 
necessary to investigate its actions in  vitro to establish  an  understanding  of its 
biological function.
3.2  Objective
Test the prototypic water soluble CO-RM  (CORM-3) to determine  its toxicity in 
various  cell  lines,  its  effect  on  the  HO  system  and  its  regulation  of  the 
inflammatory  response  inferred  from  TNF-a,  nitrite  and  iNOS  levels  in 
macrophages.
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3.3  Experimental Protocol
The following  section  details the  protocol  of experiments  relative to the results 
of Chapter 1.  The precise  methods can be found  in  more detail  in the Material 
and  Methods  chapter.  Stock  solutions  of  CORM-3  (10  mM)  were  freshly 
prepared  before  each  experiment by dissolving  the  compound  in  pure distilled 
water.  CORM-3 powder was layered with  N2 gas prior to returning it to storage 
in the freezer at -20°C.
3.3.1  Chemicals and reagents
Hemin  (ferriprotoporphyrin  IX  chloride),  tin  protoporphyrin  IX  (SnPPIX)  and 
biliverdin (biliverdin  IX hydrochloride) were purchased from  Porphyrin  Products 
Inc (Logan,  Utah,  USA).  Stock solutions of SnPPIX (10  mM) and biliverdin  (10 
mM) were prepared by dissolving the compounds in 0.1  M NaOH. The solutions 
were  kept  on  ice  and  protected  from  light  until  use.  Hemin  (2  mM)  was 
dissolved  in  1   ml  0.1  M  NaOH  and  the  pH  adjusted  to  7.4  using  phosphate 
buffered  saline.  Tricarbonylchloro(glycinato)ruthenium  (II)
([Ru(CO)3CI(glycinate)]  or  CORM-3)  was  synthesised  as  previously  described 
(Clark,  Naughton,  Shurey,  Green,  Johnson,  Mann,  Foresti,  & Motterlini  2003b; 
Foresti,  Hammad,  Clark,  Johnson,  Mann,  Friebe,  Green,  &  Motterlini  2004). 
CORM-3 was freshly prepared as a 10 mM stock solution in pure distilled water. 
Tricarbonyldichlororuthenium(ll)  dimer  ([Ru(CO)3Cl2]2  or  CORM-2)  was 
obtained  from  Sigma  Aldrich  and  solubilized  in  dimethyl  sulfoxide  (DMSO)  to 
obtain  a  10  mM  stock.  The  chemical  structures  of CORM-2  and  CORM-3  are 
represented in Fig 1.  Inactive forms of each compound (negative controls) were 
also  used  in  some  experiments  and  they were  prepared  as follows:  CORM-3
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was  ‘inactivated’  (iCORM-3)  by  adding  the  compound  to  cell  culture  medium 
and leaving  it for 18 h at 37 °C  in a 5% CO2 humidified atmosphere to liberate 
CO.  The  iCORM-3  solution  was  finally  bubbled  with  nitrogen  to  remove  the 
residual  CO  present in the  solution.  In the case of CORM-2,  the  inactive form 
was  Ru(DMSO)4Cl2  (iCORM-2),  a  molecule  where  the  carbonyl  groups  have 
been  replaced with  DMSO  (Clark,  Naughton,  Shurey,  Green,  Johnson,  Mann, 
Foresti,  & Motterlini 2003b).  Lipopolysaccharide (LPS - E.Coli serotype 026:B6) 
was  obtained  from  Sigma.  Polyclonal  antibodies  against  HO-1  were  from 
Bioquote  Ltd  (York,  UK)  and  polyclonal  anti-iNOS  antibodies  were  purchased 
from  Santa  Cruz  Biotechnology  Inc  (Wembley,  Middlesex,  UK).  Antibodies 
against  p-actin  were  purchased  from  Abeam  (Cambridge,  UK).  All  other 
chemicals  were  reagent  grade  and  obtained  from  Sigma  unless  otherwise 
stated.
3.3.2  Myoglobin Assay
To  prepare  a  stock  solution  of  CORM-3  for  the  myoglobin  assay,  1   mg  of 
CORM-3  was  added  to  100  pi  of  dH20   to  give  a  34  mM  stock.  From  this 
solution,  4,  8  and  12  mM  working  stocks were  prepared.  The  myoglobin  was 
warmed  (37  °C),  sodium  dithionite  (0.1  %)  added  and  a  1   ml  sample  of the 
myoglobin  measured  for  the  deoxy-Mb  curve.  This  1   ml  sample  of  deoxy-Mb 
was then  bubbled with  CO  gas for  10  seconds to  saturate the  myoglobin  and 
give a MbCO curve.  Six cuvettes were then  loaded  into the spectrophotometer 
carousel each containing 1   ml of deoxy-Mb solution each.  Five pi of 4, 8, and 12 
mM CORM-3 working stocks were then added in duplicate to each cuvette. The 
resultant final concentrations of CORM-3 being 20 (from 4 mM), 40 (from 8 mM)
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and 60 pM (from  12 mM). The myoglobin was then mixed gently using a pipette 
and  layered  with  500  pi  of  mineral  oil.  The  samples  were  then  read  at  set 
intervals for a set period of time.
3.3.3  Cell Culture
Murine  RAW264.7  monocyte  macrophages  (European  Collection  of  Cell 
Cultures - Salisbury, Wiltshire,  UK) were cultured as per Material  and  Methods. 
Cultures  were  maintained  at  37  °C  in  a  5%  CO2  humidified  atmosphere  and 
experiments were conducted on cells at approximately 80-90% confluence.
3.3.4  Experimental Protocol
Macrophages  were  exposed  for  24  h  to  LPS  (1  pg/ml)  in  the  presence  or 
absence  of  CORM-3  or  CORM-2  (10,  50  and  100  pM)  and  nitrite  levels  and 
iNOS  protein  expression  were  determined  at  the  end  of  the  incubation.  In  a 
similar  set  of experiments,  50  and  100  pM  CORM-3  were  added  to  cells  6  h 
after incubation with LPS and nitrite measured at 24 h. The production of nitrite 
was  also  assessed  in  cells  exposed  simultaneously to  LPS  and  CORM-3  (10, 
50 and 100 pM) at 0 h followed by subsequent additions of CORM-3 at 3 and/or 
6  h.  Experiments  were  repeated  with  the  negative  controls  iCORM-3  and 
iCORM-2 to assess whether the effects observed were due to the CO  liberated 
by the CO-RMs or caused by other components of the molecules.  The effect of 
CO-RMs and their inactive counterparts on the  haem oxygenase pathway was 
also investigated.  Specifically,  cells were treated for 6 h in the presence of 10, 
50 and  100 pM CO-RMs and haem oxygenase activity as well as HO-1  protein 
expression  determined.  Furthermore,  haem  oxygenase  activity was  measured
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in  cells  treated  with  LPS  in  the  presence  or  absence  of  CORM-3.  Haem 
oxygenase  activity  and  HO-1  expression  were  also  evaluated  in  cells  pre­
incubated with  1mM NAC prior to exposure to 100 pM CORM-3. To exclude the 
possibility that endogenously generated haem degradation products would exert 
potential anti-inflammatory effects,  the experiments were also conducted  in the 
presence  of  SnPPIX  (10  pM),  an  inhibitor  of  haem  oxygenase  activity. 
Furthermore,  we  investigated  the  effect  of the  haem  oxygenase  pathway  on 
nitrite  production  by pre-treating  cells for 6 h with either hemin  (10,  25 and 50 
pM)  or  biliverdin  (1,  5,  10  and  20  pM)  before  exposure  to  LPS  for  24  h. 
Experiments  were  also  conducted  using  SnPPIX,  which  was  present  both 
during the pre-incubation with hemin and the exposure to LPS. The effect of 10, 
50  and  100  pM  CORM-3  on  the  cellular  redox  status  was  assessed  by 
measuring glutathione levels at 30 min, 2 h and 4 h after CORM-3 exposure.
3.3.5  Assay for Nitrite Levels
Nitrite  levels were  determined  using  the  Griess  method.  The  measurement  of 
this  parameter  is  widely  accepted  as  indicative  of  NO  production.  Briefly,  the 
medium from treated  cells cultured  in 24 well  plates was  removed  and  placed 
into a 96 well plate (50 pi per well). The Griess reagent was added to each well 
to begin the reaction, the plate was shaken for 10 min and the absorbance read 
at 550 nm on a Molecular Devices VERSAmax plate reader.  The nitrite level  in 
each  sample  was  calculated  from  a  standard  curve  generated  with  sodium 
nitrite (0 pM to 300 pM in cell culture medium).
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3.3.6  Western Blot Analysis
Samples of RAW264.7 cells were analysed by Western immunoblot.  Briefly,  an 
equal  amount  of  protein  (30  pg)  for  each  sample  was  separated  by  SDS- 
polyacrylamide  gel  electrophoresis,  transferred  overnight  to  nitrocellulose 
membranes  and  the  non-specific  binding  of  antibodies  was  blocked  with  3% 
non-fat dried milk in PBS.  Membranes were then probed with a polyclonal rabbit 
anti-HO-1  antibody  (Bioquote  Ltd.,  York,  UK)  or with  a  polyclonal  rabbit  anti- 
iNOS antibody (Santa Cruz Biotechnology Inc,  Insight biotechnology, Wembley, 
Middlesex,  UK)  (1:1000  dilution  in  Tris-buffered  saline,  pH  =  7.4).  After  three 
washes with PBS containing 0.05% (v/v) Tween 20,  blots were visualised using 
an  amplified  alkaline  phosphatase  kit  from  Sigma  (Extra-3A.  To  verify  equal 
loading,  samples were  also  probed with  p-actin  polyclonal  antibodies  (Abeam, 
Cambridge,  U.K.).
3.3.7  Assay for Haem Oxygenase Activity
Haem  oxygenase  activity  was  determined  in  RAW264.7  cells  after  various 
treatments.  Briefly,  harvested  cells  were  subjected  to  three  cycles  of  freeze- 
thawing before addition to a reaction  mixture consisting of phosphate buffer (1 
ml final volume,  pH = 7.4) containing magnesium chloride (2 mM),  NADPH (0.8 
mM),  glucose-6-phosphate  (2  mM),  glucose-6-phosphate  dehydrogenase  (0.2 
Units),  rat  liver cytosol  as  a  source  of  biliverdin  reductase,  and  the  substrate 
hemin  (20  pM).  The  reaction was  conducted  at  37  °C  in  the  dark for  1   h  and 
terminated  by  the  addition  of  1   ml  chloroform;  the  extracted  bilirubin  was 
calculated  by the  difference  in  absorbance  between  464  and  530  nm  (e  =  40 
mM'1cm'1).
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3.3.8  Determination of cellular glutathione content
The  5,5’ . dithiobis-(2-nitrobenzoic  acid)  colorimetric  assay  was  used  for  the 
measurement  of  glutathione.  Briefly,  cells  at the  end  of the  incubation  period 
were washed with PBS and 600 pi of a 2% (w/v) solution of 5-sulfosalicylic acid 
were added for cell lysis and deproteinization. The samples were centrifuged for 
5  min  at  10,000  x  g  and  500  pi  aliquots  were  reacted  with  500  pi  of  5,5’ 
dithiobis-(2-nitrobenzoic acid)  solution  (0.3  M  sodium  phosphate  buffer, 10  mM 
EDTA  and  0.2  mM  5,5’  dithiobis-(2-nitrobenzoic  acid),  freshly  prepared)  and 
after 5 min the absorbance was read at 412 nm (extinction coefficient was  14.3 
mM'1   cm"1).  Positive  and  negative  controls  were  obtained  by  incubating 
macrophages  with  1   mM  NAC,  a  precursor  of  glutathione,  or  1   mM  DL- 
buthionine-[S,R]sulfoximine (BSO), an inhibitor of glutathione biosynthesis.
3.3.9  Determination of TNF-a levels
The  level  of  TNF-a  present  in  each  sample  was  determined  using  a  kit 
commercially  available  from  R&D  Systems  (Abingdon,  UK).  The  assay  was 
performed  according  to  the  manufacturers’  instructions.  Briefly,  cell  culture 
supernatants were collected immediately after the treatment and spun at 13,000 
x g for 2  min to remove any particulates.  The medium was added to a 96 well 
plate  pre-coated  with  affinity  purified  polyclonal  antibodies  specific for  mouse 
TNF-a.  An  enzyme-linked  polyclonal  antibody  specific  for  mouse  TNF-a  was 
added to the wells and  left to react for 2  h followed  by a final wash to remove 
any unbound antibody-enzyme reagent.  The intensity of the colour detected at 
450  nm  (correction  wavelength  570  nm)  was  measured  after  addition  of  a 
substrate solution and was proportional to the amount of TNF-a produced.
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3.3.10  Cell Viability 
Alamar Blue
Cell metabolism was determined using an Alamar Blue assay kit and carried out 
according to the manufacturer’s instructions (Serotec,  UK). The assay is based 
on the detection of metabolic activity of living cells using a redox indicator which 
changes from  an oxidised (blue) form to a reduced  (red) form.  The  intensity of 
the red colour is proportional to the metabolism of the cells, which is calculated 
as the difference in absorbance between 570 nm and 600 nm and expressed as 
a percentage of control.
Trypan Blue
The  status  of  the  cell  membrane  was  investigated  using  Trypan  blue.  The 
medium  of treated  cells  is  removed  and the cells then washed with  PBS  10X. 
Then a  1:1  solution of PBS (10X) and Trypan blue dye was added to cells. The 
dye  permeates  cell  in  which  the  membrane  has  been  compromised.  By 
counting the number of cell dyed compared to those which are not the number 
of viable cells can be determined.
Lactate Dehydrogenase
Damage  of  the  phopholipid  bi-layer  of  cells  was  investigated  using  an  LDH 
assay  kit  and  carried  out according  to  the  manufacturer’s  instructions  (Roche, 
UK).  The  medium  of  treated  cells  is  collected,  spun  to  remove  any  cellular 
debris  and  then  a  reaction  mixture  containg  an  INT  dye  added.  LDH  activity 
reflects its release from the cell membrane and a loss of viability.
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3.3.11  Statistical Analysis
Statistical  analysis  was  performed  using  one-way  ANOVA  combined  with 
Bonferroni test.  Differences were considered to be significant at P < 0.05.
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3.4  Results
3.4.1  CORM-3  Releases  a  Quantifiable  Amount  of  CO  using  the 
Myoglobin Assay
Having synthesised CORM-3, a water soluble transition metal carbonyl, the first 
factor to  establish  was  that  it  was  capable  of  releasing  CO.  This  was  tested 
using the myoglobin  assay technique (paragraph 2.4).  Figure  3.1 A shows that 
indeed  CORM-3  converted  deoxymyoglobin  (deoxyMb)  to  MbCO.  In  this 
instance,  there  is  little  change  from  time  zero  to  60  min  which  means  that 
CORM-3  releases  almost  instantly  all  of  its  available  CO  into  the  myoglobin 
solution. The saturated MbCO curve, using CO gas, represents the maximal CO 
capacity  of  the  myoglobin  stock  prepared  that  specific  day.  This  is  also 
quantified  by  the  MbCO  value  reported  at  the  top  of  the  page  (-51  pM). 
Although the stock concentration of myoglobin is 66 pM we can only saturate it 
to -51  - 54  pM  using  CO  gas.  This  is because the  myoglobin  purchased from 
sigma  is  impure and comes as 90%  myoglobin,  therefore,  the concentration of 
MbCO  we  measure  having  saturated  the  myoglobin  with  CO  gas  is  the  real 
concentration of our myoglobin stock (54 pM is indeed -90% of the expected 66 
pM).  Importantly, this effect was consistent throughout all myoglobin assays. 
Subsequent  conversion  of  the  MbCO  curve  to  empirical  data  (Figure  3.1 B) 
gives  us an  idea of the CO  released  in  solution.  CORM-3  released  -35  pM  of 
CO instantly and then went on to release a maximal of -40 pM CO after only 5 
min.  Thus,  the  kinetics  of the  reaction  are  instant  and  the  half life  very  short. 
The  overall  CO  release  suggests  that  one  carbonyl  group  per  CORM-3 
molecule is liberated which is in agreement with earlier tests (Clark,  Naughton, 
Shurey,  Green,  Johnson,  Mann,  Foresti,  & Motterlini 2003b;  Foresti,  Hammad,
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Clark,  Johnson,  Mann,  Friebe,  Green,  &  Motterlini  2004).  The  release  of  CO 
from  CORM-3 was concentration  dependent.  Also 20  pM  and  60  pM  CORM-3 
released  CO  in  an  approximately  1:1  ratio.  Addition  of  CORM-3  to  biological 
buffers  results  in  CO  release  and  leaves  an  inactive  CORM-3  (iCORM-3)  not 
capable  of  further  CO  release  (Clark,  Naughton,  Shurey,  Green,  Johnson, 
Mann,  Foresti,  &  Motterlini  2003b;  Foresti,  Hammad,  Clark,  Johnson,  Mann, 
Friebe,  Green,  &  Motterlini  2004).  This  was  demonstrated  by  using  the 
myoglobin  assay  and  showed  that  iCORM-3  was  incapable  of  converting 
deoxyMb to MbCO.
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Figure  3.1:-  CORM-3  releases  a  quantifiable  amount  of  CO  using  the 
myoglobin assay.
(A)  CORM-3 (40 pM) was added to a provisional 66 pM myoglobin solution the 
effective concentration  is 51  pM  as  shown  by the  saturation with  CO  gas  (see 
text  on  page  127  for  details).  The  conversion  of  myoglobin  to  MbCO  was 
followed  over time  by  measuring the changes  in the  absorption  spectra  of this 
protein  at  pH  =  7.4.  The  maximal  absorption  peak of myoglobin  at  560  nm  is 
gradually converted over time by CORM-3 to spectra typical of MbCO with two 
maximal  absorption  peaks  at  540  and  578  nm,  respectively.  Myoglobin  was 
saturated  (MbCO)  by  bubbling  deoxyMb  with  CO  for  5  min.  (B)  The  MbCO 
concentration  was  derived  from  the  increase  in  absorption  between  deoxyMb 
(not shown) and sample readings at 540 nm. This is the amount of CO released 
in solution.
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3.4.2  CO-RMs attenuate LPS-mediated nitrite production
Our group has previously reported some of the biological properties of CORM-2 
and CORM-3 (Motterlini,  Clark,  Foresti,  Sarathchandra,  Mann,  & Green 2002a; 
Motterlini,  Mann,  Johnson,  Clark,  Foresti,  &  Green  2003b;  Clark,  Naughton, 
Shurey,  Green,  Johnson,  Mann,  Foresti,  &  Motterlini  2003b),  two  transition 
carbonyl complexes which contain ruthenium as their metal centre.  Despite both 
containing  ruthenium,  two  major  differences  exist  between  CORM-2  and 
CORM-3.  Specifically,  CORM-2  contains  two  ruthenium  atoms  whereas  only 
one ruthenium  lies at the centre of CORM-3.  In addition,  CORM-2  is soluble in 
DMSO  while  CORM-3  has  been  designed  to  render  it  water-soluble  (Clark, 
Naughton,  Shurey,  Green,  Johnson,  Mann,  Foresti, & Motterlini 2003b).  Recent 
publications have highlighted important anti-inflammatory actions exerted by CO 
gas (Otterbein et al. 2000a) and these findings prompted us to assess whether 
CO-RMs  could  affect  the  inflammatory  response  in  LPS-activated 
macrophages.  As  shown  in  Figure  3.2A  and  Figure  3.3B,  both  CORM-2  and 
CORM-3  significantly  attenuated  LPS-induced  nitrite  production  in  a 
concentration-dependent manner. This effect appeared to be strictly dependent 
on  the  CO  released  by  the  compounds  since  neither  iCORM-2  nor  iCORM-3, 
which do not liberate CO, had any effect on nitrite levels.  Interestingly,  CORM-3 
decreased  nitrite  even  when  added  6  h  after  LPS  treatment  (Figure  3.4A), 
suggesting  that  CO  directly  influences  the  production  of  NO  by  iNOS. 
Corroborating  this  idea,  nitrite  levels  were  lower  in  cells  exposed  to  LPS  and 
CORM-3  at 0  h followed  by  subsequent additions of CORM-3  at  3  and/or 6  h 
compared to treatment with LPS and CORM-3 at 0 h only (Figure 3.4B).  Indeed, 
100 pM CORM-3 delivered in multiple additions reduced nitrite to control levels.
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It is important to note that cell viability was not affected by the concentrations of 
CO-RMs  or  the  inactive  forms  used  (Figure  3.2B,  Figure  3.3B,  Figure  3.5, 
Figure 3.6 and Figure 3.7), indicating that the results observed are not related to 
potential  cytotoxicity of the compounds.  These data suggest that CORM-2  and 
CORM-3 can modulate the production of nitrite by liberation of CO.
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CORM-3 (pM)  -  -  10  50  100
iCORM-3 (pM)  -  -  -  -  100
LPS (1  pg/ml)  -  +  +  +  +  +
CORM-3 (pM)  -  -  10  50  100
iCORM-3 (pM)  -  -  -  -  100
Figure  3.2:-  Effect  of  CORM-3  on  LPS-stimulated  nitrite  production  and 
cell viability.
(A)  RAW264.7  macrophages were exposed to  1   pg/ml  LPS  in the presence or 
absence of CORM-3 (10-100 pM) and nitrite production was assessed at 24 h. 
The  inactive  compound  iCORM-3  (100  pM)  was  also  used  to  determine  the 
contribution  of  CO  released  by  CORM-3  to  the  observed  effect.  Control  cells 
were  incubated  with  medium  alone.  (B)  Cell  viability was  assessed  24  h  after 
exposure  of  macrophages  to  1   pg/ml  LPS  in  the  presence  or  absence  of 
CORM-3  (10-100  pM)  or  iCORM-3  (100  pM).  Viability  was  expressed  as 
percentage  of  control.  Data  represent  the  mean  ±  S.E M.  of  6  independent 
experiments.  * indicates  P  < 0.05 vs.  control  (white bars);  t indicates  P  <  0.05 
vs.  LPS alone.
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Figure  3.3:-  Effect  of  CORM-2  on  LPS-stimulated  nitrite  production  and 
cell viability.
(A)  RAW264.7  macrophages were exposed to  1   pg/ml  LPS  in the presence or 
absence of CORM-2 (10-100 pM) and nitrite production was assessed at 24 h. 
iCORM-2  (10-100  pM),  an  inactive  compound  that  does  not  release  CO,  was 
also used as  a negative control for CORM-2.  Control cells were  incubated with 
medium  alone.  (B)  Cell  viability  was  assessed  24  h  after  exposure  of 
macrophages to  1   pg/ml  LPS  in the presence or absence  of CORM-2  (10-100 
pM) or iCORM-2 (10-100 pM). Viability was expressed as percentage of control. 
Data represent the mean ± S.E.M.  of 6  independent experiments.  * indicates P 
< 0.05 vs. control (white bars); t  indicates P < 0.05 vs.  LPS alone.
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Figure  3.4:-  Multiple  additions  of  CORM-3  or  its  delivery  after  LPS 
challenge decrease nitrite production.
(A)  RAW264.7  macrophages were exposed to  1   pg/ml  LPS  in the presence (0 
h) or absence of CORM-3 (10-100  pM)  and nitrite  production was assessed at 
24 h.  In some experiments,  CORM-3 was added also at 3 h after LPS (0 h + 3 
h)  or  at  3  and  6  h  after  LPS  (0  h  +  3  h  +  6  h).  (B)  Nitrite  production  was 
measured at 24 h in macrophages incubated with LPS alone or LPS followed 6 
h  later  by  a  single  addition  of CORM-3  at  50  or  100  pM.  Data  represent  the 
mean  ± S. EM.  of 6  independent experiments.  * indicates  P  <  0.05 vs.  control 
(CON); t indicates P < 0.05 vs.  LPS alone.
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Figure 3.5:- CORM-3 does not affect cell metabolism at the concentrations 
used.
Cell  metabolism  was  assessed  24  h  after  exposure  of  macrophages  to  (A) 
CORM-3  (10-1000  pM)  or  (B)  iCORM-3  (10-1000  pM)  using  the  Alamar  blue 
assay.  Viability  was  expressed  as  percentage  of  control.  Data  represent  the 
mean  ± S.E.M.  of 6  independent experiments.  * indicates  P  <  0.05 vs.  control 
(CON).
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Figure  3.6:-  CORM-3  does  not  affect  cell  membrane  permeability  at  the 
concentrations used.
Cell membrane permeability was assessed 24 h after exposure of macrophages 
to  (A)  CORM-3 (10-1000  pM)  or (B)  iCORM-3  (10-1000  pM)  using  the Trypan 
blue  assay.  Viability was  expressed  as  percentage  stained  cells  compared  to 
the total  number of cells.  Data  represent the  mean  ± S.E.M.  of 6  independent 
experiments. * indicates P < 0.05 vs. control (CON).
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Figure  3.7:-  CORM-3  does  not  affect  LDH  release  at  the  concentrations 
used.
The release of LDH was assessed 24 h  after exposure of macrophages to  (A) 
CORM-3  (10-1000  pM)  or  (B)  iCORM-3  (10-1000  pM)  using  the  LDH  assay. 
Viability was expressed as percentage of maximal  damage (triton) and  minmal 
damage  (control).  Data  represent  the  mean  ±  S.E.M.  of  6  independent 
experiments. * indicates P < 0.05 vs. control (CON).
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3.4.3  CORM-2  and  CORM-3  increase  haem oxygenase activity and  HO-1 
protein expression
The  presence  of  a  metal  and  the  CO  released  by  CO-RMs  could  be  factors 
stimulating  the  induction  of  HO-1,  which  per  se  may  exert  anti-inflammatory 
effects  (Lee  &  Chau  2002;  Wagener  et  al.  2003a).  We  therefore,  incubated 
macrophages for 6 h with different concentrations of CO-RMs  or their inactive 
counterparts  and  measured  haem  oxygenase  activity  and  HO-1  expression. 
CORM-3 (10-100 pM) caused a concomitant concentration-dependent increase 
in  haem  oxygenase  activity and  HO-1  expression,  an  effect that  started  to  be 
evident  at  50  pM  (Figure  3.8A  and  Figure  3.9).  CORM-2  produced  a  similar 
effect at the  concentration  of  100  pM  (Figure 3.8B).  In  marked  constrast,  both 
iCORM-2 and iCORM-3 (100 pM) did not change the levels of haem oxygenase 
activity  or  HO-1  protein  expression  (Figure  3.8A,  Figure  3.8B  and  Figure  3.9) 
suggesting  that  CO  liberated  from  the  compounds  is  responsible  for  the 
observed  effect  while  the  rest  of  CORM-2  or  CORM-3  molecules  is  inactive 
once CO is liberated. Since endotoxin is known to up-regulate HO-1  expression 
in  a  variety  of  tissues,  we  assessed  the  effect  of  LPS  and  CORM-3  on 
macrophage  haem  oxygenase  activity.  Table  3.1  shows  that  treatment  of 
macrophages with LPS for 6 h resulted in a slight increase of haem oxygenase 
activity while the combination of LPS and CORM-3 did not differ from CORM-3 
alone.  In  contrast,  haem  oxygenase  was  significantly  increased  after  24  h 
exposure  to  LPS  and  co-incubation  of  LPS  with  CORM-3  produced  results 
similar  to  LPS  alone.  Previous  reports  have  shown  that  induction  of  HO-1 
suppresses  the  production  of  nitrite  in  macrophages  stimulated  with  LPS 
(Turcanu,  Dhouib,  & Poindron  1998c). The above data therefore,  could suggest
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that  CORM-2  and  CORM-3  decrease  nitrite  production  not  because  of  their 
ability  to  release  CO  but  rather  by  inducing  HO-1  expression.  To  further 
investigate  this  possibility,  we  performed  experiments  in  which  macrophages 
were  exposed  to  LPS  and  CORM-3  in  the  presence  of  SnPPIX  (10  pM),  a 
known inhibitor of haem oxygenase activity. We found that the nitrite production 
was  not  significantly  different  between  macrophages  stimulated  by  LPS  and 
CORM-3  versus  those  treated  with  LPS  and  CORM-3  in  the  presence  of 
SnPPIX (Figure 3.11).  This suggests that HO-1  induction is not responsible for 
the  decrease  in  nitrite  levels  observed  in  the  presence  of  CORM-3  and 
substantiates  the  idea  that  CO  released  by  CORM-3  mediates  this  anti­
inflammatory effect.  By using  NAC,  a thiol donor and glutathione precursor,  we 
observed a complete suppression of HO-1  induction by CORM-3 (Figure 3.10), 
pointing to the potential of CO to modulate the redox status of the cell. We also 
examined  the  possibility that  CORM-3  could  affect the  protein  levels  of iNOS, 
the  inducible  isoform  of  NO  synthase  which  is  stimulated  by  LPS  and  is 
accountable  for  the  increased  generation  of  NO  during  a  variety  of  stress- 
related  conditions.  Figure  3.12  indicates  that  CORM-3  at  different 
concentrations did not change the basal or LPS-stimulated expression of iNOS, 
emphasizing  the  possibility that  CORM-3  interferes with the  enzymatic activity 
of the protein.
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Figure  3.8:-  Effect  of  CORM-3  and  CORM-2  on  haem  oxygenase  activity.
(A)  RAW264.7  macrophages were  incubated with  increasing  concentrations of 
CORM-3  (10-100  pM)  or  iCORM-3  (100  pM).  Haem  oxygenase  activity  was 
determined  6  h  after  exposure  to  the  different  concentrations.  (B)  Haem 
oxygenase  activity  was  measured  in  cells  exposed  to  100  pM  CORM-2  or 
iCORM-2  for  6  h.  Data  represent  the  mean  ±  S.E.M.  of  6  independent 
experiments. * indicates P < 0.05 vs. control (CON).
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Figure 3.9:- Effect of CORM-3 on HO-1  protein expression.
RAW264.7  macrophages  were  incubated  with  increasing  concentrations  of 
CORM-3  (10-100  pM)  or  100  pM  iCORM-3  and  HO-1  protein  levels  were 
determined  by  Western  blot  analysis  after  24  h.  (A)  The  graph  shows  the 
average  expression  of  HO-1  following  densitometric analysis  of three  different
(B)  blots from three  independent experiments  and one  representative  image  is 
reported,  p-actin was used as an internal control for equal loading.  * indicates P 
< 0.05 vs. control (CON).
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Figure  3.10:-  N-acetylcysteine  abolishes the  increase  in  haem  oxyegnase 
activity and HO-1  expression elicited by CORM-3.
RAW264.7 macrophages were incubated with 100 pM CORM-3 in the presence 
or  absence  of  1   mM  NAC.  (A)  Haem  oxygenase  activity  and  (B)  HO-1 
expression  were  assessed  after  6  h  incubation.  Data  represent  the  mean  ± 
S.E.M.  of 6  independent experiments.  Western  blot  image  is  representative of 
three different blots,  p-actin was used as an internal control for equal loading.  * 
indicates P < 0.05 vs. control (CON); t  indicates P < 0.05 vs. CORM-3.
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Figure 3.11:- Effect of CORM-3 on  LPS-stimulated nitrite production in the 
presence of SnPPIX, an inhibitor of haem oxygenase activity.
RAW264.7  macrophages  were  exposed  to  1   pg/ml  LPS  in  the  presence  or 
absence  of  CORM-3  (10-100  pM)  and  SnPPIX  (10  pM)  and  nitrite  production 
was assessed after 24 h.  Control cells were incubated with medium alone.  Data 
represent the mean ± S.E.M. of 6 independent experiments.  * indicates P < 0.05 
vs. control (white bar); t  indicates P < 0.05 vs.  LPS alone.
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Figure 3.12:-  Effect of CORM-3 on  LPS-stimulated  expression of inducible 
NO synthase (iNOS).
Macrophages  were  exposed  to  1   pg/ml  LPS  in  the  presence  or  absence  of 
CORM-3 (10-100  pM) for 24 h  and  iNOS  protein  expression was examined  by 
Western  blot  analysis.  (A)  The  graph  shows  the  average  expression  of  iNOS 
protein  following  densitometric  analysis  of  three  different  blots  from  three 
independent experiments and (B) one representative image is reported.  (3-actin 
was  used  as  an  internal  control  for  equal  loading.  *  indicates  P  <  0.05  vs. 
control.
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Table 3.1:- Haem oxygenase activity in macrophages incubated with  LPS 
and/or CORM-3.
Macrophages  were  incubated  for 6  or 24  h  in  the  presence  of  medium  alone 
(Control),  LPS,  CORM-3  alone  or  the  combination  of  CORM-3  and  LPS. 
Experiments  were  also  conducted  with  the  negative  control  iCORM-3.  At  the 
end  of  the  incubation,  cells  were  collected  for  the  haem  oxygenase  activity 
assay.  Data  represent  the  mean  ±  S.E.M.  of  4  independent  experiments.  * 
indicates P < 0.05 vs. Control.
Sample Haem oxygenase activity 
(pmol bilirubin/mg protein/h)
6 h 24 h
Control 310.70 ±9.21 408.98 ±27.17
1 pg/ml LPS 342.60  ±9.30 672.37 ± 27.95*
50 pM CORM-3 418.25 ±16.3* 434.41  ± 8.07
50 pM CORM-3 + 1  pg/ml LPS 452.85 ± 30.23 623.27 ± 22.50*
50 pM iCORM-3 387.44 ±13.8* 339.66 ± 23.89
50 pM CORM-3 + 1  pg/ml LPS 350.88 ± 6.49 541.18 ±85.56
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3.4.4  Effect of CORM-3 on cellular glutathione content
The  results  showing  that  NAC  abolished  the  induction  of  HO-1  by  CORM-3
suggested  that  CO  exerted  a  degree  of cellular  oxidative  stress.  To  examine 
this phenomenon  more closely,  we assessed the changes in glutathione levels 
during exposure to CORM-3 (10, 50 and  100 pM). As reported in Table 3.2,  the 
glutathione  content  did  not  vary  between  control  and  CORM-3-treated  cells 
following  a  30  min  incubation.  However,  after  2  h  there  was  a  significant 
decrease in glutathione in macrophages exposed to 100 pM CORM-3, while 10 
and 50 pM CORM-3 only caused a slight change.  Interestingly, at 4 h there was 
a complete  recovery of the glutathione content with  all  three concentrations  of 
CORM-3,  suggesting that cells were rapidly reacting to the CO-mediated stress 
by  stimulating  cfe  novo  glutathione  synthesis  and  thus  re-establishing  the 
normal  endogenous  redox  balance.  Since  iCORM-3  did  not  affect  glutathione 
(data not shown), we conclude that the effect caused by CORM-3 is due to CO 
liberated by the compound.
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Table 3.2:- Glutathione content measured in macrophages incubated with 
CORM-3.
Macrophages were incubated for 30 min, 2 h or 4 h in the presence of medium 
alone  (Control),  or  10,  50  or  100  pM  CORM-3  and  glutathione  content  was 
assessed using a spectrophotometric assay.  Experiments were also conducted 
with  the  negative  control  iCORM-3  without  significant  changes  (data  not 
shown).  Data  represent the  mean  ± S.E.M.  of 3-5  independent experiments.  * 
indicates P < 0.05 vs. Control.
Sample Glutathione (% of control)
30 min 2 h 4h
Control 100±9.47 100±5.26 100±4.78
CORM-3 (10 pM) 110.02±1.50 97.94±2.62 102.51 ±2.35
CORM-3 (50 pM) 107.34 ±1.79 92.41 ±0.71 99.69±3.47
CORM-3 (100 pM) 109.97±1.04 81.17±5.66 * 106.26±3.15
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3.4.5  CORM-3 attenuates LPS-mediated TNF- a production
Having  established  that  CORM-3  could  attenuate  LPS-induced  nitrite
production,  we investigated its effect on the generation of TNF-a,  an additional 
marker of  inflammation  (Otterbein,  Bach,  Alam,  Soares,  Tao  Lu,  Wysk,  Davis, 
Flavell,  &  Choi  2000a).  As  shown  in  Figure  3.13A,  LPS  caused  a  significant 
production  of  TNF-a  in  macrophages  and  the  addition  of  10  pM  CORM-3 
completely abolished this inflammatory response.  Conversely,  iCORM-3 did not 
change TNF-a levels, suggesting once again that CO is the active component of 
the  CORM-3  molecule  that  elicits  this  effect.  Considering  that  CORM-3  can 
induce  HO-1  (see  earlier results  of Figure 3.8A and  Figure 3.9),  we  assessed 
whether haem  oxygenase  activity was  involved  in the mechanisms  modulating 
TNF-a  production.  Interestingly,  treatment  of  macrophages  with  LPS  in  the 
presence of SnPPIX caused  an  even greater increase  in TNF-a levels  (Figure 
3.13B),  implying  that  endogenous  haem  oxygenase  activity  inhibits  the 
production  of this  pro-inflammatory  mediator.  However,  the  amount  of  TNF-a 
was reduced to that of LPS alone when CORM-3 was added in the presence of 
LPS  and  SnPPIX  (Figure  3.13B).  These  data  suggest  that  CO  plays  an 
important role in the attenuation of LPS-induced TNF-a production,  highlighting 
that inhibition of haem oxygenase activity also  profoundly influences the  levels 
of TNF-a.
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Figure  3.13:-  CORM-3  modulates  the  production  of TNF-a  stimulated  by 
LPS.
(A)  Macrophages were exposed to  1   ng/ml  LPS  in the  presence or absence of 
10 pM CORM-3 or iCORM-3 and the level of TNF-a in the culture medium was 
measured  at  24  h  by  a  commercially  available  immunoassay.  (B)  TNF-a 
production was  measured  in  macrophages  stimulated  by  LPS  in the  presence 
or  absence  of  CORM-3  and  SnPPIX  (10  pM).  Data  represent  the  mean  ± 
S.E.M.  of 6 independent experiments.  * indicates P  < 0.05 compared to control 
(CON); f  indicates P < 0.05 vs.  LPS alone.
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3.4.6  Effect of hemin and  bile pigments on  nitrite production stimulated 
by LPS
To  assess  the  contribution  of  haem  oxygenase  and  endogenously-produced 
metabolites of its enzymatic activity (i.e.  biliverdin/bilirubin,  CO and ferrous iron) 
in  regulating  nitrite  levels,  we  incubated  cells  with  hemin,  an  inducer  and 
substrate  of  haem  oxygenase.  As  expected,  macrophages  exposed  to  hemin 
(10-50  pM)  exhibited  a  concentration-dependent  increase  in  haem  oxygenase 
activity (Figure 3.14A).  This  effect was accompanied  by a  significant reduction 
in LPS-stimulated nitrite production (Figure 3.14B) and was partially reversed by 
inhibition  of  haem  oxygenase  activity  with  SnPPIX  (Figure  3.15A).  We  also 
noted  that  stimulation  of  macrophages  with  LPS  in  the  presence  of  SnPPIX 
resulted  in  an  enhancement  of  nitrite  levels  compared  to  LPS  alone  (Figure 
3.15A),  suggesting  that  haem  oxygenase  exerts  a  negative  feedback 
mechanism on  NO  generation during endotoxin treatment.  As  shown  in  Figure 
3.15B,  biliverdin  (or  bilirubin,  data  not  shown)  did  not  affect  this  response, 
suggesting that the nitrite reduction caused by hemin treatment is mediated  by 
CO or possibly by degradation of the iNOS cofactor haem by haem oxygenase 
(Albakri & Stuehr 1996).
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Figure  3.14:-  Pre-incubation  with  hemin  reduces  LPS-stimulated  nitrite 
production.
(A)  Macrophages  were  treated  with  hemin  (10-100  pM)  for  6  h  and  haem 
oxygenase activity was measured at the end of the incubation as described.  (B) 
Pre-treatment of macrophages with hemin (6 h) was followed  by exposure to  1  
pg/ml  LPS  and  nitrite  production was  assessed  after 24  h.  Data  represent the 
mean  ± S. EM.  of 6  independent experiments.  * indicates  P  <  0.05 vs.  control 
(white bars); t  indicates P < 0.05 vs.  LPS alone.
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Figure  3.15:-  Haem  oxygenase  activity,  but  not  biliverdin,  contributes  to 
the reduction in nitrite production elicited by hemin.
(A) Macrophages were stimulated with 1   pg/ml LPS in the presence or absence 
of  SnPPIX  (10  pM)  and  nitrite  production  was  measured  at  24  h.  In  some 
experiments nitrite levels in the medium of macrophages pre-incubated with  10 
pM  hemin  and  SnPPIX  prior to  exposure  to  LPS  were  determined.  (B)  Nitrite 
levels were measured  in  medium  of macrophages  pre-incubated with  biliverdin 
(1-20  pM)  prior to  exposure  to  LPS.  Data  represent  the  mean  ±  S.E.M.  of 6 
independent  experiments.  *  indicates  P  <  0.05  vs.  control  (white  bars);  t 
indicates P < 0.05 vs. LPS alone.
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3.5  Discussion
The  anti-inflammatory  role  of endogenously derived  CO from  the  activation  of 
HO-1  has been highlighted in recent studies by Otterbein and Nakao (Otterbein 
et  al.  2000b;  Otterbein  2002;  Nakao  et  al.  2003c).  CO  is  part  of a  concerted 
response  elicited  by  HO-1  activity  that  includes  BR,  BV  and  iron.  The 
antioxidant  and  anti-inflammatory  actions  of  this  system  are  vitally  important 
considering  that  both  oxidative  and  inflammatory  reactions  underlie  many 
disease  states  (Slebos,  Ryter,  &  Choi  2003;  Dedon  & Tannenbaum  2004).  A 
fact highlighted by the human HO-1  deficient case described by Yachie in  1999 
(Yachie et al.  1999).  Many groups  have investigated the effect of BR,  BV and 
iron  on various  biological  pathways.  However,  the  lack of a  suitable  means  to 
simulate CO has hindered research on this important gaseous mediator.  In the 
last few years our group began to synthesise metal carbonyl-based compounds 
(CO-RMs)  based  on  an  old  concept  which  we  set  in  a  new  field  (Mann  & 
Motterlini  2002;  Motterlini,  Clark,  Foresti,  Sarathchandra,  Mann,  &  Green 
2002a;Johnson,  Mann,  Clark,  Foresti,  Green,  &  Motterlini  2003).  These 
molecules  have  the  ability  to  release  CO  in  biological  systems  and  we  have 
shown  the  vasocative,  antihypertensive  and  antirejection  effects  of these  CO- 
RMs  is  CO  dependent  (Motterlini,  Mann,  Johnson,  Clark,  Foresti,  &  Green 
2003b;  Clark,  Naughton,  Shurey,  Green,  Johnson,  Mann,  Foresti,  &  Motterlini 
2003b;  Foresti,  Hammad,  Clark,  Johnson,  Mann,  Friebe,  Green,  &  Motterlini 
2004). The success of these early studies led to continuing research to discover 
better and more biologically applicable CO-releasing agents.
CORM-3,  the  prototypic  water  soluble  CO-RM,  was  found  to  elicit  anti­
inflammatory  actions  in  an  in  vitro  model  of  LPS-stimulated  murine
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macrophages.  There was  both  a  marked  reduction  in  nitrite  levels  and  TNF-a 
production,  however,  no effect on  iNOS  protein expression was observed.  For 
comparison  cells  were  also  incubated  with  hemin,  a  potent  inducer  of  HO-1, 
prior  to  LPS  addition.  This  resulted  in  a  decrease  in  nitrite  similar  to  that 
witnessed with CORM-3.  Interestingly incubating cells with either BV or BR had 
no  effect.  These  data  suggest  an  anti-inflammatory  action  for  CORM-3 
comparable to endogenously generated CO from HO-1.
The  most  likely  explanation  for the  decrease  in  nitrite  levels  of  macrophages 
exposed  to  LPS  in  the  presence  of  CORM-3  is  that  NOS  activity  could  be 
inhibited by CO.  Indeed,  CO gas has already been shown to potently inhibit the 
conversion of L-arginine to NO and citrulline by neuronal and macrophage NOS. 
This is due to a conformational change at the active site of the enzyme elicited 
when  CO  binds  the  two  haem  moieties  present  in  the  active  enzyme.  This 
rationale  is  further  supported  by  the  fact  CORM-3  did  not  affect  iNOS 
expression  and  by the  data  showing  nitrite  levels  were  reduced  further when 
CORM-3  was  added  after  LPS  treatment  or  in  multiple  additions  when  iNOS 
protein was  already present.  In  addition,  inactive  CORM-3 did not affect nitrite 
implicating CO as the modulator of the observed effect. The inactive form of the 
compound also allows us to exclude the compound  itself as an  NO scavenger 
or that it interferes with NO generation.
Interestingly,  CORM-3 has a half-life of 10.2 min  in  DMEM culture medium  (as 
determined  by the  myoglobin  assay),  which  is  lessened  in  myoglobin  itself,  a 
more comparative reflection of the cellular milieu, to just 1-2 min.  The intriguing 
question therefore remains how can CO elicit a significant reduction of nitrite 24 
h after co-incubation with LPS? Cytotoxicity of CORM-3 can be excluded at the
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concentrations  used  (10 -   100  |jM)  since  neither the  lactate  dehydrogenase, 
Alamar blue or Trypan blue viability assays showed any reduction in overall cell 
viability.  It is tempting to speculate that once CO is liberated it will tightly bind to 
cellular targets that preserve CO bioactivity over time in a manner similar to S- 
nitrosothiols  (such  as  S-nitrosoalbumin  and  S-nitrosoglutathione)  which  are 
long-lived  species  acting  as  an  apparent  reservoir  of  NO  bioactivity.  Cellular 
targets  that  could  act  as  a  CO  sink  include  haem  dependent  proteins  or 
metalloproteins due to the high affinity of haem/metal prosthetic groups for CO. 
A  plausible  alternative  for  the  results  observed  is  that  CO  could  modulate 
pathways influencing NO production by NOS.
A key anti-inflammatory action of CORM-3 was demonstrated by its significant 
attenuation  of  LPS-mediated  TNF-a  production.  These  data  highlight  two 
important  issues:  i)  HO  intrinsically modulates  inflammation,  since  its  inhibition 
during  LPS  exposure  results  in  an  enhancement of TNF-a  productions  and  ii) 
endogenously  applied  CO  carriers  are  an  effect  means  to  counteract  HO 
pathway blockade. This data also confirms observations made by Otterbein and 
colleagues  that  low  concentrations  of  CO  gas  inhibit  the  expression  of  LPS- 
induced  TNF-a  production in  vitro (Sethi,  Otterbein,  & Choi  2002b).  Further to 
this,  a collaborative study we are  involved in has shown that TNF-a production 
by  isolated  peripheral  blood  mononuclear  cells  stimulated  with  LPS  in  pigs 
treated  with  CORM-3  is  significantly  attenuated  (data  not  published).  The 
increase  in  HO-1  induction  associated with  the  use  of CORM-3  suggests  that 
the  release  of  CO  causes  some  form  of  cellular  stress.  This  concept  was 
supported  by  results  demonstrating  that  NAC  completely  abolished  CORM-3 
mediated  HO-1  up-regulation  and  by  measurements  of total  glutathione which
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decreased  significantly  after 2  h  but  begun  to  increase  at  4  h  using  100  pM 
CORM-3.  The  fact  10  and  50  pM  CORM-3  had  no  effect  on  glutathione 
suggests cellular stress is only associated with higher concentrations of CORM- 
3.  This  data  correlates  well  with  the  finding  that  CORM-3  induced  HO-1  at 
concentrations  above  50  pM.  The  increase  in  HO-1,  however,  was  not 
associated  with  the  reduction  in  nitrite  levels,  possibly  due  to  a  limitation  in 
substrate availability, since cells treated with CORM-3 and LPS  in the presence 
of Sn-PPIX did  not display any marked  difference from those  treated with just 
CORM-3 and LPS.
3.6  Conclusion
CORM-3  by  way  of  CO  suppresses  LPS  induced  nitrite  accumulation  in  a 
murine  macrophage  model  of inflammation.  The  likely  mechanism  of action  is 
via the direct inhibition of iNOS via CO binding and subsequent conformational 
distortion  of the  active  site.  This would  explain  the  high  iNOS  expression  and 
concomitant decrease in nitrite levels.  CORM-3 would appear to be a valuable, 
non-toxic,  tool  in  the  elucidation  of the  role  of  CO  in  biological  systems  and 
more  specifically  has  highlighted  the  action  of  CO  in  its  anti-inflammatory 
regulation.
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4  Chapter 4: Search and Characterisation of New CO-RMs; CO 
Release
4.1  Introduction
Having  established  that  CORM-3  is  bioactive in  vitro,  our chemist  collaborator 
Professor Brian Mann (University of Sheffield) began to generate more CO-RMs 
based on the data and principles derived from CORM-3.
These  metal  carbonyls  have  different  metal  centres  and  biological  ligands 
added.  The  very  nature  of  metal  carbonyl  compounds  allows  for  a  great 
diversity  of variants.  Simple  ligand  substitution  and  changing  the  metal  ion  at 
the  centre  can  completely  alter the  chemistry.  This  allows  us  to  look  at  more 
biologically  compatable  metals  such  as  iron.  The  original  CO-RMs  (CORM-2 
and  CORM-3)  contained  ruthenium,  although,  ruthenium  was  easy  to 
manipulate  chemically  speaking  in  the  developmenbt  of early  CO-RMs  and  is 
currently  being  used  in  a  number  of  drugs  and  compounds  currently  being 
researched  (Alessio  et  al.  2000;  Alessio  et  al.  2004a;  Alessio  et  al.  2004b)  it 
was  alluring  to  try  and  develop  CO-RMs  based  on  metals  present  in  biology 
such as  Fe and manganese (Mn) found commonly in enzymes (Groves 2003). 
Inherently this would have a number of desirable benefits:  (i) make the CO-RM 
more  biologically  compatible  and  (ii)  reduce  any  potential  toxicity  associated 
with  the  compound.  There  is  also  the  potential  for the  body to  assimilate  the 
post CO release compound due to the presence of the iron, whereas, ruthenium 
does not occur in the body naturally and thus no system exists for its removal. 
The overall aim being to try to generate a mixture of CO-RMs that could release 
large  or small  amounts  of CO,  that  had  various  half-lives  and  were  even  less
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likely to  be toxic.  Such  variation  is crucial  not  only from  a  research  tool  stand 
point  but  also  in  the  ultimate  goal  of  developing  a  therapeutic  agent.  For 
example,  the  constitutive  action  of  HO  may  best  be  mimicked  by  a  small  CO 
release  over  a  long  period  of  time,  whilst,  an  inducible  HO  response  would 
require  a  large  CO  release  in  a  short  time.  Such  diversity  could  allow  for  a 
detailed  examination  of  the  role  of  CO  in  a  variety  of  models,  whilst,  this 
variation would also be required  in  pathophysiological therapeutic treatment  of 
chronic and acute conditions. The first step to establish with these new CO-RMs 
was which,  if any,  released CO. This was achieved using the myoglobin assay. 
The determination of CO  released  over time would  also enable us to calculate 
the half life for each CO-RM.
4.2  Objective
Investigate the  ability  of  newly  synthesised  CO-RMs  to  release  CO  using  the 
myoglobin  assay  to  determine  new  CO-RMs  with  the  potential  to forward  the 
study.
4.3  Experimental Protocol
The following  section  details  the  protocol  of specific experiments  of which  the 
general  methods  used  can  be  found  in  the  Material  and  Methods  chapter. 
Further  to  this  an  exact  list  of  all  the  CO-RMs  tested  can  be  found  in  the 
appendix  (paragraph  11.1).  Stock  solutions  of CO-RMs  (10  mM)  were  freshly 
prepared  before each  experiment.  CO-RMs were  layered  with  N2  gas  prior to 
returning them to storage in the freezer at -20°C.
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4.3.1  Myoglobin Assay
To  prepare  a  stock  of  each  CO-RM  for  the  myoglobin  assay  1   mg  of  each 
compound was added to 100 pi of dH20.  From this initial stock, 4, 8 and  12 mM 
working  stocks  were  prepared.  The  myoglobin  was  warmed  (37  °C),  sodium 
dithionite (0.1  %) added and a  1   ml sample of the myoglobin measured for the 
deoxy-Mb curve.  This  1  ml  sample of deoxy-Mb was then  bubbled with  CO gas 
for 10 seconds to saturate the myoglobin and give a MbCO curve.  Six cuvettes 
were then loaded into the spectrophotometer carousel with 1   ml of deoxy-Mb in 
each,  5  pi  of  4,  8,  and  12  mM  CO-RM  working  stocks  were  then  added  in 
duplicate to each cuvette. The resultant final concentrations of CO-RM being 20 
(from  4  mM),  40  (from  8  mM)  and  60  pM  (from  12  mM).  The  myoglobin  was 
then  mixed  gently  using  a  pipette  and  layered with  500  pi  of  mineral  oil.  The 
samples were then read at set intervals for a set period of time.
4.3.2  Inactivation of CO-RM
Very  few  of  all  the  CO-RMs  investigated  could  be  inactivated  in  the  same 
manner as CORM-3.  It was found that by leaving both CORM-307 and  CORM- 
308 in ethanol for 48 h they all  but released their entire CO  (as determined  by 
the myoglobin assay).  CORM-319 was also able to be inactivated by preparing 
1  mg  in  100 pi  H2O  and  leaving  it to stand for 24 h in an open eppendorf after 
which the solution was bubbled with nitrogen (N2) gas for 5 min to remove any 
CO trapped in solution.
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4.4  Results
4.4.1  Overview
This  section  contains  an  assortment  of  CO-RMs  tested  using  the  myoglobin 
assay to give an  idea  of CO-RMs which  release CO,  and  if so  how  much and 
how fast.  The  number of  CO-RMs  tested  makes  it  impractical  to  show  all  the 
data  collected;  however,  all  the  data  is  presented  in  a  tabular  form  in  the 
appendix (paragraph 11.1) for comparison.
4.4.2  CORM-303 Does not Release CO using the Myoglobin Assay
The spectrophotometric assay that detects the formation of MbCO from deoxy-
Mb  has  been  shown  to  be  a  reliable  method  for  assessing  the  extent  and 
kinetics  of  CO  liberation  from  CO-RMs.  A  number  of  the  CO-RMs  tested 
displayed little (<5 pM) or no CO release.  Figure 4.1 A gives an example of such 
a CO-RM. There is no significant change in the myoglobin curve over time using 
CORM-303.  In  fact  the  curve  retains  the  single  peak  characteristics  of  the 
deoxyMb  curve  unlike the  double  peak  associated  with  the  MbCO  curve  (Mb 
saturated with CO gas). There is no change in the curves characteristics over a 
60  min  period  thus  confirming  its  inability  to  release  CO.  Many  similar 
chemically  structured  CO-RMs  were  also  shown  to  be  unable to  release  CO. 
The bioactivity of such CO-RMs was not investigated any further, although, they 
were not entirely useless since we could  use them  as a comparison to  related 
molecules to try and identify components that may cause toxicity and maybe as 
inactive forms of closely related compounds.
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Figure 4.1:- Effect of CORM-303 on myoglobin:  analysis of the conversion 
of Mb to MbCO.
(A)  CORM-303  (40  pM)  was  added  to  a  66  pM  myoglobin  solution.  The 
conversion  of  myoglobin  to  MbCO  was  followed  over  time  by  measuring  the 
changes  in  the  absorption  spectra  of this  protein  at  pH  =  7.4.  The  maximal 
absorption  peak  of  myoglobin  at  560  nm  is  gradually  converted  over  time  by 
CORM-303 to  spectra typical  of MbCO  with two  maximal  absorption  peaks  at 
540  and  578  nm,  respectively.  Myoglobin  was  saturated  (MbCO)  by  bubbling 
deoxyMb with CO for 5 min. (B) Chemical structure of CORM-303.
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4.4.3  CORM-307  Instantly  Releases  CO  and  Effectively  Saturates  the 
Myoglobin to form MbCO
The  CO  released  by  CORM-307  effectively  requires  that  each  molecule  of 
CORM-307  liberates  one  carbonyl  group  and,  therefore,  40  pM  CORM-307 
generates ~40 pM CO.  Figure 4.2A indicates that CORM-307 almost saturated 
the  myoglobin  since the  double  peak curve of CO  gas  saturated  myoglobin  is 
barely  visible  and  is  in  stark  comparison  to  the  deoxyMb  curve  shown  for 
CORM-303.  CORM-307  is  a  good  example  of  an  instant  release  CO-RM.  It 
demonstrates  a  1:1  ratio of CO  release and ear-marks this  particular chemical 
structure as a promising CO-RM. Figure 4.2B shows the empirical conversion of 
absorbance  into a  representative  CO  concentration.  The  CO  concentration  is 
basically determined  by the change  in  absorbance  at 540  nm.  Deoxygenating 
myoglobin with sodium dithionite gives the minimum, while,  bubbling myoglobin 
with  CO  gas  gives  the  maximal  MbCO  concentration  for  that  myoglobin.  CO 
release from CO-RMs will fall  in between these figures allowing us to calculate 
the level of myoglobin saturation and hence the CO released.  As an iron based 
CO-RM, CORM-307 may have interesting bioactivity, coupled with its strong CO 
release  makes  it worthy  of further study.  Unfortunately  its  solubility  in  ethanol 
and  not water is  not ideal for either cell  or animal  studies.  But it offers  a good 
starting point for investigation of this class of CO-RMs.
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Figure 4.2:- Effect of CORM-307 on myoglobin CO saturation.
(A)  CORM-307  (40  pM)  was  added  to  a  66  pM  myoglobin  solution.  The 
conversion  of  myoglobin  to  MbCO  was  followed  over  time  by  measuring  the 
changes  in  the  absorption  spectra  of  this  protein  at  pH  =  7.4.  The  maximal 
absorption  peak  of  myoglobin  at  560  nm  is  gradually  converted  over  time  by 
CORM-307  to  spectra  typical  of MbCO  with  two  maximal  absorption  peaks  at 
540  and  578  nm,  respectively.  Myoglobin  was  saturated  (MbCO)  by  bubbling 
deoxyMb with CO for 5 min.  (B) The MbCO concentration was derived from the 
increase in  absorption  between  deoxyMb  (not shown)  and  sample  readings  at 
540 nm.  This is the amount of CO  released  in solution.  (C) Chemical  structure 
of CORM-307.
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4.4.4  CORM-308  has  an  Almost  Instant  Maximal  CO  Release  in  the 
Myoglobin Assay
CORM-308  generates  a  very  similar  CO  release  to  CORM-307  (Figure  4.3A 
and  Figure  4.3B).  This  could  be  predicted  since  both  compounds  have  very 
similar chemical  structures.  The comparison of these new CO-RMs  could thus 
let  us  identify  chemical  structures  that were  more  likely to  release  CO  and  to 
refine them. This particular structure, therefore,  looks to be a promising CO-RM 
template.  Again  significant  myoglobin  saturation  compared  to  CO  gas  is 
achieved  witht  the  double  peak  curve  of  CO-RM  added  to  myoglobin  almost 
superimposing  on  to  that  of  myoglobin  saturated  with  CO  gas.  The  half  life, 
again  like  CORM-307,  is  very  short  and  a  1:1  ratio  of  CO  released  and 
compound  is  achieved.  The  substitution  of  bromine  (CORM-308)  for  iodine 
(CORM-307)  seems to offer little in the way of increasing  CO  release.  It could 
be that the halogen group is unimportant in the release of CO.  However, as with 
CORM-307,  CORM-308  is only soluble in  ethanol  and the  halogen  group  may 
play a greater role in any related toxicity.
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Figure 4.3:- Effect of CORM-308 on myoglobin:  analysis of the conversion 
of Mb to MbCO.
(A)  CORM-308  (40  pM)  was  added  to  a  66  pM  myoglobin  solution.  The 
conversion  of  myoglobin  to  MbCO  was  followed  over  time  by  measuring  the 
changes  in  the  absorption  spectra  of  this  protein  at  pH  =  7.4.  The  maximal 
absorption  peak  of  myoglobin  at  560  nm  is  gradually  converted  over time  by 
CORM-308 to  spectra typical  of MbCO  with  two  maximal  absorption  peaks  at 
540  and  578  nm,  respectively.  Myoglobin  was  saturated  (MbCO)  by  bubbling 
deoxyMb with CO for 5 min.  (B) The MbCO concentration was derived from the 
increase  in  absorption  between  deoxyMb  (not shown)  and  sample  readings  at 
540 nm.  This is the amount of CO  released  in solution.  (C)  Chemical  structure 
of CORM-308.
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4.4.5  Inactive  Forms  of  Both  CORM-307  and  CORM-308  Exhibit 
Significantly  Diminished  CO  Release  Compared  to  their  Active 
Counterparts
It  was  found  that  by  leaving  CORM-307  and  CORM-308  in  ethanol  over  a 
period of two days resulted in a significantly reduced ability to release CO in the 
myoglobin  assay  (Figure  4.4A  and  Figure  4.4B).  Not  all  CO-RMs  can  be 
inactivated  in such a fashion due to their contrasting chemistry.  Comparison of 
the  myoglobin  curves of Figure 4.2A and  Figure 4.3A to  Figure 4.4A indicates 
just how dramatic a decrease it is.  Both inactivated CORM-307 and CORM-308 
(referred  to  as  iCORM-307  and  iCORM-308)  when  added  to  deoxyMb  fail  to 
convert  any  significant  amount  to  MbCO  unlike their active  counterparts.  The 
release of CO  determined  by the myoglobin assay  is ~4 fold  lower  in  iCORM- 
308  and  almost  20  fold  lower  in  iCORM-307.  The  generation  of  inactive 
versions of each will be beneficial  in understanding their bioactivity as they can 
be used to investigate whether CO or the compound itself is responsible for any 
effects observed.  Obviously inactivation  is achieved  by the release of CO from 
each  CO-RM,  thus,  the  carbonyl  ligands  are  replaced.  This  implies  the 
compounds are unstable in ethanol and will spontaneously decompose.  CO-RM 
stability  is  another  important  issue  to  consider  in  the  long  term  goal  of  a 
pharmamceutical  viable compound  since storage of the drug  prior to treatment 
is essential.
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Figure  4.4:-  Inactive  forms  of  both  CORM-307  and  CORM-308  exhibit 
severely diminished CO release compared to their active counterparts.
Prior  to  testing  with  the  myoglobin  assay,  both  CORM-307  and  CORM-308 
stocks were prepared in ethanol and left to stand for 48 h in an open eppendorf 
to inactivate.  Subsequently (A) iCORM-307 or iCORM-308 (40 pM) were added 
to  a  66  pM  myoglobin  solution.  Readings  of  any  conversion  of  deoxyMb  to 
MbCO were taken  every 5 min for the first 30 min  and then at  1h time  points. 
Myoglobin was saturated (MbCO)  by bubbling deoxyMb with  CO for 5 min.  (B) 
The MbCO concentration was derived from the increase in absorption between 
deoxyMb  (not  shown)  and  sample  readings  at  540  nm.  This  is the  amount  of 
CO released in solution.
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4.4.6  CORM-311: an Example of a Slow CO Releaser
CO-RMs .that release CO either released that CO instantly (such a CORM-3) or
gradually  over  time,  as  is  the  case  for  CORM-311  (Figure  4.5A  and  Figure 
4.5B).  The  myoglobin  curve (Figure 4.5A)  illustrates the  gradual  conversion  of 
the deoxyMb (single peak) to a partially saturated MbCO (double peak of sorts). 
Such  slow  release  CO-RMs  have  various  half  lives  associated  with  the 
steepness of the curve.  CORM-311   has an approximate half life of 15 min.  The 
rate of CO release slows over the hour it was followed.  Initially CO  is released 
quite quickly but it begins to tail-off,  although a plateau is not reached.  CORM- 
31 1, therefore,  is not releasing a molecule of CO per molecule of compound. An 
interesting facet which might make this particular structure good for generating 
slow to  medium  kinetic  CO-RMs.  Again though,  CORM-311   is  soluble  only  in 
ethanol which could raise problems relating to toxicity.
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Figure 4.5:- CORM-311  an example of a slow CO releaser.
(A)  CORM-311  (40  pM)  was  added  to  a  66  pM  myoglobin  solution.  The 
conversion  of  myoglobin  to  MbCO  was  followed  over  time  by  measuring  the 
changes  in  the  absorption  spectra  of this  protein  at  pH  =  7.4.  The  maximal 
absorption  peak  of  myoglobin  at  560  nm  is  gradually  converted  over time  by 
CORM-311   to  spectra typical  of MbCO  with two  maximal  absorption  peaks  at 
540  and  578  nm,  respectively.  Myoglobin  was  saturated  (MbCO)  by  bubbling 
deoxyMb with CO for 5 min.  (B) The MbCO concentration was derived from the 
increase  in  absorption  between  deoxyMb  (not  shown) and  sample  readings  at 
540  nm.  This  is  the  amount  of  CO  released  in  solution.  (C)  The  chemical 
formula of CORM-311.
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4.4.7  CORM-312:  a  Manganese  Centred  Metal  Carbonyl  which  Releases 
CO
As  a  comparison  to  the  other  Fe  containg  CO-RMs,  CORM-312  is  based 
around  a  manganese  metal  ion.  The  centre  can  be  changed  to  a  number  of 
various  metal  ions.  Iron was originally chosen  since  it  is common  in  biological 
systems.  However,  other metals offer different structural  properties and  hence, 
different CO releasing capabilities and bioactivity.  The myoglobin curve (Figure 
4.6A)  is a very good example of deoxyMb conversion to MbCO over time.  The 
curve changes from the single peaked deoxyMb curve to the two peaked MbCO 
curve with  a  prominent peak at 540 nm.  It releases  CO  in  a similar fashion to 
CORM-311  although  it has a shorter half life (~10  min) and  releases  about  10 
pM more CO (Figure 4.6B). Again there is a gradual reduction in rate over time 
with the myoglobin not being completely saturated. Another good example of a 
slow  to  medium  CO  releaser  and  another  chemical  structure  worth  refining 
further.
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Figure  4.6:-  CORM-312:  a  manganese  centred  metal  carbonyl  which 
releases CO.
(A)  CORM-312  (40  pM)  was  added  to  a  66  pM  myoglobin  solution.  The 
conversion  of  myoglobin  to  MbCO  was  followed  over  time  by  measuring  the 
changes  in  the  absorption  spectra  of  this  protein  at  pH  =  7.4.  The  maximal 
absorption  peak of  myoglobin  at  560  nm  is  gradually  converted  over time  by 
CORM-312  to  spectra typical  of MbCO  with two  maximal  absorption  peaks  at 
540  and  578  nm,  respectively.  Myoglobin  was  saturated  (MbCO)  by  bubbling 
deoxyMb with CO for 5 min.  (B) The MbCO concentration was derived from the 
increase  in  absorption  between  deoxyMb  (not shown)  and  sample  readings at 
540 nm.  This is the amount of CO  released  in solution.  (C)  Chemical  structure 
of CORM-312.
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4.4.8  CORM-319: an Iron-Based Water Soluble CO-RM Releases CO while 
its Inactive Form does not
Many  of  the  newly  synthesised  CO-RMs  containing  iron  which  released  CO 
were soluble in ethanol (EtOH). The best of the water soluble CO-RMs in terms 
of CO release was CORM-319. CORM-319 released a significant amount of CO 
after 30 min using the myoglobin assay (Figure 4.7A) with a positive correlation 
between time and MbCO concentration.  CORM-319 also has a fairly short half- 
life of approximately 10 min (Figure 4.7B).
The conversion of deoxy-Mb to MbCO can be followed over time by measuring 
the changes in the absorption spectra of this protein. As shown  in Figure 4.7A, 
the addition of 40 pM CORM-319 to a phosphate buffer solution containing Mb 
at  37  °C  and  pH  =  7.4  resulted  in  the  gradual  change  of  the  deoxy-Mb 
spectrum,  which has a maximal absorption peak at 560 nm,  into spectra typical 
of  MbCO.  Predictably,  the  inactive  compound  (iCORM-319)  did  not  generate 
any  MbCO.  The  conversion  of  the  carboxyl  group  to  CO  in  the  CORM-319 
molecule  goes  to  completion  as  one  mole  of  CO  per  mole  of  CORM-319  is 
formed (Figure 4.7B).
CORM-319 was made all the more appealing by the development of an inactive 
version which released no CO when tested using the myoglobin assay. As such 
CORM-319  was  deemed  a  compound  of significant  interest  and  its  bioactivity 
would be tested.
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Figure  4.7:-  CORM-319:  an  iron-based  water soluble  CO-RM  releases  CO 
while its inactive form does not.
Prior to testing using the myoglobin assay iCORM-319 was prepared. This was 
done by heating the stock to 100°C for 10 min followed by the addition of 1   drop 
of 1   M  HCI and finally bubbling with nitrogen to displace any liberated CO from 
solution.  Subsequently (A) iCORM-319 or CORM-319 (40 pM) were added to a 
66  pM  myoglobin  solution.  Readings  charting  any  conversion  of  deoxyMb  to 
MbCO were taken every 5 min for the first 30 min and then once more after an 
hour.  Myoglobin  was  saturated  (MbCO)  by  bubbling  deoxyMb  with  CO  for  5 
min.  (B) The MbCO concentration was derived from the increase in absorption 
between  deoxyMb  (not  shown)  and  sample  readings  at  540  nm.  This  is  the 
amount of CO released in solution. (C) Chemical structure of CORM-319.
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4.5  Discussion
Having begun the development of many new CO-RMs,  based on the initial work 
on CORM-3, the first priority was to establish that the CO-RMs lived  up to their 
name  and  did  indeed  release  CO.  This  was  established  using  the  myoglobin 
assay which  is  now a  proven  and accurate  method for expressing the  amount 
and rate of CO release.
In collaboration with the university of Sheffield we have been able to synthesize 
a plethora of novel CO-RM compounds based on metal carbonyls with different 
metal  centres  and  different  biological  ligands  attached.  The  testing  of  CO 
release  would  allow  us  to  select  the  most  interesting  and  noteworthy 
compounds  to  investigate  the  biological  activities,  whilst,  also  allowing  us  to 
determine  whether  certain  chemical  structures  and  ligand  combinations  are 
more  inclined to release CO that others.  Several  CO-RMs were tested but only 
a selection of the most interesting ones have been presented graphically in this 
chapter.  A comparison of all the CO-RMs tested can be found  in the appendix 
(paragraph 11.1).
CORM-303,  an  iron-based  carbonyl  complex,  was  a  CO-RM  which  did  not 
release  CO.  There were  many such  CO-RMs which failed to convert deoxyMb 
to  MbCO  and  subsequently  did  not  release  any  CO.  These  CO-RMs  are  not 
totally  useless  as  they  might  provide  us with forms  of negative  control  in  that 
they are metal carbonyls which do not release CO and  have similar structured 
counterparts which do.
CORM-307  and  CORM-308  are  both  potent  CO-releasing  agents.  Upon 
addition  to  myoglobin  they  release  their  maximal  concentration  of  CO 
instantaneously in a 1:1  ratio with compound concentration (40 pM CO-RM = 40
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|jM  MbCO  concentration).  A useful facet of these two  CO-RMs  is that inactive 
versions  of  each  (iCORM-307  and  iCORM-308)  have  been  prepared. 
Compared to their active counterparts,  both inactive compounds release almost 
no CO (20 fold lower for iCORM-307 and 4 fold lower for iCORM-308). As such 
elucidation  of their  biological  activity will  be  easier  and  offer  a  greater  insight 
into  their  mechanism  of  action.  It  should  be  noted  that  both  are  similar  CO 
releasers to CORM-3, although, they are soluble in ethanol and not water. 
CORM-311   and CORM-312 are also soluble in ethanol but offer a slower kinetic 
of  CO  release.  CORM-311  has  a  half-life of ~15  min  while  CORM-312  has  a 
*-10  min  half-life.  Both  would  provide  a  useful  tool  to  study  prolonged  CO 
release  in  biological  systems,  particularly  in  an  inflammatory  or some  form  of 
chronic diseased state model.
The final CO-RM evaluated in this chapter was CORM-319, a water soluble CO- 
RM,  capable of a slow kinetic release of ~15  min  but delivery of an  equivalent 
MbCO  concentration  as  CORM-307  and  CORM-308.  Such  a  powerful  CO 
release combined with the slow kinetics and water solubility makes CORM-319 
an attractive and potentially important compound  in the long-term study of CO- 
RMs.  The  allure  of  CORM-319  was  increased  when  an  inactive  version  was 
prepared.  CORM-319  is  a very promising  CO-RM determining  its  bioactivity  is 
of utmost importance.
The  CO-RMs  selected to  be  investigated further after determining  the  amount 
and  kinetics  of  CO  release  would  first  have  to  be  tested  for  cellular  toxicity, 
again an attribute that will no doubt be dependent on its chemical structure and 
the type of ligand coordinated to the metal centre.
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4.6  Conclusion
The  diverse  chemistry  of  transition  metal  carbonyls  makes  them  excellent 
compounds  for  deriving  novel  CO  releasing  molecules  from.  The  ease  of 
synthesis  and  variation  means  molecules  can  be  generated  that  release  CO 
slowly, quickly,  in large or small amounts and have varying degrees of solubility 
in  aqueous  solutions  or  are  lipid  soluble.  The  further  elucidation  of  these 
compounds  will  allow  a  greater  understanding  of  their  action  and  for  the 
refinement  of  their  properties  to  generate  new  and  improved  versions  better 
suited to specific roles.
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5  Chapter  5:  Search  for  new  CO-RMs:  characterisation  of 
biological features
5.1  Introduction
Having established which of the new CO-RMs release CO, the biological activity 
of each was investigated.  Firstly, it was important to identify which,  if any, of the 
CO-RMs  was  toxic  and  thus  incompatible  with  the  macrophage  model  used. 
Although  all  the CO-RMs contained  biological  ligands,  they also contain  metal 
centres  and are  completely  novel  molecules,  thus  determining  toxicity was  an 
important starting point. Any CO-RMs found to be toxic would then be discarded 
and  the  remaining  ones  would  be  used  to  investigate  various  biological 
activities. The main aim of this was to establish CO as the mediator of action for 
CO-RMs.
As with  CORM-3,  for the  purpose  of this Thesis  much  of the work centred  on 
the  anti-inflammatory  action  of  CO  in  a  murine  macrophage  model  of 
inflammation triggered using LPS.  Further work includes investigating the effect 
of  CO-RM  on  HO  activity,  since  CO-RMs  contain  a  transition  metal,  it  was 
reasonable  to  think that  this  could  activate  HO-1  and  elicit  any  of the  effects 
otherwise attributed to CO release.  The structures of the CO-RMs tested in this 
chapter  can  be  seen  in  Figure  5.1.  Note  how  they  all  have  a  similar  overall 
structure and that variations lie in generally only one of the ligands bound to the 
metal centre.
The findings from both Chapter 2 and this chapter detailing the overall effects of 
the  new  CO-RMs  could  then  be  used  by  our  chemist  collaborator  (Professor 
Brian Mann) to develop less toxic,  more water soluble and  better CO-releasing
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compounds.  As  such,  the  investigation  of  these  molecules  is  an  ongoing 
process to derive the best combination of factors.
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Figure 5.1:- Structure of CO-RMs to be tested in this Chapter.
Note the underlying similarity in structure.
5.2  Objective
Test  compounds  deemed  to  be  worthy  of  further  study  from  Chapter  4  to 
determine  their  toxicity,  effect  on  the  HO  system  and  regulation  of  the 
inflammatory response.
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5.3  Experimental Protocol
The following section details the protocol of specific experiments of which more 
precise  methods  can  be  found  in  the  Material  and  Methods  chapter.  Stock 
solutions  of CO-RMs  (10  mM)  were freshly prepared  before  each  experiment. 
CO-RMs was layered with IS I2 gas prior to returning to storage in the freezer at - 
20°C.
5.3.1  Chemicals and reagents
CORM-307,  CORM-308,  CORM-311,  CORM-312  and  CORM-319  were 
synthesised  by  Professor  Brian  Mann  (University  of  Sheffield).  CORM-307, 
CORM-308,  CORM-311   and CORM-312 were freshly prepared as 10 mM stock 
solutions in ethanol. While CORM-319, was prepared as a 10 mM stock solution 
in pure distilled water.  CORM-319 was inactivated (iCORM-319) by adding it to 
complete  DMEM  and  leaving  for  18  h  at  37  °C  in  a  5%  CO2  humidified 
atmosphere to  liberate  CO  after which  the  solution  was  bubbled with  nitrogen 
(N2) gas for 5 min to remove any CO trapped in solution.  Both CORM-307 and 
CORM-308 could be inactivated (iCORM-307 and iCORM-308) by leaving them 
in ethanol for 48 h to release their CO (as determined by the myoglobin assay). 
Lipopolysaccharide  (LPS  - E.Coli serotype  026:B6) was  obtained from  Sigma. 
All  other  chemicals  were  reagent  grade  and  obtained  from  Sigma  unless 
otherwise stated.
5.3.2  Myoglobin Assay
To  prepare  a  stock of CO-RM  for the  myoglobin  assay,  1   mg  of CO-RM  was 
added  to  100  pi  of dH20   to  give  a  main  stock.  From  this  2,  4,  8  and  12  mM
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working  stocks  were  prepared.  The  myoglobin  was  warmed  (37  °C),  sodium 
dithionite (0.1  %) added and a  1   ml sample of the myoglobin  measured for the 
deoxy-Mb curve. This 1   ml sample of deoxy-Mb was then bubbled with CO gas 
for 10 sec to saturate the myoglobin and give a MbCO curve.  Six cuvettes were 
then loaded into the spectrophotometer carousel with 1   ml of deoxy-Mb in each, 
5 pi of 2, 4, 8, and 12 mM CO-RM working stocks were then added in duplicate 
to each cuvette. The resultant final concentrations of CO-RM  being  10  (from 2 
mM), 20 (from 4 mM), 40 (from 8 mM) and 60 pM (from 12 mM). The myoglobin 
was  then  mixed  gently  using  a  pipette  and  layered with  500  pi  of mineral  oil. 
The samples were then read at set intervals for a set period of time.  CORM-319 
stability  was  determined  by  preparing  a  stock  solution  of  CORM-319  in  pure 
distilled water.  From this stock 60 pM CORM-319 was added to myoglobin and 
left to  release  CO for  10 min  at 37  °C  after which the  spectra was  read.  This 
was repeated at 5 min intervals using the original stock.
5.3.3  Cell Culture
Murine  RAW264.7  monocyte  macrophages  and  Girardi  (human  heart)  cells 
were cultured as per Material and Methods.  Cultures were maintained at 37 °C 
in a 5%  CO2 humidified atmosphere and experiments were conducted on cells 
at approximately 80-90% confluence.
5.3.4  Experimental Protocol
To  give  an  indication  of  cell  viability  macrophages  were  treated  with  CORM- 
307,  CORM-308, CORM-311,  CORM-312 (10,  50 and 100 pM) and CORM-319 
(10, 50,  100,  500, 750 and 1000 pM) for 24 h after which an Alamar blue assay
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was  run.  CORM-319  (10,  50,  100,  500,  750  and  1000  |j M )   toxicity  was  also 
determined  by  LDH  and  Trypan  blue  exclusion  after  24  h  incubation  of 
macrophages.  CO-RMs  of which  iCO-RMs  had  been  generated  (CORM-307, 
CORM-308  and  CORM-319)  were  also tested  in  the  same  manner.  The  non­
toxic CO-RMs were tested for their anti-inflammatory effect on nitrite production. 
Macrophages  were  exposed  for  24  h  to  LPS  (1  pg/ml)  in  the  presence  or 
absence  of CORM-311  or  CORM-319  (10,  50  and  100  pM)  and  nitrite  levels 
were determined at the end of the incubation.  Experiments were repeated with 
the negative control  iCORM-319 to assess whether the effects observed were 
due to the  CO  liberated  by the  CO-RM  or caused  by other components  of the 
molecule.  The effects of CORM-311,  CORM-319 and iCORM-319 on the haem 
oxygenase  pathway were  also  investigated.  Specifically,  murine  macrophages 
and Girardi cells were treated for 6 h in the presence of 10, 50 and  100 pM CO- 
RM after which haem oxygenase activity was determined.
5.3.5  Assay for Nitrite Levels
Nitrite  levels were  determined  using  the  Griess  method.  The  measurement  of 
this  parameter  is widely  accepted  as  indicative  of  NO  production.  Briefly,  the 
medium from treated  cells cultured  in  24 well  plates was  removed  and  placed 
into a 96 well plate (50 pi per well). The Griess reagent was added to each well 
to begin the reaction, the plate was shaken for 10 min and the absorbance read 
at 550 nm on a Molecular Devices VERSAmax plate reader.  The nitrite level  in 
each  sample  was  calculated  from  a  standard  curve  generated  with  sodium 
nitrite (0 pM to 300 pM in cell culture medium).
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5.3.6  Assay for Haem Oxygenase Activity
Haem  oxygenase activity was determined  in  RAW264.7 cells and  Girardi  cells 
after various treatments.  Briefly,  harvested cells were subjected to three cycles 
of freeze-thawing  before addition to a reaction mixture consisting of phosphate 
buffer  (1  ml  final  volume,  pH  =  7.4)  containing  magnesium  chloride  (2  mM), 
NADPH  (0.8  mM),  glucose-6-phosphate  (2  mM),  glucose-6-phosphate 
dehydrogenase (0.2 Units),  rat liver cytosol  as a source of biliverdin reductase, 
and the substrate hemin (20 pM).  The reaction was conducted  at 37  °C  in the 
dark for  1   h  and  terminated  by the  addition  of  1   ml  chloroform;  the  extracted 
bilirubin was calculated  by the difference in absorbance between 464 and  530 
nm (e = 40 mM'1cm"1).
5.3.7  Cell Viability 
Alamar Blue
Cell metabolism was determined using an Alamar Blue assay kit and carried out 
according to the manufacturer’s instructions (Serotec,  UK). The assay is based 
on the detection of metabolic activity of living cells using a redox indicator which 
changes from an oxidised  (blue) form to a reduced  (red) form.  The intensity of 
the red colour is proportional to the metabolism of the cells, which is calculated 
as the difference in absorbance between 570 nm and 600 nm and expressed as 
a percentage of control.
Trypan Blue
The  status  of  the  cell  membrane  was  investigated  using  Trypan  blue.  The 
medium  of treated  cells  is  removed  and the cells then washed with  PBS  10X.
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Then a 1:1  solution of PBS (10X) and Trypan blue dye was added to cells. The 
dye  permeates  cell  in  which  the  membrane  has  been  compromised.  By 
counting the number of cell dyed compared to those which are not the number 
of viable cells can be determined.
Lactate Dehydrogenase
Damage  of  the  phopholipid  bi-layer  of  cells  was  investigated  using  an  LDH 
assay  kit and  carried  out according  to the  manufacturer's  instructions  (Roche, 
UK).  The  medium  of  treated  cells  is  collected,  spun  to  remove  any  cellular 
debris  and  then  a  reaction  mixture  containg  an  INT  dye  added.  LDH  activity 
reflects its release from the cell membrane and a loss of viability.
5.3.8  Statistical Analysis
Statistical  analysis  was  performed  using  one-way  ANOVA  combined  with 
Bonferroni test.  Differences were considered to be significant at P < 0.05.
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5.4  Results
5.4.1  Determining the viability of CO-RMs
Having  established  in  Chapter  4  a  number  of  CO-RMs  deemed  worthy  for 
further  study  the  first  requirement  was  to  test  their  toxicity  in  murine 
macrophages  (the  cells  used  in the  LPS  model  of nitrite  generation).  In  some 
cases we were also able to test iCO-RM versions;  however,  not all the CO-RMs 
tested  could  be  inactivated  owing  to  their  chemistry.  It  was  decided  for 
efficiencies  sake  to  test  the  CO-RMs  using  the  Alamar  blue  assay  which  is 
quick and  simple to perform  and  is widely  used  as  an  indicator of cell  viability 
(Benghuzzi  1995;  Nakayama  et  al.  1997;  Voytik-Harbin  et  al.  1998).  Both 
CORM-307 and CORM-308 displayed very similar effects on cell health (Figure
5.2  and Figure 5.3). Toxicity was evident at only 10 pM CORM-307 and CORM- 
308,  while  at  50  pM  there  was  a  100  %  loss  in  viability  using  both  CO-RMs 
(Figure 5.2A and Figure 5.3A).  In both cases iCO-RM version of each displayed 
an almost identical effect on cell viability as the active counterpart (Figure 5.2B 
and  Figure 5.3B).  CORM-311   meanwhile,  had no effect on cellular metabolism 
at any concentration thus,  ruling out an effect of the methanol used to solubilise 
itself,  CORM-307,  CORM-308  and  CORM-312  (Figure  5.4A).  In  a  similar 
fashion to both CORM-307 and CORM-308,  CORM-312 was almost 95 % toxic 
at  50  pM  but  unlike  the  others  was  only  5  %  toxic  at  10  pM  (Figure  5.4B). 
Finally, CORM-319, a charged variation on the other CO-RMs rendering it water 
soluble, displayed little toxicity up to 500 pM. There was a 20 % reduction in cell 
viability at 750 pM and an almost 90 % reduction at 1000 pM (Figure 5.5A).  But 
importantly,  no effects at the concentrations regularly used. These results were 
almost  mirrored  by  those  of  iCORM-319  in  which  1000  pM  iCORM-319  was
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slightly  less  toxic than  the  active  version  (Figure  5.5B).  Based  on  these  data 
CORM-311  and  CORM-319 were  taken  forward  for further  study.  CORM-319 
especially interesting due to its water solubility and presence of an iron.
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Figure 5.2:- Effect of CORM-307 and iCORM-307 on cellular metabolism.
Cell  metabolism  was  assessed  24  h  after  exposure  of  macrophages  to  (A) 
CORM-307 (10-100 pM) or (B)  iCORM-307 (10-100 pM)  using the Alamar blue 
viability  assay.  Viability  was  expressed  as  a  percentage  of  control.  Data 
represent the mean ± S.E M.  of 6 independent experiments.  * indicates P<0.05 
vs. control.
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Figure 5.3:- Effect of CORM-308 and iCORM-308 on cellular metabolism.
Cell  metabolism  was  assessed  24  h  after  exposure  of  macrophages  to  (A) 
CORM-308 (10-100 pM) or (B)  iCORM-308 (10-100 pM) using the Alamar blue 
viability  assay.  Viability  was  expressed  as  a  percentage  of  control.  Data 
represent the mean ± S. E M.  of 6 independent experiments.  * indicates P<0.05 
vs. control.
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Figure 5.4:- Effect of CORM-311  and CORM-312 on cellular metabolism.
Cell  metabolism  was  assessed  24  h  after  exposure  of  macrophages  to  (A) 
CORM-311  (10-100  pM)  or (B)  CORM-312 (10-100  pM)  using the Alamar blue 
viability  assay.  Viability  was  expressed  as  a  percentage  of  control.  Data 
represent the mean ± S.E.M.  of 6 independent experiments. * indicates P<0.05 
vs. control.
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Figure 5.5:- Effect of CORM-319 and iCORM-319 on cellular metabolism.
Cell  metabolism  was  assessed  24  h  after  exposure  of  macrophages  to  (A) 
CORM-319  (10-1000  pM)  or  (B)  iCORM-319  (10-1000  pM)  using  the  Alamar 
blue  viability  assay.  Viability was  expressed  as  a  percentage  of control.  Data 
represent the mean ± S.E.M.  of 6 independent experiments.  * indicates P<0.05 
vs. control.
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5.4.2  Both CORM-311  and CORM-319 have no effect on HO activity.
The  effect  of  both  CORM-311  and  CORM-319  on  HO  activity were  assessed
since  both  contain  a  metal  centre  (iron)  and  because  of  the  increase  in  HO 
activity observed with CORM-3 in Chapter 3.  In murine macrophages treated for 
6  h  in  the  presence  of either  CORM-311  or  CORM-319  (10,  50  and  100  pM) 
there was  no  significant  increase  in  HO  activity  (Figure  5.6B  and  Figure  5.7). 
This was true also for Girardi  cells treated for 6  h with  CORM-319 (10,  50 and 
100  pM) (Figure 5.6A).  In this  instance any effect observed with either CO-RM 
when  investigating  their  anti-inflammatory  action  can  not  be  attributed  to  an 
increase in  HO and, therefore,  an increase in the biologically active products of 
HO activity.
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Figure  5.6:-  Effect  of  CORM-319  on  haem  oxygenase  activity  in  various 
cell lines.
(A)  Girardi  cells  were  treated  with  CORM-319  (10-100  jjM)  for  6  h.  (B) 
RAW264.7  macrophages  were  exposed  to  CORM-319  (10-100  pM)  for  6  h. 
Haem  oxygenase  activity  was  determined  after  exposure  to  the  different 
treatments.  Data represent the mean ± S.E.M.  of 6 independent experiments.  * 
indicates P < 0.05 vs. control.
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Figure 5.7:- Effect of CORM-311  on  haem oxygenase activity in  RAW264.7 
macrophages.
Murine  macrophages  were  exposed  to  CORM-311  (10-100  pM)  for  6  h.  Haem 
oxygenase  activity  was  determined  after  exposure  to  the  different  treatments. 
Data  represent the  mean ± S.E.M.  of 6  independent  experiments.  *  indicates  P 
< 0.05 vs.  control.
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5.4.3  LPS induced nitrite production is attenuated by both CORM-311  and 
CORM-319.
To  indicate  the  potential  anti-inflammatory  action  of either  CO-RM,  both  were 
tested to see if they elicited a reduction in nitrite (a widely accepted indicator of 
inflammation)  in  murine  macrophages.  Importantly,  CORM-319,  its  inactive 
version  (iCORM-319)  and  CORM-311  had  no  effect  on  nitrite  alone  (Figure 
5.8A,  Figure 5.8B and Figure 5.9). Figure 5.8A demonstrates that CORM-319 is 
capable  of  significantly  attenuating  LPS  induced  nitrite  production  in  a 
concentration  dependent  manner  at  concentrations  of  50  and  100  pM.  This 
effect  was  not  seen  with  iCORM-319,  although  there  was  still  some  slight 
reductions at 100 pM but not enough to infer that nitrite reduction is linked to the 
compound itself and not the CO released (Figure 5.8B). CORM-311   meanwhile, 
is potent at reducing the increased nitrite levels associated with LPS treatment. 
Indeed,  100 pM CORM-311  reduced nitrite (compared to LPS alone) by around 
85  %  (Figure  5.9).  Since  no  inactive  version  of  CORM-311  exists  the  exact 
mechanism  by which CORM-311   works  is difficult to speculate on,  although,  in 
the case of both CORM-3 and  CORM-319 which attenuate  LPS  induced  nitrite 
generation  there  is  no  effect  by  either  inactive  version  suggesting  CO  is  the 
mediator of action.
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Figure 5.8:- Effect of CORM-319 on LPS-stimulated nitrite production.
(A)  RAW264.7  macrophages were  exposed to  1   pg/ml  LPS  in the presence or 
absence of CORM-319 (10-100 pM)  and  nitrite production was assessed at 24 
h.  (B)  The  inactive  compound  iCORM-319  (10  -  100  pM)  was  also  used  to 
determine the contribution of CO released by CORM-319 to the observed effect. 
Control  cells  were  incubated  with  medium  alone.  Data  represent  the  mean  ± 
S.E.M.  of  6  independent  experiments.  *  indicates  P  <  0.05  vs.  control;  t  
indicates P < 0.05 vs.  LPS alone.
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Figure 5.9:- Effect of CORM-311  on LPS-stimulated nitrite production.
RAW264.7  macrophages  were  exposed  to  1   pg/ml  LPS  in  the  presence  or 
absence of CORM-311  (10-100 pM) and nitrite production was assessed  at 24 
h.  Control cells were incubated with medium alone.  Data represent the mean ± 
S.E M.  of  6  independent  experiments.  *  indicates  P  <  0.05  vs.  control;  t  
indicates P < 0.05 vs. LPS alone.
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5.4.4  Further studies on CORM-319 and cell toxicity.
Having  proven that CORM-319  is potentially the  most promising  Fe containing
CO-RM we next examined the potential toxicity of this compound in more detail 
using  both  the  LDH  assay  and  the  Trypan  blue  assay.  CORM-311  did  not 
undergo further testing due to its poor solubility, even in ethanol, and the failure 
of generating  an  inactive form.  Using  both  the  LDH  and  Trypan  blue  assays, 
CORM-319  did  not  display  any  significant  toxicity  (Figure  5.10A  and  Figure 
5.11 A).  Even with the Alamar blue assay significant loss of cell metabolism was 
only  observed  at  1000  pM  making  CORM-319  the  least  toxic  CO-RM  tested 
thus  far.  However,  the  inactive  version,  iCORM-319,  proved  to  be  toxic  at 
concentrations  of  500  pM  and  above  in  both  LDH  and  Trypan  blue  assays 
(Figure 5.10B and Figure 5.11B). LDH measurements showed approximately 50 
% cytotoxicity at 1000 pM while the Trypan blue assay suggested  100 % of the 
cells were dead  at this concentration.  Both,  although  not in  perfect agreement, 
are in stark contrast to Alamar blue data which reports only a 40 % drop in cell 
viability  at  1000  pM  iCORM-319  (Figure  5.5B).  This  again  highlights  the 
requirement for multiple assays for cell viability. We can conclude from this set 
of  experiments  that  both  CORM-319  and  iCORM-319  are  not toxic  in  murine 
macrophages  at  the  concentrations  used  in  the  various  treatments  but 
inactivation  of CORM-319  leads  to  a  compound  capable,  at concentrations  of 
500  pM  and  above,  of  interfering  with  the  metabolism  of  cells  and  causing 
damage to the cell membrane.
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Figure  5.10:-  Effect  of  CORM-319  on  LDH  release  in  RAW264.7 
macrophages.
The release of LDH was assessed 24 h after exposure of macrophages to (A) 
CORM-319  (10-1000  pM)  or  (B)  iCORM-319  (10-1000  pM)  using  an  LDH  kit 
purchased from  Roche Diagnostics. Viability was expressed as a percentage of 
maximal  damage  (triton)  and  minimal  damage  (control).  Data  represent  the 
mean ± S.E M. of 6 independent experiments. * indicates P< 0.005 vs. control.
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Figure 5.11:- Effect of CORM-319 on cell membrane permeability to Trypan 
blue dye.
Cell membrane permeability was assessed after 24 h exposure of macrophages 
to  (A)  CORM-319  (10-1000  pM)  or  (B)  iCORM-319  (10-1000  pM)  using  the 
Trypan  blue exclusion  assay.  Viability was  expressed  as  a percentage  of cells 
stained with the dye compared to the total  number of cells.  Data represent the 
mean ± S.E.M. of 6 independent experiments. * indicates P<0.05 vs. control.
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5.4.5  CORM-319 elicits a concentration dependent increase in the release 
of CO using the myoglobin assay.
When  initially  testing  CO-RMs  for  CO  release,  we  use  a  mid-range 
concentration of 40 pM to determine the extent of that release and whether the 
compound warrants further testing.  Due to the favourable results of CORM-319 
thus  far  we  repeated  the  myoglobin  assay  using  10,  20,  40  and  60  pM 
concentrations.  Figure 5.12 and Figure 5.13 show that CO release from CORM- 
319  is  concentration  dependent.  The graph  showing  the  spectra  of myoglobin 
(Figure 5.12A to D) demonstrates how with increasing concentrations of CORM- 
319 the spectra more closely matches that of saturated MbCO and in a quicker 
time.  This  is  clearer  in  Figure  5.13,  which  shows  the  MbCO  concentration 
derived from the spectra in Figure 11. The rate of CO release increases steadily 
as concentration of CORM-319 is increased until 60 pM at which point there is a 
marked  increase  in the  rate with  myoglobin  being saturated  after only 30  min. 
Its is interesting to note that the concentration of CORM-319 is equivalent to the 
concentration of MbCO measured in the myoglobin assay suggesting a 1:1  ratio 
of CO to CORM-319 concentration.
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Figure  5.12:-  Conversion  of  deoxy-myoglobin  to  carboxy-myoglobin  by 
CORM-319.
(A)  10mM  CORM-319,  (B)  20)jM  CORM-319,  (C)  40|jM  CORM-319  and  (D) 
60[jM CORM-319 was added to a 66 |jM myoglobin solution. The conversion of 
myoglobin  to  MbCO  was followed  over time  by  measuring  the  changes  in  the 
absorption  spectra of this  protein at pH  = 7.4.  The maximal  absorption  peak of 
myoglobin  at  560  nm  is  gradually  converted  over  time  by  CO-RM  to  spectra 
typical  of  MbCO  with  two  maximal  absorption  peaks  at  540  and  578  nm, 
respectively.  Myoglobin  was  saturated  (MbCO)  by  bubbling  deoxyMb with  CO 
for 5 min.
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Figure  5.13:-  The  release  of  CO  from  CORM-319  is  concentration 
dependent.
10[jM  CORM-319,  20pM  CORM-319,  40pM  CORM-319 and 60pM  CORM-319 
was  added  to  a  66  pM  myoglobin  solution.  The  conversion  of  myoglobin  to 
MbCO  was  followed  over  time  by  measuring  the  changes  in  the  absorption 
spectra of this protein at pH  = 7.4.  The maximal  absorption  peak of myoglobin 
at  560  nm  is  gradually  converted  over  time  by  CO-RM  to  spectra  typical  of 
MbCO  with  two  maximal  absorption  peaks  at  540  and  578  nm,  respectively. 
Myoglobin was saturated (MbCO) by bubbling deoxyMb with CO for 5 min. The 
MbCO  concentrations  were  derived  from  the  increase  in  absorption  between 
deoxyMb  (not  shown)  and  sample  readings at  540  nm.  This  is  the  amount  of 
CO released in solution.
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5.4.6  Stability of CORM-319 in water.
The stability of CO-RMs in water and buffers commonly used in biological tests 
is very important information as it tells us how long we can store a CO-RM prior 
to  its use.  This is especially important in the investigation of its effects and the 
long term goal  of developing  pharmaceutical  agents.  In the case of CORM-3 it 
was  found  to  be  stable  in  water  for  a  number  of  days  which  was  a  highly 
desirable attribute (Clark,  Naughton,  Shurey,  Green,  Johnson,  Mann,  Foresti,  & 
Motterlini  2003b).  Interestingly,  CORM-319  proved  to  be  highly  unstable  in 
water (Figure 5.14). A 12 mM stock became inactive in less than 3.5 h.  In fact, 
nearly 50 % of the CO loss occurred within the first 5 min after which there was 
a  steady  and  continuous  loss  of  CO  releasing  capability  until  the  3.5  h  time 
point  (Figure  5.14).  As  a  consequence of this  property,  CORM-319  should  be 
prepared and administered immediately to minimise the spontaneous release of 
CO  associated  with  preparing  the  compound  in  water.  However,  CORM-319 
remained quite stable in air after a number of experiments were conducted over 
a couple of months using the same vial containing the dry compound.
This set of experiments  highlights the  need to  understand  in greater detail  the 
exact  chemistry  behind  the  compounds  tested.  The  variation  in  activities  is 
diverse  and  only  by further  exploring  the  inherent  chemical  properties  of  CO- 
RMs  can  we  fully  appreciate  the  true  mechanisms  of  these  compounds  in 
biology.
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Figure  5.14:-  Stability  of CORM-319  in  pure  distilled  water:  effect  on  CO 
release.
(A) 60|jM CORM-319 was added to a 66 pM myoglobin solution from a  12 mM 
CORM-319  stock.  The  conversion  of myoglobin  to  MbCO  was  allowed  for  10 
min after which a reading was taken. This was repeated every 5 min for the first 
40  min  then  at  60  min  and  every  30  min  thereafter.  The  maximal  absorption 
peak  of  myoglobin  at  560  nm  is  gradually  converted  over time  by  CO-RM  to 
spectra typical of MbCO with two maximal absorption peaks at 540 and 578 nm, 
respectively.  Myoglobin was  saturated  (MbCO)  by  bubbling  deoxyMb with  CO 
for  5  min.  (B)  The  MbCO  concentrations  were  derived  from  the  increase  in 
absorption between deoxyMb (not shown) and sample readings at 540 nm. This 
is the amount of CO released in solution.
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5.5  Discussion
To  reach  the  ultimate  end  goal  of  developing  a  pharmacologically  active 
compound  based  on  the  specific  action  of  CO  released  from  CO-RMs  many 
such  molecules  will  have  to  be  tested.  This  chapter  highlights  some  of  the 
primary  steps  taken  in  determining  the  suitability  of novel  CO-RM  molecules. 
This  initially entails determining,  if any,  the CO release.  Once a compound has 
demonstrated its ability to release CO in the myoglobin assay,  its toxicity in the 
cell  line  to  be  used  for  subsequent  experiments  (in  this  case  murine 
macrophages) is tested.  Further testing of toxicity takes place with various other 
assays  and  in further cell  lines  if the  CO-RM  proves to  be  of greater interest. 
Having  established  the  degree  of  toxicity,  CO-RMs  that  prove  non-toxic  are 
tested  in  a  specific  biological  model  relating  to  a  possible  pharmacological 
action  of CO  e.g.  a  murine  macrophage  model  of inflammation,  isolated  aortic 
rings model of vasorelaxation, or others. Thus, we can slowly build up a potfolio 
of CO-RMs  and  their actions  in  a  number of models  allowing  us to  determine 
which CO-RMs are most promising.
Having  proven  that  CORM-307,  CORM-308,  CORM-311,  CORM-312  and 
CORM-319 were  all  capable  of releasing  CO  in  the  myoglobin  assay  all were 
tested  to  determine  their toxicity.  This  chapter  is  representative  for the  many 
CO-RMs  that  have  been  tested  and  only  a  small  selection  of  CO-RMs  are 
actually shown  (see appendix  11.1  for the full  list).  We found that CORM-307, 
CORM-308  and  CORM-312  could  be  immediately  excluded  from  further 
investigation since they all proved to be highly toxic in the macrophage cell  line 
used.  This toxicity can  not be attributed to the  methanol  used to  solubilise the 
CO-RMs since CORM-311   is also solubilised in methanol and is not toxic.  Due
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to the solubility of CORM-319 in water its effect on cell viability was determined 
up  to  1000  pM.  Both  CORM-319  and  iCORM-319  had  very  silimar  effects  on 
cell viability with no observable loss at 10 to 100 pM.
Interestingly,  CORM-311  and  CORM-319 had no effect on  HO  activity (10-100 
pM).  This  is  useful  to  know  since  an  increase  in  HO  activity  could  be 
responsible for actions attributed to the CO released by both CO-RMs.
LPS  induced  nitrite  generation  in  murine  macrophages  was  attenuated  by 
CORM-311  and  CORM-319.  CORM-311  caused  a  potent  reduction  in  nitrite 
levels;  however,  without  a  negative  control  (iCO-RM  version)  we  can  not  be 
certain as to whether the compound  itself or the CO released is responsible for 
the observed effect.  CORM-319  although  not quite as effective  as  CORM-311 
did  also  significantly  reduced  nitrite  levels  at  both  50  and  100  pM.  The 
ineffectiveness  of iCORM-319  and  the fact there  is  no  increase  in  HO  activity 
with CORM-319 strongly implicates CO as the mediator of this function.
Owing  to  its  poor solubility  in  ethanol,  the  fact  its  not water  soluble  and  that 
there  is  no  iCO-RM  version  available  CORM-311   was  not tested  any  further. 
This is not to say it will  not be used ever again  but that it is a good compound 
for  the  chemists  to  develop  further  by  ironing  out  some  of  the  problems 
associated with its use, which is the purpose of this methodology of testing. 
Being the most promising compound so far,  CORM-319 was tested for toxicity 
in a number of cell viability assays.  In both LDH and Typan blue assays CORM- 
319 displayed little observable reductions in viability which is in agreement with 
data  obtained  with  the  Alamar  blue  assay.  Interestingly,  iCORM-319  is 
significantly toxic in  both the  LDH  and  Trypan  blue assay at concentrations of 
500  pM  and  above.  This  intriguingly does  not  correlate with Alamar blue  data
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showing  at 750  pM  there  is  only a 20  %  loss  in viability while the Typan  blue 
assay indicates ~95 % of cells are dead and the LDH assay inferred cytotoxicity 
is  ~40  %.  In  spite  of  the  data  there  is  a  general  trend  towards  iCORM-319 
concentrations  of  500  pM  and  above  being  detrimental  to  the  cell  membrane 
integrity and structure.  The lack of effect with CORM-319 suggests the inactive 
version is chemically quite different and as such it would be beneficial to try and 
identify its exact structure to better understand  its chemistry and,  therefore,  the 
biological effects.  Despite this, toxicity in the 10 -  100 pM range of both CORM- 
319 and iCORM-319 was insignificant.
Having already demonstrated CO release by CORM-319 in Chapter 4 a number 
of  other factors  affecting  CO  release  were  investigated.  Intitally,  the  effect  of 
increasing concentrations of CORM-319 was determined.  It was found that CO 
release was concentration dependent and that the concentration of CORM-319 
added was very similar to the MbCO concentration attained suggesting  1   pmole 
of CO  per  1   pmole of CORM-319  is generated.  Also of note was  the fact that 
10,  20  and  40  pM  CORM-319  result  in  a  gradual  conversion  of deoxyMb  into 
MbCO  while  60  pM  elicits  quite  a  striking  increase  in  the  rate  saturating 
myoglobin in only 30 min.  However,  when assessing the stability of CORM-319 
in  water  it was  surprising  to  find  that within  5  min  ~50  %  of  its  CO  releasing 
ability  is  lost  and  in  less  than  3.5  h  the  CO  loss  is  approximately  99  %.  The 
instability  of  CORM-319  in  water  has  important  implications  for  its  use  in 
research  and  any  future  therapeutic  applications.  Preparation  of  CORM-319 
requires it to be administered  immediately and thus makes its use complicated. 
As mentioned previously, CORM-319 in powder form is stable in air for a couple 
of months.
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5.6  Conclusion
The systematic testing and evaluation of novel CO-RMs is vital to establishing a 
core  group  of  compounds  capable  of  eliciting  benefical  biological  effects 
through  the  action  of  CO.  The  basic  protocol  set  out  in  the  last  2  chapters 
allows  the  quick  identification  of promising  candidates  and  highlights  CO-RMs 
that  although  not  perfect can  be  redesigned to  produce  a  more  biocompatible 
version  (i.e.  CORM-311).  In this  instance CORM-319  is a promising contender 
but  issues with  its  stability require  resolving  before  it can  be  investigated  as  a 
potential drug to deliver CO for therapeutic purposes.
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6  Chapter  6:  CORM-A1:  a  newly  discovered  CO-releasing 
compound
6.1  Introduction
In  the  search  for  additional  compounds  capable  of  liberating  CO  but  with  a 
chemical  structure different to the transition metal  carbonyls used thus far,  our 
group  identified  sodium  boranocarbonate  (Na2[H3BC02])  (CORM-A1),  the 
structure of which can be seen in Figure 6.1.
Figure 6.1:- Structure of CORM-A1. A non-metal containing CO-RM.
The idea of testing a boranocarbonate as a potential CO-RM originated from an 
interesting  publication  reporting  the  necessity  of a  CO  source to  synthesize  a 
transition  metal  carbonyl  (["m Tc(OH2)3-(CO)3]+)  specifically designed for  radio­
imaging technology.  This carbonyl  can  be  prepared  in  a  single-step  procedure 
from aqueous ["m Tc0 4 ]~  in the presence of CO gas and sodium borohydride as 
a  reducing  agent.  However,  the  published  preparation  of  [99m Tc(OH2)3-(CO)3]+  
relying  on  gaseous  CO  was  unsuitable  for  use  in  commercial
2-  2 Na+
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radiopharmaceutical kits (Zhou et al.  1987;  Kothari et al. 2000).  The solution to 
this  problem  has  been  presented  in  a  recent  study  reporting  the  first 
commercially feasible preparation of ["m Tc(OH2)3-(CO)3]+  in physiological media 
using  a  boron-based  carbonylating  agent,  potassium  boranocarbonate,  which 
acts as a CO source and a reducing agent simultaneously (Alberto et al. 2001). 
CORM-A1  does  not  contain  a  transition  metal  carbonyl  but  a  carboxyl  group 
(COO")  covalently  bound to the  boron  atom.  At room temperature,  it is  known 
that  aqueous  solutions  of  CORM-A1  are  alkaline  and  very  stable  but  in  the 
presence of hydrogen ions the compound starts to decompose and liberate CO. 
As  with  the  other  CO-RMs  the  release  of  CO  and  the  toxicity  had  to  be 
established prior to investigating its biological activities.  In this chapter we again 
concentrate on the effect of CO on  LPS  induced  nitrite generation in  a  murine 
macrophage model of inflammation.
6.2  Objective
Determine  the  CO  releasing  profile  and  bioactive  properties  of  CORM-A1,  a 
newly identified CO generator that does not contain a transition metal.
6.3  Experimental Protocol
The following section details the protocol of specific experiments of which more 
precise  methods  can  be  found  in  the  Material  and  Methods  chapter.  Stock 
solutions of CORM-A1  (10 mM) were freshly prepared  before each experiment 
by dissolving the compound  in pure distilled water.  CORM-A1  was layered with 
N2 gas prior to returning it to storage in the freezer at -20°C.
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6.3.1  Chemicals and reagents
Sodium  .  boranocarbonate  (CORM-A1)  and  Tricarbonylchloro- 
(glycinato)ruthenium  (II)  ([Ru(CO)3CI(glycinate)]  or CORM-3) were  synthesised 
as  previously  described  (Clark,  Naughton,  Shurey,  Green,  Johnson,  Mann, 
Foresti,  &  Motterlini  2003b;  Foresti,  Hammad,  Clark,  Johnson,  Mann,  Friebe, 
Green,  &  Motterlini  2004;  Alberto  et  al.  2001).  CORM-A1  and  CORM-3  were 
freshly  prepared  as  10  mM  stock  solutions  in  pure  distilled  water.  CORM-A1 
was inactivated (iCORM-A1) by adding a single drop of 1   M HCL to the CORM- 
A1  stock and  bubbling the  solution with  nitrogen  (ISfe)  gas for 5 min to  remove 
any  CO trapped  in  solution.  The addition of acid  caused a vigorous release  of 
CO much like the initial release of gas from a carbonated drink.  Inactive CORM- 
3 (iCORM-3) was also used in some experiments and was prepared by adding 
the compound to cell  culture  medium  and  leaving  it for  18  h  at 37  °C  in a  5% 
CO2  humidified  atmosphere  to  liberate  CO.  The  iCORM-3  solution  was finally 
bubbled  with  nitrogen  to  remove  the  residual  CO  present  in  the  solution. 
Lipopolysaccharide  (LPS  - E.Coli serotype  026:B6) was  obtained  from  Sigma. 
Polyclonal  antibodies  against  HO-1  were  from  Bioquote  Ltd  (York,  UK). 
Antibodies  against  (3-actin  were  purchased  from  Abeam  (Cambridge,  UK).  All 
other chemicals were reagent grade and obtained from Sigma unless otherwise 
stated.
6.3.2  Myoglobin Assay
To  prepare  a stock of CORM-A1  for the  myoglobin  assay,  1   mg  of CORM-A1 
was added to 100 pi of dH20  to give a 96 mM stock.  From this 4,  8 and 12 mM 
working  stocks  were  prepared.  The  myoglobin  was  warmed  (37  °C),  sodium
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dithionite (0.1  %) added and a  1   ml sample of the myoglobin measured for the 
deoxy-Mb curve.  This  1   ml sample of deoxy-Mb was then bubbled with CO gas 
for 10 seconds to saturate the myoglobin and give a MbCO curve.  Six cuvettes 
were then loaded into the spectrophotometer carousel with 1   ml of deoxy-Mb in 
each,  5  pi  of 4,  8,  and  12  mM  CORM-A1  working  stocks were  then  added  in 
duplicate to each cuvette. The resultant final concentrations of CORM-A1  being 
20 (from 4 mM),  40 (from 8 mM)  and 60 pM (from 12  mM).  The myoglobin was 
then  mixed  gently  using  a  pipette  and  layered  with  500  pi  of mineral  oil.  The 
samples were then read at set intervals for a set period of time.  The release of 
CO  from  CORM-A1  was  also  determined  at  room  temperature  (25°C).  When 
investigating the effect of pH on the release of CO by CORM-A1  myoglobin was 
prepared in  PBS  in which the pH  had been altered to pH = 5.5,  pH = 6.5,  pH =
7.0,  pH  = 7.4 and pH  =  8.0.  Standard  pH  = 7.4  PBS  was  used  and  either 1   M 
HCL  or  1   M  KCI  used  to  acidify  or  alkalise  the  PBS,  repectively.  CORM-A1 
stability was determined  by preparing  the  stock solution of CORM-A1  in either 
citrate (pH = 6.6) or saline (pH = 6.6).  From these stocks 40 pM CORM-A1  was 
added to myoglobin and  left to  release CO for 10 min at 37  °C after which the 
spectra was  read.  This was  repeated  at 30  min  and  60  min  using the original 
stocks.
6.3.3  Cell Culture
Murine  RAW264.7  monocyte  macrophages,  Girardi  (human  heart)  cells,  wild 
type  smooth  muscle  cells  (European  Collection  of  Cell  Cultures  -  Salisbury, 
Wiltshire,  UK)  and  bovine  aortic  endothelial  cells  (Coriell  Cell  Repositories  - 
Camden,  NJ,  USA) were cultured as  per Material  and Methods.  Cultures were
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maintained at 37 °C in a 5% CO2 humidified atmosphere and experiments were 
conducted on cells at approximately 80-90% confluence.
6.3.4  Experimental Protocol
Macrophages  were  exposed  for  24  h  to  LPS  (1  pg/ml)  in  the  presence  or 
absence  of  CORM-A1  (10,  50,  100  and  500  pM)  and  nitrite  levels  were 
determined  at the  end  of the  incubation.  In  a  similar set of experiments,  cells 
were preincubated for 3 h with LPS (1  pg/ml) prior to the addition of CORM-A1 
(50,  100 and 200 pM)  in the presence or absence of LPS  (1  pg/ml)  and  nitrite 
measured at 18 h. The production of nitrite was also assessed in cells exposed 
simultaneously to LPS (1  pg/ml),  CORM-A1  (10,  50 and 100 pM) and iCORM-3 
(100  pM)  for 24  h.  Further experiments  were  carried  out  in which  RAW264.7 
macrophages were pre-incubated with CORM-A1  (100 pM)  prepared in PBS at 
various pH (6.0, 6.5,  7.0 and 7.4) for 30 min after which the PBS was replaced 
with  medium containing  100 pM CORM-A1  in the presence or absence of LPS 
(1  pg/ml)  and  incubated  for  a  further  24  h  after which  nitrite  production  was 
assessed.  For comparison  CORM-3  (100  pM) was pre-incubated for 30  min  in 
PBS  (pH  =  7.4)  after  which  the  PBS  was  replaced  with  medium  containing 
CORM-3 (100 pM) in the presence or absence of LPS (1  pg/ml) for a further 24 
h.  Experiments  were  repeated  with  the  negative  control  iCORM-A1  to  assess 
whether the  effects  observed  were  due  to the  CO  liberated  by the  CO-RM  or 
caused  by other components  of the  molecule.  The effect of CORM-A1  and  its 
inactive  counterpart  on  the  haem  oxygenase  pathway  was  also  investigated. 
Specifically,  bovine  aortic  endothelial  cells,  murine  macrophages,  wild  type 
smooth muscle cells and Girardi cells were treated for 6 or 24 h in the presence
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of 10,  50,  100 and 500 pM CORM-A1  and haem oxygenase activity as well as 
HO-1  protein expression determined.
6.3.5  Assay for Nitrite Levels
Nitrite  levels  were  determined  using  the  Griess  method.  The  measurement  of 
this  parameter  is  widely  accepted  as  indicative  of  NO  production.  Briefly,  the 
medium from treated  cells cultured  in 24 well  plates was  removed  and  placed 
into a 96 well plate (50 pi per well). The Griess reagent was added to each well 
to begin the reaction, the plate was shaken for 10 min and the absorbance read 
at 550 nm on a Molecular Devices VERSAmax plate reader.  The nitrite level  in 
each  sample  was  calculated  from  a  standard  curve  generated  with  sodium 
nitrite (0 pM to 300 pM in cell culture medium).
6.3.6  Western Blot Analysis
Samples of RAW264.7 cells were analysed by Western immunoblot.  Briefly,  an 
equal  amount  of  protein  (30  pg)  for  each  sample  was  separated  by  SDS- 
polyacrylamide  gel  electrophoresis,  transferred  overnight  to  nitrocellulose 
membranes  and  the  non-specific  binding  of  antibodies  was  blocked  with  3% 
non-fat dried milk in PBS.  Membranes were then probed with a polyclonal rabbit 
anti-HO-1  antibody  (Bioquote  Ltd.,  York,  UK)  (1:1000  dilution  in  Tris-buffered 
saline,  pH  =  7.4).  After three washes with  PBS  containing  0.05%  (v/v)  Tween 
20,  blots  were  visualised  using  an  amplified  alkaline  phosphatase  kit  from 
Sigma  (Extra-3A.  To  verify  equal  loading,  samples  were  also  probed  with  p- 
actin polyclonal antibodies (Abeam, Cambridge,  U.K.).
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6.3.7  Assay for Haem Oxygenase Activity
Haem  oxygenase  activity  was  determined  in  cells  after  various  treatments. 
Briefly,  harvested cells were subjected to three cycles of freeze-thawing before 
addition to a reaction mixture consisting of phosphate buffer (1  ml final volume, 
pH = 7.4) containing magnesium chloride (2 mM),  NADPH (0.8 mM),  glucose-6- 
phosphate  (2  mM),  glucose-6-phosphate  dehydrogenase  (0.2  Units),  rat  liver 
cytosol  as  a  source  of biliverdin  reductase,  and the  substrate  hemin  (20  pM). 
The reaction was conducted at 37  °C  in the dark for 1   h and terminated  by the 
addition  of  1   ml  chloroform;  the  extracted  bilirubin  was  calculated  by  the 
difference in absorbance between 464 and 530 nm (s = 40mM'1cm'1).
6.3.8  Cell Viability 
Alamar Blue
Cell metabolism was determined using an Alamar Blue assay kit and carried out 
according to the manufacturer’s instructions (Serotec,  UK). The assay is based 
on the detection of metabolic activity of living cells using a redox indicator which 
changes from  an oxidised  (blue) form to a reduced  (red) form.  The  intensity of 
the red colour is proportional to the metabolism of the cells, which is calculated 
as the difference in absorbance between 570 nm and 600 nm and expressed as 
a percentage of control.
Trypan Blue
The  status  of  the  cell  membrane  was  investigated  using  Trypan  blue.  The 
medium  of treated  cells  is  removed  and  the  cells then washed with  PBS  10X. 
Then a  1:1  solution of PBS (10X) and Trypan blue dye was added to cells. The
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dye  permeates  cell  in  which  the  membrane  has  been  compromised.  By 
counting the number of cell dyed compared to those which are not the number 
of viable cells can be determined.
Lactate Dehydrogenase
Damage  of  the  phopholipid  bi-layer  of  cells  was  investigated  using  an  LDH 
assay  kit  and  carried  out according to  the  manufacturer’s  instructions  (Roche, 
UK).  The  medium  of treated  cells  was  collected,  spun  to  remove  any  cellular 
debris  and  then  a  reaction  mixture  containg  an  INT  dye  added.  LDH  activity 
reflects its release from the cell membrane and a loss of viability.
6.3.9  Statistical Analysis
Statistical  analysis  was  performed  using  one-way  ANOVA  combined  with 
Bonferroni test. Differences were considered to be significant at P < 0.05.
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6.4  Results
6.4.1  CORM-A1  CO  release  is  dependent  on  concentration,  pH  and 
temperature.
As  with  the  CO-RMs  tested  thus  far,  the  first  priority  was  to  establish  the 
release  of  CO  from  CORM-A1.  CO  release from  CORM-A1  in  the  myoglobin 
assay  is slow and  gradual  compared to CO-RM-3 but shares a similar release 
to  CORM-319  (Figure  6.2D).  The  CO  release  is  concentration-dependent  but 
each  concentration  of CO-RM fails to yield  an  equilivant to the amount put  in, 
suggesting  less  than  a  1:1  return  on  CORM-A1  to  CO.  The  conversion  of 
deoxyMb  to  MbCO  over  time  at  each  concentration  is  shown  in  Figure  6.2A, 
Figure  6.2B  and  Figure  6.2C.  Note  the  gradual  change  from  a  single  peak 
spectra in Figure 6.2B to the double peak associated with MbCO. As predicted, 
iCORM-A1  was unable to convert the myoglobin to MbCO (Figure 6.2D).
From  its  chemistry  we  predicted  that  CORM-A1  would  be  unstable  in  the 
presence  of  protons  (H+)  which  should  accelerate  the  release  of  CO.  To 
investigate this we tested CORM-A1  in  myoglobin prepared with  PBS solutions 
of varying  pH  (Figure  6.3).  Important  to  note  is  that  the  myoglobin  spectra  of 
both  deoxyMb  and  MbCO  was  unchanged  by  the  different  pH.  As  pH  was 
increased from  pH  =  5.5 to  pH  =  8.0 there  is a striking  change  in the spectra. 
We  see  that  CORM-A1  at  low  pH  almost  instantaneously  releases  and 
saturates  the  myoglobin,  while  increasing  the  pH  results  in  a  much  more 
prolonged  CO  release  and  conversion  of the  spectra  from  the  single  peaked 
deoxyMb curve to the double peaked MbCO spectra (Figure 6.3A,  Figure 6.3B, 
Figure 6.3C,  Figure 6.3D and  Figure 6.3F).  This significant increase in the rate
- Page 223 -CHAPTER 6 BIOACTIVITY OF CORM-A1
of  release  is  better  displayed  in  Figure  6.4  which  shows  the  MbCO 
concentrations.
Changes in pH  result in the  greatest change in rate from pH  = 7.0 to pH  = 7.4 
where  near  instantaneous  release  suddenly  becomes  gradual.  Further 
increasing pH seems to affect the CO release little possibly suggesting there is 
an  all  or nothing  like switch  between  pH  =  7.0  and  pH  = 7.4 where the  proton 
concentration is enough to stimulate an immediate release.
Interestingly,  we  also  show that temperature  has  some  role  in  the  rate  of CO 
release (Figure 6.3E  and  Figure 6.4).  Performing the myoglobin assay at room 
temperature  results  in  a  markedly  decreased  rate  of CO  release  compared  to 
37  °C  (Figure  6.3D  and  Figure  6.3E).  Overall  the  end  point  is  similar  but the 
time  taken  to  reach  ‘saturation’  is  more  than  doubled.  This  could  possibly  be 
related in some part to pH since pH is dependent on temperature.
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Figure 6.2:- Effect of increasing concentrations of CORM-A1  on myoglobin 
CO saturation.
(A)  20  pM  CORM-A1  (B)  40  pM  CORM-A1  and  (C)  60  pM  CORM-A1  was 
added  to a 66  ( jM  myoglobin  solution.  The  conversion  of myoglobin to  MbCO 
was followed over time by  measuring the changes in the absorption spectra of 
this protein at pH = 7.4. The maximal absorption peak of myoglobin at 560 nm is 
gradually converted over time by CORM-A1  to spectra typical of MbCO with two 
maximal  absorption  peaks  at  540  and  578  nm,  respectively.  Myoglobin  was 
saturated  (MbCO)  by  bubbling  deoxyMb  with  CO  for  5  min.  (D)  The  MbCO 
concentrations were derived from the increase in absorption between deoxyMb 
(not shown) and sample readings at 540 nm. This is the amount of CO released 
in solution.
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Figure  6.3:-  Conversion  of  deoxy-myoglobin  to  carboxy-myoglobin  by 
CORM-A1  in myoglobin of varying pH.
(A)  60  pM  CORM-A1  pH  =  5.5,  (B)  60  pM  CORM-A1  pH  =  6.5,  (C)  60  pM 
CORM-A1  pH = 7.0,  (D) 60 pM CORM-A1  pH  = 7.4, (E) 60 pM CORM-A1  pH =
7.4  room temperature (RT) and (F) 60 pM CORM-A1  pH  = 8.0 was added to a 
66 pM myoglobin solution.  The conversion of myoglobin to MbCO was followed 
over time by measuring the changes in the absorption spectra of this protein at 
pH  =  7.4.  The  maximal  absorption  peak  of myoglobin  at  560  nm  is  gradually 
converted over time by CORM-A1  to spectra typical of MbCO with two maximal 
absorption  peaks  at  540  and  578  nm,  respectively.  Myoglobin  was  saturated 
(MbCO) by bubbling deoxyMb with CO for 5 min.
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Figure 6.4:- CO release from CORM-A1  is affected by pH and temperature.
60  pM CORM-A1  pH = 5.5, 60 pM CORM-A1  pH  = 6.5,  60 pM CORM-A1  pH =
7.0,  60  pM  CORM-A1  pH  =  7.4,  60  pM  CORM-A1  pH  = 7.4  room temperature 
(RT) and 60 pM CORM-A1  pH  = 8.0 was added to a 66 pM myoglobin solution. 
The conversion of myoglobin to MbCO was followed over time by measuring the 
changes  in  the  absorption  spectra  of  this  protein  at  pH  =  7.4.  The  maximal 
absorption  peak  of  myoglobin  at  560  nm  is  gradually  converted  over  time  by 
CORM-A1  to  spectra  typical  of  MbCO  with  two  maximal  absorption  peaks  at 
540  and  578  nm,  respectively.  Myoglobin  was  saturated  (MbCO)  by  bubbling 
deoxyMb with  CO for 5  min.  The  MbCO  concentrations were derived from the 
increase  in  absorption  between  deoxyMb  (not shown)  and  sample  readings  at 
540 nm. This is the amount of CO released in solution.
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6.4.2  CORM-A1 stability: effect of buffer composition.
We know from  previous  reports that CORM-A1  is stable in water for a number
of days (Clark,  Naughton,  Shurey,  Green,  Johnson,  Mann,  Foresti,  & Motterlini 
2003b).  However,  its  stability  in  other buffers  and  solutions was  unknown  and 
due  to  its  inherent  instability  in  solutions  containing  protons  we  examined  the 
release of CO from CORM-A1  in two common buffers: citrate and saline (Figure
6.5). An overall stock of 10 mM CORM-A1  in citrate (pH = 6.6) and saline (pH =
6.6) was prepared and 40 pM from each added to deoxyMb and left to stand for 
10  min  to  allow for  CO  release  at which  point  a  reading was taken.  This was 
repeated at both 30 min and  1   h,  taking  CORM-A1  from the solutions originally 
prepared  and  thus,  investigating  its  stability  in  each.  The  decomposition  of 
CORM-A1  was similar in both solutions,  despite the large difference in readings 
at  To  (Figure  6.5A,  Figure  6.5B  and  Figure  6.5C).  This  experiment  helps  to 
highlight  that  when  using  CORM-A1  prepared  in  biological  buffers  and 
commonly  used  vehicles,  CORM-A1  administration  should  be  immediate 
otherwise the CO release will be greatly diminished.
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Figure  6.5:-  Stability  of  CORM-A1  in  myoglobin  prepared  with  biological 
buffers.
(A)  Stability of  10 mM  CORM-A1  left to stand  in  a citrate solution pH  = 6.6 for 
60 min.  (B)  Stability of 10 mM  CORM-A1  left to stand  in a saline solution pH =
6.6  for 60 min.  At 0,  30 and 60 min 40  pM  CORM-A1  from either solution was 
added  to  a  66  pM  myoglobin  solution.  The  conversion  of myoglobin to  MbCO 
was  then  followed  for  10  min  by  measuring  the  changes  in  the  absorption 
spectra of this  protein  at  pH  = 7.4.  The  maximal  absorption  peak of myoglobin 
at  560  nm  is  gradually converted  over time  by  CORM-A1  to  spectra typical  of 
MbCO  with  two  maximal  absorption  peaks  at  540  and  578  nm,  respectively. 
Myoglobin was saturated (MbCO)  by bubbling deoxyMb with  CO for 5 min.  (C) 
The  MbCO  concentrations  were  derived  from  the  increase  in  absorption 
between  deoxyMb  (not  shown)  and  sample  readings  at  540  nm.  This  is  the 
amount of CO released in solution.
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6.4.3  Effect of CORM-A1 on cell viability.
Cell  viability  was  determined  by  a  combination  of  3  commercially  available 
assays.  All  report  a  specific  factor  associated  with  cell  health.  Figure  6.6A 
indicates  that  LDH  release  is  significantly  increased,  thus  cell  viability  is 
decreased,  at concentrations of 500 pM CORM-A1  and above.  However,  there 
is  some  slight  LDH  release,  although  not  significant,  at  100  pM  CORM-A1. 
Figure  6.6B  shows  that  iCORM-A1  has  slightly  less  effect  on  LDH  release 
possibly  implicating  CO  as  a  partial  mediator  of  the  increase  in  toxicity 
associated  with  active  CORM-A1.  This,  however,  was  not  mirrored  by  results 
using the Trypan blue exclusion assay.  In this case cells treated with CORM-A1 
did not cause any cells to take up the dye meaning they were all  100 % viable 
(Figure 6.7A), while exposure of cells to 750 and  1000 pM  iCORM-A1  resulted 
in  100 % of the cells taking  up the dye meaning they were all  unviable (Figure 
6.7B).  It  is  possible  since  LDH  release  is  representative  of  cell  membrane 
damage and Trypan  blue  uptake of cell  membrane  integrity that we could  see 
damage to the cell membrane without a loss of integrity (Figure 6.6A and Figure 
6.7A).  While,  the damage caused  by  iCORM-A1  resulted  in  a dramatic loss of 
cell membrane integrity allowing the Trypan blue to enter the cell and LDH to be 
released  in  large  volumes  (Figure  6.6B  and  Figure  6.7B).  The  Alamar  blue 
assay  gives  us  an  alternative  to  the  cell  membrane  associated  assays  and 
relies  on  cell  metabolism  as  an  indicator  of  cell  health.  CORM-A1  in  this 
instance  seems  to  have  less  of an  effect  on  metabolism  than  cell  membrane 
components with  only  1000  pM  CORM-A1  causing  any significant reduction  in 
viability (Figure 6.8A).  Interestingly,  iCORM-A1  has no effect on  metabolism  at 
all  (Figure  6.8B)  which  is  in  disagreement  with  both  LDH  and  Trypan  blue
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assays which suggest a complete loss of viability (Figure 6.6B and Figure 6.7B). 
This justifies the  need for multiple assays for cell  viability as each  has its  own 
limitations.  Indeed,  Alamar  blue  relies  upon  the  reduction  of  a  dye  to  infer 
cellular  metabolism  but  CORM-A1  is  a  known  reducing  agent  which  could 
potentially  interfere with the assay (Voytik-Harbin,  Brightman,  Waisner,  Lamar, 
&  Badylak  1998;  Clark,  Naughton,  Shurey,  Green,  Johnson,  Mann,  Foresti,  & 
Motterlini 2003b).
The  most  important  aspect  to  note  is  that  at  the  concentrations  used  most 
frequently  (10-100  pM)  there  is  no  observable  loss  of  viability  in  any  of  the 
three assays.
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Figure  6.6:-  The  effect  of  CORM-A1  on  LDH  release  in  RAW264.7 
macrophages.
The release of LDH was  assessed 24 h  after exposure of macrophages to (A) 
CORM-A1  (10-1000  pM)  or  (B)  iCORM-A1  (10-1000  pM)  using  an  LDH  kit 
purchased from Roche Diagnostics. Viability was expressed as a percentage of 
maximal  damage  (triton)  and  minimal  damage  (control).  Data  represent  the 
mean ± S.E.M. of 6 independent experiments. * indicates P< 0.005 vs. control.
- Page 232 -A CHAPTER 6 BIOACTIVITY OF CORM-A1
■ O (0 0) -O
U )
a; o
100-
90-
80-
70-
60-
50-
40-
30-
20-
10-
0-
CON 1% Triton CORNI-A1 
10 mM
CORM-A1  CORM-A1 
50 pM  100 mM
CORM-A1 
500 pM
CORM-A1  CORM-A1 
750 pM  1000 mM
B   110i
CON  1% Triton  iCORM-A1  iCORM-A1  iCORM-A1  iCORM-A1  iCORM-A1  iCORM-A1 
10 pM  50 pM  100 pM  500 pM  750 pM  1000 pM
Figure  6.7:-  The  effect  of  CORM-3  on  cell  membrane  permeability  to 
Trypan blue dye.
Cell  membrane  permeability was  assessed  24  h  exposure  of macrophages to 
(A)  CORM-A1  (10-1000  pM)  or (B)  iCORM-A1  (10-1000  pM)  using the Trypan 
blue  exclusion  assay.  Viability  was  expressed  as  a  percentage  of  the  cells 
stained with the dye  compared to the total  number of cells.  Data represent the 
mean ± S.E.M. of 6 independent experiments. * indicates P<0.05 vs. control.
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Figure 6.8:- The effect of CORM-3 on cellular metabolism.
Cell metabolism was assessed 24 h exposure of macrophages to (A) CORM-A1 
(10-1000  pM)  or  (B)  iCORM-A1  (10-1000  pM)  using  the Alamar  blue  viability 
assay.  Viability was  expressed  as  a  percentage  of control.  Data  represent the 
mean ± S.E.M. of 6 independent experiments. * indicates P<0.05 vs. control.
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6.4.4  CORM-A1  has no apparent effect on LPS-induced nitrite production.
As with. previous  CO-RMs we  have  used the  nitrite assay  in this  chapter as  a
means  to  investigate  the  biological  activities  of  this  compound.  Figure  6.9A 
demonstrates  CORM-A1,  up  to  concentrations  of  500  pM,  has  no  apparent 
effect  on  nitrite  production  induced  by  LPS  in  murine  macrophages.  This  is, 
unsurprisingly,  reflected  in  experiments  run  with  iCORM-A1  (Figure  6.9B). 
Importantly,  neither compound affects nitrite production on its own (Figure 6.9A 
and Figure 6.9B).
Since  CORM-A1  releases  CO  more  gradually  than  CORM-3,  we  wondered 
whether administering CORM-A1  after LPS addition would make any difference, 
since iNOS transcription is known to occur 4 h post stimulation (Liu et al.  1993; 
Park  &  Murphy  1994).  Once  again  we found  there was  no  reduction  in  nitrite 
(Figure  6.10A).  With  the  success  of  CORM-3  in  reducing  nitrite  we  then 
hypothesised that maybe it is the combination of the metal and the CO release 
that was responsible for the observed effect. To test this, we prepared iCORM-3 
which  contains  the  metal,  ruthenium,  but would  not  release  CO  and  interfere 
with the nitrite assay (as reported in Chapter 5) and co-incubated it with CORM- 
A1  and  LPS for 24 h.  Once again,  there was  no effect on the  nitrite generated 
(Figure 6.1 OB).
Since  CORM-3  releases  CO  instantaneously,  we  then  investigated  whether  it 
could be the gradual release of CO from CORM-A1  that in some way prevented 
it  from  decreasing  nitrite.  Having  already  shown  in  Figure  6.4  that  pH  could 
increase the rate at which CO is released by CORM-A1, we pre-incubated cells 
for  30  min  with  CORM-A1  and  LPS  in  PBS  of  varying  pH  (6.0  to  7.4)  to 
stimulate increased  CO  release.  After 30  min,  PBS was replaced with  medium
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containing  the  corresponding  CORM-A1  and  LPS  concentrations  so  as  not to 
overexpose  the  cells  to  PBS  which  can  be  toxic  over extended  periods.  Cell 
viability  was  assessed  and  the  cells  remained  viable  but  there  was  no 
detectable  decrease  in  the  amount  of  nitrite  generated  (Figure  6.11).  For 
comparison,  CORM-3 (100 pM) alone was also exposed to the same treatment 
and still elicited a significant reduction in nitrite production (Figure 6.11).
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Figure 6.9:- Effect of CORM-A1  on LPS-stimulated nitrite production.
(A)  RAW264.7  macrophages were exposed to  1   pg/ml  LPS  in the presence or 
absence of CORM-A1  (10-500 pM) and nitrite production was assessed at 24 h.
(B) The inactive compound iCORM-A1  (0 - 500 pM) was also used to determine 
the  contribution  of  CO  released  by  CORM-A1  to  the  observed  effect.  Control 
cells were incubated with medium alone.  Data represent the mean ± S.E.M. of 6 
independent experiments. * indicates P < 0.05 vs. control.
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Figure  6.10:-  Effect  of  LPS  pre-incubation  and  co-incubation  of iCORM-3 
and CORM-A1  on LPS-stimulated nitrite production.
(A) RAW264.7 macrophages were either pre-incubated with 1   pg/ml LPS for 3 h 
prior  to  CORM-A1  addition  or  co-incubated  with  CORM-A1  (50-200  pM)  and 
nitrite  production was  assessed  at  18  h.  (B)  macrophage  cells were  incubated 
with  1   pg/ml LPS in the presence of both CORM-A1  (10-100 pM) and iCORM-3 
(100  pM)  after  which  nitrite  was  determined  24  h  later.  Control  cells  were 
incubated  with  medium  alone.  Data  represent  the  mean  ±  S.E.M.  of  6 
independent experiments.  * indicates P < 0.05 vs. control.
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Figure 6.11:- Effect of decreasing  pH  on the ability of CORM-A1  to reduce 
nitrite.
RAW264.7  macrophages  were  pre-incubated  with  CORM-A1  (100  pM) 
prepared in PBS at various pH  (6.0,  6.5,  7.0 and 7.4) for 30 min after which the 
PBS was  replaced with  medium  containing  100  pM  CORM-A1  in the  presence 
or absence of LPS  (1  pg/ml) and  incubated for a further 24 h after which nitrite 
production  was  assessed.  For  comparison  CORM-3  (100  pM)  was  pre- 
incubated for 30 min in  PBS  (pH  =  7.4) after which the PBS was  replaced with 
medium  containing  CORM-3  (100pM)  in  the  presence  or  absence  of  LPS  (1 
pg/ml) for a further 24 h.  Control cells were incubated with medium alone.  Data 
represent the mean ± S.E.M.  of 6 independent experiments. * indicates P < 0.05 
vs. control; f  indicates P < 0.05 vs.  LPS (pH = 7.4).
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6.4.5  CORM-A1  has no effect on HO activity or HO-1  protein expression.
Having been unable to reduce nitrite levels using CORM-A1, we investigated its
effects on HO activity and HO-1  expression. Unlike CORM-311,  CORM-319 and 
CORM-3,  CORM-A1  does not contain a metal  centre and,  therefore,  is unlikely 
to  induce  either  HO  activity  or  an  increase  in  HO-1  expression.  Indeed,  we 
found  that  in  bovine  aortic  endothelial  cells  (BAEC),  wild  type  smooth  muscle 
cells (WTSMC), and Girardi cells we did not observe any increase in HO activity 
at concentrations of CORM-A1  up to 500  pM  (Figure 6.12C,  Figure 6.12D and 
Figure 6.12E).  In  RAW264.7  macrophages there was  no  effect  except  at  500 
pM  where  there  was  a  significant  increase  in  both  HO  activity  and  HO-1 
expression (Figure 6.12A,  Figure 6.12B,  Figure 6.13A and  Figure 6.13B).  This, 
however,  is likely due to the associated increase in toxicity observed in both the 
LDH assay (Figure 6.6A) and the Alamar blue assay (Figure 6.8A).
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Figure  6.12:-  Effect  of  CORM-A1  on  haem  oxygenase  activity  in  various 
cell lines.
RAW264.7  macrophages were  incubated with  increasing  concentrations of (A) 
CORM-A1  (10-100  pM)  for 6  h  and  (B)  CORM-A1  (100-500  pM)  for 24h.  (C) 
wild type smooth muscle cells and (D) Girardi cells were treated with CORM-A1 
(10-100  pM) for 6  h.  (E) while,  bovine aortic endothelial  cells were exposed to 
CORM-A1  (100-500  pM)  for  24  h.  Haem  oxygenase  activity  was  determined 
after exposure to the different treatments.  Data represent the mean ± S.E.M.  of 
6 independent experiments.  * indicates P < 0.05 vs. control.
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Figure  6.13:-  Effect  of  CORM-A1  on  haem  oxygenase-1  (HO-1)  protein 
expression.
RAW264.7  macrophages  were  incubated  with  increasing  concentrations  of 
CORM-A1  (10-500  pM)  and  HO-1  protein  levels were  determined  by Western 
blot analysis after 24 h.  (A) The graph  shows the average expression  of HO-1 
following  densitometric  analysis  of  three  different  (B)  blots  from  three 
independent experiments and one representative image is reported.  (3-actin was 
used as an internal control for equal loading. * indicates P < 0.05 vs. control.
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6.5  Discussion
There is an important rationale behind creating a non-metal containing CO-RM. 
Metal  carbonyl  chemistry is complex and the  reactions of such a compound in 
situ are not fully understood.  Metals themselves are often intimately involved in 
biology, such as iron, and CO-RMs based on biological metals are desirable but 
the  issue  stills  remains  as  to  the  exact  actions  of the  compound  in  the  cell. 
Removing  the  metal  can  significantly  reduce  the  potential  interactions  of  CO- 
RMs  in  situ  not  to  mention  creating  a  compound  that  is  more  water  soluble, 
possibly less  toxic  and  is  likely  to  be  more  biocompatible.  CORM-A1  (sodium 
boranocarbonate) was the first such CO-RM identified.  Extremely water soluble, 
CORM-A1  was  shown  to  have  a  CO  release  similar  to  that  obtained  with 
CORM-319.  In this Thesis we have again demonstrated the gradual CO release 
associated  with  CORM-A1.  Interestingly,  due  to  its  chemistry  CORM-A1  is 
unstable  in  the  presence  of  protons  and  releases  CO.  We  confirmed  this  by 
running the myoglobin assay using myoglobin prepared with PBS at various pH. 
The  increase  in  CO  release  at  acidic  pH  is  striking  with  near  instantaneous 
release.  It  is  interesting  to  note  that  the  change  in  the  rate  of  CO  release 
between pH  = 7.0 to pH  =  5.5  is  not particularly significant,  although,  between 
pH  =  7.4 and  pH  =  7.0 there  is  a  large  increase  in  rate.  This  could  suggest a 
switch  like  response where  a  small  change  in  proton  gradient  results  in  a  big 
increase in  CO  release but further increases  in  proton concentration  have  little 
affect  on  subsequent  CO  release.  We  also  found  that  temperature  plays  an 
important role in CO  release.  CORM-A1  tested  in the myoglobin assay at room 
temperature  (25°C)  has a  considerably  slower CO  release than  at 37  °C.  This
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could be as a result of the effect of temperature on pH, thus affecting the proton 
gradient (Kipp & Schuck 1995).
Having established the ability of CORM-A1  to release CO,  next it was important 
to  determine  its  toxicity  in  the  murine  macrophage  cell  line  to  be  used  for the 
nitrite  study.  We  found  that  CORM-A1  at  the  concentrations  most  frequently 
used  (10-100  pM)  was  not toxic  in  any  of the  assays.  Interestingly,  at  higher 
concentrations  (500-1000  pM),  there  was  some  disagreement  between  the 
cytotoxicity  assays  utilised.  CORM-A1  elicited  LDH  release  at  500  pM  and 
above but did not affect Trypan blue and only affected Alamar blue at 1000 pM. 
Meanwhile,  iCORM-A1  at 750 and  1000 pM was almost 100 % toxic in both the 
LDH  assay  and  Trypan  blue  assay  but  did  not  affect Alamar blue at all.  From 
the  data  obtained  with  these  assays  we  can  conclude  that  CORM-A1  at  high 
concentrations  seems  to  elicit  some  damage  to  the  cell  membrane enough  to 
cause  LDH  release but not to actually split the cell  membrane and also  seems 
to affect the cellular metabolism probably as a direct result. Most importantly,  no 
effect was seen in any assay at the most frequently used concentrations which 
have  been  known  to  cause  a  pharmacological  effect  in  the  vasculature 
(Motterlini et al. 2005).
Having determined the toxicity we then began to test the ability of CORM-A1  to 
reduce nitrite.  Unlike CORM-3 we found  CORM-A1  had  effect on  LPS-induced 
nitrite generation in murine macrophages. This we summised could be due to:  i) 
the slower rate of CO release compared to CORM-3,  ii) the absence of a metal 
centre,  iii)  the  localisation  of  CO  release.  As  such  we  devised  a  number  of 
methods to explore these options with the exception of iii) which is a particularly 
complicated  area of research  and  not feasible.  We know that CORM-3  has an
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instantaneous  release  of  CO  and  that  its  actions  appeared  to  be  as  a  direct 
result of CO  binding  to  iNOS  and  limiting  its  ability to  generate  nitrite.  Having 
already established that the  release of CO from  CORM-A1  could  be increased 
at acidic pH, we  incubated cells in  PBS at various pH containing CORM-A1.  In 
theory,  the  accelerated  CO  release  should  result in  CO  levels equal to that of 
cells exposed to CORM-3.  However, there was no reduction in nitrite as a result 
of this approach.  Nor was it affected by delaying the addition of CORM-A1  until 
such time that iNOS would  have been transcribed thus allowing  CO  release to 
occur  concomitantly  with  the  period  of  iNOS  activity.  Finally,  cells  were 
incubated  with  iCORM-3  and  CORM-A1.  The  presence  of  the  metal,  we 
hypothesised,  would  in  some  way function  to  allow CO  to  reduce  nitrite.  This, 
however,  also failed to achieve the desired result. This is most interesting since 
in  our  laboratory,  ex  vivo  experiments  showed  that  CORM-A1  promotes 
pharmacological  activities.  Indeed,  CORM-A1  has  been  shown  to  have  a 
significant vasodilatory effect in an  isolated aortic ring model  (Motterlini,  Sawle, 
Hammad,  Bains,  Alberto,  Foresti,  &  Green  2005).  In  this  instance  the  effect 
would  appear  to  involve  endothelium  independent  relaxation  that  is  partially 
mediated  by  sGC  and  does  not  require  the  activation  of potassium  channels, 
unlike  CORM-3  which,  is  both  endothelium-dependent  and  does  require 
potassium channel  activation.  While it has also been shown (data unpublished) 
that  CORM-A1  has  a  beneficial  effect  in  a  Langendorff  model  of  ischemia 
reperfusion  injury.  Studies  have  also  been  carried  out  showing  a  vasodilatory 
effect of CORM-A1  on  kidney function  and  modulation  of oxygen  saturation  in 
an  isolated  mitochondria  preparation.  It  was  assumed  a  more  gradual  CO 
release  would  have  more  of  an  effect  on  inflammation  due  to  the  prolonged
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nature of such an  insult.  It is  possible that CORM-A1  acts in a different cellular 
location  to  CORM-3  and  thus  does  not  elicit  a  similar  response.  The  exact 
mechanism  of  release  and  subsequent  fate  of  the  compound  and  the  CO 
released  are  unkown  and  need  to  be  investigated  further  to  understand  the 
difference between their actions.
Unlike CORM-3,  CORM-A1  has also no effect on  HO activity in a variety of cell 
types  or  HO-1  expression  in  murine  macrophages.  This  is  likely  due  to  the 
absence of both a metal and the biological ligand haem precursor glycine. Thus, 
any biological activity attributed to CORM-A1  is not due to HO activity but due to 
the CO released or the compound itself.
6.6  Conclusion
There  is  no  apparent  effect  of CORM-A1  on  LPS  induced  nitrite generation  in 
murine macrophages.  The compound  is not toxic between  10 and  100  pM and 
neither  is  the  negative  control  (iCORM-A1).  CO  release  is  gradual  and 
dependent  on  concentration,  pH  and  temperatue.  CORM-A1  has  no  effect on 
HO  activity  in  various  cell  lines  and  no  effect  on  HO-1  protein  expression  in 
murine macrophages. The compound seems well suited to be used in biological 
systems  and  its  success  in  other  systems  should  encourage  further 
investigation  in  to  the  exact  mechanism  of  its  CO  release  in  the  cellular 
environment  in  an  attempt to  elucidate the differences between  its actions and 
CORM-3.
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7  Chapter 7: CORM-F:  An Example of the Multiplicity of Metal 
Carbonyl Compounds
7.1  Introduction
In  recent  years  our group  has  been  testing  and  characterising  metal  carbonyl 
complexes,  and  more  recently  non  metal  compounds,  as  a  means to  release 
CO endogenously. Metal carbonyl complexes have long been used in chemistry 
to  purify  metals  but  their  use  in  biological  systems  is  novel,  although  quickly 
finding  favour.  These  compounds  have  been  used  in  areas  as  diverse  as 
cancer  therapy,  drug  receptor  interactions  and  malarial  research.  Bio- 
organometallic  chemistry  has  now  become  an  emerging  discipline  that  may 
offer innovative solutions to many biological problems.
These metal carbonyl complexes or carbon monoxide-releasing molecules (CO- 
RMs)  are  capable  of  releasing  CO  in  the  biological  milieu  and  already  have 
been  shown to elicit numerous  biological  effects already attributed to CO such 
as  anti-inflammatory,  anti-hypertensive,  anti-rejection  and  vasoregulatory 
activities.  Interestingly,  minor modifications  of the chemical  structure can  allow 
for  improved  CO  release,  various  rates  of  CO  release,  reduced  toxicity  and 
greater solubility.
By  manipulating  the  ligands  the  rate  at which  CO  is  released  can  be  altered, 
allowing for slow delivery of CO over a period of time or a faster release where 
needed.  CO-RMs  that  release  CO  very  rapidly  (‘fast  releasers’)  in  biological 
systems would be ideal for therapeutic applications where CO acts as a prompt 
signalling  mediator  (i.e.  neurotransmission,  acute  hypertension,  angina, 
ischemia-reperfusion).  However,  the  discovery  of  chemicals  that  release  CO
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with  a  slow  kinetic  (‘slow  releasers’)  would  implement  the  design  of 
pharmaceuticals that could be more versatile in the treatment of certain chronic 
diseases  (i.e.  inflammatory  states  and  chronic  hypertension;  rejection  of 
transplanted organs) where the continuous and  long-lasting effects of CO may 
be required.  The attempt to diversify the  multiplicity of CO-RMs that possess a 
variety  of  chemical  characteristics  (i.e.  water  vs.  lipid-soluble;  slow  vs.  fast 
releasers)  will  help  elucidate  the  biological  function  of cellular targets that are 
responsive to CO and will facilitate in due course the design of versatile agents 
that could be used for the therapeutic delivery of CO in a safe and measurable 
fashion.
CORM-F  compounds  are  a  group  of  molecules  designed  by  Dr  Ian  Fairlamb 
(University of York)  based  on 2-pyrones  (See  Figure 7.1).  2-pyrone (2H-pyran- 
2-one)  is  a  ubiquitous  structural  motif found  in  nature  (McGlacken  &  Fairlamb 
2005).  Both  natural  and  synthetic  2-pyrone  compounds  have  been  found  to 
exhibit  a  range  of  bioactivities  such  as  the  ability  to  inhibit  human  ovarian 
carcinoma  (A2780)  and  human  chronic  myelogenous  leukaemia  (K562)  cell 
lines  at  the  sub-micromolar  level  (IC50)  (Moreno-Manas  1988;  Marrison, 
Dickinson, & Fairlamb 2002).
Figure 7.1The chemical structure of 2-pyrone
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The action  of 2-pyrone  appears to  be as  a  pro-drug where the opening  of the 
carbonyl  ring  leads  to  the  bioactive  form  (Fairlamb  et  al.  2004).  6-chloro-2- 
pyrones  have  been  shown  to  inhibit  yeast  cholesterol  esterase  from  Candida 
Cylindracea  in  a  similar  manner.  Fairlamb  and  co-workers  have  since 
established a plethora of functionalised 2-pyrones as broad spectrum inhibitors 
of  bacteria,  fungi  and  yeasts  -  with  inhibition  being  related  to  interference  of 
sterol  related  biosynthetic  pathways  (Fairlamb,  Marrison,  Dickinson,  Lu,  & 
Schmidt 2004).  It  is  predicted  that  the  unique  structural  properties  of the  core 
molecule could exhibit interesting  bioactivity in appropriately selected biological 
systems (Figure 7.2).
Figure 7.2:- Basic structure of CORM-F derivatives.
CORM-F compounds are a particularly good example of the malleable nature of 
CO-RMs  which  show  just  how  minor  adjustments  can  result  in  significant 
differences between compounds.  Overall they are a good demonstration of the 
power of CO-RMs to be adapted to suit a desired action.
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7.2  Objective
Demonstrate  how  structure  can  affect  CO  release,  toxicity  and  nitrite  using 
CORM-F compounds.
7.3  Materials and Methods
7.3.1  Chemicals and reagents
The  CO-RMs  tested  in  this  chapter  were  prepared  by  Dr  Ian  Fairlamb 
(University  of  York).  CO-RMs  were  prepared  as  10  mM  stock  solutions  in 
DMSO and used the same day of the experiment.  The structures of all the CO- 
RMs are represented in Figure 7.3. All other chemicals were reagent grade and 
obtained from Sigma unless otherwise stated.
Br
Fe(CO)3
Me'  O
C O R M -F 3
Cl
(OC)3Fe>
S , / S >
CORM-F7
Cl Me
Me
C O R M -F 8
Me'
C O R M -F 1 1
Figure 7.3:- The structure of CORM-F compounds in this chapter.
Note the overall structure of the compounds is identical. Variations comprise the 
addition/subtraction of a methyl group or altering the halogen atom.
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7.3.2  Detection of CO Release
The release of CO from CO-RMs  ( 4 0 | j M )   was assessed spectrophotometrically 
by measuring the conversion  of deoxymyoglobin  (deoxy-Mb)  to carbonmonoxy 
myoglobin (MbCO).
7.3.3  Cell Culture
Murine  RAW264.7  monocyte  macrophages  (European  Collection  of  Cell 
Cultures - Salisbury, Wiltshire,  UK) were cultured as per Material and Methods. 
Cultures  were  maintained  at  37  °C  in  a  5%  CO2  humidified  atmosphere  and 
experiments were conducted on cells at approximately 80-90% confluence.
7.3.4  Experimental Protocol
Macrophages were treated for 24  h with  10,  50,  100 and 200 pM  CO-RM  (F3, 
F7,  F8, and F11) in 24 well plates. After which the medium was collected for the 
lactate  dehydrogenase  assay,  while  the  cells  were  used  for  the  Alamar  blue 
assay.  The  effect  of  CORM-F3  on  nitrite  levels  was  also  investigated.  Cells 
were treated with 10, 50 and  100 pM CORM-F3 in the presence or absence of 1  
pg/ml  LPS  for  24  h.  The  medium  was  collected  and  used  for  both  a  Griess 
assay and LDH, while the cells were used for the Alamar blue assay.
7.3.5  Alamar Blue Cell Viability Assay
Cell  viability  was  determined  using  an  Alamar  Blue  assay  kit  and  carried  out 
according to the manufacturer’s instructions (Serotec,  UK). The assay is based 
on the detection of metabolic activity of living cells using a redox indicator which 
changes from  an oxidised  (blue) form to a reduced  (red) form.  The  intensity of
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the red colour is proportional to the metabolism of the cells, which is calculated 
as the difference in absorbance between 570 nm and 600 nm and expressed as 
a percentage of control.
7.3.6  Lactate Dehydrogenase Assay
The  effect  of  CO-RMs  on  cell  viability  was  also  assessed  using  the  lactate 
dehydrogenase (LDH) assay.  LDH is a stable cytoplasmic enzyme present in all 
cells.  It is rapidly released  into the cell culture supernatant upon damage of the 
plasma  membrane.  The  LDH  based  cytotoxicity  detection  kit  (Roche 
Diagnostics,  UK) is a method for the colourimetric assay for the quantification of 
cell  death  and  cell  lysis  based  on  the  measurement  of  LDH  activity  released 
from the cytosol of damaged cells  into the supernatant.  The assay was carried 
out according to the manufacturer’s instructions.
7.3.7  Assay for Nitrite Levels
Nitrite  levels  were  determined  using  the  Griess  method.  Briefly,  the  medium 
from treated cells cultured  in 24 well  plates was removed and placed  into a  96 
well  plate  in  triplicate  (50  pi  per well).  To  generate  a  standard  curve,  50  pi  of 
sodium nitrite (0 pM to 300  pM  in  medium) was added to the plate in triplicate. 
Griess  reagent was  added  to  each  well  to  begin  the  reaction.  The  plate  was 
shaken for 10 min to allow the reagents to mix and then the absorbance read at 
550  nm  on  a  Molecular  Devices  VERSAmax  plate  reader.  The  nitrite  level  in 
each sample was calculated from the standard curve.
- Page 252 -UCL CHAPTER 7 MULTIPLICITY OF CO-RMS
7.3.8  Aortic rings preparation
Transverse  ring  sections  of  aortas  were  obtained  from  male  adult 
Sprague-Dawley rats (350 g) and suspended under 2 g tension  in oxygenated 
Krebs-Henseleit  buffer  as  previously  described  (Sammut et al.  1998;  Clark et 
al.  2003).  To  establish  the  potential  vasorelaxant  effects  of  CORM-F3,  aortic 
rings were  precontracted with  phenylephrine (1  pM)  before  addition of CORM- 
F3 (100 pM).
7.3.9  Statistical Analysis
Statistical  analysis  was  performed  using  one-way  ANOVA  combined  with 
Bonferroni test. Differences were considered to be significant at P < 0.05.
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7.4  Results
7.4.1  CO release and related toxicity of CORM-F compounds
Immediately evident is the varying degrees of CO release from each compound.
CORM-F3  is  the  more  potent  CO  releaser  (Figure 7.4A and  B)  generating  18 
pM of MbCO.  CORM-F8,  in which the bromine is replaced with a chlorine, is still 
capable of releasing  CO  but generates only a third of the MbCO as CORM-F3 
in the same time  (Figure 7.6A and  B).  The  release of CO from  CORM-F3 and 
CORM-F8 is slow and  steady,  neither releasing an equilivant amount of CO as 
the  concentration  of  CO-RM  added.  Both  CORM-F7  and  CORM-F11  do  not 
release  any  CO  (Figure  7.5A  and  B;  Figure  7.7A  and  B).  CORM-F7  is 
analogous to CORM-F8 with the exception of a methyl side chain,  stressing the 
importance of the methyl  group. While,  CORM-F11  contains two methyl groups 
and  no  halogen  group,  in  this  instance  demonstrating  it  is  the  combination  of 
methyl  and  halogen  group  that  promote  CO  release.  CORM-F3 vs.  CORM-F8 
also demonstrates the halogen group can also determine the CO release.
None of these compounds show any significant reduction in metabolism at  10- 
100 pM as demonstrated by the alamar blue assay.  But they do all significantly 
reduce  metabolism  at  200  pM  (Figure  7.4D,  Figure  7.5D,  Figure  7.6D,  Figure 
7.7D).  Interestingly,  CORM-F7 and  CORM-F8 demonstrate an increase  in LDH 
release (indicating toxicity) starting at 100 pM (Figure 7.5C,  Figure 7.6C), while, 
CORM-F11  shows damage at 10 pM (Figure 7.7C). This could indicate the CO- 
RMs  are  causing  some  damage  to  the  cell  membrane  prior  to  affecting  the 
functioning of the  cell  (as  determined  by  metabolism).  CORM-F3  on  the  other 
hand is only toxic at 200 pM (Figure 7.4C), making it the least toxic of the four.
- Page 254 -l^ L CHAPTER 7 MULTIPLICITY OF CO-RMS
0) o c re .a k_ o < /> n
<
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
500
B
— 1 2 0  
•  Saturated MbCO
550
X (nm)
600
26 
24 
22 
20 
—   18
I 1 6
o  14
2   10 
8 
6 
4
2
0
Fe(CO)3
CORM-F3
0  20  40  60  80  100
Time (mins)
120
120-|
0 )  100 < /> re
«  80 
a >
a:
i
Q
60
40
20
0
CORM-F3 (pM) 
Triton (%)
0  10  50
1 0   0
120-1
100]
*
& o
-   ts  80- 
3   c
»  8
>   £   60
=   o
■
0)
O   2^,  40-
20i
L  J UJ
200 CORM-F3 (pM)
0
10  50  100  200
Figure  7.4:-  CORM-F3;  CO  release  and  effect  on  cell  viability  in 
macrophages.
(A)  C0RM-F3  (40  pM)  was  added  to  a  66  pM  myoglobin  solution.  The 
conversion  of  myoglobin  to  MbCO  was  followed  over  time  by  measuring  the 
changes  in  the  absorption  spectra  of  this  protein  at  pH  =  7.4.  The  maximal 
absorption  peak  of  myoglobin  at  560  nm  is  gradually  converted  over time  by 
CORM-F3  to  spectra  typical  of  MbCO  with  two  maximal  absorption  peaks  at 
540  and  578  nm,  respectively.  Myoglobin  was  saturated  (MbCO)  by  bubbling 
deoxyMb with CO for 5 min.  (B) The MbCO concentration was derived from the 
increase in absorption between deoxyMb and sample readings at 540 nm. This 
is the amount of CO released in solution.  Cell viability was assessed 24 h after 
exposure of macrophages to  CORM-F3 (10-200  pM)  using (C) the  LDH  assay 
or (D) Alamar Blue. Viability was expressed as percentage of maximal damage 
(triton)  and  minmal  damage  (control).  Data  represent the  mean  ±  S.E.M.  of 6 
independent experiments. * indicates P < 0.05 vs. control.
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Figure  7.5:-  CORM-F7;  CO  release  and  effect  on  cell  viability  in 
macrophages.
(A)  CORM-F7  (40  pM)  was  added  to  a  66  pM  myoglobin  solution.  The 
conversion  of  myoglobin  to  MbCO  was  followed  over  time  by  measuring  the 
changes  in  the  absorption  spectra  of  this  protein  at  pH  =  7.4.  The  maximal 
absorption  peak  of  myoglobin  at  560  nm  is  gradually  converted  over  time  by 
CORM-F7  to  spectra  typical  of  MbCO  with  two  maximal  absorption  peaks  at 
540  and  578  nm,  respectively.  Myoglobin  was  saturated  (MbCO)  by  bubbling 
deoxyMb with CO for 5 min.  (B) The MbCO concentration was derived from the 
increase in absorption between deoxyMb and sample readings at 540 nm. This 
is the amount of CO released in solution.  Cell viability was assessed 24 h after 
exposure of macrophages to  CORM-F7  (10-200  pM)  using (C) the  LDH  assay 
or (D) Alamar Blue. Viability was expressed as percentage of maximal  damage 
(triton)  and  minmal  damage  (control).  Data  represent the  mean  ± S.E.M.  of 6 
independent experiments. * indicates P < 0.05 vs. control.
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Figure  7.6:-  CORM-F8;  CO  release  and  effect  on  cell  viability  in 
macrophages.
(A)  CORM-F8  (40  pM)  was  added  to  a  66  pM  myoglobin  solution.  The 
conversion  of  myoglobin  to  MbCO  was  followed  over  time  by  measuring  the 
changes  in  the  absorption  spectra  of  this  protein  at  pH  =  7.4.  The  maximal 
absorption  peak  of  myoglobin  at  560  nm  is  gradually  converted  over time  by 
CORM-F8  to  spectra  typical  of  MbCO  with  two  maximal  absorption  peaks  at 
540  and  578  nm,  respectively.  Myoglobin  was  saturated  (MbCO)  by  bubbling 
deoxyMb with CO for 5 min.  (B) The MbCO concentration was derived from the 
increase in absorption between deoxyMb and sample readings at 540 nm. This 
is the amount of CO  released in solution.  Cell viability was assessed 24 h after 
exposure  of macrophages to  CORM-F8 (10-200  pM)  using  (C) the  LDH  assay 
or (D) Alamar Blue. Viability was expressed as percentage of maximal damage 
(triton)  and  minmal  damage  (control).  Data  represent the  mean  ±  S.E.M.  of 6 
independent experiments. * indicates P < 0.05 vs. control.
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Figure  7.7:-  CORM-F11;  CO  release  and  effect  on  cell  viability  in 
macrophages.
(A)  C0RM-F11  (40  pM)  was  added  to  a  66  pM  myoglobin  solution.  The 
conversion  of  myoglobin  to  MbCO  was  followed  over  time  by  measuring  the 
changes  in  the  absorption  spectra  of  this  protein  at  pH  =  7.4.  The  maximal 
absorption  peak  of  myoglobin  at  560  nm  is  gradually  converted  over time  by 
CORM-F11  to  spectra  typical  of MbCO  with  two  maximal  absorption  peaks  at 
540  and  578  nm,  respectively.  Myoglobin  was  saturated  (MbCO)  by  bubbling 
deoxyMb with CO for 5 min.  (B) The MbCO concentration was derived from the 
increase in absorption between deoxyMb and sample readings at 540 nm. This 
is the amount of CO  released in solution.  Cell viability was assessed 24 h after 
exposure of macrophages to CORM-F11  (10-200 pM) using (C) the LDH assay 
or (D) Alamar Blue.  Viability was expressed as percentage of maximal damage 
(triton)  and  minmal  damage  (control).  Data  represent the  mean  ±  S.E.M.  of 6 
independent experiments. * indicates P < 0.05 vs. control.
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7.4.2  CORM-F3 attenuates  LPS  induced  nitrite production and  promotes 
vasorelaxation.
Having  demonstrated  in  Chapter  3  that  CORM-3  could  reduce  LPS  induced 
nitrite  production  in  a  concentration  dependent  manner  we  assessed  the 
potential of CORM-F3 to do the same.  CORM-F3 was chosen since it released 
the most CO  and was the least toxic of the CORM-F compounds tested in this 
chapter.  Murine  macrophages  were  treated  with  CORM-F3  (10-100  pM)  and 
LPS (1  pg/ml) for 24 h before assessing the medium for nitrite content using the 
Griess  assay  (Figure  7.8A).  CORM-F3  significantly  and  in  a  concentration 
dependent  manner  reduced  nitrite  levels  compared  to  macrophages  treated 
with LPS alone. The addition of 100 pM CORM-F3 almost completely abolishing 
the increase in nitrite levels.
Bioactivity of CORM-F3 was  also  assessed  in  a  isolated  aortic rings  model  of 
vasorelaxation. Aortic rings from male Sprauge Dawley rats were precontracted 
with  phenylephrine  and  then  given  one  dose  of  100  pM  CORM-F3  (Figure 
7.8B). There was a significant relaxation compared to rings treated with vehicle 
alone.
Obviously  without  further  investigation  we  can  only  infer  that  the  bioactivity 
whitnessed with CORM-F3 is as a direct result of the CO released and not the 
compound  itself  or  a  product  of  its  metabolism.  But  we  can  be  sure  the 
compound is biologically active and worthy of such further investigation.
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Figure  7.8:- CORM-F3  ellicits  both  vasorelaxation  and  a  reduction  in  LPS 
stimulated nitrite production.
(A)  RAW264.7  macrophages were exposed to  1   pg/ml  LPS  in the presence or 
absence of CORM-F3 (10-100 pM) and nitrite production was assessed at 24 h. 
Control cells were incubated with medium alone. (B) Transverse ring sections of 
aortas  were  obtained  from  male  adult  Sprague-Dawley  rats  (350  g)  and 
suspended  under  2  g  tension  in  oxygenated  Krebs-Henseleit  buffer.  To 
establish  the  potential  vasorelaxant  effects  of  CORM-F3,  aortic  rings  were 
precontracted with phenylephrine (1  pM) before addition of CORM-F3 (100 pM).
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7.5  Discussion
As with all compounds,  structure relates to function. Subtle changes in structure 
can  result  in  remarkably  different  outcomes  in  function.  Carbon  monoxide 
releasing  molecules  are  no  different which  is what  makes them  so  interesting 
and  useful.  Minor modifications of structure can allow the tailoring of a  CO-RM 
to suit a desired action, for example varying the release of CO.  In this particular 
instance  CORM-F  compounds allow us to demonstrate the multiplicity of metal 
carbonyl  compounds  quite  strikingly.  Of  the  four  compounds  tested  all  are 
based  on  the  same  basic  chemical  Structure  (see  Figure  7.2).  Addition  of 
further groups  to  this  starting  structure  result  in  a  variety of outcomes  that  go 
some way to  explaining  how to  improve  and  shape function.  CORM-F3 which 
shows the greatest CO release contains both bromine and a methyl side chain. 
Interestingly  if  the  bromine  is  replaced  with  a  chlorine  (CORM-F8)  the  CO 
release  is  significantly  reduced  and  a  slight  increase  in  LDH  is  observed with 
100 pM. The addition of chlorine, therefore,  diminishes the compounds ability to 
release CO.
Removal  of  the  methyl  group  and  addition  of  chlorine  (CORM-F7)  practically 
abolishes CO release altogether. Thus we can infer from this that both the exact 
halogen atom and presence of the methyl group determine the release of CO to 
a  great  extent  in  these  compounds.  But  both  are  required  to  achieve  a 
significant  CO  release.  Important  to  note  is  that  altering  the  halogen  group 
and/or  adding/removing  the  methyl  group  does  not  significantly  affect  cell 
toxicity.  Interestingly,  cells  show  more  damage  to  the  cell  membrane  than  a 
reduction  in  metabolism  suggesting  that  long  term  CO-RM  exposure  may 
present more of an issue on toxicity than short term.  CORM-F11  demonstrates
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that  by removing  the  halogen  group  and  replacing with  a further methyl  group 
both  CO  release  and toxicity  are  greatly affected.  CORM-F11  releases  no  CO 
and has an effect on LDH at only 10 pM. The function of the compound entirely 
altered  compared  to  CORM-F3.  As  in  Chapter 4 the  most  important  issues to 
stress are the shear potential  of CO-RMs. Almost limitless combinations results 
in  a  plethora  of potential  activities.  We  have tested well  over 70  CO-RMs  and 
more are being generated all the time.
It  is  intriguing to  note that both  a  halogen  and  methyl  substituent are  required 
for good  CO  release.  The  observation  parallels  the  previous  reported  solution 
behaviour  of  these  complexes.  The  substituents  could  play  some  role  in 
facilitating  2-pyrone  dissociation  from  the  metal  centre  by  sterically  and 
electronically perturbing otherwise favourable du-TT* synergic effects seen in the 
parent 2-pyrone complex. Alternatively,  an increase in the strain in the carbonyl 
fragment  of the 2-pyrone  iron  tricarbonyl  complexes  could favour ring-opening 
and further reactions.
7.6  Conclusion
The  development  of  new  compounds  capable  of  releasing  CO  in  a  controlled 
fashion  is  fast  accelerating.  Ever  since  CORM-3  was  first  synthesised  the 
potential  of  metal  carbonyl  compounds  has  been  realised  and  CO-RMs  are 
being  synthesised to  build  up  a  large  portfolio of candidates for future  studies. 
CORM-F  compounds  demonstrate  the  ability to  subtly  manipulate structure to 
achieve  variation  in  function.  The  potential  number  of  CO-RMs  is  therefore 
almost limitless. Characterising the many compounds is vital to identify CO-RMs
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that  may  have  specific  roles,  which  can  be  exploited  for  certain 
pathophysiological conditions.
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8  General Discussion
8.1  Analysis of Methodology
This  Thesis  has  been  structured  according  to  the topic of each  chapter rather 
than  by  the  methodology  used.  The  chapters  therefore  are  not  presented  in 
chronological  order  of  completion  rather,  upon  completion  of  the  whole  work 
they have been arranged to best introduce each aspect of the project.
8.1.1  Cell Culture Methodology
Cell  culture  is  often  used  for  studying  the  specific  effects  of  environmental 
changes  or chemical  mediators  on  particular  cell  types.  The  macrophage  cell 
line  used  for  this  study  was  derived  from  a  murine  source,  while  endothelial 
cells  were  from  bovine  aortic  tissue.  Visually  the  cells  maintained  their 
respective  morphologies  but  it would  be  of further benefit to  compare  them  to 
primary  cells  in  respect  of  their  HO  activity,  HO-1  expression  and  further 
biological  activities.  However,  the  data  obtained  is  supported  by  a  number  of 
other  reports  using  both  macrophages  and  endothelial  cells  from  other 
mammalian species (Motterlini,  Foresti,  Intaglietta,  & Winslow 1995a;  Foresti et 
al.  2000;  Clark et al.  2000b;  Balogun et al.  2003;  Sawle et al.  2005;  Nakamichi 
et al.  2005;  Tsoumakidou et al.  2005;  Ramirez-Emiliano,  Gonzalez-Hemandez, 
&  Arias-Negrete  2005;  Paoliello-Paschoalato,  Oliveira,  &  Cunha  2005).  The 
cells  lines  were  passaged  prior  to  confluence  (~80%  which  was  determined 
visually)  and  maintained  in  both  cases  until  passage  30  at  which  point  cells 
were discarded and a new cell line aquired. Cells were maintained in a sufficient
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volume of culture medium at all times and kept in an incubator at 37 °C with an 
atmosphere of 5% CO2 balanced with air.
8.1.2  Biochemical and Molecular Biology Techniques
The major biochemical and molecular biology techniques used were;  (i) the HO
assay,  (ii)  the  nitrite  assay,  (iii)  the  myoglobin  assay,  (iv)  cell  viability  assays 
and; (v) Western blot assay for HO-1  and iNOS protein expression.
The haem oxygenase assay was first described by Tenhunen et al in  1970 and 
has been used extensively by our laborartory to measure intracellular and tissue 
HO  activity  (Tenhunen,  Marver,  &  Schmid  1969;  Motterlini  et  al.  1995b; 
Motterlini,  Hidalgo,  Sammut,  Shah,  Mohammed,  Srai,  &  Green  1996).  The 
assay  used  in  this  Thesis  reflects  the  relative  HO  activity  in  the  sample  as 
“pmol.  bilirubin/mg  prot.  /h”.  Although  the  value  obtained  is  not  directly 
comparable  to  the  amount  of  bilirubin  measured  in  the  culture  medium  after 
stimulation  of  the  HO  pathway,  the  fact  that  the  substrate  (hemin)  and  the 
cofactors  NADPH,  glucose-6-phospahte  and  glucose-6-phosphate-1- 
dehydrogenase  and  biliverdin  reductase  were  all  added  in  excess  and  the 
procedure  was  carried  out  under  controlled  conditions  must  be  considered 
when interpreting the data.
The Griess method for the measurement of nitrite is a tried and tested protocol 
for  assessing  the  nitrite  content  of  cell  culture  supernatant.  Sample  nitrite  is 
determined  by  comparison  of the  absorbance  of treated  cell  supernatant  to  a 
standard of known nitrite concentrations which is run each assay.  In this Thesis
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the  assay  is  used  to  infer  the  anti-inflammatory  effect  of  CO-RMs.  Nitrite, 
however,  is only an indication of iNOS activity and much debate still centres on 
the  true  product  of  iNOS  activity.  Measurement  of both  nitrate  and  nitrite  can 
give a better overall picture of the true effect, requiring the conversion of nitrate 
to nitrite, but in this instance measurement of nitrate proved unreliable.
The myoglobin assay is based  on the unique property of myoglobin to exist as 
various spectra depending on whether it is deoxygenated or carboxylated. This 
allows us to  measure CO  release from  CO-RMs.  Myoglobin has a high affinity 
for CO and as such,  quickly mops up any CO in the solution irreversibly (for the 
sake of this  assay)  converting  it to carboxymyoglobin with its associated  pinky 
hue.  As  mentioned  in  Chapter  2  a  mathematical  iteration  is  required  to 
determine the  CO  release of CO-RMs  assuming deoxymyoglobin  is 0  pM  and 
myoglobin  bubbled with  CO  is  100%  saturated.  The assay has proved to  be a 
reliable method for measuring CO with total CO release and kinetics of CO-RMs 
being mirrored  in tests  using a CO electrode.  There are alternative techniques 
described  in  the  literature  which  can  also  be  used  to  determine  CO 
concentration. These techniques allow for the quantification of CO levels  in cell 
culture supernatant and as such are not directly applicable to measuring the CO 
release from  CO-RMs.  One technique  in  particular developed  by Stonek et al, 
an optimised  nonradioactive spectrophotometrical detection of dissolved  CO at 
physiological concentrations with a detection limit of less than 50 pg CO/I tissue 
culture  supernatant,  is  a  relatively  simple  assay  to  detect  CO  release  from 
cultured cells (Stonek et al. 2004). The application of this as a direct method to 
test  CO  release  from  CO-RMs  is  not  practical  since  it  relies  on  the  same
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principal as the myoglobin assay (substituting haemoglobin for myoglobin) but is 
far more complicated and time consuming than the simple addition of CO-RMs 
directly to deoxy-Mb.  This technique,  however,  could be used to determine the 
extent of CO release by CO-RMs in cell culture treatments and whether the CO 
release detected in the myoglobin/CO electrode assays is comparable to that of 
the CO release in vitro.
Cell viability is often a contenscious issue especially when using only one of the 
numerous  methods  available.  Often what  is  measured  is  a factor which  infers 
the overall health of the cells rather than a definitive measurement of viability.  In 
this Thesis it was decided that the best means to overcome this problem was to 
use various methods to determine cell viability and compare the results of each 
to  give  an  overall  viability.  The Alamar blue  assay  measures  cell  metabolism. 
On its own it is a poor indicator of cell viability as metabolism can be affected by 
a  large  number of factors  including  confluence  of the  cells  and  the treatment 
itself. The assay,  however,  is quick,  simple and inexpensive. The measurement 
of  LDH  in  the  supernatant  of treated  cells was  also  measured.  This  gives  an 
indication  of the  state  of the  cell  membrane  integrity.  A  large  release  of  LDH 
indicates the cell membrane has been damaged since LDH is an integral part of 
the  cell  membrane,  which  infers  a  loss of viability.  LDH  content,  however,  can 
also  be  affected  by  confluence  and  the  treatment  apllied.  The  assay  is  quick 
and  simple,  and  leaves the cells to  be  used for subsequent assay as only the 
supernatant is required. The final indicator of cell health used in this Thesis was 
the  Trypan  blue  exclusion  assay.  Cells  that  have  had  their  cell  membrane 
breached  allow  the  uptake  of the  Trypan  blue  dye,  while  intact  cells  do  not.
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Hence,  the  percentage  of  stained  cells  to  unstained  cells  can  be  calculated 
using  a  microscope  and  the  viability  determined.  A  breached  cell  membrane 
indicates a loss of viability but does not exclude apoptotic cell death where the 
membrane  blebs  rather than  splits.  The assay  is  inexpensive,  simple  but time 
consuming and  not wholly consistent.  Each assay,  therefore,  has limitations in 
directly determining cell viability but the combination of all three can allow us to 
be more precise in the labelling of compounds as either toxic or non-toxic.
Western  blot  is  an  established  molecular  biology  technique  for  measuring 
relative protein expression in cells and tissues (Laemmli  1970); therefore,  every 
assay  was  run  with  both  negative  and  positive  controls  (untreated  cells  and 
recombinant  HO-1  protein  or  LPS  stimulated  cells  in  the  case  of  HO-1  and 
iNOS  respectively).  Since Western  blot analysis of HO-1  and iNOS  expression 
is only used in conjunction with  HO-activity and  nitrite concentration,  the actual 
amount  (pg;  pmoles  etc.)  of  HO-1 /iNOS  protein  are  not  necessary;  each 
experiment is presented by a representative blot which has been scanned  in to 
a microcomputer, cropped to the right size and printed.
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8.2  Hypothesis and Aims
The hypothesis behind the work carried out for this Thesis is:
CO-RMs,  through  the  action  of  CO,  can  mimick  the  action  of 
endogenously genereated CO in a murine model of inflammation.
The  data  presented  in  this Thesis  are  consistent with  the  hypotheis,  although 
the  mechanisms  behind  the  exact  workings  of  CO-RMs  have  not  been 
completely  explored.  However,  this  will  be  addressed  in  the  next  section 
(Paragraph 8.3, 8.4 and 8.5).
The Aims of this Thesis were stated at the close of the introduction and were;
Test  the  prototypic  water  soluble  CO-RM  (CORM-3)  to  determine  its 
toxicity in various cell lines, its effect on the HO system and its regulation 
of the inflammatory response inferred from TNF-a, nitrite and iNOS levels 
in macrophages.
In Chapter 3 we demonstrated that CORM-3 was capable of CO release in the 
myoglobin  assay  and  that  incubating  the  compound  in  biological  buffer 
overnight inactivated it preventing further CO release.
Due  to  the  overwhelming  evidence  for  a  role  for  CO  in  the  resolution  of 
inflammation  we  decided  that we would  investigate the effects  of CORM-3  on 
LPS induced nitrite production which is generally regarded as a way of inferring 
inflammation (SCHAUS 1956;  Ohta et al. 2003;  Sawle,  Foresti,  Mann,  Johnson, 
Green,  &  Motterlini  2005).  CORM-3  and  not  iCORM-3  potently  reduced  nitrite
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production  which  was  shown  to  be  independent  of  HO  activity  and  HO-1 
expression  despite  the  ability  of  CORM-3  to  increase  both  at  certain 
concentrations.  The increase in HO activity and HO-1  expression seemed to be 
reliant  on  a  change  in  the  redox  status  of  the  cell  as  NAC  was  able  to 
completely  inhibit  both,  whilst,  gluthathione  levels  were  also  shown  to  be 
reduced at CO-RM concentrations above 50 pM.  Toxicity was not an issue with 
CORM-3  found  not  to  effect  LDH,  Alamar  blue  and  Trypan  blue  with 
concentrations up to 500 pM.
CO is known to affect haem containing compounds and has been shown to act 
on guanyl cyclase in a similar fashion to NO. The exact mechanism for reducing 
nitrite  in  this  case  is  independent  of  the  redox  induction  of the  HO  pathway, 
unrelated to the compound  (ineffectiveness of iCORM-3) and is not as a result 
of increased  iNOS expression. This would suggest CORM-3 acts to reduce the 
activity of the iNOS enzyme.  Indeed,  CO has been suggested to bind iNOS and 
cause  a  conformation!  distortion  of  the  active  site  (White  &  Marietta  1992; 
McMillan,  Bredt,  Hirsch,  Snyder,  Clark,  & Masters  1992).  As well  as  nitrite the 
effect  of  CORM-3  on  TNF-a,  a  more  direct  indicator  of  inflammation  was 
investigated.  CORM-3  was  able  to  significantly  attenuate  LPS  induced  TNF-a 
production,  again  indicating  the  potent  anti-inflammatory  actions  of  this 
compound.
Investigate the ability of newly synthesised CO-RMs to release CO using 
the  myoglobin  assay  to  determine  new  CO-RMs  with  the  potential  to 
forward the study.
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Having  established  that  metal  carbonyl  compounds  can  be  manipulated  to 
serve a biological action,  in Chapter 3 we broadened the investigation into these 
intriguing  molecules.  New CO-RMs were  based  on  metals  commonly found  in 
biological  systems  such  as  iron  and  manganese.  The  early  ruthenium 
compounds,  although  extremely  easy  to  manipulate  from  a  chemical  point  of 
view  could  in  theory  cause  some  problems  with  biocompatibility  especially  if 
used  in clinical treatments for a  long period of time.  This  is not to say they are 
toxic  since  ruthenium  compounds  are  already  in  use  in  the  clinical  setting  of 
cancer therapy  (Alessio,  lengo,  Zorzet,  Bergamo,  Coluccia,  Boccarelli,  & Sava 
2000; Alessio,  Mestroni,  Bergamo,  & Sava 2004a; Alessio,  Mestroni,  Bergamo, 
&  Sava  2004b).  But  CO-RMs  based  on  metals  present  in  biology  are, 
perceptively,  more of an attraction.  Both  iron and  manganese are two common 
metals  present  in  enzymes  and  protein  structures  and  form  a  crucial  core  in 
their function and activity.  With the  help of Professor Brian Mann (University of 
Sheffield)  and  Ian  Fairlamb  (University  of  York)  further  CO-RMs  were 
developed and tested  in  Chapter 4 to allow us to select the  most promising to 
take forward.
Having  established  the  myoglobin  assay  as  a  reliable  method  for determining 
CO release we started to interpret a vast portfolio of CO-RMs for their ability to 
release CO (see appendix 11.1). The different chemistry of the CO-RMs studied 
dictated a different degree of CO release.  Many CO-RMs were found to release 
little  or  no  CO;  however,  there  were  a  number  of  compounds  that  looked 
promising:  CORM-307,  CORM-308,  CORM-311,  CORM-312  and  CORM-319, 
of which  all  contained  iron  as  a  metal  centre except CORM-312.  Interestingly, 
the  kinetics of CO release was quite varied demonstrating the potential of CO-
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RMs  to  be  refined  and  tailored  to  release  CO  dependent on  the  requirement. 
This  ‘tailoring’  is  best  exemplified  in  Chapter 7  by  the  CORM-F  series  where 
minor  modification  to  structure  drastically  alters  function,  whilst,  Chapter  6 
explores the characteristics of CORM-A1  an entirely novel non-metal containing 
CO-RM.  By  learning  from  each  CO-RM  we  can  forward  the  development  of 
future  new  and  improved  CO  carriers  for  the  therapeutic  delivery  of  CO  in 
humans.
Test compounds deemed to be worthy of further study from Chapter 4 to 
determine  their toxicity,  effect  on  the  HO  system  and  regulation  of the 
inflammatory response.
Among  the  CO-RMs  that  showed  a  promising  release  of  CO  reported  in 
Chapter 4 only CORM-311   and CORM-319 were found to be non-toxic and thus 
investigated  further.  Both  CO-RMs  liberated  CO  gradually  over  time  in  stark 
contrast  to  the  instantaneous  release  by  CORM-3.  The  effect  of  both  these 
compounds  was  investigated  on  HO  activity  and  HO-1  expression  as  well  as 
nitrite  levels  in  LPS  induced  macrophages  in  a  range  of  concentrations  that 
have been found to be biologically active from CORM-1. We found that CO-RM- 
311  and  CORM-319  were  not  toxic,  and  that  both  were  able  to  reduce  nitrite 
whilst having  no  effect on either HO  activity or HO-1  expression.  The effect of 
CORM-319 could be associated with its ability to release CO since iCORM-319 
was unable to elicit any response.  The  lack of a proper iCORM-311,  however, 
made  it  impossible  to  confirm  that  CO  was  involved  in  its  bioactivity.  Without 
further investigation  it is speculative to suggest the  kinetics of CO release play 
any role in the actions of CO-RMs in comparison to CORM-3.
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Determine the CO releasing profile and bioactive properties of CORM-A1, 
a newly identified CO generator that does not contain a transition metal.
The rationale for the development of a non-metal contaning CO-RM came as a 
surprise,  albeit a welcome one,  which allowed us to investigate and compare a 
completely novel class of CO-RM with the existing metal carbonyl ones. Without 
the presence of the transition metal centre such CO-RMs could be less reactive, 
have a greater solubility in water and have a high biocompatibility. The potential 
of  sodium  boranocarbonate  (CORM-A1)  to  release  CO  had  been  used 
chemically  to  synthesise  carbonyl  compound  but  never  biologically.  The 
compound  itself  releases  CO  in  the  presence  of  protons  (H+).  The  release  of 
CO was found to be dependent on concentration, temperature and pH.  In water, 
the compound is stable for many days,  however,  it can be inactivated by adding 
a single drop (10 pi) of 1   M HCL which stimulates a vigorous release of CO. The 
release of CO,  under standard conditions used to test all the previous CO-RMs, 
demonstrates  that  CORM-A1  is  a  gradual  CO  releaser  similar  to  CORM-319 
(half life  =  21  min  at  37  °C,  pH  =  7.4).  It  is  unable  to  attenuate  LPS  induced 
nitrite  generation  in  macrophages  and  was  found,  unlike  CORM-3,  not  to 
stimulate HO activity.  It had no effect on HO activity in either bovine aortic cells 
or  girardi  cells.  Its  apparent  lack  of  pharmacological  activity  is  in  apparent 
contrast  to  its  effects  in  the  isolated  aortic  rings,  Langendorff  and  isolated 
kidney  perfusion  system  where  CORM-A1  has  been  shown  to  induce 
vasodilation  and  offer  protection  against  ischeamia-reperfusion  respectively 
(Heart data  unpublished;  Kidney  data  in  press;  Aortic rings  data  in  (Motterlini, 
Sawle,  Hammad,  Bains,  Alberto,  Foresti,  & Green 2005)). The different actions 
of the various CO-RMs tested  could very well  depend on  how and where they
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release CO and the effect of the resultant post CO release compound.  It should 
be noted that CORM-A1  is also quite a relatively good reducing agent.
Demonstrate  how  structure  can  affect  CO  release,  toxicity  and  nitrite 
using CORM-F compounds.
Having  investigated  such  a  large  number of CO-RMs  Chapter 7  illustrates the 
process  of  developing  new  versions  of  CO  carriers.  A  number  of  variations 
based  on  a  core  structure  were  investigated  and  it  was  shown  that  small 
alterations  in  structure  could  lead  to  big  differences  in  function.  Important for 
these compounds was the type of halogen group and the presence of a methyl 
side  chain.  Both  determined  the  amount  of  CO  released  and  the  observed 
toxicity. This chapter elegantly demonstrates how many potential structures can 
be  put forward  on  a  set core  structure.  Having  identified the  important factors 
regarding  CO  release  and  toxicity  further  CO-RMs  based  on  this  information 
can  then  be  developed  to  improve  and  advance  the  original,  whilst  better 
mimicking the function of CO biologically.
The  data from  Chapters  3,  5  and  7  support the  overall  hypothesis.  The  exact 
mechanism  by which  CORM-3,  CORM-319  and  CORM-F3  achieve this  is  not 
yet fully understood  although,  it is likely through the actions of CO.  CORM-311  
also  was  able  to  mimick the  anti-inflammatory  action  of CO  but the  lack of  a 
inactive version prevented CO from being directly implicated in its action.  Of the 
other CO-RMs tested none were capable of eliciting a biological effect, including
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CORM-A1  which is interesting since it has been shown to be active in a number 
of other systems.
8.3  Reflections
CO  has  been  an  intrinsic  part  of  life  on  this  planet  since  long  before  human 
history began.  Recently suggested to have been involved in the synthesis of the 
first  amino  acids  there  is  now  consistent  publication  of studies  supporting  the 
beneficial  effects  elicited  by  CO.  Only twenty years  ago this would  have  been 
almost  unthinkable.  Long  regarded  as  a  poisonous  gas  the  once  considered 
‘waste’ product of HO activity is finding favour amongst the scientific community 
eager to elucidate  more about this  simple diatomic molecule.  CO derived from 
HO  activity  acts  as  a  signalling  molecule  with  anti-hypertensive,  anti­
proliferative  and  anti-apoptotic  properties  (Morita,  Perrella,  Lee,  & 
Kourembanas  1995;  Durante  &  Schafer  1998;  Johnson,  Kozma,  &  Colombari 
1999;  Brouard,  Otterbein,  Anrather,  Tobiasch,  Bach,  Choi,  &  Soares  2000; 
Morse & Sethi 2002).  Other physiological roles of CO described to date include 
prolonged  survival  of  transplanted  organs,  suppression  of  atherosclerotic 
lesions,  prevention  of  reperfusion-induced  ventricular  fibrillation  in  the 
myocardium,  and  protection  against  ischemic lung  injury (Otterbein,  Mantell,  & 
Choi  1999;  Luckraz,  Tsui,  Parameshwar,  Wallwork,  &  Large  2001;  Clark, 
Naughton,  Shurey,  Green,  Johnson,  Mann,  Foresti,  & Motterlini  2003a;  Nakao 
et al. 2003a).  Not to mention the ability of CO at low concentrations to modulate 
the  production  of  inflammatory  mediators  by  decreasing  pro-inflammatory 
cytokines  such  as  TNF-a  and  increasing  crucial  anti-inflammatory  molecules 
such as  IL-10 in various in vitro and in vivo experimental  models (Tamion et al.
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1999;  Sethi,  Otterbein,  &  Choi  2002a;  Wagener  et  al.  2003b;  Sawle,  Foresti, 
Mann, Johnson,  Green, & Motterlini 2005).
It was  only just  over  10  years  ago  not  long  after the  discovery  of  NO  as  the 
EDRF,  that the first scientific groups began to investigate and propose that CO 
may not just be a by-product of HO activity and that it may function instead in a 
fashion  similar to  NO  (Marks,  Brien,  Nakatsu,  &  McLaughlin  1991;  Dawson  & 
Snyder  1994;  Anfossi  et  al.  2001).  Since  those  first  publications,  the  study  of 
CO  has  intensified  and  as  with  all  things  it  has  been  shown  that  it  is 
concentration which determines  if it is toxic or a cure.  The development of NO- 
releasing compounds has, made dramatic improvements in the way in which we 
can  investigate  the  role  of  NO  in  biological  systems  and  has  opened  up  new 
stratergies  in  the  treatment  of  chronic  cardiovascular  disease  in  the  clinic 
(Napoli  &  Ignarro 2003).  Research  in to the CO field has been  hampered  by a 
lack of an equilivant group of compounds. The question was and still  is;  how to 
emulate  the  action  of  CO?  i)  CO  gas?  Too  non-specific  and  unfeasibly 
complicated to administer to humans,  not to mention potential  long-term health 
problems.  Most of the work to date though  has  been carried out using  CO gas 
as a substitute for endogenous CO, although, not perfect the use of CO gas has 
facilitated  the  elucidation  of  many  now  well  known  aspects  of  CO  function. 
Important  in  the  discussion  of  this  Thesis  is  the  work  by  Otterbein  et  al 
demonstrating  the  anti-inflammatory effects of CO  and that these effects were 
mediated  through  p38MAPK  (Otterbein  et  al.  2000b).  The  use  of  CO  gas  by 
White and Marietta also helped to demonstrate that CO can potently inhibit the 
conversion  of  l-arginine  to  citrulline  and  NO  by  nNOS  and  macrophage  NOS 
(White & Marietta  1992).  Not to mention observations made by Sethi et al that
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CO  gas  could  inhibit the  expression  of  LPS-induced TNF-a  production in  vitro 
(Sethi,  Otterbein,  &  Choi  2002b).  In fact  CO  gas  has  been  vitally important  in 
understanding the effects of CO in inflammation.  It is, therefore, intriguing to see 
whether the use of CO-RMs, which generate a more physiological  relevant CO 
release,  agree  or  dispute  the  current findings with  CO  gas.  CO  gas  has  also 
been  used  to  demonstrate  a  role  in  inhibition  of  platelet  aggregation,  sGC 
activation,  transplant  survival,  protection  against  ischaemia/repurfusion  injury 
and  other  important  physiological  processes  which  are  highlighted  in  the 
introduction  (paragraph  1.11.3).  ii)  Methylene  chloride  and  other  pro-drugs? 
Again  non-specific,  highly  carcinogenic  and  require  good  liver  function,  iii) 
Which  leaves  us  with  increasing  HO  activity to  generate  CO  as  a  by-product. 
There  is  potential  here  but  most ways  of increasing  HO  in  a  living  person  are 
impractical,  are  non-specific  for  only  HO  activity,  are  likely  only  to  affect  an 
acute  response  and  also  involves the generation  of various other compounds; 
biliverdin;  bilirubin;  and  Fe  with  subsequent  ferritin  synthesis.  As  such, 
attributing any observed effects in such a model specifically to CO is not easy. 
The discovery that transition metal  carbonyls used for the purification of metals 
could release CO in a  myoglobin assay determined  by the resultant convertion 
of myoglobin to MbCO offered  a potential novel solution to harnessing the very 
real  protective  power  of  CO  in  a  convenient,  safe  and  specific  manner 
(Motterlini,  Clark,  Foresti,  Sarathchandra,  Mann,  &  Green  2002b;  Clark, 
Naughton,  Shurey,  Green,  Johnson,  Mann,  Foresti,  & Motterlini 2003a).  These 
compounds  termed  CO-RMs  have  been  investigated  and  developed  by  our 
group and collaborators as an experimental tool for the elucidation of the role of 
CO in the body with the long term goal to develop therapeutic agents.  Early CO-
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RMs  allowed  us  to  determine  the  potential  of manipulating  the  compounds  to 
suit  biological  compatibility.  Preliminary  experiments  with  the  ruthenium  and 
manganese carbonyl  complexes (CORM-2  and  CORM-1  respectively),  soluble 
only  in  organic  solvents,  revealed  they  could  be  used  safely  at  low 
concentrations to promote blood vessel  relaxation and mitigate hypertension in 
vivo.  Since  those  initial  experiments  the  bioactivity  of  CORM-1  and  CORM-2 
has  been confirmed  by a number of other laboratories  in experimental  models 
that  have  been  used  to  implicate  CO  as  an  important  contributor to  cerebral 
vasodilatation,  suppression  of  SMC  proliferation,  angiogenesis,  inhibition  of 
apoptosis,  improved  renal  function,  anti-inflammatory  and  immunological 
responses  (Fiumana  et  al.  2003;  Lee,  Tsai,  &  Chau  2003;  Jozkowicz  et  al. 
2003; Guo et al. 2004;  Koneru & Leffler 2004; Chatterjee 2004a).
The  success of these early CO-RMs was  such that the  development of newer 
potentially  more  biologically  compatible  CO-RMs  was  a  necessity for  steering 
the  studies  towards  a  possible  pharmaceutical  development  based  on  CO 
delivery  to  mammals.  A  collaboration  between  Dr  Roberto  Motterlini  and 
Professor Brian  Mann  (University of Sheffield)  accelerated  the development of 
the  first  prototypic  water  soluble  transition  metal  carbonyl  (CORM-3).  As  a 
ruthenium  based  compound,  CORM-3,  demonstrated  the  potential  of  the 
carbonyl  complexes  to  release  CO  and  be  biologically  active.  By  adding  a 
biological ligand, in the form of an amino acid (glycine), the molecule was made 
water soluble. CORM-3, released CO instantaneously when added to buffer in a 
1:1  ratio  with  that  of  the  concentration  of  CORM-3  added.  Not  toxic  in 
macrophages at concentrations up to 500 pM as shown  by the combination of 
Alamar Blue,  Trypan  Blue and LDH  assays,  CORM-3 was the prototypic water
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soluble,  biologically compatible CO-RM.  Similarly ligand modification could also 
be  used  in  the future  to  manipulate  CO  release.  The  diversity  of compounds, 
therefore, that could be synthesised was almost endless.
With  the  discovery  of  CORM-A1  a  non-metal  containing  CO-RM  there  now 
exists a new generation of CO carriers that can be compared and evaluated for 
their potential  therapeutic activity.  Such  diversity  in  the  number of compounds 
that can release CO in a biological system offers great potential in attaining the 
goal of a compound that can be used in the clinical setting.
8.4  Future Directions
The overall  end goal  of CO-RM  research and development is the creation of a 
therapeutic  agent  capable  of  carrying  and  delivering  CO  in  the  right 
concentration to a specific target in the body whereupon it acts to counteract a 
pathophysiological  event.  There  are  many  short  terms  goals  to  be  achieved 
prior to this and many ways for furthering this study which include:
1)  The CO-releasing capabilities and bioactivities of many CO-RMs have to 
be investigated to allow the refinement and creation of new formulations 
that are more biological compatible.
2)  Investigations  should  be  carried  out  on  the  effect  of  CO-RMs  on 
additional  markers of inflammation. These should include interleukins IL- 
1   and  IL-6,  two  pro-inflammatory  cytokines  and  IL-10  an  anti­
inflammatory  cytokine.  The  effect  on  adhesion  molecules  and  platelet 
aggregation  should  also  be  investigated  since  these  factors  also 
contribute  to  the  inflammatory  response  and  have  been  shown  to  be
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affected  by  CO.  Simple  investigation  using  ELISA  is  possible  in  this 
instance.
3)  Test CO gas as a direct comparison with CO-RMs.  There are numerous 
studies which have already produced convincing data as to the effect of 
CO in inflammation (and many other models) but it would be of benefit to 
replicate  this  research  in  relation  to  this  project  in  order to  confirm  the 
effect in our models.
4)  Using the method developed by Stonek et al mentioned earlier to test the 
CO  levels  in  cell  culture  supernatant  after  administration  of  CO-RMs. 
This  would  help  us  to  determine  the  exact  level  of CO  release  in  vitro 
which  we  can  only  infer  from  the  data  collected  using  the  myoglobin 
assay. The more complex environment of cells in culture may accelerate 
or  even  hinder  the  release  of  CO  by  CO-RMs  which  is  of  crucial 
importance when reviewing the data.
5)  Investigations  should  be  carried  out  using  the  p38MAPK  inhibitor 
SB203580.  p38MAPK  has  been  implicated  in  the  effect  of  CO  on 
inflammation,  as  such  inhibition  of  this  pathway  would  allow  us  to 
determine  if CO-RMs  mediate their effect through the same pathway as 
CO gas and other methods of simulating CO.  This may help to elucidate 
the different effects on nitrite observed with CORM-3 and CORM-A1.
6)  Further research clarifying the exact mechanisms by which  CO released 
from  CO-RMs  acts  in  other  models  is  also  required.  The  chemical 
pathways involved such as NF-kB or cGMP and the identification of new 
targets for CO (mitochondria and NADPH oxidase) may help to establish 
key components in the activity of CO-RMs.
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Current  investigations  into  CO-RMs  have  studied  it  in  particular  models  and 
systems  (i.e.  murine  macrophage  model  of inflammation).  These  early  studies 
allow us to define the biological  suitability,  toxicity,  concentration  range of use, 
mechanism  of action  and the overall  therapeutic potential.  Further studies  into 
wider  ranging  aspects  of CO  function  are  required.  The  role  of CO  has  been 
investigated  in  many  models  and  its  effect on  various  biological functions  has 
been  reported.  CO-RMs  should  be  investigated  in  as  many  such  systems  as 
possible  to  corroborate  or  dispute  the  existing  findings  of  CO  gas  and  HO 
upregulation based experiments.  Having established in vitro and ex vivo actions 
of CO,  major research should be conducted  into the in vivo effects of CO-RMs 
that  have  been  proven  to function well,  elicit no  obvious toxicity  in  any  model 
they have been tested in and provide a desired therapeutic action.
Of  particular  interest  is  the  identification  of  sodium  boranocarbonate 
(Na[H3BC02]  (CORM-A1),  a  non-metal  containing  agent.  Its  apparent  lack  of 
biological  activity despite  a  CO  release  similar to that of both  CORM-319  and 
CORM-311, two active CO-RMs,  raises a number of important issues;  (i) is CO 
responsible for the effects observed or is it due to the presence of a metal? and 
(ii)  where  precisely  are  the  CO-RMs  acting?  These  questions  must  be 
addressed considering the success of CORM-A1  in other models.
In regards to this study an end goal should be to attenuate inflammation in an in 
vivo  model  using  CO-RMs,  thus,  proving  its  function  in  an  actual  biological 
system.
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8.5  Overall Conclusion
CO-RMs  offer  a  great  opportunity  for  the  development  of  a  novel  class  of 
therapeutic agents based around the action of CO, which has been considered 
a  poison for a  long time.  CORM-3,  a  prototypic water soluble  CO-RM,  already 
has a number of desirable characteristics which can  be improved upon for the 
refinement  and  development  of  future  transition  metal  carbonyls.  Here,  we 
report that  CORM-3  is  capable  of CO  release with  a  half-life  of less  than five 
min,  is  non-toxic,  and  suppresses  LPS-induced  nitrite  generation  model  of 
inflammation  in  macrophages.  The  mechanism  of  action  is  very  likely  by  the 
direct  action  of  CO  released  from  CORM-3  as  was  highlighted  by  the 
investigation into HO activity,  HO-1  expression, iNOS expression and the use of 
SnPPIX.  Further investigation may reveal greater promise for this first in line of 
the  new  CO-RMs,  but,  at  a  minimum  highlights  the  extreme  potential  of  the 
transition metal carbonyls as CO-RMs.
The  study  into  the  CO  release  of the  new  CO-RMs  emphasizes  the  adaptive 
potential of the metal carbonyl complexes.  Simple  ligand addition and variation 
of metal  centre  results  in an exciting  portfolio of CO-RMs capable of a slow or 
fast  kinetic  of  CO  release,  different  solubilities  in  biological  constituents  and 
diverse biological activities.
It is this diversity and ability to refine CO-RMs that makes the development of a 
biologically  compatible  compound  capable  of  therapeutic  application  an 
achievable goal. The development of CO-RMs has been requird for some time, 
considering the  evolutionary  importance  of CO,  and  has  opened  up  a window 
into understanding the biological function and possible therapeutic interventions 
of CO.
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11  Appendices
11.1  Appendix 1: Summary of CO-RMs Tested
This  section  comprises  a  list  of  all  the  CO-RMs  tested  during  my  period  of 
research.  Structure,  solubility and  CO  release  are specified  in  all  cases,  while 
toxicity (determined by the Alamar blue assay) and vasorelaxtion (determined in 
an  aortic rings  model)  are  listed for selected  CO-RMs.  Although the screening 
of CO-RMs was  routine  it was  necessary to  identify  suitable  compounds with 
which to investigate biological activities. This is highlighted by the fact that from 
this large number of CO-RMs only a handful were chosen to test further.
- Page 322 --
 
P
a
g
e
 
3
2
3
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(M M)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
3F
C0  H
° C/V
_Ru
oc  N o A 0
Cl  0
Ru(CO)3-CI-glycinato
294 Ru Water 20 Instant No
CORM-
3J
Ru(CO)3-CI-glycinato 294 Ru Water 25 • Instant No
CORM-
3K
Ru(CO)3-CI-glycinato 294 Ru Water Old
= 33 
New 
=22
33
22
Instant No
CORM-
3L
Ru(CO)3-CI-glycinato 294 Ru Water 11 “ Instant No
CORM-
3M
Ru(CO)3-CI-glycinato 294 Ru Water 24 Instant No
CORM-3
3/12/03
Ru(CO)3-CI-glycinato 294 Ru Water 30 30 Instant No
CORM-3
7/01/04
Ru(CO)3-CI-glycinato 294 Ru Water 19 “ Instant No
CORM-
3P
Ru(CO)3-CI-glycinato 294 Ru Water 19 " Instant No
A
P
P
E
N
D
I
X
 
1-
 
P
a
g
e
 
3
2
4
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(MM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
3T
Ru(CO)3-CI-glycinato 294 Ru Water 24 “ Instant
CORM-
3N
Ru(CO)3-CI-glycinato 294 Ru Water 46 53 Instant
CORM-
3U
Ru(CO)3-CI-glycinato 294 Ru Water 37 50 Instant
CORM-
X1
Bis(2,4-dinitrophenyl) oxalate 422.2 DMSO N/A N/A N/A ***
CORM-
A1 r   Na+
H\   / °
H-------B-------Cv
h '  % o
Na2[H3BCC>2]
103.8 None Water 8 34 Medium / 
Fast
No +  +
CORM-
A4
None Water 0 0 N/A
CORM-
A5
None Ethanol 0 0 N/A
CORM-
A6
None Ethanol 0 0 N/A
CORM-
A7
108.12 None Water 0 0 N/A
CORM-
A8
591 None Water-
 
P
a
g
e
 
3
2
5
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(pM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
A9
95.8 None Water 5 18
(60
mins)
Slow No
CORM-
Z1
[CpFe(C0)2(C8H7N20 2)] 338.1 Fe Ethanol 0 0 N/A +
CORM-
Z2
[CpFe(CO)2(C9H8N20 2)]+  [I]' 466 Fe Water >1 11 Slow/
Medium
No -
CORM-
Z3
[CpFe(C0)2(C4H2N02)] 273 Fe Water 0 0 N/A No +  +
CORM-
Z4
[CpFe(C0)2(C4H4N02)] 275 Fe Water 0 0 N/A +
CORM-
Z5
[CpFe(CO)2(C6H7N02S)] 348.2 Fe Water >1 0 N/A -
CORM-
303 +  BPh4-
0
/ | \  
oc  I  nh3
CO
[CpFe(CO)2(NH3)f BPh4‘
513 Fe Ethanol 0 0 N/A No
A
P
P
E
N
D
I
X
 
1-
 
P
a
g
e
 
3
2
6
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(pM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
304
OC  I  N  7 
CO  H
[CpFe(CO)2(para-to
ch3
lyl-sulfonamide)
347 Fe Ethanol >0.5 1 Slow No
CORM-
307 I
/   \   CO
< o K „
CO
Fe(CO)3l(C3H5)
308 Fe Ethanol 47 48 Instant *** +  +
CORM-
308 Br
/   \   I  .CO
4 / |  \o
CO
Fe(CO)3Br(C3H5)
261 Fe Ethanol 47 48 Instant *** +  +
A
P
P
E
N
D
I
X
 
1-
 
P
a
g
e
 
3
2
7
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(MM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
309 E
°°///,
IV
O C ^
c
MnBr
3r
> C0
^CO
:o
(CO)5
275 Mn Ethanol 2 10 Slow No +
CORM-
310
o c//„
OC^
(
Mnl(
[
> co
" > c o
:o
CO)5
322 Mn Ethanol 0 8 Slow No
CORM-
311
[Et3NH][HFe3(CO)11] 496 Fe Ethanol 10 28 Medium No +
CORM-
312 r   -  [PPN]+ 
CO
o c '/,,  I  X N \\\CI
OC^  |  ^Cl 
CO
(PPN)[Mn(CO)4Cl2]
776.5 Mn Ethanol 12 32 Slightly 
faster 
than 311
*** +
A
P
P
E
N
D
I
X
 
1Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(pM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
313 C
OC.
M
oc
\
MnC
;o
X
l(CC
,ci
JU
>)3(bpy)
330.6 Mn Ethanol >1 0 N/A ** +  +
CORM-
314 Cl
4   > k i
CO
Fe(n-C3H5)(CO)3CI
260.9 Fe Ethanol 34 45 Medium / 
Fast
** +  +
CORM-
315
c
y
c
CpFe(
i >
\
:o
CO)2l
303.9 Fe Ethanol 0 11 Slow / 
Medium
No-
 
P
a
g
e
 
3
2
9
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(PM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
316
y
c
CpFe(
> \
Br
CO)2Br
256.9 Fe Ethanol 0 8 Slow / 
Medium
No
CORM-
317 t
y
(
CpFe(
$ \
Cl
:o
CO)2CI
212.4 Fe Ethanol 0 6 Slow No
CORM-
318 C
OC//„
OCw
c
Mn(C
:o
> CI
\ o
:o
0)5CI
230.4 Mn Ethanol >1 2 V Slow No +-
 
P
a
g
e
 
3
3
0
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(M M)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
319 r   “i  +  [BF4]" CO
^>{<00 
/   CO
[Fe(n-C3H5)(CO)4][BF4]
352 Fe Water 4 19 Slow / 
Medium
No +
CORM-
320
C
O C ^
OC
\
c
MnCI(C
/ Cl
n.
N  \
v V
ch 3
;h 3
0)3((CH3)2-bpy)
358.6 Mn Ethanol 0 0 N/A ***
A
P
P
E
N
D
I
X
 
1Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(|iM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
321 OC
o c \
IV
O C ^
J
MnC
/ Cl
n.
N  \
\
C(CH3)3
C(CH3)3
l(CO)3(diBu-bpy)
442.6 Mn Ethanol 0 0 N/A **★
CORM-
322
O C ^
o c x
MnCI(
OC
'
>
CO
/ “   o
rk  / W /
N  \ 
)3Br(liquinoline)
420 Mn Ethanol 0 0 N/A *-
 
P
a
g
e
 
3
3
2
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(MM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
323
H3°   /
C   I  CO 
o -----CO
Fe-(CO)3-allyl-lactone
252 Fe Ethanol 2 33 Slow/
Medium
**
CORM-
324 P(OME)3
o c 'h,.
Mn
O C ^   ^ C O  
P(OME)3
trans-Mn(CO)3Br[POMe3]2
409 Mn Ethanol 0 0 N/A Slightly 
-  not 
cone 
depen
CORM-
325
[Ph3PMn(CO)4]2 864 Mn Ethanol 0 0 N/A No
CORM-
326 CO
oc////  ^ oso2cf3  
IV  ri' 
o c ^   ^ c o
CO
[Mn(C0)5(0S02CF3)]
344 Mn Ethanol 
(Sparingly 
in Water)
7 11
(60
mins)
Almost
Instant
No
A
P
P
E
N
D
I
X
 
1-
 
P
a
g
e
 
3
3
3
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(MM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
327
CO  f > T * |PF,r
OC//,,
Mri
ocw   ^ c o
CO
[Mn(NC5H5)(CO)5 ]+  [PF6 ]-
419 Mn Ethanol >1 >1 Almost
Instant
No
CORM-
328 OC
° c " „ . I  , ^ Br
O c< Mn^ N / ^
rN r
[MnBr(CO)3(bi-pyridine)]
375 Mn Ethanol >1 1.5 Almost
Instant
**
A
P
P
E
N
D
I
X
 
1-
 
P
a
g
e
 
3
3
4
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(M M)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
329
C
0C//„
M
o c ^
c
[Mn<
' +  N "
)0
n \NCCH3
n> c o
;o
CH3CN)(C0)5 ]+  [PFe]
381 Mn Ethanol 1.5 2.2 Almost
Instant
No
CORM-
330 NHR
CO
Mn  ^ 0   R_  > ___ / \   K - - P  ------ C
OC^  ^NH2R  X  \  
CO
[Mn(CO)4(CONHR)(NH2R)]
312 Mn Ethanol 1.7 2.8 Almost
Instant
No
A
P
P
E
N
D
I
X
 
1Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release
(MM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
331 OC
OC/,,,  I
M
o c ^
Mn(CC
n>
\
))3c
JPI  I
r *
l(‘Pr-DAB)
314.65 Mn Ethanol 0 0 N/A
CORM-
332 OC
OC/,,,.
IV
O C ^
J
%
MnC
n>
vi^
il(C
* CI
if  °  
0
0)3(dpq)
384.61 Mn Ethanol 0 0 N/A-
 
P
a
g
e
 
3
3
6
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(MM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
333
oc  "1  +  bf4
°C//„. 1  , ^ co  
M n ,^
O C *   N  \ 
fMn(CO)4(bi-pyridine)][BF4 ]
409.97 Mn Water 0 >1 N/A
CORM-
334
C
O C ^
__-IV
O C ^
(
[Cl1
[  Choline  ]
:o  1   J
/ Cl
n
N a
:o
ioline][Mn(CO)4CI2 ]
341 Mn Water 31 40 Fast No
A
P
P
E
N
D
I
X
 
1-
 
P
a
g
e
 
3
3
7
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
<UM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
335
CO
° ° K  1  
o c^T
-©   BF4e
- >
s .
w -
347 Fe Water 10 19 Slow *
CORM-
336
Q ,CO
8/ ^F e -— CO
CO
[Fe(CO)3(C7H9 )]BF4
320 Fe Water 0 1 Slow-
 
P
a
g
e
 
3
3
8
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(MM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
337
0
o c ^ c o C O
©
r  1 6 
F \ | / F  
F
438 Fe Water 12 22 Slow No
CORM-
338 r   -i ©  r
9°  1  M
0C\ J   1
OC  ^1  Me 
CO
-  ©
e
/   "-oh
Me
525 Mn Water 4 14 Slow No-
 
P
a
g
e
 
3
3
9
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(pM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
339
—  _   e
i   bf4
CO
OC in ,,.
oc^ |  -y
o T
h2 n^   ^ 0
390 Fe Water 7 12 Slow No
CORM-
340 r  n®  r  “Ie
Et  CO
OC^  I  /B r
Et  Et  OC  |  CO 
Et  CO
446 Mo Water 8 37 Medium **
CORM-
341 c7
i ^  © 
Fe  BF4 /   i \
OC  |  CO 
CO
306 Fe Water 0 0 N/A-
 
P
a
g
e
 
3
4
0
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(MM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
43 I'M
° \ i   A
v 'f V   I   N   N H *
o / l   V ' - ' V   H
C l  o 
Ru(CO)3CI-arginine
392 Ru Water 26 27 Almost
Instant
No
CORM-
46 OC.  ? °  H  /(C H 3)4NH2
" 4 < " NY
00  Cl
Ru(CO)3CI-lysine
364 Ru Water 42 42 Instant No
CORM-
70 +  ci-
©
Fe
OC  I  CO 
CO
[Fe(nC5H5)(CO)3 ]+  cr
240.5 Fe DMSO 2 17 Medium / 
Fast
No +  +
A
P
P
E
N
D
I
X
 
1-
 
P
a
g
e
 
3
4
1
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(M M)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
74 ro
OC,  |  H  ,CH(OH)CH3
W
Ru.
OC  I
Cl  x o
Ru(CO)3CI-threonine
337 Ru Water 36 36 Instant No
CORM-
F1 ^ ^ ^ F e ( C O ) 3
\ 0 ^ N >
236 Fe Water 0 0 N/A
CORM-
F2 H
^ 4 ^ / Fe(CO)3
Me  0  °  
C9H6Fe05
250 Fe DMSO 0 0 N/A
A
P
P
E
N
D
I
X
 
1-
 
P
a
g
e
 
3
4
2
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(MM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
F3 Br
C9H5BrFeC
=e(CO)3
k>
5
329 Fe DMSO 2 15 Medium / 
Fast
200 pM +  +
CORM-
F4 —
—  e  bf4
Mo 7 12 Slow
(OC)3Mo®
O
\v
H3oc
^ M e
CORM-
F5-
 
P
a
g
e
 
3
4
3
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(MM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
F6 r   e bf^
(OC)2Fe©
O
H3OC
Fe 0.5 1 Slow
CORM-
F7 Cl
(OC)3F e ^ 4 ^
C8H3CIFe05
270.4 Fe DMSO 0 0.5 Slow 200 |jM-
 
P
a
g
e
 
3
4
4
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(MM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
F8 Cl
(O C)3F e ^ x L
C9H5CIFe05
284.43 Fe DMSO 1 4.5 Slow 200 pM
CORM-
F9
P   ~ I °  BF/i
(OC)2Fe©
0
/ ^ ^ Me
h3o c
403 Fe DMSO 0.7 4 Slow 200 liM
A
P
P
E
N
D
I
X
 
1-
 
P
a
g
e
 
3
4
5
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(pM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
F10 r   —i e BFi
(OC)2Mo®
0
H3OC
551 Mo DMSO 8 50 Fast 200 pM
CORM-
F11 Me
(OC)3Fe
V^S
Me  0   ^ 0
262 Fe DMSO 0 0 N/A 200 pM
CORM-
1CO
[Na] [t-RuCI4CO(DMSO)] 372.011 Ru Water 0 0 N/A
CORM-
2CO
cis, cis, trans-RuCI2(DMSO)2(DMSO)CO 434.37 Ru Water >1 >1 N/A
A
P
P
E
N
D
I
X
 
1-
 
P
a
g
e
 
3
4
6
 
-
Code Formula / Structure Molecular
Weight
(Theor)
Transition
Metal
Solubility CO Release 
(pM)
Kinetics 
of  CO 
Release1
Toxic
effect
on
cells3
Vessel
Relaxation2
5
min
90
min
CORM-
3CO
[cis, cis, cis RuCI2(CO)2(DMSO)(DMSO)] 384.25 Ru Water 8 9 Instant
CORM-
4CO
[cis, cis, trans-RuCI^CO^DMSO)^ 384.25 Ru Water 17.5 19 Instant
CORM-
5CO
[cis, pac-RuCI2(CO)3(DMSO)] 334.13 Ru Water 20 31 Medium
CORM-
Z1
338.1 Ethanol 0 0 Slow
CORM-
Z2
466 Water 0 11 Slow
CORM-
Z3
273 Water 0 0 Slow
CORM-
Z4
275 Water 0 0 Slow
CORM-
Z5
348.2 Water 0 0 Slow
CORM-
Picolinic
[Ru(Picolinic)(CO)2Cl2]H 351.17 Ru Water 3 3 Slow
A
P
P
E
N
D
I
X
 
1-
 
P
a
g
e
 
3
4
7
 
-
Key:
(1) The myoglobin (Mb) assay, which quantifies the production of MbCO from deoxy-Mb, was used to measure the rate of CO released over 
time in order to classify the compounds as fast (F) or slow (S) releasers of CO.  Forty micromolar (40 pM) of each compound were added to a 
solution containing 40 pM Mb.
(2) The experiments using the isolated aortic rings were conducted to assess the extent of vasorelaxation. One hundred micromolar (100 pM) of 
each compound were added to a pre-contracted ring and vasorelaxation was assessed as a percentage of the initial contraction, which was 
expressed as good (+) or very good (++). The sign -  indicates that no relaxation was detected.
(3) Cytotoxicity was measured in RAW264.7 macrophages incubated for 24 h with 10, 50 or 100 pM of each compound. The loss in cell viability 
was measured as a percentage of control. * indicates toxicity detected at 100 pM; ** indicates toxicity detected at 50 pM; *** indicates toxicity 
detected at 10 pM; V indicates that cells were viable and no toxicity was detected up to 100 pM.M ____________     APPENDIX 2
11.2  Appendix  2:  The  Effect  of  CORM-2  and  CORM-3  on  Human  Blood 
Aggregation
11.2.1 Introduction
It has been shown  in a number of studies that CO has an important role to play 
in the circulatory system. The effects of CO on blood pressure may be regulated 
directly  through  the  promotion  of  vasodilation  or  indirectly  via  acting  on  the 
nucleus tractus solitaius which alters glutamatergic transmission and  ultimately 
lowers  blood  pressure  (Maines  1997; Johnson,  Kozma,  &  Colombari 
1999;Morse  &  Sethi  2002).  The  ablumenal  release  of CO  by endothelial  cells 
may  play  an  important  fundamental  role  in  regulating  blood  flow  by  inhibiting 
smooth  muscle  tone  and  SMC  proliferation  (Morita,  Perrella,  Lee,  & 
Kourembanas  1995).  It  has  also  been  found  that  CO  released  into the vessel 
lumen may modulate blood fluidity by preventing the aggregation and adhesion 
of  platelets  (Morita,  Perrella,  Lee,  &  Kourembanas  1995).  With  the  long  term 
goal  of  CO-RM  reasearch  and  development  being  the  creation  of  a 
pharmacologically  viable  agent  this  last  action  of  CO  posed  an  interesting 
question as to the effect CO-RMs may have on blood. Would CO-RMs have the 
potential to prevent platelet aggregation in human blood?
11.2.2 Materials and Methods
Whole  blood  (50  ml)  was  aquired  from  healthy  adult  human  volunteers  and 
added to a tube containing EDTA to prevent coagulation.  Blood was then either 
used  to  prepare  platelet  rich  plasma  (PRP)  or  used  directly  as  whole  blood. 
PRP was prepared by centrifuging whole blood for 10 min at 100 x g after which 
the  yellow top  layer  (PRP)  was  removed  being  careful  not  to  disturb  the  red 
blood  cell  layer  underneath.  The  number  of  platelets  in  the  PRP  was  then
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counted  using  a  haemocytometer  and  the  dilution  factor  required  to  give  an 
overall  platelet concentration  of  108 platelets per  ml  determined.  To adjust the 
platelet levels the PRP was spun for 5 min at 1000 x g to obtain a platelet pellet. 
This pellet was then resuspended using enough saline (0.9 % w/v) to attain 108  
platelets per ml.
Blood  aggregation  was  determined  using  a  dual  channel  Chrono-log  Whole 
Blood Aggregometer (USA) as follows.  Either 1   ml PRP or 500 pi whole blood + 
500 pi saline was added to a cuvette containg an iron bar stirrer. This was then 
placed  into the device where  it was warmed  and stirred for 10 min.  The probe 
was  then  added,  which  measures  aggregation  by the  impedence  to  electrical 
current  passed  between  two  metal  wires.  Having  allowed  a  brief  period  for 
equilibration, the sample was set to baseline by holding the baseline button and 
setting the chart recorder to zero,  the sample was now ready to test.  Initially the 
extent to which the stock whole blood or PRP aggregates was tested by adding 
10  pM  of  adenosine  diphosphate  (from  a  10  mM  stock)  to  the  sample  and 
leaving  it  for  5  minutes.  This  gives  us  the  maximal  aggregation  that  can  be 
achieved  by  the  current  PRP  or  whole  blood  stock.  The  process  was  then 
repeated  adding  CO-RMs  prior  to  adensosine  diphosphate  treatment  to 
determine if any the effect of CO-RMs on aggregation.
11.2.3  Results
The following  section  briefly  presents  all the experiments carried out using the 
whole  blood  aggregometer.  Aggregation  is  determined  as  the  difference  in 
ohmes  between  blood  or  PRP  treated  with  adenosine  diphosphate  alone  and 
blood or PRP pretreated with CO-RMs.
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Platelet Studies - Using the Whole Blood Aggregometer (WBA)
Date Sample
! ype
Compound Cone
(pM)
Treatment Max Ohms aggreagation
~%
|Chart Recorder Data  j
07/09/2001 WB AD 10 Blood treated solely with AD I  35 n/a
07/09/2001 WB CORM-2 50 1  min  preinc with CORM then 10pM AD added 29 82.9
07/09/2001 WB CORM-2 20 1  min  preinc with CORM then  10pM AD added 35 100
10/09/2001 WB AD 10 Blood treated solely with AD 20 n/a
10/09/2001 WB AD 10 Blood treated solely with AD 26 n/a
10/09/2001 WB AD 10 Blood treated solely with AD 31 n/a
10/09/2001 WB AD 10 Blood treated solely with AD 27 n/a
10/09/2001 WB CORM-3 300 1  min  preinc with CORM-3and then  10pM AD added 30 115.4
10/09/2001 WB CORM-3 200 1  min  preinc with CORM-3and then  10pM AD added 19 73.1
10/09/2001 WB CORM-3 100 1  min  preinc with CORM-3and then  10pM AD added 40 153.8
10/09/2001 WB CORM-3 300 1  min  preinc with CORM-3and then  10uM AD added 20 76.9
I
11/09/2001 WB CORM-3 300 10 min  preinc with CORM-3and then  10pM AD added 16 47.1
11/09/2001 WB CORM-3 200 10 min  preinc with CORM-3and then  10pM AD added 17 50
11/09/2001 WB CORM-3 100 10 min  preinc with CORM-3and then 10pM AD added 20 58.8
11/09/2001 WB CORM-3 50 10 min  preinc with CORM-3and then 10pM AD added 17 50
11/09/2001 WB CORM-3 50 10 min  preinc with CORM-3and then 10pM AD added 14 41.2
11/09/2001 Blood treated solely with AD n/a
11/09/2001 WB AD 10 Blood treated solely with AD 34 n/a
11/09/2001 WB AD 10 Blood treated solely with AD 36 n/a
11/09/2001 WB AD 10 Blood treated solely with AD 36 n/a
29/10/2001  | l_ W B   |I  AD  I~ T T | Blood treated solely with AD  J 35  1 n/a  I-
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Date Sample
Type
Compound Cone
(pM)
T  reatment Max Ohms aggreagation
~%
02/11/2001 WB AD 10 Blood treated solely with AD 25 n/a
02/11/2001 WB CORM-3 200 10 min  preinc with CORM-3and then  10pM AD added 13 65
02/11/2001 WB CORM-3 50 10 min  preinc with CORM-3and then  10pM AD added 21 105
02/11/2001 WB AD 10 Blood treated  solely with AD 16 n/a
02/11/2001 WB AD 10 Blood treated  solely with AD 20 n/a
02/11/2001 WB AD 10 Blood treated solely with AD 25 n/a
02/11/2001 WB CORM-3 100 10 min  preinc with CORM-3and then 10pM AD added 11 48.7
02/11/2001 WB AD 10 Blood treated  solely with AD 27 n/a
02/11/2001 WB CORM-3 25 10  min  preinc with CORM-3and then  10pM AD added error
02/11/2001 WB AD 10 Blood treated  solely with AD 16 n/a
02/11/2001 WB AD ;   10 Blood treated solely with AD 30 n/a
02/11/2001 WB CORM-3 25 10 min  preinc with CORM-3and then 10pM AD added 20 61.5
02/11/2001 PRP CORM-3 25 10 min  preinc with CORM-3and then 10pM AD added 36 85.7
02/11/2001 WB AD 10 Blood treated solely with AD 35 n/a
02/11/2001 WB AD 10 Blood treated solely with AD 29 n/a
02/11/2001 WB CORM-3 75 10 min  preinc with CORM-3and then 10pM AD added 21 72.4
02/11/2001 PRP AD 10 Blood treated solely with AD 42 n/a
02/11/2001 PRP CORM-3 75 1  min  preinc with CORM-3and then  10pM AD added 37 88.1
02/11/2001 WB CORM-3 25 3  min  preinc with CORM-3and then  10pM AD added 38 131
08/11/2001 WB AD 10 Blood treated solely with AD 25 n/a
08/11/2001 WB CORM-3 50 10 min  preinc with CORM-3and then  10pM AD added 14 65.1
08/11/2001 WB SN 50 10 min preinc with SN  and then  10pM AD added 18 83.7
08/11/2001 WB AD 10 Blood treated solely with AD 15 n/a-
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Date Sample
Type
Compound Cone
(M M)
Treatment Max Ohms aggreagation
~%
08/11/2001 WB CORM-3 100 10  min  preinc with CORM-3and then 10pM AD added 15 61.7
08/11/2001 WB AD 10 Blood treated solely with AD 20 n/a
08/11/2001 WB SN 100 10 min  preinc with SN  and then  10pM AD added 14 57.6
08/11/2001 WB AD 10 Blood treated  solely with AD 28 n/a
08/11/2001 WB AD 10 Blood treated solely with AD 21 n/a
08/11/2001 WB CORM-3 50 10  min  preinc with CORM-3and then 10pM AD added 23 109.5
08/11/2001 WB SN 50 10 min preinc with SN  and then  10pM AD added 13 61.9
08/11/2001 WB SN 10 10 min  preinc with SN  and then  10pM AD added 15 71.4
08/11/2001 WB AD 10 Blood treated solely with AD 21 n/a
08/11/2001 WB iCORM-3 50 10 min  preinc with iCORM-3 and then 10pM AD added 24 77.4
08/11/2001 WB AD 10 Blood treated solely with AD 32 n/a
08/11/2001 WB CORM-2 50 10 min  preinc with  CORM-2 and then  10pM AD added 18 58.1
08/11/2001 WB CORM-3 50 10 min  preinc with CORM-3and then 10pM AD added 20 64.5
08/11/2001 WB AD 10 Blood treated solely with AD 30 n/a
Computer Di
14/11/2001 WB AD 10 Blood treated solely with AD 15 n/a
14/11/2001 WB iCORM-3 10 10 min  preinc with iCORM-3 and then  10pM AD added 15 100
14/11/2001 WB iCORM-3 50 10  min  preinc with iCORM-3 and then 10pM AD added 18 120
14/11/2001 WB iCORM-3 100 10 min  preinc with iCORM-3 and then 10pM AD added 18 120
14/11/2001 WB iCORM-3 100 10  min  preinc with  iCORM-3 and then 10pM AD added 16 106.7
14/11/2001 WB iCORM-3 150 10 min  preinc with iCORM-3 and then 10pM AD added 5 33.3
14/11/2001 WB AD 10 Blood treated solely with AD 14 n/a
14/11/2001 WB CORM-3 10 10 min preinc with CORM-3and then 10pM AD added 18 128.6
14/11/2001 WB CORM-3 50 10 min  preinc with CORM-3and then  10pM AD added 20 142.9
14/11/2001 WB CORM-3 100 10 min  preinc with CORM-3and then  10pM AD added 20 142.9
14/11/2001 WB CORM-3 100 10 min  preinc with CORM-3and then 10pM AD added 18 128.6-
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27/11/2001 WB AD 10 Blood treated  solely with AD 10 n/a
27/11/2001 WB CORM-3 100 10  min  preinc with CORM-3and then  10pM AD added 10 100
27/11/2001 WB AD 10 Blood treated solely with AD 5 n/a
27/11/2001 WB AD 10 Blood treated solely with AD 10 n/a
27/11/2001 WB AD 10 Blood treated solely with AD 10 n/a
27/11/2001 WB CORM-3 100 10 min  preinc with CORM-3and then 10pM AD added 10 100
27/11/2001 WB AD 10 Blood treated solely with AD 10 n/a
04/12/2001 PRP AD 10 Blood treated solely with AD 15 n/a
04/12/2001 PRP iCORM-3 100 10 min  preinc with  iCORM-3 and then 10pM AD added 15 100
04/12/2001 PRP SN 100 10 min  preinc with SN  and then  10pM AD added 0 0
04/12/2001 PRP AD 10 Blood treated solely with AD 16 n/a
04/12/2001 PRP CORM-3 100 10  min  preinc with CORM-3and then  10pM AD added 5 31.3
04/12/2001 PRP CORM-3 50 10  min preinc with CORM-3and then 10pM AD added 18 112.5
04/12/2001 PRP CORM-3 50 10 min  preinc with CORM-3and then  10pM AD added 19 172.7
04/12/2001 PRP CORM-3 100 10 min  preinc with CORM-3and then 10pM AD added 19 172.7
04/12/2001 PRP AD 10 Blood treated solely with AD 11 n/a
04/12/2001 PRP SN 50 10 min  preinc with SN and then  10pM AD added 0 0
04/12/2001 PRP iCORM-3 100 10  min  preinc with iCORM-3 and then 10pM AD added 5 31.3
13/12/2001 WB AD 10 Blood treated solely with AD 20 n/a
13/12/2001 WB TJ35 100 10 min  preinc with TJ35 and then  10pM AD added 17 85
13/12/2001 WB TJ35 200 10  min  preinc with TJ35 and then  10pM AD added 17 85-
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13/12/2001 WB SN 20 10 min preinc with SN  and then  10pM AD added 0 0
13/12/2001 WB SN 10 10 min  preinc with SN and then  10pM AD added 0 0
18/12/2001 PRP AD 10 Blood treated solely with AD 20 n/a
18/12/2001 PRP TJ35 100 10 min  preinc with TJ35 and then  10pM AD added 20 100
18/12/2001 PRP TJ35 100 5 min  preinc with TJ35 and then  10pM AD added 19 95
18/12/2001 PRP TJ35 200 5  min  preinc with TJ35 and then  10pM AD added 20 100
18/12/2001 PRP AD 10 Blood treated solely with AD 16 n/a
18/12/2001 PRP TJ36 100 10 min  preinc with TJ36 and then  10pM AD added 17 130.8
18/12/2001 PRP TJ36 100 5 min  preinc with TJ36 and then  10pM AD added 18 138.5
18/12/2001 PRP TJ36 200 5 min  preinc with TJ36 and then  10pM AD added 16 123.1
18/12/2001 PRP AD 10 Blood treated solely with AD 10 n/a
21/01/2002 PRP AD 10 Blood treated solely with AD 19 n/a
21/01/2002 PRP TJ35 100 10 min  preinc with TJ35 and then  10pM AD added 19 100
21/01/2002 PRP TJ35 100 10 min  preinc with TJ35 and then  10pM AD added 17 89.5
21/01/2002 PRP AD 10 Blood treated solely with AD 17 n/a
21/01/2002 PRP TJ35 200 10 min  preinc with TJ35 and then  10pM AD added 18 105.9
21/01/2002 PRP TJ35 200 10  min  preinc with TJ35 and then  10pM AD added 17 100
21/01/2002 PRP AD 10 Blood treated solely with AD 23 n/a
21/01/2002 PRP TJ36 100 10 min  preinc with TJ36 and then  10pM AD added 22 95.7
21/01/2002 PRP TJ36 100 10 min  preinc with TJ36 and then  10pM AD added 21 91.3
21/01/2002 PRP AD 10 Blood treated solely with AD 24 n/a
21/01/2002 PRP TJ36 200 10 min  preinc with TJ36 and then  10pM AD added 22 91.7
21/01/2002 PRP TJ36 200 10 min  preinc with TJ36 and then  10pM AD added 20 83.3
29/01/2002 PRP AD 10 Blood treated solely with AD 18 n/a
29/01/2002 PRP TJ36 100 2 min  preinc with TJ36 and then  10pM AD added 18 100.0-
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29/01/2002 PRP TJ36 100 2  min  preinc with TJ36 and then  10pM AD added 18 100.0
29/01/2002 PRP AD 10 Blood treated solely with AD 23 n/a
29/01/2002 PRP SNP 100 2 min preinc with SNP and then  10pM AD added 4 17.4
29/01/2002 PRP SNP 100 2 min  preinc with SNP and then  10pM AD added 0 0.0
29/01/2002 PRP AD 2 Blood treated solely with AD 21 n/a
08/02/2002 PRP AD 0.1 Blood treated solely with AD 0 n/a
08/02/2002 PRP AD 1 Blood treated solely with AD 20 n/a
08/02/2002 PRP AD 0.5 Blood treated solely with AD 5 n/a
08/02/2002 PRP AD 0.5 Blood treated solely with AD 0 n/a
08/02/2002 PRP TJ35 100 10 min  preinc with TJ35 and then  1pM AD added 17 85
08/02/2002 PRP AD 1 Blood treated solely with AD 20 n/a
08/02/2002 PRP AD 0.1 Blood treated solely with AD 0 n/a
08/02/2002 PRP AD 1 Blood treated solely with AD 20 n/a
08/02/2002 PRP AD 0.5 Blood treated solely with AD 0 n/a
08/02/2002 PRP AD 0.5 Blood treated solely with AD 5 n/a
08/02/2002 PRP TJ36 100 10 min  preinc with TJ36 and then  1pM AD added 15 69.8
08/02/2002 PRP AD 1 Blood treated solely with AD 23 n/a
12/02/2002 PRP AD 1 Blood treated solely with AD 19 n/a
12/02/2002 PRP TJ35 100 10 min  preinc with TJ35 and then  1pM AD added 19 100
12/02/2002 PRP TJ35 100 10  min  preinc with TJ35 and then  1pM AD added 18 94.7
12/02/2002 PRP AD 1 Blood treated solely with AD 17 n/a
12/02/2002 PRP AD 1 Blood treated solely with AD 17 n/a
12/02/2002 PRP TJ35 200 10 min  preinc with TJ35 and then  1pM AD added 17 17
12/02/2002 PRP TJ35 200 10  min  preinc with TJ35 and then  1pM AD added 16 94.1
12/02/2002 PRP TJ35 100 TJ35 added  and then  1pM AD added  immediately afterwards 18 ?-
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12/02/2002 PRP AD 1 Blood treated solely with AD 22 n/a
12/02/2002 PRP TJ36 100 10  min  preinc with TJ36 and then  1pM AD added 20 90.9
12/02/2002 PRP TJ36 100 10  min  preinc with TJ36 and then  1pM AD added 19 86.4
12/02/2002 PRP AD 1 Blood treated solely with AD 20 n/a
12/02/2002 PRP TJ36 200 10 min  preinc with TJ36 and then  1pM AD added 20 100.0
12/02/2002 PRP TJ36 200 10 min  preinc with TJ36 and then  1pM AD added S.A. n/a
12/02/2002 PRP TJ36 200 10 min  preinc with TJ36 and then  1pM AD added 20 100.0
19/02/2002 PRP AD 1 Blood treated solely with AD 19 n/a
19/02/2002 PRP TJ35 100 5 min  preinc with TJ35 and then  1pM AD added 10 52.6
19/02/2002 PRP TJ35 100 5 min  preinc with TJ35 and then  1pM AD added 19 100.0
19/02/2002 PRP AD 1 Blood treated solely with AD 19 n/a
19/02/2002 PRP TJ35 200 5 min  preinc with TJ35 and then  1pM AD added 12 68.6
19/02/2002 PRP TJ35 200 5 min  preinc with TJ35 and then  1pM AD added 15 85.7
19/02/2002 PRP AD 1 Blood treated solely with AD 16 n/a
19/02/2002 PRP AD 1 Blood treated solely with AD 15 n/a
19/02/2002 PRP TJ36 100 5 min  preinc with TJ36 and then  1pM AD added 18 102.9
19/02/2002 PRP TJ36 100 5 min  preinc with TJ36 and then  1pM AD added 20 114.3
19/02/2002 PRP AD 1 Blood treated solely with AD 20 n/a
19/02/2002 PRP TJ36 200 5 min  preinc with TJ36 and then  1pM AD added 6 32.4
19/02/2002 PRP TJ36 200 5 min  preinc with TJ36 and then  1pM AD added 17 91.9
19/02/2002 PRP AD 1 Blood treated solely with AD 17 n/a
27/02/2002 PRP+T AD 1 Blood treated solely with AD 0 n/a
27/02/2002 PRP+T AD 10 Blood treated solely with AD 0 n/a
27/02/2002 PRP+T AD 1 Blood treated solely with AD 0 n/a
27/02/2002 PRP+T AD 10 Blood treated solely with AD 0 n/a-
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26/03/2002 PRP+T AD 1 Blood treated solely with AD 0 n/a
26/03/2002 PRP+T AD 10 Blood treated solely with AD 14 n/a
26/03/2002 PRP+T AD 5 Blood treated solely with AD 7 n/a
26/03/2002 PRP+T AD 10 Blood treated solely with AD 21 n/a
26/03/2002 PRP+T AD 1 Blood treated solely with AD 4 n/a
Key:
WB = Whole Blood
PRP = Platelett Rich Plasma
T = Tyrodes Buffer
AD = Adenosine Diphosphate
SN = Sodium Nitroprusside
S.A. = Spontaneous AggregationT ^ L APPENDIX 2
11.2.4  Discussion
The  data  obtained  in  this  particular  study  using  CO-RMs  was  inherently 
inconsitent.  Overall  there  was  a  trend  that  suggested  CO-RMs  did  attenuate 
aggregation;  however,  this was  neither significant nor consistent.  Experiments 
carried  out  using  the  NO  donor  sodium  nitroprusside  (SNP)  proved  to  be  far 
more  reliable  and  demonstrated  a  significant,  consistent  and  reproducable 
inhibition  of  ADP  associated  aggregation.  The  preparation  of  PRP  caused 
further  problems  since  after  collecting  blood  there  is  only  a  3  hour  period  in 
which the aggregating ability is retained.  To generate PRP took nearly 2 hours 
and often yielded very small volumes compared to the original amount of blood 
collected.  This  data  neither  supports  nor  disputes  the  ability  of  CO  to  inhibit 
blood  aggregation.  It  also  does  not  answer the  question  of whether  CO-RMs 
can replicate the action of CO in blood since any effects observed were difficult 
to  reproduce.  With the  potency of NO  donor SNP to  inhibit aggregation  it may 
be the  CO-RMs  are just  unable  to  elicit  a  response.  However,  it may  also  be 
possible that the assay needs to be refined possibly by warming CO-RMs prior 
to  addition  since  in  these  early  CO-RM  experiments  they  were  kept  on  ice. 
Needless  to  say  there  is  still  much  to  investigate  and  elucidate  from  further 
studies on CO-RMs and their effect on blood aggregation.
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11.3  Appendix  3:  Preliminary  Tests  Using  Alpha-Meso-Methyl-Haem  a 
Novel Haem Oxygenase Substrate that does not Generate CO
11.3.1  Introduction
Haem oxygenase  (HO)  is the  rate limiting step  in the catabolism of haem.  The 
products  of  its  activity  are  Fe(lll),  carbon  monoxide  (CO)  and  biliverdin which 
goes on to  be catabolised further to bilirubin by biliverdin reductase.  Biliverdin, 
bilirubin and  CO have all in the last decade or so been shown to be involved in 
the  cytoprotective  effects  associated  with  an  increase  in  HO  activity  and 
expression.  Both biliverdin and bilirubin are powerful antioxidants while CO has 
been shown to be anti-inflammatory, anti-apoptotic, vasodilatory and involved in 
cytoprotection in ischaemia/repurfusion injury to name but a few of its functions. 
The contribution of each of these products of HO activity has been investigated 
by  the  addition  of  each  compound  individually  and  in  comibantion  with  one 
another.  Obviously  this  is  not  an  ideal  way  to  investigate  the  various  effects 
each has since the use of these compounds in combination does not accurately 
reflect what happens physiologically in terms of the final concentrations of each. 
The  use  of  a  haem  isomer,  a-meso-methyl-haem  (aMMH),  which  when 
catabolised  by HO does not go on to generate CO  lends itself well to studying 
the  end  products  of HO  activity  in  a  more  biologically relevant manner (Figure 
11.1).  Normally the oxidation of haem by HO  results in regiospecific elimination 
of the a-meso-carbon  as CO  and the formation of biliverdin  IXa.  It is generally 
accepted  that  this  reaction  proceeds  via  the  a-meso-hydoxylation  of  haem. 
Torpey & Ortiz de  Montellano found that  HO-1  can oxidise an  a-meso-methyl- 
substituted  haem  to  biliverdin  IXa without  proceeding  via  the  a-meso-hydroxy
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intermediate and as such does not generate CO (Torpey & Ortiz de Montellano 
1996).'
This  novel  compound  also  enables  a  unique  opputunity  to  use  a  newly 
synthesised group of compounds developed by our group to replace the lost CO 
function.  Carbon  monoxide-releasing  molecules  (CO-RMs)  are  a  group  of 
compounds able to release CO in biological buffers to simulate endogenous CO 
release.  Depending on the structure of the CO-RM the kinetics and the amount 
of CO  released  can  be  altered  to  suit the  desired  action.  In this  instance  the 
comparison of cells treated with aMMH or hemin can allow us to investigate the 
contribution of biliverdin/bilirubin  in the presence or absence of CO, whilst,  CO- 
RMs can enable us to replace the lost function of CO.
Me
Fe' Fe'
Haem  a-meso-methyl-haem
Figure  11.1:-  Structural  differences  between  haem  and  a-meso-methyl- 
haem (aMMH).
The presence of a methyl  substituent in aMMH  prevents a-meso-hydroxylation 
of  haem  as  demonstrated  by  the  failure  of  aMMH  to  generate  CO  when 
catabolised by HO-1.
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11.3.2 Material and Methods
aMMH'  was  prepared  as  per  the  protocol  outlined  by  Torpey  &  Ortiz  de 
Montellano (Torpey & Ortiz de Montellano  1996).  It was prepared fresh prior to 
each experiment as a final stock concentration of 1.5 mM in 1   ml of dH20 and 5 
pi of 2 M  NaOH.  Bovine aortic endothelial  cells (BAEC) were treated for 6 h in 
the  presence of 5,  25  and  50  pM  aMMH  or hemin to  investigate the  effect on 
HO activity.
HO  activity was  determined  as follows.  Briefly,  harvested  cells were  subjected 
to three cycles of freeze-thawing before addition to a reaction mixture consisting 
of  phosphate  buffer  (1  ml  final  volume,  pH  =  7.4)  containing  magnesium 
chloride  (2  mM),  NADPH  (0.8  mM),  glucose-6-phosphate  (2  mM),  glucose-6- 
phosphate dehydrogenase  (0.2  Units),  rat liver cytosol as a source of biliverdin 
reductase,  and the substrate hemin (20 pM). The reaction was conducted at 37 
°C  in  the  dark for  1   h  and  terminated  by  the  addition  of  1   ml  chloroform;  the 
extracted bilirubin was calculated by the difference in absorbance between 464 
and 530 nm (e = 40 mM'1cm'1).
11.3.3 Results
Both aMMH and hemin caused a concentration dependent increase in the level 
of HO activity.  Interestingly, the use of hemin (at all concentrations) significantly 
increased HO activity compared to an equilivant aMMH concentration. This was 
most  evident  at  5  pM  where  aMMH  did  not  increase  HO  activity  significantly 
compared to control but hemin did.
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Figure  11.2:-  Effect  of  hemin  and  aMMH  on  HO  activity  in  bovine  aortic 
endothelial cells.
Bovine  aortic  endothelial  cells  (BAEC)  were  incubated  with  increasing 
concentrations  of  aMMH  (5-50  pM)  or  hemin  (5-50  pM).  Haem  oxygenase 
activity was determined 6 h after exposure to the different concentrations.  Data 
represent the mean ± S.E.M. of 6 independent experiments. * indicates P < 0.05 
vs. control (0); t  indicates P < 0.05 vs. aMMH.
11.3.4  Discussion
The  treatment  of  BAEC  with  aMMH  resulted  in  a  less  of  an  increase  in  HO 
activity  compared  to  cells  treated  with  hemin.  The  way  in  which  HO  utilises 
aMMH  may be responsible for the reduction in activity since it may be less likely 
to induce HO protein expression. As such,  it would be of interest to compare the 
effect  of hemin  and  aMMH  on  HO-1  protein  expression  via Western  blot.  It  is 
also  likely that the  generation  of CO,  which  can  go on to further stimulate  HO
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induction,  is  responsible.  The  reduction  in activity with aMMH  makes it difficult 
to compare aMMH with hemin  in other models (such as cell  injury in which the 
protective  effect  of  CO  could  be  elucidated)  since  aMMH  evokes  less  HO 
activity and thus  comparative  amounts  of biliverdin/bilirubin will  not be  present 
compared to hemin stimulated cells.  It would be of interest, however, to use the 
technique  by  Stonek  et  al  described  in  the  discussion  (paragraph  8.1.2)  to 
determine  whether  or  not  any  CO  is  released  by  aMMH.  The  testing  of  this 
compound  and  the  principles  behind  the  long  term  aims  of  its  study  did, 
however,  lead to the development of the study of CO-RMs in this Thesis.
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11.4  Appendix 4: Step by Step Protocol for the Myoglobin Assay
The following section comprises a step by step guide to performing a myoglobin 
assay to test the CO release from CO-RMs.
1)  Prepare the spectrophotometer making sure the cuvettes (1.5 ml plastic) 
(Sarstedt) are in place and that they are at 37 °C (heated carousel).
2)  Zero the baseline using 1   ml PBS (0.01 M, pH = 7.4) (Sigma)
3)  Prepare a 66 pmol/l (final concentration) stock of myoglobin (lysophilised 
horse heart) (Sigma) by adding 50 ml PBS (0.01 M,  pH = 7.4) (Sigma) to 
56 mg myoglobin.
4)  Warm the myoglobin in a water bath at 37 °C.
5)  Once  warm  add  sodium  dithionite  (0.1  %  or  -   2  heaped  spatulas) 
(Sigma) to convert the myoglobin stock to deoxymyoglobin (deoxy-Mb).
6)  Add  1   ml  deoxy-Mb to a cuvette and  read the absorbance between 500 
and  600  nm.  This should  be a single peak around 560 nm.  This  is your 
zero MbCO value.
7)  With  the  same  cuvette  bubble  the  deoxy-Mb with  CO  gas for  1   min  to 
saturate the  myoglobin.  Read  the  sample  again.  The  curve  should  now 
have  two  peaks  with  the  second  peak  smaller  than  the  first.  The  first 
peak should be around 540 nm and the second 578 nm. This is your 100 
% MbCO value.
8)  Using the deoxy-Mb stock add  1   ml to a cuvette.
9)  Prepare  the  CO-RM  you  wish  to  test.  The final  concentrations  used  in 
this study were 20,  40 and 60  pM.  These were prepared as 4,  8 and  12 
mM stocks respectively. The final volume added, therefore, was 5 pi.
10) Add your compound to the myoglobin.
- Page 364 -______________________________________________APPENDIX 4
11) Mix the  myoglobin-CO-RM  solution  gently  using  a  Gilson  pipette (1000 
pi) so as not to oxygenate the solution. This would result in two peaks of 
equal size.
12) Layer  the  myoglobin  with  500  pi  of  mineral  oil  (Sigma)  to  prevent  CO 
escaping and the myoglobin becoming oxygenated.
13) Read  the  sample.  For  the  purpose  of  this  study  samples  were  read 
every 5  min for the first 30  min  and every 30 min thereafter.  Depending 
on the CO-RM there will either be no change, a gradual conversion from 
deoxy-Mb to MbCO or a near instant conversion.
14)  Using the readings obtained and the calculations specified in paragraph
2.4  it  is  then  possible  to  determine  the  concentration  of  MbCO  and, 
therefore, the CO release.
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11.5  Appendix 5: Full Publications by the Author
Presented in this section are the full articles which  I  have written or contributed 
to during my PhD.  The papers are presented in chronological order and are set 
out  as  published  with  the  exception  of  the  most  recent  paper  “Bioactive 
properties  of iron-containing  carbon  monoxide-releasing  molecules  (CO-RMs)”  
in the JPET which is currently only available as an Epub ahead of print.
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